Mark Steven FREEDMAN 2 - ECTRIMS

Summary

Publications

CURRICULUM VITAE

NAME: MARK STEVEN FREEDMAN RANK: Professor of Medicine (Neurology) University of Ottawa Senior Scientist, OHRI EMPLOYEE NUMBER: 90715 OFFICE ADDRESS: 501 Smyth Road Ottawa General Hospital Ottawa, Ontario K1H 8L6 TELEPHONE (office): (613)737-8917 TELEFAX: (613)737-8857 e-mail: [email protected] (hospital) [email protected] (home) HOME ADDRESS: 1035 Bank St., suite 1903 Ottawa, Ontario K1S 5K3

HOME TELEPHONE: (613) 226-6440 CITIZENSHIP: Canadian LANGUAGES: English, French, Hebrew DATE AND PLACE OF BIRTH: May 3, 1955 Toronto, Ontario GENDER: Male MARITAL STATUS: Married with 3 children DEGREES: BSc (1976) University of Toronto (Science) Hon. BSc (1977) University of Toronto (Zoology) MSc (1980) University of Toronto (Molecular Neurochemistry) MD (1983) University of Toronto PROFESSIONAL FRCP(C) (1987) (Neurology) #373306 CERTIFICATION: CSPQ (1988) (Neurology) #12046 LICENSURE: Ontario (CPSO) #52527 Québec (CPMQ) #90009

mailto:[email protected]

mailto:[email protected]

Mark Steven FREEDMAN 2

PROFESSIONAL TRAINING:

Sept 1980 - May 1982: Sunnybrook Medical Centre: Undergraduate Medical Student (years II & III)

Sept 1980 - May 1982: Mount Sinai Hospital: 1 day per week for the entire year plus the entire summer in: Clinical Neurology, (Elective)

Sept 1982 - Oct 1982: Institute of Neurology, The National Hospital, Queen Square (London, England): 2 month elective in Clinical Neurology

June 1982 - June 1983: Mount Sinai Hospital: Clinical Clerkship June 1983 - June 1984: Sunnybrook Medical Centre: Straight internship in Internal

Medicine July 1984 - Sept 1984: Toronto General Hospital: Resident in Neurology Oct. 1984 - Dec 1984: Hospital for Sick Children: Resident in Pediatric Neurology Jan. 1985 - June 1985: Wellesley Hospital: Senior Resident in Neurology July 1985 - Dec 1985: St. Michael's Hospital: Senior Resident in Neurology Jan. 1986 - June 1986: St. Michael's Hospital: 1 day per week in: Multiple

Sclerosis Assessment Clinic Jan. 1986 - June 1986: Toronto Western Hospital: Resident in Neuropathology July 1986 - Dec 1986: Toronto General Hospital: Resident in Neurophysiology

(EEG & evoked potentials); Resident in Chief, Dept. Neurology

Jan. 1986 - June 1987: Toronto Western Hospital: Senior Resident and Resident in Chief, Dept. Neurology

BASIC RESEARCH: 1977-1980: University of Toronto: Standard Biochemistry: Molecular Biochemistry,

Neurochemistry: Electron Microscopy 1980: Weizmann Institute of Science (Rehovot, Israel): Molecular Biology 1981-82: Mount Sinai Hospital, Dept. Clinical Biochemistry: Enzyme Kinetics and

Assays 1982-83: Mount Sinai Hospital, Dept. Clinical Biochemistry, Surgical Oncology 1987-93: Montréal neurological Institute, McGill University, Dept. Neuro-

immunology: The cellular mechanisms of immune-mediated demyelination as related to multiple sclerosis

1993- : The Ottawa Hospital, General Site, Division of Neurology, University of Ottawa: Cellular mechanisms of immune-mediated damage in multiple sclerosis; the role of heat shock protein T cell interactions

CURRENT POSITION: Professor

Department of Medicine (Neurology), (May 2000) Department of Microbiology, Immunology & Biochemistry (cross-appointment), (November, 1993) University of Ottawa, Ottawa, Ontario Director, Multiple Sclerosis Research Clinic The Ottawa Hospital, General Campus

Senior Scientist, Ottawa Hospital Research Institute (June 2003)


PREVIOUS ACADEMIC APPOINTMENTS: July 1990-June 1993: Assistant Professor, Department of Neurology and Neurosurgery,

McGill University, Montréal, QC July 1992-June 1993: Cross appointment to Department of Microbiology &

Immunology, McGill University, Montréal, QC July 1993-April 1995: Assistant Professor, Department of Medicine (Neurology),

University of Ottawa, Ottawa, ON May 1995-April 2000: Associate Professor, Department of Medicine (Neurology),

University of Ottawa, Ottawa, ON HONOURS AND AWARDS: 1978: University of Toronto Open Master’s Fellowship. Pure & Applied Science

Research Grant, Dept. Zoology, University of Toronto 1979: Pure & Applied Science Research Grant Ontario Graduate Fellowship* NSERC Post-Graduate Fellowship* Addiction Research Foundation Research Scholarship* 1980: Walter F. Watkins Scholarship (U of T for honour standing in year I

medicine) 1981: MRC Summer Research Scholarship 1986: St. Michael's Hospital, Toronto; Clinical Research Prize 1987: MRC Research Fellowship Multiple Sclerosis Society of Canada Research Fellowship. (Declined in favour of the MRC award) 1998: Recognition Award from the International Society for Neuroimmunology

for contribution to the field 2002: Recipient of the McEwan Visiting Professor Lectureship, University of

Toronto 2009-2013: Department of Medicine Mid-Career Salary Award 2012-2013: Department of Medicine Research Salary Award 2013: Herndon Award for Outstanding International Journal of MS Care Article 2016: Department of Medicine Research Award 2017: Canadian Neurological Sciences Federation 2018 Richardson Lecturer *These awards were regretfully declined in order to accept entrance into the Faculty of Medicine at the University of Toronto in the Fall of 1979.

HOSPITAL APPOINTMENTS: Jan. 1988-Dec. 1994: St. Vincent de Paul and Brockville General Hospital, Brockville

ON, Consultant Neurologist Oct. 1988-present: Brockville Psychiatric Hospital, Brockville, ON: Staff Neurology

Consultant; Head, EEG Department Mar. 1990-June 1993: Montréal Neurological Hospital and Institute: Staff Neurologist. Mar. 1990-June 1993: Queen Elizabeth Hospital, Montréal: Staff Consultant Neurologist


Jan. 1991-June 1993: Director Clinical Neuroimmunology Laboratory, Montréal Neurological Hospital

July 1993-present: Staff Consultant Neurologist with cross appointment in Pathology and Laboratory Medicine, The Ottawa Hospital, General Site

April 1994-present: Royal Ottawa Hospital Rehabilitation Centre, Consultant Neurologist

March 1995-present: Pembroke General Hospital, Consultant Neurologist June 2007- present: Perth Smith Falls Memorial Hospital, Consultant Neurologist SCHOLARLY AND PROFESSIONAL ACTIVITIES: Committees: 1990-93: Member, Special Laboratories Committee, Montréal Neurological Hospital 1992-93: Member, Clinical Research Committee, Montréal Neurological Hospital 1993-99: Examiner, Medical Council of Canada 1995-: Member, OSAC Committee, Multiple Sclerosis Society of Canada 1995-: Member, Multiple Sclerosis Society of Canada, Research Grants Review

Committee 1995-: Member, University of Ottawa Research Subcommittee 1997-: Member, Neurology Selection Committee 1999: Member of International Scientific Committee for 15th Congress of The European

Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 4th Annual Meeting of the America’s Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

2000: Member of International Consensus Group for developing Treatment Guidelines for Multiple Sclerosis.

2000: Member Scientific Advisory for the Canadian Congress of Neurological Sciences 2001-: Member Medical Advisory Committee for the Canadian Multiple Sclerosis

Society 2001-: Member of the America’s Committee for Treatment and Research in Multiple

Sclerosis (ACTRIMS) Programming Committee 2001: Member of the America’s (ACTRIMS) and European (ECTRIMS) Committees

for Treatment and Research in Multiple Sclerosis Programming Committee for joint meeting in 2002

2001: Member of Organizing Committee for the Guidelines for Diagnosis of Multiple Sclerosis Forum (http://www.mscare.org/professional)

2002: Head of Steering Committee on the Standardization of Spinal Fluid Analysis for the Diagnosis of Multiple Sclerosis for the Consortium of MS Clinics (CMSC)

2003: Member of Joint CBS/Bayer Grant Competition Committee; Canadian IVIG Research Committee

2004: Member, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trial of New Drugs in MS

2004: Member, Executive Committee, Consortium of Multiple Sclerosis Clinics 2006: Member, New York Academy of Science 2007-: Secretary, Consortium of Multiple Sclerosis Centers 2007-: President, Canadian Network of Multiple Sclerosis Clinics 2009: Member, Editorial Board, The European Neurological Journal 2009: Member, Editorial Board, Multiple Sclerosis International 2010: Member, Québec-Ottawa endMS Regional Research and Training Centre 2010: Member, Editorial Advisory Board, Clinical Investigation

http://www.mscare.org/professional


2011: Member, National Institute of Neurological Disorders and Stroke (NINDS)

Working Group to Develop Common Data Elements (CDE's) for MS (Short Title:

NINDS MS Common Data Elements)

2012: Secretary, Americas Committee for Treatment and Research in Multiple Sclerosis

(ACTRIMS)

2012: President, Ottawa Chapter for the Canadian Society for the Weizmann Institute of

Science

2012: Secretary / Treasurer, ACTRIMS

2014: Relapse Adjudication Committee for NMO Study for Tocilizumab, run by Chugai

Data Safety Monitoring Boards: 2004-2006: Member, Data Safety Monitoring Board, Bayhill Therapeutics, Palo Alto, CA.

Study Name: Phase I trial of immunotherapy with BHT-3009 alone or combined

with atorvastatin in patients with multiple sclerosis (Protocol BHT-3009-01.

2004-2007: Phase IV, rater-blinded, randomized study, comparing the effects of 250 μg of

Betaseron with 20 mg of Copaxone in patients with the relapsing-remitting or

clinically isolated forms of multiple sclerosis using 3 Tesla MRI with triple-dose

Gadolinium, (the BECOME study), Berlex Laboratories, USA.

2004-2007: A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center

Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of

Multiple Sclerosis, Protein Design Labs, USA.

2008- : Member DSMB NIH/NIAID monitoring several clinical trials. NIH Bethesda,

MD.

Steering Committee Memberships: 2003- : Member of BENEFIT Study (Schering AG) Steering Committee

Study Name: Double-blind, placebo controlled, randomized, parallel group, multicenter, phase III study in patients with a first clinical demyelinaing event suggestive of multiple sclerosis to evaluate the safety, tolerability, and efficacy of 8 MIU (250 mcg) interferon beta-1b (Betaseron) given subcutaneously every other day over a period of up to 24 months.

2003-05: Member of Steering Committee for the Study of NBI-5788 (Neurocrine) Study Name: A randomized, double-blind, placebo-controlled study to evaluate

the safety, tolerability and efficacy of NBI-5788 in patients with relapsing multiple sclerosis. Neurocrine BioSciences.

2004: Member and principal investigator of IMPLEMENT Study Steering Committee (Pfizer).

Study Name: Implementation study of treatment optimization recommendations comparing subjects continuing treatment with IFN 1a 30mcg qw IM (Avonex) or glatiramer acetate 20mg qd SC (Copaxone) to those randomized to IFN-1a 44mcg tiw SC (Rebif), in a multicenter study of subjects with RRMS currently on disease-modifying therapy.

2004-: Member of NIH Combi Study Steering Committee


Study Name: A multicenter, double-blind, randomized study comparing the

combined use of Interferon Beta-1a and glatiramer acetate to either agent alone in

patients with relapsing remitting multiple sclerosis (CombiRx-Phase III).

2004- : A double-blind, placebo controlled multicenter study to evaluate the efficacy and

safety of MBP8298 in subjects with secondary progressive multiple sclerosis.

BioMS (Eli-Lilly), Canada. (MAESTRO #1); An open-label follow-on study to

assess the ongoing safety of MBP8298 in subjects with secondary progressive

multiple sclerosis. BioMS (Eli Lilly) (MAESTRO #2). 2007-: HMR1726D/ 2003 Randomized, multinational, double-blinded, placebo-

controlled, pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with Interferon-ß in subjects with multiple sclerosis. Sanofi-Aventis (PDY 6045). Global principal investigator.

2007-: HMR1726D/ 2003 Randomized, multinational, double-blinded, placebo-controlled, pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis. Sanofi-Aventis (PDY 6046). Global principal investigator.

2007-10: A phase III, randomized, double-blind, placebo-controlled, multicentre clinical

trial of Rebif new formulation (44 mcg tiw and 44 mcg ow) in subjects at high

risk of converting to multiple sclerosis. Merck Serono, Switzerland (REFLEX

study). Merck Serono. (REFLEX trial).

2008-09: ATAMS Trial Steering Committee. A four-arm, randomized, double-blind,

placebo-controlled, multicenter Phase II study to evaluate the safety, tolerability

and efficacy as assessed by frequent MRI measures of three doses of Atacicept

monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 week

treatment course. (Atacicept in RMS). Merck Serono Inc., Germany.

2008- : ORACLE Study (Merck Serono). A phase III, randomized, double-blind,

placebo-controlled, multi-center clinical trial of oral cladribine in subjects with a

first clinical event at high risk of converting to MS. 2008: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study

comparing the efficacy and safety of 1.25mg FTY 720 administered orally once daily VS placebo in patients with primary progressive multiple sclerosis, Novartis Pharmaceuticals, Switzerland.

2008-09: Long-term extension of PDY 6045 and PDY 6046 of Teriflunomide when added with Interferon or glatiramer acetate in MS. Sanofi-Aventis Inc.

2009: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing remitting multiple sclerosis. Actelion.

2009: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif® New Formulation (REFLEXION).

2011: Phase 1B, randomized, placebo-controlled dose study of IV infusion of human placenta-derived cells (PDA001). Celgene

2011: A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta.. (TERACLES). Sanofi-Aventis Inc.


Task Forces:

2002-04: CMSC Task Force on CSF guidelines for the diagnosis of MS

2008- : AAN Task Force: Group leader for “Prognosis” – development of a treatment

guideline Memberships: Fellow, Royal College of Physicians and Surgeons of Canada Member, Federation of Medical Specialists of Québec Member, Ontario Medical Association Member, Canadian Neurological Society Associate Member, American Academy of Neurology Member, American Society for Neurological Investigation Member, Clinical Immunology Society Member, International Society for Neuroimmunology Fellow Member, American Academy of Neurology Member, Executive Committee, Consortium of Multiple Sclerosis Clinics Member, New York Academy of Science Fellow, American Neurological Assocation Organized Symposia: Montréal Neurological Institute Symposium on The matter of neurological disease: Idiopathic

Parkinson’s disease: the role of surgical transplantation, March 1993, Montréal, QC.

Organizing and Scientific Advisory Committee member for the 1998 International Society for

Neuroimmunology Conference, Montréal, QC.

Organizing Committee for the Annual Meeting of the Canadian Congress of Neurological

Sciences Conference, Ottawa, ON. 2000.

Organized Multiple Sclerosis Satellite Symposium for the Canadian Congress of Neurological

Sciences Conference, Ottawa, ON. 2000.

Organized Industry course for the Canadian Congress of Neurological Sciences Conference,

Ottawa, ON. 2000.

Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia: Grey Matter Disease in MS: The Untold Story Standardizing CSF Analysis Sheraton Hotel & Marina, San Diego CA. May 30, 2003. Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia: Defining Sub-Optimal Response to MS Treatment De-diagnosing MS


Toronto, ON. June 2004. Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia: Diagnosing MS in 2005: Focus on Accuracy The Use of Serological or Cerebrospinal Fluid Diagnostic Tests Orlando, FL. June 2005. Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia: Contemporary Issues in Multiple Sclerosis Ottawa, ON. June 2005. Schering MS Fireplace Talks. Responsible for the following Scientific Program: MS Treatment in Practice (Chair) Berlin, Germany. March 24, 2006. American Academy of Neurology Annual Conference 2006: Responsible for the following program: Multiple Sclerosis Therapy: Demyelinating Disorders San Diego, CA. April 7, 2006. American Academy of Neurology Annual Conference 2006: Responsible for the following program: Multiple Sclerosis Therapy: Demyelinating Disorders San Diego, CA. April 7, 2006. Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Chairperson Paris, France. March 11-12, 2009. Stem Cell in Neurology, Symposium, 50th Anniversary Academic Conference, Northern Neuroscience Center, Chiang Mai University, Thailand: November 2, 2009. Annual Conference of the Consortium of MS Clinics (CMSC): Organized and moderated the following symposia:

Making an Accurate Diagnosis of MS Mesenchymal Stem Cell

San Antonio, Texas, June 2-5, 2010 CONy – The 4th World Congress on Controversies in Neurology Chairperson:

Multiple Sclerosis Barcelona, Spain, October 30, 2010 SSIF CME Annual Meeting Workshop: How to Treat Early MS St. Petersburg Russia, May 6 2011 DIME - Discovery Institute of Medication Education in conjunction with Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting Faculty: Critical Issues in the Long-Term Management of Multiple Sclerosis


Montréal QC, June 2 2011 CONy Co-Chair:

Multiple Sclerosis Scientific Program Debate Host:

To tap or not to tap: Is there still a role for lumbar puncture and CSF analysis in MS diagnosis?

Vienna, Austria, March 2012 Bone Marrow Transplant in MS Transplants for MS: Moving Forward CMSC Annual Meeting June 2 2012 An early start for treatment success. ENS Prague Czech Republic, June 10 2012 Treatment options for Fingolimod in clinical practice Novartis Symposia Prague, Czech Republic, June 11 2012 Get on track, stay on track: patient journeys in MS

Merck Serono Symposia

ECTRIMS, Lyon France, Oct 10 2012.

Chair, Satellite Symposium: Evolving the management of MS: new insights and new directions.

ECTRIMS. Copenhagen Denmark. Oct 3 2013.

Chair: Parallel Session 12: Looking into the future: experimental studies of new therapies.

ECTRIMS. Copenhagen Denmark. October 4 2013.

Chair: Parallel Session: Myasthenia Gravis and Multiple Sclerosis.

9th International Congress on Autoimmunity. Nice, France. March 28, 2014.

Chair: Parallel Session: Cell-based Therapies (PS1.1-PS1.6)

A/ECTRIMS. Boston MA Sept 2014

Speaker: Innovation and Optimization: Engaging Today’s Patients: Treating to target

Merck Serono Symposia

A/ECTRIMS. Boston MA. Sept 2014

Speaker: Latest advances towards changing the course of MS

Novartis Symposia


Speaker: Treating to target and beyond: is improvement in functioning a realistic treatment goal

in multiple sclerosis?: Are We Changing the Natural History of MS with Current Therapies?


Abbvie Symposia


Speaker: CSF in MS: Current Assays and Significance oligoclonal IgG and IgM bands, IgG

index, MBP, cells/protein)

Conference of the Consortium of MS Clinics (CMSC). Indianapolis, IA May 2015

Speaker: Status of Stem Cell Therapy 2015

Conference of the Consortium of MS Clinics (CMSC). Indianapolis, IA May 2015

Speaker: Long-term disability prevention: the ultimate goal.

Merck Symposia.

ECTRIMS. Barcelona, Spain. October 2015.

Speaker: Evolving Treatment Goals in MS (Dis)Ability Rehabilitation, Recovery?

Genzyme Symposia

ECF. Baveno, Italy. November 2015.

Chair: Review of Available Therapies and Interactive Expert panel discussion. Advanced

Curriculum for Multiple Sclerosis. New Orleans, LA. February 17, 2016.

Speaker: The Great MS Debate: Part II: Induction Therapy vs Escalation. Adanced

Curriculum for Multiple Sclerosis. New Orleans, LA. February 18, 2016.

Co-Chair: The Treatment Pipeline: New Experimental Therapies. AAN. New Orleans, LA.

February 20, 2016.

Speaker: Future therapies in MS. XXII Colombian Congress of Neurology, Cali,

Columbia.February 26, 2016.

Debate: EM Controversies: Should the concept NEDA be considered the “Gold Standard” in

order to treat MS? Yes: Ludwig Kappos No: Mark Freedman. XXII Colombian

Congress of Neurology, Cali, Columbia. February 26, 2016.

Debate: EM Controversies: Is the regeneration and remyleination in MS possible?

Yes: Ludwig Kappos No: Mark Freedman. XXII Colombian Congress of Neurology,

Cali, Columbia. February 26, 2016.

Speaker: “Long term disability prevention-the ultimate goal of MS treatment”.

Merck Neurology Congress. Warsaw, Poland. March 4, 2016.

Co-Chair: Current and future treatments for MS. EAN. Copenhagen, Denmark. May 2016.

Speaker: Cell-based Therapies in MS Symposium- “Blood Derived Stem Cells in the

Treatment of MS”. CMSC. Natinal Harbor, Maryland. June 2016.


Speaker: “Recent Scientific Advancements of S1P immunomodulators” and “Clinical Trial Data

Analysis: Interpreting S1P Evidence Based Medicine for Relapsing MS”. Live Satellite Symposium at the Advanced Curriculum for MS 2017 CME Program. ACTRIMS. Orlando, FLA. February 22, 2017.

Speaker: “Clinical Trial Update for Selective S1P Receptor Modulators”. Interactive Live

Satellite Symposium CME at ACTRIMS 2017. Orlando, FLA. February 24, 2017.

Speaker: MS Plenary Symposium: “Balancing the risks of immunosuppression in MS “

CONy . Athens, Greece. March 24, 2017.

Speaker: MS Symposium: “What we can learn from failed drug studies in MS”. CONy. Athens, Greece. March 24, 2017 Guest Speaker: “Stem Cell Considerations for the Treatment of Multiple Sclerosis: Are We Ready for Prime Time?” UAlberta MS Centre Research Symposium. Edmonton, AB. May 5, 2017.

Speaker: “Reconsidering the concept of induction” ECF Symposium. A/ECTRIMS 2017. October 25, 2017

Chair: Parallel Session 14: Safety issues in MS therapeutic management. A/ECTRIMS 2017. Paris, France. October 27, 2017 Co-Chair: “Providing solutions to treatment burden in MS” Merck Satellite Symposium. A/ECTRIMS. 2017. Paris, France. October 27, 2017 Co-Chair: “Women and MS” ECF Symposium. Menatrims 2017. Dubai, UAE. Nov 24 2017 Speaker: “Long Term Data and Evidence Story in MS” Novartis Satellite Symposium. Menactrims 2017. Dubai, UAE. November 25, 2017. Chair: Sesssion II “The changing Landscape of basic studies”. ECF. Baveno, Italy. November 30 2017.

Preceptorships:

Organizer and lead contributor to the bi-annual one week MS Conference for visiting Italian

Neurologists; Symposia held May 1999; November 1999; April 2000, November 2000, May

2001, November 2001, November 2003 at the Ottawa Hospital General Campus, Ottawa, ON.

Organizer and lead contributor to the bi-annual one week MS Conference for visiting German

Neurologists; Symposia held February 2001, June 2001, February 2002 at the Ottawa Hospital

General Campus, Ottawa, ON.

Organized first Canadian Preceptorship Program for Canadian Neurologists, on behalf of the Canadian Network of

MS Clinics, Ottawa, ON. November, 2000.


Organizer and lead contributor to a one week MS Conference for visiting European

Neurologists; Symposia held November 2005, November 2006, February and April 2007 at the

Ottawa Hospital General Campus, Ottawa, ON.

Organizer and lead contributor to a one week MS Conference for visiting Korean Neurologists; Symposia held October 2008 at the Ottawa Hospital General Campus. October 22 2008 ½ day preceptorship: Ellen Dempsey, Biogen November 4 2008 ½ day preceptorship: Luc Renaud, Teva Neuroscience February 24 2009 ½ day preceptorship: Annick Laplante, Novartis April 14 2009 ½ day preceptorship: Marc Massé, EMD Serono April 14 2009 ½ day preceptorship: Waseem Kalair, EMD Serono April 21 2009: ½ day preceptorship: Dr. H. Gonzalez, EMD Serono June 21 2010 ½ day preceptorship: Susan Stone, NOVARTIS July 27 2010 ½ day preceptorship: Jim Hunt, EMD Serono August 18 2010 ½ day preceptorship: Nital Patel, EMD Canada Inc. November 17 2010 ½ day preceptorship: Guylaine Vigneault, BIOGEN IDEC November 24 2010 ½ day preceptorship: Vincent Renaud, BIOGENIDEC April 19 2011 Full day preceptorship: Daniel Bonhomme, NOVARTIS April 26 2011 Full day preceptorship: Orchid Jahanshahi, NOVARTIS June 6 2012 Full day preceptorship: Julie Kruse, NOVARTIS June 19 2012 Full day preceptorship: Karen Chow, NOVARTIS October 24 2012 Full day preceptorship: M. Pierre Bourdage, NOVARTIS August 7 2013 Full day preceptorship: Amirault-Laing, EMD Serono November 6 2013 Full day preceptorship: Paola Haddad January 7 2014 Full day preceptorship: Raffi Toniklan, Medical Science Liasons August 27 2014 Full day preceptorship: Pinay Kainth, NOVARTIS December 16 2014 Full day preceptorship: Jovna Kapur, Medical Dir, EMD Serono July 16, 2015 ½ day preceptorship: Parissa Khataei, Genzyme July 29, 2015 Full day preceptorship: Jean Francois Dansereau, NOVARTIS


August 12, 2015 Full day preceptorship: Fabien Bakdache, Genzyme November 10, 2015 Full day preceptorship: Dominic Girard, Genzyme December 9, 2015 Full day preceptorship: Geoff Matthews, Genzyme December 14, 2015 ½ day preceptorship: Kristin Ouiment, Genzyme February 22, 2016 ½ day preceptorship: Jeff Maartens, Novartis May 9, 2016 ½ day preceptorship: Ruth Elgrably, EMD Serono Courses: Symposium for American Academy of Neurology 50th Annual Meeting Therapeutic Poisoning: Immunosuppressive Therapy for Non-neoplastic Neurologic

Disease Case Presentations: Demyelinating Disease Chicago IL. May 2008. SSIF MS Academia – Multiple Sclerosis Advanced Course for ECTRIMS MS Treatment in Practice Montréal QC. September 2008. Hot Topics in MS Course – American Academy of Neurology 51st Annual Meeting Immunosepression: Haematopoietic stem cell transplantation and intense immunosuppression – Should they have a role in the treatment of multiple sclerosis? Seattle WA. April 2009. Hot Topics Review – American Academy of Neurology 52nd Annual Meeting Toronto ON. April 2010. SSIF MS Academia – Multiple Sclerosis Advanced Course for ECTRIMS Current Disease Modifying Drugs: Evaluating the Evidence Gothenburg Sweden October 2010. Multiple Sclerosis Advanced Course for ECTRIMS - 12th MS Nurse Workshop Nurses: Key Interface between Patients and Physicians Gothenburg Sweden October 2010. Multiple Sclerosis Advanced Course for ECTRIMS - 13th MS Nurse Workshop Improving Organization and Optimize Treatment: MS Centers Organization Amsterdam Netherlands October 2011. Debate: Clinical issues in multiple sclerosis – American Academy of Neurology 53rd Annual Meeting

AFFIRMATIVE: Resolved: Fingolimod and Cladribine should both be donsidered first-line oral treatments for MS with comparable efficacy and safety profiles? Chronic Cerebrospinal Venous Insufficiency (CCSVI): Do the initial claims hold up? How much more study is necessary?


Honolulu HI. April 2011. SSIF MS Academia - Multiple Sclerosis Advanced Course for ECTRIMS Current Disease Modifying Drugs: Evaluating the Evidence Amsterdam Netherlands October 2011. Teaching Course: ECTRIMS Stem Cell Therapy Amsterdam Netherlands October 2011. Teaching Course: MS Overview II: Clinical Advances – American Academy of Neurology 54th Annual Meeting Emerging MS therapies New Orleans LA. April 2012. Teaching Course Chair: MS Course CNSF June 8 2012. Teaching Course: MS Advanced Course. ECTRIMS Current disease modifying drugs: Evaluating the evidence Lyon France. October 2012 Teaching Course: Multiple Sclerosis Overview: Clinical Advances Demyelinatinig Disorders San Diego SF. March 22 2013. Teaching Course: Present and emerging therapies for multiple sclerosis San Diego CA. AAN March 2013. Teaching Course: CNSF 2014 New and emerging therapies in multiple sclerosis Banff AB. June 5 2014. Teaching Course: CNSF 2015 Emerging Therapies in Multiple Sclerosis Totonto, ON June 10 2015. Teaching Course/CME: ECTRIMS 2016 Utilizing Individualized Treatment Plans to Optimally Manage Patients with Multiple Sclerosis

Invited Lectures, Talks and Presentations:

1. Corporation Des Physiothérapeutes du Québec lecture series. Management of head

injury. November 1988.

2. Hôpital Notre Dame, Université de Montréal. Interleukins. May 1989.

3. Corporation des Physiothérapeutes du Québec Lecture series. Neurological approach to

back injuries. November 1989.


4. Montréal Neurological Institute, McGill University, Grand Rounds. Immunological

circuits in multiple sclerosis. December 1989.

5. Royal Victoria Hospital, McGill University, Resident Rounds. An assessment of lower

back pain. May 1990.

6. Corporation des Physiothérapeutes du Québec Lecture series. Management of head

injury, November 1990.

7. Montréal Neurological Institute, McGill University, Neuroscience Conference. The role

of heat shock proteins and T cells in multiple sclerosis. February 1991.

8. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Multiple

Sclerosis. February 1991.

9. St. Michael's Hospital, University of Toronto, Medical Grand Rounds. Role of T

cells and heat shock proteins in multiple sclerosis. May 1991.

10. Health Sciences Centre, University of Manitoba, Immunology Seminar. Role of T

cells and heat shock proteins in multiple sclerosis. August 1991.

11. Leeds-Grenville Medical Community, Brockville, ON. New concepts in the management

of Parkinson's Disease. October 1991.

12. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Approach to the

management of the first seizure. September 1991.

13. Guest Expert on Visa Santé, a Québec television health program on Multiple Sclerosis.

October 1991.

14. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Anti-

phospholipid antibodies and neurological disease. December 1991.

15. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Diagnosis and

management of Parkinson's Disease. February 1992.

16. Queen Elizabeth Hospital, Department of Medicine, Special Lecture. Au Vieux St.

Gabriel, Montréal, QC. New advances in stroke management. February 1992.

17. Ste. Anne de Bellevue VA Hospital, Medical Grand Rounds. New concepts of stroke

management. March 1992.

18. Leeds-Grenville Medical Community, Brockville, ON. New advances in stroke

management. April 1992.


19. Hôpital Notre Dame, Université de Montréal. New strategies in the management of

multiple sclerosis: Potential role of TNF. May 1992.

20. St. John Medical Society, St. John, NB. New approaches to the management of

Parkinson's Disease. May, 1992.

21. Calgary General Hospital, University of Calgary, City-Wide Neurology Rounds.

Immunopathogenesis of multiple sclerosis. June 1992.

22. Department of Immunology Seminar, University of Calgary. Immunopathogenesis of

multiple sclerosis. June 1992.

23. Queen Elizabeth Hospital, McGill University, Medical Grand Rounds. Neurological

Emergencies. August 1992.

24. University Hospital, University of Colorado School of Medicine, Neurology-

Neurosurgery Grand Rounds, New concepts in the immunopathogenesis of MS.

September 1992.

25. Ottawa General Hospital, University of Ottawa,

Neuroradiology/Neurology/Neurosurgery Rounds. New concepts in the

immunopathogenesis of MS. September 1992.

26. Queen Elizabeth Hospital, McGill University, Montréal, QC. Medical Grand Rounds.

Diagnosis and management of headache. October 1992.

27. Lakeshore General Hospital. Pointe-Claire, QC. The role of DHE in the treatment of

migraine. November 1992.

28. Royal Victoria Hospital and Jewish General Hospital Combined Resident Special

Lecture. New advances in stroke management. November 1992.

29. Guest expert on Medically Speaking, a PBS television health program on Multiple

Sclerosis. November 1992.

30. Queen Elizabeth Hospital, McGill University, Montréal, QC, Medical Grand Rounds.

Neurosarcoidosis. March 1993.

31. Workshop participant on heat shock/stress proteins in multiple sclerosis and other

disorders, sponsored by the National (US) MS Society. MHC unrestricted killing of

oligodendrocytes by T- cells, La Toja, Galicia Spain. April 2-6 1993.

32. Course Lecturer, The immunology of multiple sclerosis, Canadian Congress of

Neurological Sciences. Toronto ON. June 1993.


33. MS Society Local Chapter, Pembroke, ON. Interferon- and the treatment of multiple

sclerosis. September 1993.

34. MS Society, Ottawa/Carleton Chapter, Annual General Meeting, Ottawa ON. Treatment

of multiple sclerosis. October 1993.

35. Ottawa Civic Hospital, University of Ottawa, Neurology and Rehabilitation Medicine for

Family Practitioners. Multiple sclerosis - new theories, new therapies. November 1993.

36. Ottawa General Hospital, Neurology Grand Rounds. MS.: Interfering with interferons

and other new strategies. January 1994.

37. Health & Welfare Canada, Tunney’s Pasture. Disability due to demyelinating disorders

(MS). February, 1994.

38. Leeds Grenville Medical Society, Brigadoon Restaurant. Multiple Headache Disorder.

February 1994.

39. Neurology Update 1994, Ottawa Congress Centre. New hope for MS patients. April

1994.

40. Ottawa General Hospital Annual Research Day. Cerebral spinal fluid analysis in

multiple sclerosis. April1994.

41. Westin Hotel. New trials using -interferon in the treatment of MS. April 1994.

42. Ottawa General Hospital. Educational evening for newly diagnosed MS patients. April

1994.

43. Grand Rounds, Brockville General Hospital. Update on stroke prevention. May 1994.

44. The Rehabilitation Centre, Royal Ottawa Hospital. Physiotherapy Departmental Rounds,

The use of cyclophosphamide in the management of multiple sclerosis. August 1994.

45. Ottawa General Hospital. Guest Speaker for the Canadian Association of Neuroscience

Nurses, Innovations in neurosciences: Use of cyclophosphamide in the treatment of

multiple sclerosis. October 1994.

46. Chelsea Inn, Toronto, ON. Main speaker for the medical update session, Multiple

Sclerosis Society of Canada, annual general meeting, New strategies in the treatment of

multiple sclerosis. November 1994.

47. Ottawa General Hospital, Grand Rounds, Department of Medicine, When the heat is on,

007 cells may not come to the rescue. A story in the cold war against MS. May, 1995.


48. Best Western Heritage Inn, Pembroke, ON, Medication induced headache: Strategies for

diagnosis and management. May 1995.

49. Ottawa Congress Centre, Cerebrospinal fluid analysis: What can we learn from the

brain’s soup? Canadian Society of Laboratory Technologists Congress. June 1995.

50. Victoria Congress Centre, Immunologic manipulation in multiple sclerosis, Neurobiology

Review Course, XXXth Canadian Congress of Neurological Sciences. June 1995.

51. Ottawa General Hospital, Neurology Grand Rounds, MRI in the diagnosis and

management of MS. September 1995.

52. Holiday Inn, Sudbury, ON, Northern Education Conference, Immune directed therapies

in the treatment of multiple sclerosis. October 1995.

53. Tom Brown Arena, Ottawa, ON. Annual General Meeting of local MS Chapter, New

and upcoming treatments for multiple sclerosis. October 1995.

54. Royal Ottawa Hospital, Rehabilitation Centre. Pathophysiology of multiple sclerosis.

December 1995.

55. Ottawa Civic Hospital, Neurology Grand Rounds, Role of -interferon in the

management of MS. December 1995.

56. Ottawa General Hospital, Nursing and Paramedical Care In Service, -Interferon: First

of a new kind of therapy. December 1995.

57. Royal Ottawa Rehabilitation Centre, Advances in the understanding and treatment of MS.

May 1996.

58. The Canadian Society for The Weizmann Institute of Science, Ottawa Chapter,

Promising new treatments for multiple sclerosis. May 1996.

59. Jewish General Hospital, Montréal, QC. Grand Rounds on Advances in the treatment of

MS. September 1996.

60. Mississauga General Hospital, Mississauga, ON. Neuroscience Rounds on Rationale for

new treatments in MS. October 1996.

61. Royal Brock Hotel, Brockville, ON, Health Professional Education Day, MS Society of

Canada, Ontario Division, Eastern Region. Keynote speaker on (MS) Symptom

management and research update. October 1996.

62. Health Sciences Centre, Winnipeg, MB. Neuroscience Rounds, Rationale for new

therapies in MS. October 1996.


63. Eldorado Hotel, Kelowna, BC. Neurology Review on Advances in the treatment of MS.

November 1996.

64. Maison de Gouverneurs, Montréal, QC. Special evening lecture on Immunological basis

for treatment of MS. November 1996.

65. Ottawa Civic Hospital, Neurology Grand Rounds on MRI and MS. December 1996.

66. Ottawa General Hospital, Neurology Grand Rounds on: Magnetic resonance imaging:

What’s the attraction to MS? January 1997.

67. Ottawa Congress Centre, Ottawa Valley Drug Information Service Update on: Advances

in multiple sclerosis. March 1997.

68. Michelangelo’s, Québec City, QC, Neurology update on Rationale for rational therapy in

MS. March 1997.

69. Ottawa General Hospital, Neurology Grand Rounds on: Blasting away at MS: Is it time

for the big guns? April 1997.

70. Ottawa Civic Hospital, 46th Annual Refresher Course for Family Practitioners, What’s

new in multiple sclerosis? April 1997.

71. Hotel Lac Carling, Pine Hill, QC. MS: Clinical issues and decisions,

Immunopathogenesis of MS. June 1997.

72. Canadian Congress of Neurological Sciences, Sheraton Hotel, Saskatoon, SK. MS

satellite symposium, MRI as an outcome measure. June 1997.

73. Canadian Congress of Neurological Sciences, Sheraton Hotel, Saskatoon, SK. MS

satellite symposium, Immune mechanisms of treatment. June 1997.

74. Waterfront Centre Hotel, Vancouver, BC. Special symposium on Multiple Sclerosis:

Clinical Issues & Decisions, Immunopathogenesis of MS. October 1997.

75. Sheraton Harbor Hotel & Marina, San Diego, CA. Annual Meeting of the International

Society for Interferon and Cytokine Research, Guest speaker for a symposium on

Interferon and Multiple Sclerosis, -interferon-1a treatment of multiple sclerosis: results

of a clinical trial using Rebif in relapsing-remitting disease. October 1997.

76. Camberley Club Hotel, Toronto, ON, Meeting of TEVA Advisory Board. Mechanism of

copolymer-1 in multiple sclerosis. November 1997.

77. Treatment Advances in Immunology Symposium, Tampa, FL. Immunological

mechanism of copaxone. February 1998.


78. Multiple Sclerosis - an update: What’s wrong with the myelin in multiple sclerosis?

Sheraton Gateway Hotel, Toronto, ON. Guest speaker for the Association of Community

Neurologists. February 1998.

79. Immunological rationale for MS therapy: What, how, who and when? Community

Neurologists, Le Latini Restaurant, Montréal QC. March 1998.

80. Charles-Lemoyne Hospital, Greenfield Park, QC. Neurology Grand Rounds

Immunological rationale for MS therapy: What, how, who and when? March 1998.

81. Corel Centre, Kanata, ON, Teva-Marion Partners Symposium. Lecture on Copaxone:

Mechanism of action in MS. March 1998.

82. Place Bonaventure, Montréal, QC. Canadian Congress of Neurological Sciences,

Neurobiology Review Course: The immunology of MS sesion generation. June 1998.

83. Marriott Chateau Champlain, Montréal, QC, Continuing Medical Education Seminar,

Multiple Sclerosis, An Update for Nurses: The immunology of MS: From chaos to

clarity. June 1998.

84. Universidad Internacional Menéndez Pelayo, Santander, Spain, La destruccion de la

mielina y su reparacion: nuevas terapéuticas. Interferones: Interferon beta-1a (Rebif).

June 1998.

85. El Dorado Hotel, Santa Fe, NM, Southwest Teva Advisory Board Meeting, Mechanism

of action of copaxone. July 1998.

86. Aronsborg Conference Centre, Balsta, Sweden, Proposed mechanism of action of

copaxone to international roundtable conference. September 1998.

87. ECTRIMS Satellite Symposium, Stockholm Conference Centre, Stockholm, Sweden,

Mechanism of action of copaxone in multiple sclerosis. September 1998.

88. Drug Information Association International Workshop on Bioequivalence or Biocomparability of Complex

Molecules, Sheraton Centre Hotel, Toronto, ON. Interferon beta therapy in multiple sclerosis: A clinician’s

perspective. September 1998.

89. Royal University Hospital, University of Saskatoon, Saskatoon, SK, Immunologic

perspectives, Pathology, diagnosis and prevalence of MS in symposium on Management

of MS in the Era of Immunotherapy. October 1998.

90. Sheraton Halifax Hotel, Halifax, NS. Current thoughts on treatment of MS. October

1998.

91. Dalhousie University Neuroscience Rounds, Halifax, NS. Mechanism of action of

copaxone. October 1998.


92. Hotel Intercontinental, Montréal QC. Nurses Forum on Management of MS in the era of

immunotherapy: New options in the management of MS and Advances in the treatment

of secondary progressive MS. October 1998.

93. Therapeutics Program, Health Canada, Banting Building, Ottawa, ON. A physician’s

perspective of what to look for in an interferon- product for multiple sclerosis.

November 1998.

94. The Living Arts Centre, Bank of Montréal Room, Mississauga, ON, The current role of

Rebif in the management of MS: Results of the PRISMS Study and beyond. November

1998.

95. Sault Ste. Marie Annual Clinical Day, Water Tower Inn, Sault Ste. Marie, ON. Plenary

session: 1998 update on multiple sclerosis. November 1998.

96. Second Annual Montréal Neurology Symposium, Hôpital Notre-Dame, Montréal, QC.

Multiple Sclerosis Symposium: Immunopathogenesis and Disease modifying therapies,

special role in transitional MS. November 1998.

97. Neurology Rounds at Jewish General Hospital, Montréal, QC, Advances in the treatment

of secondary progressive multiple sclerosis. January 1999.

98. Hotel Sofitel, Paris, France. Multiple Sclerosis (MS) Frontiers: Symposium on

Copaxone-new developments. Mechanism of action of copaxone. January 1999.

99. American Academy of Neurology, Toronto, ON. Guest faculty for course No. 7AC.008

on Immunosuppressive Treatment for Neurologists: Multiple sclerosis: further therapies.

May 1999.

100. Dubrovnik Restaurant, Winnipeg, MB. Multiple sclerosis-The basics. May 1999.

101. Health Sciences Centre, University of Manitoba, Winnipeg, MB. Multiple sclerosis-

What, why, who & when. May 1999.

102. The Deerhurst, Huntsville, ON. Lecture on Mechanism of Action of Copaxone in MS &

The newer therapies. Part of a symposium on MS: Now a treatable disease. June 1999.

103. The Provincial Museum of Alberta, Edmonton AB. Special lecture in conjunction with

the CCNS. Results of the Rebif secondary progressive study. June 1999.

104. Janet Lynn’s Bistro, Waterloo ON. Multiple sclerosis-what, why, who & when. June

1999.

105. Lights and Lesions aboard the Mariposa Belle in Toronto Harbour, a discussion of

pertinent management points in the use of Copaxone in treating MS patients. June 1999.


106. Chateau Mt. Tremblant, Mt. Tremblant, QC. MS: Newer therapies and their

immunological rationale. Part of a symposium on Prise en charge de la SEP au temps de

l’immunothérapie. June 1999.

107. Courtyard Restaurant, Ottawa, ON. , The current role of Rebif in the management of MS:

The results of PRISMS, OWIMS & SPECTRIMS Trials. August 1999.

108. Muskoka Sands Resort, Gravenhurst, ON. MS: Newer therapies and their immunological

rationale, part of a symposium on Management of MS in the era of immunotherapy.

August 1999.

109. Maverick’s Restaurant, Moncton NB. Rationale for immunotherapy in multiple

sclerosis-what, why, who & when. August 1999.

110. Hilton Hotel, St. John NB. Rationale for immunotherapy in multiple sclerosis-what,

why, who & when. August 1999.

111. Guest speaker of the Polish Neurological Society Meeting, Lublin Poland. The role of

Interferon -1a (Rebif) in the management of MS. August 1999.

112. Newfoundland Education Day, Memorial University of Newfoundland, St. John’s, NF. 3

Lectures: Diagnosis and differential, use of MRI. Rationale for immunotherapy,

pathogenesis, MOA’s and Current therapy choices. October 1999.

113. Xth Pan American Congress of Neurology, Cartagena Columbia. Immune mechanisms in

multiple sclerosis, and Overview of -interferon-1a (Rebif) in the treatment of multiple

sclerosis. October 1999.

114. The Victoria Conference Centre, Victoria BC. Immunological basis for the treatment of

MS as part of a symposium of the on Management of MS in the Era of Immunotherapy.

October 1999.

115. Delta Chelsea Hotel, Toronto ON. Address to the Ontario Division of the Multiple

Sclerosis Society of Canada at their Annual General Meeting entitled MS: A Millennium

of Research. November 1999.

116. Park Hyatt Hotel, Toronto ON. Neuroimmunological rationale for interferon therapy as

part of a symposium entitled MS: Inside and Out, in which I was also the Chairman.

November 1999.

117. Corel Centre, Kanata ON. The new MS drugs at the Collaborative Educational Session

of the Ottawa-Carleton MS Chapter and the MS Clinic of the Ottawa Hospital-General

Campus. November1999.

118. Holiday Inn, Minneapolis, MN. The role of glatiramer acetate in the treatment of

relapsing-remitting MS. December 1999.


119. Inselspital, Hopital de L’Ile, Berne Switzerland. Dose and timing of interferon therapy,

in the Second Annual ‘State of the Art Symposium’ on the Diagnosis and Therapy of

Multiple Sclerosis. January 2000.

120. Chateau Laurier Hotel, Ottawa ON. New approach to secondary progressive MS in a

Conference and Workshop in Multiple Sclerosis. February 2000.

121. Associacao Nacional de Jovens Empresarios, Porto Portugal. Dose and timing of

interferon therapy, In Simposio Novos Avancos Na Esclerose Multipla. February 2000.

122. Presenter: Results of the 4 year PRISMS Study at the 2000 Meeting of the Charcot

Foundation, Hotel Beau Rivage, Lausanne Switzerland. March 2000.

123. Presentation at the lecture series in Relapsing MS and the disease continuum: Addressing

early treatment and therapeutic options: the disease modifying drugs. Maclean Estates,

Toronto ON. April, 2000.

124. Lecture at the Ostsee-Symposium, Klinische Neuroimmunologie, Universitat Rostock,

Experiences with long-term immunomodulatory therapy of multiple sclerosis. Rostock-

Warnemünde. May 2000.

125. American Academy of Neurology, San Diego CA. Guest Faculty for course No.

7AC.008 on Immunosuppressive Treatment for Neurologists: Lecture entitled Multiple

sclerosis: Current therapy. May 2000.

126. Immunology update at Symposium Treating MS-An update for clinical practitioners,

Rocky Crest Golf Resort, Mactier ON. June 2000.

127. PRISMS 4 year results at the Serono Symposium, European Neurological Society

Meeting, Jerusalem Convention Centre, Jerusalem Israel. June 2000.

128. Presentation at Physician Educational Program of Multiple Sclerosis: Recent advances &

current opinion, The American Club, Kohler WI. July 2000.

129. Lecture in Symposium entitled Multiple Sclerosis: Relapsing MS, Managing the

Continuum. The 2000 Lecture Series. Relapsing MS and the disease continuum:

addressing early and aggressive treatment and therapeutic options: the disease modifying

drugs, The Royal Canadian Lodge, Banff AB. August 2000.

130. Guest lecturer: Sally Letson Foundation Series in Neuro-Ophthalmology, Treatment

update in MS, The Westin Ottawa, Ottawa ON. September 2000.

131. Guest Speaker: Ottawa-Carleton Chapter of the MS Society of Canada’s Annual General

Meeting on Research update in MS. October 2000.


132. Guest Speaker: Immunological rationale for BMT in MS, ACTRIMS (Americas

Committee for Treatment and Research in MS) Meeting, Boston MA. October 2000.

133. Presentation of the PRISMS 4 year results and the role for immunomodulatory agents at

LACTRIMS, Buenos Aires. November 2000.

134. Presentation of the PRISMS 4 year results at the Mexican Neurological Society Meeting,

Acapulco Mexico. November 2000.

135. Grand Rounds, University of Calgary, Foothills Hospital on The Rationale for bone

marrow transplantation in MS. December 2000.

136. Presenter: Lecture series: SP rémittente: Gestion du continuum, Mont Tremblant, QC,

Canada. Review of Immunomodulator Therapy. January 19-21 2001.

137. Guest Presentation of the International statement on the use of disease modifying agents

at the 3rd Annual Multiple Sclerosis Meeting for Italian Neurologists, Grand Hotel Plaza,

Rome Italy. February 2001.

138. Presenter: Targeting MS: Time Matters, Bermuda. Debate: Which cells are implicated

in MS? February 2001.

139. Presenter: The Canadian MS Clinics Network: Multiple Sclerosis Preceptorship.

Progressive MS. Calgary AB. March 1-4 2001.

140. Presenter: Managing multiple sclerosis and clinical decision-making and Diagnostic

dilemmas, The Boulders, Carefree AZ. March 31 2001.

141. Guest Lecturer: Dose and frequency of interferon- 1a therapy in MS, European

Neurological Society, Paris France. April 2001.

142. MS Links: Multidisciplinary advances in patient care, Co-chair, organizer and speaker.

Scottsdale AZ. May 31-June 3 2001.

143. RRMS and Treatment options in clinically isolated syndromes, Adelaide Australia. May

2001.

144. Toronto Public Forum, MS treatment: Review, rethink, respond, Serono Canada and

National Pharma Com, Crowne Plaze, Toronto ON. June 2001.

145. Lecturer: Multiple Sclerosis Course of the Canadian Congress of Neurological Sciences:

Beyond modifying treatments: what to do if they are not effective, including the selection

of innovative approaches. Halifax NS. June 2002.

146. Special Lecturer: Leeds and Grenville MS Chapter Research update in MS. Brockville,

ON. June 2001.


147. Guest Presenter: Bone marrow transplantation in MS: Rationale for the Canadian study,

ECTRIMS (European committee for treatment and research in MS). Dublin Ireland.

September 2001.

148. Keynote Speaker: Annual General Meeting, Multiple Sclerosis Society of Canada,

Ontario Division, Delta Chelsea Hotel. Update on research and treatment of MS.

November 2001.

149. Guest speaker: Multiple Sclerosis Society of Canada, Toronto Chapter. Update on

symptomatic treatment. November 2001.

150. Special Guest Speaker: Comparison of different dose and application regimen of

interferon b-1a. Hotel Adlon, Kaminzimmer, Berlin Germany. November 2001.

151. Special Guest Speaker at symposium Multiple Sklerose, on Comparison of different dose

and application regimen of interferon b-1a. Cologne Germany. November 2001.

152. Lecturer at special conference of the Consortium of MS Clinics on Long term benefits of

interferon- therapy and the usefulness of CSF studies in the diagnosis of MS. Dallas,

TX. December 2001.

153. Guest presenter at conference on the use of IGIV Is multiple sclerosis a target for IGIV

therapy? Case Western Reserve University, Pinehurst NC. March 2002.

154. Medical Grand Rounds, University of Ottawa, Ottawa Hospital-General Campus: New

concepts in the pathogenesis of MS. March 2002.

155. Consortium of Multiple Sclerosis Clinics Meeting, Special Symposium on ‘Do we have

enough evidence today to optimize MS Treatment’: Clinical parameters and their role in

monitoring therapy. Chicago Hyatt Hotel. June 2002.

156. Consortium of Multiple Sclerosis Clinics Meeting, Symposium on Surrogate Markers in

MS:Diagnostic Criteria revisited: Role of CSF in MS diagnosis. Chicago Hyatt Hotel.

June 2002.

157. 3rd Annual Comprehensive Spring Neurology Update, Updated diagnostic considerations

in MS: Use of the new ‘McDonald’ criteria and value of early treatment. White Oaks

Conference Resort & Spa, Niagara-on-the-Lake ON. June 2002.

158. Toronto CME program, Using interferons to treat RRMS: Dosing and long term

considerations. Toronto Park Hyatt Hotel. June 2002.

159. Comprehensive Spring Neurology Update, EVIDENCE-48 week data, Hockley Valley

Resort ON. June 2002.


160. Educational Forum, Newport RI, Review of the AAN guidelines for treatment of MS.

June 2002.

161. Canadian Congress of Neurological Sciences Annual MS Course, Canadian consensus on

the use of disease modifying agents for the treatment of MS. Vancouver BC. June 2002.

162. Serono Regional Advisory Board Meeting, Mt. Tremblant QC. A look at the

EVIDENCE. July 2002.

163. MAMSI Health Plans Continuing Medical Education Seminar, Tysons Corner VA.

Multiple Sclerosis: Clinical update and treatment strategy. July 2002.

164. Southeast Medical Center, CME program, The importance of dose and frequency in MS

interferon therapy, Dothan AL. August 2002.

165. University of Utah, Neurology Grand Rounds, Exploring bone marrow transplantation as

a treatment for aggressive MS, Utah Medical Center. September 2002.

166. Presentation of New advances in the treatment of MS to the Board of the Toronto MS

Chapter, Park Hyatt Hotel. October 2002.

167. Keynote Speaker: Annual General Meeting of the Toronto MS Chapter, Emerging issues

in MS Today. York Reception Centre. Toronto ON. October 2002.

168. Faculty presenter: CSF Considerations at a Roundtable on Primary Progressive Multiple

Sclerosis. Warwick Hotel, Houston TX. November 2002.

169. Annual University of Toronto McEwan Lectureship, Immunological perturbations in MS.

Toronto Western Hospital. November 2002.

170. Guest Lecturer: Neurology Faculty Research Day, University of Toronto, Intensive

immunotherapy of MS: Role for bone marrow transplantation. Park Hyatt Hotel.

November 2002.

171. Guest CME Lecturer: Optimizing the benefits of immunomodulating therapy. Sheraton

Hotel, Montréal QC. November 2002.

172. Medical College of Georgia School of Medicine, Grand Rounds on Interferons in

multiple sclerosis: Importance of dose and frequency. Augusta GA. December 2002.

173. Guest Speaker: Analyzing the evidence for the treatments of MS. Waterford Marriott

Hotel, Oklahoma City OK. February 2003.

174. Guest Speaker: An update on diagnosis and treatment of MS? Tulsa Neuro-Sciences

Society. Summit Club, Tulsa OK. February 2003.


175. Moderator and Co-Chair: Serono Expert Panel Workshop. Treatment optimization in

MS. Bermuda. March 2003.

176. Special Guest Lecturer: University of Texas Medical School. Early treatment of multiple

sclerosis. Houston TX. March 2003.

177. Special Guest Lecturer: Pappas Bros Steak House, Houston TX. Early treatment of

multiple sclerosis. March 2003.

178. Special Guest Lecturer: A review of treatment in multiple sclerosis. Eddie V’s

Edgewater Grille, Austin TX. March 2003.

179. Special Guest Lecturer: Early treatment of multiple sclerosis. Aldo’s Ristorante Italiano,

San Antonio TX. March 2003.

180. Special Guest Lecturer: Early treatment of multiple sclerosis. Ruth’s Chris Steakhouse,

San Antonio TX. March 2003.

181. Guest Lecturer: A titration approach to the treatment of MS. Marriott Hotel Vanderbilte,

Nashville TN. March 2003.

182. Guest Lecturer: MS treatment options: Real world experience. La Piazza Restaurant,

Dallas/Fort Worth TX. April 2003.

183. Guest Lecturer: MS research trends and current research regarding ASCT. Annual

meeting of the National MS Society, Long Island Chapter, Melville NY. April 2003.

184. Guest Lecturer: NAbs in clinical trials with more frequent administration of IFNB-1a.

NABS Workshop - The relevance of antibodies to interferon-beta in MS therapy, Vienna

May 2003.

185. Special Guest Speaker: Optimizing therapy in multiple sclerosis, Clio’s, Boston MA.

May 20 2003.

186. Guest Speaker: Leadership in MS: Putting current issues in MS treatment in perspective.

Toronto ON. May 2003.

187. Symposia organizer and lecturer: Grey matter disease in MS: The untold story. CMSC

2003 Annual Conference, Sheraton Hotel & Marina San Diego CA. May 2003.

188. Symposia Organizer and Lecturer: Standardizing CSF analysis. CMSC 2003 Annual

Conference, Sheraton Hotel & Marina. May 2003.

189. Special Guest Speaker: Medical Grand Rounds, Griffin Hospital, Westchester NY.

Advances in understanding the pathogenesis of multiple sclerosis. June 2003.


190. Special Guest Speaker: Medical Grand Rounds. St. Francis Hospital, Hartford CT,

Advances in understanding the pathogenesis of multiple sclerosis. June 2003.

191. Guest Speaker: MS Research Update: Current research projects and treatments. MS

Society Educational Event, Toronto ON. June 2003.

192. Guest Speaker: Clinical efficacy driving choice of therapy. Schering Satellite

Symposium at The European Neurological Society, Challenges of Choosing the Optimal

MS Therapy. Istanbul Turkey. June 2003.

193. Lecturer: MS Immunobiology Course, When and why the CSF study is still useful.

Canadian Congress of Neurological Sciences Annual Meeting. Québec City QC. June

2003.

194. Guest Speaker: MRI and its link to clinical outcomes, in Workshop on MRI

Standardization and Use in Management of MS. Millennium Hotel, Minneapolis MN.

August 2003.

195. Chair and Speaker: Symposium entitled: From bench to bedside: Theory and practice of

MS care, The history of copaxone as a therapy for MS and How can the immune system

offer neuroprotection? The Deerhurst Inn, Huntsville ON. August 2003.

196. Co-Chair and Speaker: Immunology Workshop: Neuroprotection: The Good - Atelier en

Immunologie La neuroprotection: Le bon. 2nd Annual Northern MS Workshop: The

good, the bad and the ugly: A focus on immunology. Finger Lake Kuujjuak. August

2003.

197. Special Grand Rounds Invited Speaker: Does aggressive MS warrant aggressive

treatment? Role of intensive immunosuppression and ASCT. Mayo Clinic, Scottsdale

AZ. Sept 2003

198. Special Guest Lecturer: Early treatment of MS. University of Arizona, Tucson AZ. Sept

2003.

199. Special Evening Lecture: New treatment strategies in the management of multiple

sclerosis. Phoenix AZ. Sept 2003.

200. Faculty Lecturer of 1st International MS Nurse Network Workshop: Update on current

MS treatment and research, ECTRIMS Meeting. Milan Italy. Sept 17-20 2003.

201. Guest Lecturer: Clinical efficacy driving choice of therapy. Schering International MS

Symposium. Amsterdam. Oct 25 2003.

202. Guest Lecturer: MS: Learning, leading living – Keeping up with MS. MS research

updates: Highlighting stem cell research, MS Society of Canada, Manitoba Division.

Nov 2003.


203. Special Grand Rounds Invited Speaker: Multiple Sclerosis: An aggressive disease

warranting aggressive treatment, Royal University Hospital. Saskatoon SK. Nov 7 2003.

204. Guest Lecturer: Teva Nurses Retreat, Toronto ON. The mode of action of DMD’s in the

treatment of RRMS. Nov 23 2003.

205. Guest Lecturer: Teva Nurses Retreat Toronto ON, Nabs to DMD’s: Issue of non-issue.

Nov 23 2003.

206. Guest Lecturer: Fireplace Talks on Multiple Sclerosis, Early treatment in MS. Berlin.

Nov. 29 2003.

207. Guest Lecturer: MS: A disease lacking in good inflammation. An interactive educational

evening. Ottawa ON. Dec. 1 2003.

208. Guest Lecturer: Clinical efficacy driving choice of therapy in Multiple Sclerosis. Dublin

Ireland. Dec 5 2003.

209. Guest Lecturer: Paraclinical tests for diagnostic and follow-up of MS patients. Trois

Rivières QC. Dec 11 2003.

210. Morning Rounds Guest Speaker: Paraclinical tests for diagnostic and follow-up of MS

patients. Charles Lemoyne Hospital, Sherbrooke QC. Dec 12 2003.

211. Guest Speaker: Treating multiple sclerosis, General CME Symposium. Grove Park Inn,

Asheville NC. January 10 2004.

212. Chairman and Guest Speaker: Defining the standards of multiple sclerosis research.

International Schering Symposium, Copenhagen. March 2004.

213. Guest Speaker: Dose-efficacy relationship in MS treatment / Importance of high dose-

high frequency therapies. International Schering Conference, Treatment of MS:

Improving Quality of Life. Istanbul. March 20 2004.

214. Guest Speaker: Early treatment of MS, International Schering Conference, Treatment of

MS: Improving Quality of Life, Istanbul. March 20 2004.

215. Guest Speaker: Addressing early treatment and therapeutic options in MS. the disease

modifying drugs. Sioux Falls SD. March 2004.

216. Guest Speaker: Get the most out of MS therapies today. Nebraska Chapter of National

Multiple Sclerosis Society and University of Nebraska Medical Centre at Embassy

Suites, Omaha NE. March 24 2004.

217. Guest Speaker: Dose and timing of interferon therapy in MS, Omaha NE. March 2004.


218. Guest Speaker: Current treatment strategies for multiple sclerosis. Sal & Curvaos,

Downers Grove IL. March 2004.

219. Guest Speaker: New Rebif slide data. Harvey IL. March 2004.

220. Guest Speaker: Treatment advances in multiple sclerosis: Treat early? Treat with high

dose? Nabs? Chicago IL. March 2004.

221. Guest Speaker: Rebif Consultant Forum Treatment Optimization. Evidence-based review

of clinical data. New York NY. April 2004.

222. Guest Speaker: Rebif Consultant Forum Treatment Optimization. Antibodies in

perspective. New York NY. April 2004.

223. Guest Speaker: Rebif Consultant Forum Treatment Optimization. MS patient

management: The analog model. New York NY. April 2004.

224. Guest Lecturer: Baltic Symposium Clinical Neuroimmunology. Stem cell transplantation

in multiple sclerosis. Berlin. May 8 2004.

225. Guest Lecturer: Multiple Sclerosis and Neuroinflammation. CIHR Training. The role of

autologous stem cell transplantation & immunoablation as a treatment for aggressive MS.

Montréal QC. May 15 2004.

226. Guest Speaker: The development of IFN1a as a treatment for RRMS. Pfizer, Roanoke

VA. May 25 2004.

227. Guest Speaker: The development of IFN1a as a treatment for RRMS. Pfizer,

Fishersville VA. May 26 2004.

228. Guest Speaker: The development of IFN1a as a treatment for RRMS. University of

Virginia, Charlottesville VA. May 26 2004.

229. Guest Speaker: The development of IFN1a as a treatment for RRMS. Neurological

Associates of Richmond, Richmond VA. May 27 2004.

230. Keynote Speaker: Neurology 2004: 2nd Annual Meeting – New & Emerging Ideas in

Clinical Care: MS & Parkinson’s Disease. Optimizing therapy with disease modifying

agents in MS. La Malbaie QC. May 2004.

231. Chair: CNS Fireplace Talks Scientific Program. Early MS. June 12 2004.

232. Guest Speaker: Making the most out of DMD’s for RRMS. Ruth’s Chris Steak House.

Parsippany NJ. June 16 2004.


233. Guest Speaker: Treatment optimization in RRMS. Stony Hill Inn, Hackensack NJ. June

17 2004.

234. Guest Speaker: The importance of dose and frequency in Interferon therapy. Cardwell’s

Restaurant, Clayton MI. July 2004.

235. Keynote Speaker: The changing paradigm of inflammation and neuroprotection. MS

2004: Bridging Neurology Research & Clinical Practice, PEI. July 1 2004.

236. Guest Speaker: When is an effect not an effect? MS 2004: Bridging Neurology Research

& Clinical Practice, PEI. July 17 2004

237. Guest Speaker: Interactive case discussion: What is the optimal approach to

management? MS 2004: Bridging Neurology Research & Clinical Practice, PEI. July 17

2004.

238. Neurology Grand Rounds: Optimization of treatment of MS patients. William Beaumont

Hospital, Royal Oak MI. July 21 2004.

239. Workshop: Immunosuppression vs Immunomodulation. Teva Copaxone Advisory Board,

Sonora Resort BC. August 22 2004.

240. Workshop: Treatment optimization. Teva Copaxone Advisory Board, Sonora Resort, BC.

August 22 2004.

241. Guest Speaker: Optimization recommendations in the treatment of RRMS. March

Restaurant, NY. September 21 2004.

242. Guest Speaker Optimization in the treatment of relapsing remitting multiple sclerosis,

35th Congresso Societa Itialian di Neurologia. September 28 2004.

243. Guest Speaker: Tomorrow – Benefit right from the start. Schering Satellite Symposium:

Treating MS – Today, Tomorrow and in the Future, ECTRIMS Meeting 2004. October

8, 2004.

244. Invited Lecturer: Diagnosis and management of multiple sclerosis, 11th Asian Oceanic

Congress of Neurology, Singapore. November 26 2004.

245. Invited Lecturer: Update on the immunological diagnosis of MS, 11th Asian Oceanic

Congress of Neurology, Singapore. November 26 2004.

246. Guest Speaker: Therapeutic update – Developments in 2003/2004, MS Forum Pan-Asian

Congress, Ho Chi Minh City Vietnam. November 20 2004.

247. Guest Speaker: Treatment optimization in MS, Nordic Serono Symposia in MS. Oslo

Norway. December 10 2004.


248. Guest Speaker: Treatment optimization in MS, Nordic Serono Symposia in MS, Oslo

Norway. December 10 2004.

249. Guest Speaker: The importance of early diagnosis and treatment of multiple sclerosis, La

Cote d’Or, Arlington VA. December 16 2004.

250. Guest Speaker: Benefit to risk: A fine balance, Toronto ON. January 19 2005.

251. Guest Speaker: Recent data in treatment of MS, Tyson’s Corner VA. January 25 2005.

252. Round Table Discussion: Recent data in treatment of MS, Bethesda MD. January 25

2005.

253. Guest Speaker: Rebif, PRISMS LTFU, MS research, Taylor Medical Group, Towson

MD. January 26 2005.

254. Guest Speaker: Rebif, PRISMS LTFU, MS research, Johns Hopkins Outpatient Clinic,

Baltimore MD. January 26 2005.

255. Guest Speaker: Current treatment options for MS: What’s new in your physician’s bag,

Phoenix AZ. February 16 2005.

256. Co-Chair & Speaker: Emerging therapies: Future look, practicum in neurology 2005,

Carefree AZ. February 19 2005.

257. Guest Speaker: Optimizing the treatment of RRMS: What’s new in your physician’s bag,

Starkers Restaurant, Kansas City MI. February 22 2005.

258. Guest Speaker: Treatment algorithms: Maximizing the impact of treatment optimization,

at Conference: Treatment Optimization – Taking Science into Practice, Madrid Spain.

March 5-6 2005.

259. Guest Speaker: Long term Rebif, Mistral Restaurant, Boston MA. March 8 2005.

260. Guest Speaker: Long term Rebif, MS Centre, Cambridge MA. March 9 2005.

261. Guest Speaker: Long term Rebif, Brigham Womens’ Centre, Cambridge MA. March 9

2005.

262. Guest Speaker: MS and neuropathic pain, Toronto ON. March 22 2005.

263. Guest Speaker: Treatment options in RRMS: Maximizing the benefit, Chance Restaurant,

Edmonton AB. March 22 2005.


264. Guest Speaker: Treatment options in RRMS: Maximizing the benefit, Health Sciences

Centre, Calgary AB. March 23 2005.

265. Guest Speaker: Maximizing the benefit of treatment of RRMS, Cleveland OH. April 25

2005.

266. Guest Speaker: Maximizing the benefit of treatment for RRMS – Importance of early

initiation, Japan. May 2005.

267. Special Rounds Guest Speaker: Effective treatment of RRMS – Maximizing the benefit,

University of Chiba, Tokyo Japan. May 2005.

268. Guest Speaker Rounds: Rediscovering the role of CSF in the diagnosis of MS, Tohuku

University, Sendai Japan. May 2005.

269. Japanese Neurology Society. Maximizing the benefit of treatment for RRMS –

Importance of early initiation, Kogoshima Japan. May 2005.

270. Guest Speaker: Neuropathic Pain in MS, Chateau Laurier, Ottawa ON. May 30 2005.

271. Symposia: Diagnosing MS in 2005: Focus on accuracy, The use of serological or

cerebrospinal fluid diagnostic tests, Consortium of Multiple Sclerosis Clinics, Orlando,

FL. June 1 2005

272. Workshop: Bone marrow transplants, Consortium of Multiple Sclerosis Clinics, Orlando

FL. June 1 2005.

273. Guest Speaker: Sunday Housecalls – MS: Living with it, incidence, latest treatments and

research, CFRA, Ottawa ON. June 5 2005.

274. Guest Speaker: Cannabinoids: an exciting new treatment option for neuropathic pain,

Beckta Dining & Wine, Ottawa ON. June 6 2005.

275. Guest Speaker: The use of serological or cerebrospinal fluid diagnostic tests.

Presentation to Community Neurologists, Harrisburg PA. June 9 2005.

276. Guest Speaker: The bone marrow stem cell transplantation study. MS Society of Canada

North York Chapter, Glenway Country Club, Newmarket ON. June 13 2005.

277. Guest Speaker: Multiple Sclerosis: A disease of white and gray matter, CAET/NETO

Educational Seminars and AGM 2005, Ottawa ON. June 17 2005.

278. Chair: Diagnosing MS in 2005: Standards for CSF analysis, CME Teleconference hosted

by Consortium of Multiple Sclerosis Centers. June 29 2005.

279. Guest Speaker: New therapy concepts for early MS, Fireplace Talks Scientific Program.

Mykonos Greece. July 9 2005.


280. Grand Rounds: Immunoablative therapy & autologous stem cell transplant for aggressive

MS, Johns Hopkins University, Baltimore, Washington. September 13 2005.

281. Grand Rounds: Neuropathic pain in MS: The under-told story. Kingston General

Hospital, Kingston ON. September 15 2005.

282. Guest Speaker: Treatment optimization in MS. Boston MA. September 2005.

283. Guest Speaker: MS Society of Canada, Immunoprotection. Hamilton ON. October 6

2005.

284. Guest Speaker: Current concepts in neuroprotection: From bench to bedside, Interactive

educational event, Restaurant Anise. Montréal QC. October 11 2005.

285. Guest Speaker: MS Forum: Benefit of early treatment of MS, Latin America Schering

Symposium. Panama. October 2005.

286. Guest Speaker: Symposium: BENEFIT Study: Clinical results, 18th World Congress of

Neurology. Sydney Australia. November 2005.

287. Guest Speaker: Bone marrow transplantation: Does it stop MS progression?, European

Charcot Foundation. Lisbon Portugal. November 18 2005.

288. Guest Speaker: MS diagnosis, International Congress on Multiple Sclerosis, Iran

Hospital. Tehran Iran. November 2005.

289. Guest Speaker: MS treatment optimization, International Congress on Multiple Sclerosis,

Iran Hospital Tehran Iran. November 2005.

290. Guest Speaker: The BENEFIT Study: Early treatment of MS, Betaferon Symposium.

Athens Greece. November 25 2005.

291. Guest Speaker: Diagnosis and utilization of CSF markers in PPMS, Genentech / Biogen

Idec MS National Advisory Board Program. Sonoma CA. December 2 2005.

292. Neurology Grand Rounds: Optimizing MS therapy of RRMS. University of Michigan.

December 7 2005.

293. Guest Speaker: Optimizing MS therapy of RRMS, Gandi Dancer Restaurant. Ann Arbor

MI. December 7 2005.

294. Guest Speaker: Current disease-modifying drugs: Evaluating the evidence. Serono

Symposia: Unravelling the puzzle of MS: Today and tomorrow. January 14-15 2006.


295. Guest Speaker: Benefits of long-term disease-modifying agents, MS Forum Europe

Meeting MS Across Europe: Maximizing MS management. January 20 2006.

296. Pathogenesis of multiple sclerosis. Academic Program - Annual Congress of the

Neurological Association of South Africa. Durban South Africa. March 10 2006.

297. Current management of multiple sclerosis. Academic Program - Annual Congress of the

Neurological Association of South Africa. Durban South Africa. March 10 2006.

298. Chair: Schering MS Fireplace Talks: Scientific Programme: MS Treatment in Practice,

MS Treatment in Practice. Berlin. March 24 2006.

299. Chair: Schering MS Fireplace Talks: Scientific Programme: Early Signs of MS:

Predicting Late Outcome, Therapeutic options in early MS. Berlin. March 25 2006.

300. Grand Rounds: Pushing reset on the immune system: A treatment for aggressive multiple

sclerosis, Pediatric Neurology Grand Rounds, Sick Kids Hospital for Sick Children.

Toronto ON. March 29 2006.

301. Panel Member: Taking a socratic approach to assessing treatment pathways in multiple

sclerosis, Association of British Neurologists Spring Meeting. Brighton UK. April 19

2006.

302. Guest Speaker: Treatment optimization in multiple sclerosis, Black & Tan Grille.

Appleton WI. April 20 2006.

303. Guest Speaker: Stem cell applications in multiple sclerosis,New York Academy of

Sciences: The Neuroimmunology Discussion Group. New York NY. April 27 2006.

304. Guest Speaker: Combination therapy in MS: When, what and why? Practicum in

Neurology. Chicago IL. April 29 2006.

305. Guest Speaker: Update on treatment optimization, Multiple Sclerosis Review. St. Marc-

Sur-Richelieu QC. May 6 2006.

306. Guest Speaker: MS & neuropathic pain. Bayer, Beckta Restaurant. Ottawa ON. May 17

2006.

307. Guest Speaker: Update on the bone marrow transplant study, Ask the Experts, MS

Society of Canada and MS Society Ottawa Chapter. Ottawa ON. May 26 2006.

308. Guest Speaker: Canadian MS treatment optimization / IFN antibody update, Restaurant

Les Chèvres. Montréal QC. June 7 2006.

309. Participant: Symposium on Basic & Translational Aspects of Neuroinflammation Jeanne

Timmins Amiphitheatre. Montréal QC. June 18-19 2006.


310. Guest Speaker: Clinical Update: Canabinoids in pain management, Signatures

Restaurant. Ottawa ON. June 22 2006.

311. LACTRIMS: MRI findings in diseases that mimic MS. Isla Margarita Venezuela. June

29 2006.

312. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS,

No VI Chop House. Detroit MI. July 13 2006.


Novi Sheraton. Detroit MI. July 13 2006.


Southern Arizona Health Care. Tuczon AZ. July 18 2006.


Brigham & Womens’ Hospital. Boston MA. August 2 2006.

316. Guest Speaker: Patient management, therapy and treatment optimization, Garden of Eden

Restaurant. Boston MA. August 3 2006.


Carney Hospital. Boston MA. August 3 2006.

318. Guest Speaker: MS: Yesterday, today, tomorrow, Andrés Restaurant. Las Vegas NV.

August 15 2006.

319. Guest Speaker: New insights into the immunopathogenesis of MS. XXII Congresso

Brasileiro de Neurologia. August 28 2006.

320. Guest Speaker: CIS High Risk. XXII Congresso Brasileiro de Neurologia. August 28

2006.

321. Guest Speaker: Impact of available multiple sclerosis therapy. XXII Congresso

Brasileiro de Neurologia. August 28 2006.

322. Guest Speaker: Multipl skleroz tedavisi: Ne kadar erken? Klinik Kanitlar. MS

tedavisinde on yil. Turkey. September 16 2006.

323. Lecturer: Mending the Brain: Stem cells and repair in multiple sclerosis. European

Charcot Foundation Symposium 2005 – 12th European Charcot Foundation Lecture.

Taormina. Sicily Italy. November 16-18 2006.

324. Guest Speaker: BENEFIT-A view insider opinion. Fireplace Talks Betaferon. Germany.

December 1 2006.


325. Guest Speaker: Treatment in practice: Early causes of MS. Fireplace Talks Betaferon.

Germany. December 1 2006.

326. Guest Speaker: La prise en charge de la sclérose en plaques: le traitement précoce. Hotel

Place d’Armes. Montreal QC. December 5 2006.

327. Neurology Grand Rounds: Treating MS: Yesterday, today & tomorrow. Ottawa Hospital.

December 15 2006.

328. Guest Speaker: Autologous stem cell transplants for the treatment of MS. National MS

Society. San Francisco. January 16-19 2007.

329. Guest Speaker: The immunopathogenesis of multiple sclerosis: Therapeutic implications

for disease management. North American Neuro-Ophthalmology Society. Snowbird

Utah. February 15 2007.

330. Guest Speaker: The evolution of multiple sclerosis therapy: yesterday, today and

tomorrow. North American Neuro-Ophthalmology Society. Snowbird Utah. February

15 2007.

331. Guest Speaker: Therapeutic gain. SSIF Conference. Barcelona. March 9-10 2007.

332. Guest Speaker: How to treat a failing patient. BAYER Inernational Scientific

Symposium. Rome. March 17 2007.

333. Guest Speaker: Why high dose, high frequency Interferon therapy is important in RRMS.

Springfield MA. April 3 2007.


Hartford CT. April 3 2007.


Hartford CT. April 4 2007.

336. Guest Speaker: Long-term follow-up of clinical trials of MS therapies: The PRISMS

Study. Miami, Florida. April 14 2007.

337. Guest Speaker: Multiple sclerosis: What’s in the pipeline? OMA Annual Meeting. April

27 2007.

338. Guest Speaker: Betaferon Symposium: The benefits of early treatment for MS.

Kaohsiung, Taiwan. May 15 2007.

339. Guest Speaker: The benefits of early treatment for MS. Ching Medical University

Hospital. Taichung, Taiwan. May 16 2007.

340. Guest Speaker: Update on the 3-year BENEFIT Study. Taipei, Taiwan. May 16 2007.


341. Guest Speaker: Moving forward in MS Therapy: Benefits of early and long-term

treatment and the importance of adherence. 1st Pan Asian MS Nurses Forum.

Singapore. May 20 2007.

342. Guest Speaker: Moving forward in MS Therapy: Keys to improved treatment

tolerability: Recent trial observations. 1st Pan Asian MS Nurses Forum. Singapore.

May 20 2007.

343. Guest Speaker: The advantages of treating MS early: 3-year follow-up data from the

BENEFIT Study. Bayer HealthCare. Alice Springs Australia. May 21 2007.

344. Meet the Expert: Benefit of early treatment of MS: 3-year follow-up data from the

BENEFIT Study. ANZAN Meeting. Alice Springs Australia. May 22 2007.

345. Guest Speaker: Benefit of early treatment of MS: 3-year follow-up data from the

BENEFIT Study. Perth Australia. May 23 2007.

347. Guest Speaker: Treatment of MS over the next 5 years. ANZAN Meeting. Ayers Rock

Australia. May 25 2007.

348. Guest Speaker: Clinical laboratory analysis: Diagnostic and prognostic significance.

Satellite Symposium. Washington DC. CMSC. May 30 2007.

349. Lecturer: BENEFIT from timely treatment: New perspectives for treatment decisions.

Satellite Symposium of ENS 2007. Rhodes Greece. June 18 2007.

350. Lecturer: Treating neurological disorders: New approaches, new therapies, new

prospects. Satellite Symposium of ENS 2007.

351. Lecturer: Optimizing MS therapy: A step further with Rebif® new formulation. Rhodes

Greece. June 19 2007.

352. Guest Speaker: Relevance of Nabs for dose optimisation. MS preceptorship:Updating

knowledge on multiple sclerosis. Barcelona Spain. June 24 2007.

353. Guest Speaker: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. Burlington Country Club. Burlington VT. September 19 2007.


multiple sclerosis. Norwich Inn. Norwich VT. September 20 2007.

355. Grand Rounds: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. Fletcher Allen Health Center. Burlington VT. September 20 2007.


356. Grand Rounds: Betaseron in the early and long-term management of relapsing forms of

multiple sclerosis. Hitchcock Foundation: Dartmouth-Hitchcock Medical Center.

September 21 2007.


multiple sclerosis. Brigham Womens’ MS Clinic. Boston MA. October 3 2007.


multiple sclerosis. New Haven CT. October 3 2007.


multiple sclerosis. Associated Neurologists of Southern Connecticut. Fairfield CT.

October 4 2007.


multiple sclerosis. Eastern Standard. October 4 2007.

361. Guest Speaker: From bench to bedside: The history of copaxone® (Copolymer-1) as a

therapy for MS. TEVA Pre-ECTRIMS Program. Vienna Austria. October 9 2007.

362. Guest Speaker: Initial MS therapy: Making the right choice. ECTRIMS Satellite

Symposium. Prague. October 12 2007.

363. Lecturer: Experimental therapies & the role of nurses in the research centre. Serono

Symposium International Foundation (SSIF) 9th International MS Nurse Workshop on

MS. Prague CZ. October 2007.

364. Lecturer: Current disease modifying drugs: Evaluating the evidence. Serono Symposium

International Foundation (SSIF). MS Academia: Multiple Sclerosis Advanced Course.

Prague CZ. October 2007.

365. Lecturer: Achieving optimum results for patients MS. Bayer Schering Pharma

Symposium. Prague CZ. October 2007.

366. Lecturer: Recent experience with higher doses of Betaferon Bayer Schering Pharma


367. Lecturer: Rebif new formulation: Balancing efficacy & safety. Merck Serono


368. Lecturer: Rebif new formulation in early MS: Maximising the benefits of treatment.

Satellite Symposium. Prague CZ. October 2007.

369. Lecturer: Initial MS therapy: Making the right choice. Satellite symposium for

ECTRIMS on the window of opportunity for successful MS treatment. Prague CZ.

October 2007.


370. Guest Speaker: Novel therapies for treatment of relapses (IVIg & ACTH). MS

Consensus Conference. Ft. Worth TX. October 27 2007.

371. Guest Speaker: Maximizing benefits in MS therapy. Iran MS Congress. November 22

2007.

372. Guest Speaker: Best treatment algorithm for MS patients. 4th International Congress on

MS. Tehran Iran. November 22 2007.

373. Guest Speaker: Evidence based MS management: Evaluating benefit-to-risk. Isfahan MS

Symposium. November 24 2007.

374. Guest Speaker: Making treatment count. Shiraz MS Symposium. November 26 2007.

375. Guest Speaker: Therapeutic gain and new efficacy measures in multiple sclerosis.

Multipl Sklerozda Terapötik Kazanim ve Yeni Etkinlik Ölçutleri. Antalya Turkey.

November 12 2007.

376. Guest Speaker: Early treatment and initiating MS therapy. Finnish MS Symposium.

Helsinki Finland. January 31 2008.

377. Guest Speaker: Non- and partial response to therapy. Finnish MS Symposium. Helsinki

Finland. January 31 2008.

378. Guest Speaker: Practical treatment for today’s RRMS patient. UNSOM Neurology.

Henderson NV. March 18 2008.

379. Guest Speaker: Today’s treatment of RRMS. Marriott Las Vegas Resort. Las Vegas

NV. March 18 2008.

380. Guest Speaker: A discussion surrounding treatment for today’s RRMS patient. Marriott

Las Vegas Resort. Las Vegas NV. March 18 2008.

381. Guest Speaker: A discussion surrounding a treatment for today’s RRMS patient. Reno

NV. March 19 2008.

382. Guest Speaker: Clinical considerations in managing RRMS. Reno NV. March 19 2008.

383. Guest Speaker: The RRMS spectrum: Parameters for balancing efficacy and safety.

Hotel Teatro. Denver CO. March 20 2008.

384. Guest Speaker: The RRMS spectrum: Parameters for balancing efficacy and safety.

Northwest Neurology. Wheat Ridge, CO. March 20 2008.


385. Guest Speaker: Practical treatment for today’s RRMS patient. Bistro Bella Vita. Grand

Rapids, MI. March 26 2008.

386. Guest Speaker: A discussion surrounding a treatment for today’s RRMS patient.

Wyoming MI. March 27 2008.

387. Guest Speaker: A discussion surrounding a treatment for today’s RRMS patient. Grand

Rapids MI. March 27 2008.

388. Guest Speaker: A discussion surrounding a treatment for today’s RRMS patient.

Wyoming MI. March 28 2008.

389. Guest Speaker: Evidenze cliniche. Updates in Clinical Neurology. Instituto Filosofico

Asoisianum Gallarte XVII Riunione Annuale. Gallarte Italy. April 4 2008.

390. Guest Speaker: Bone marrow-derived stem cells and multiple sclerosis. National

Institutes of Health Symposium: Challenges & Promise of Cell-Based Therapies.

Bethesda MD. May 6 2008.

391. Lecturer: A sea change in MS treatment: The potential of small molecules. Satellite

Symposium at The Consortium of Multiple Sclerosis Clinics 2008. Denver CO. May 30

2008.

392. Guest Speaker: Treatment for today’s RRMS patient. Cornell University. New York

NY. July 9 2008.

393. Guest Speaker: Treatment for today’s RRMS patient. Canlis. Seattle WA. August 12

2008.

394. Guest Speaker: Treatment for today’s RRMS patient Puyallup WA. August 13 2008.

395. Guest Speaker: Clinical considerations in balancing RRMS therapy. El Gaucho

Restaurant. Portland OR. August 13 2008.

396. Guest Speaker: Discussion surrounding a treatment for today’s RRMS patient. Overlake

Neurology. Bellevue WA. August 13 2008.

397. Guest Speaker: Primary progressive multiple sclerosis: What can we do? Multiple

Sclerosis Educational Seminars 2008. Athens Greece. Sept 5-7 2008.

398. Guest Speaker: Progress multiple sclerosis with severe disability (EDSS >7): treatment

decisions. Multiple Sclerosis Educational Seminars 2008. Athens Greece. Sept 5-7

2008.


399. Guest Speaker: Review of Rebif long-term data: Benefit-to-risk profile. Maximizing

Benefits, Minimizing Risks Through All Stages of MS. Geneva Switzerland. September

8 2008.

400. Lecturer: Management of experimental therapies: The compassionate use. 10th

International MS Nurse Workshop. WCTRIMS. Montréal QC. September 16 2008.

401. Lecturer: A decade of experience with Interferons in MS. Satellite Symposium –

Improving MS Treatments. WCTRIMS. Montréal QC. September 18 2008.

402. Lecturer & Chair: Contemporary approaches to MS management. Satellite Symposium –

Montréal QC. September 17 2008.

403. Guest Speaker: Understanding disease progression in MS. MS Society Progressive

Talks. Halifax NS. October 4 2008.

404. Guest Speaker: Understanding disease progression in MS. MS Society Progressive

Talks. London ON. October 5 2008.

405. Guest Speaker: Early intervention in patients with suspected MS. University of Texas

Southwestern MS Center. Houston TX. October 29 2008.

406. Grand Rounds: Early intervention in patients with suspected MS. University of Texas

Health Science Center. Houston TX. October 31 2008.

407. Guest Speaker: BENEFIT: 5-Year Results. Vermont National Country Club. So.

Burlington VT. April 15 2009.

408. Chair: La SEP débutante: actualités. Neurologies Revue Pluridisciplinaire en Neurologie.

Paris France. December 17 2008.

409. Grand Rounds: The rationale for very early treatment in MS. Baystate Medical Center.

Springfield MA. March 4 2009.

410. Guest Speaker: The rationale for very early treatment in MS. Springfield MA. March 4

2009.

411. Guest Speaker: The rationale for very early treatment in MS. Lenox MA. March 4

2009.

412. Guest Speaker: An update on MS research and clinical trials – BMT and basic stem cell

research. Foundation Neurology. Burlington VT. March 5 2009.

413. Guest Speaker: Round Table: The rationale for very early treatment in MS. New

Hampshire Multiple Sclerosis Case Presentation Dinner. Centennial Inn, Concord NH.

March 5 2009.


414. Guest Speaker: The rationale for very early treatment in MS. Whidden Memorial

Hospital. Concord NH. March 6 2009.

415. Guest Speaker: Multiple sclerosis: Translating Pathophysiology into clinical practice.

Session: Treatment Individualization: Tailoring treatment to suit the individual. March

14 2009.

416. Guest Speaker: News in Early Disabilities in MS. Marseille, France. March 21 2009.

417. Guest Speaker: Therapy of MS. 5th Dubrovnik International Conference on Multiple

Sclerosis. Dubrovnik. May 5 2009.

418. Chair: Mechanisms of Tissue Injury. 5th Dubrovnik International Conference on

Multiple Sclerosis. Dubrovnik. May 5 2009.

419. Guest Speaker: Differential diagnosis of MS. Severance Hospital. Seoul Korea. July 10

2009.

420. Guest Speaker: Treatment optimization in multiple sclerosis. Korean Study Group for

Multiple Sclerosis. Seoul Korea. July 11 2009.

421. Guest Speaker: Rescue therapies in MS. Korean Study Group for Multiple Sclerosis.

Seoul Korea. July 11 2009.

422. Guest Speaker: Grand Rounds: Stem Cell Research in Multiple Sclerosis. Lahey Clinic

Medical Center, Lexington MA. Sep 24 2009.

423. Guest Speaker: Stem Cell Research in Multiple Sclerosis. Taboo Resort, Gravenhurst,

Muskoka ON. Oct 3 2009.

424. Guest Speaker: Use of haematopoietic stem cells for the treatment of MS. Kitchener

Waterloo District MS Society. Oct 8 2009.

425. Guest Speaker: Optimizing treatment in multiple sclerosis. EMD Serono Web Event.

Windsor ON. Oct 14 2009.

426. Guest Speaker: The evolution of treatment for MS: Current & future approaches. World

Congress of Neurology. Bangkok Thailand. Oct 27 2009.

427. Guest Speaker: Molecular target therapy in demyelinating disease. World Congress of

Neurology. Bangkok Thailand. Oct 27 2009.

428. Guest Speaker: Stem cell in neurology. 50th Anniversary Academic Conference.

Northern Neuroscience Center, Chiang Mai University, Chiang Mai Thailand. Nov 2

2009.


429. Guest Speaker: Drug treatment of MS: The current situation and what the future holds.

MS Trust Annual Conference. Warwickshire UK. Nov 9 2009.

430. Guest Speaker: How to evaluate the treatment response. CHARCOT. Lisbon Portugal.

Nov 13 2009.

431. Guest Speaker: MS treatment and clinical trials update. MS Society Ottawa Chapter.

Nov 24 2009.

432. Guest Speaker: Basis of Treatment Selection: Treatment of Progressive Forms of MS

New Insight in MS Management, Mexico City Mexico. Nov 27 2009.

433. Guest Speaker: Treatment Optimization in Practice: Responders and Non-Responders

New Insight in MS Management, Mexico City Mexico. Nov 28 2009.

433. Guest Speaker: Liberation Treatment for MS: What is it and why is it so controversial?

Ottawa ON. Feb 9 2010.

434. Guest Speaker: Optimizing Treatment in MS. Bish Restaurant. Halifax NS. Feb 23

2010.

435. Neuroscience Rounds: BMT & Stem Cell Research in MS. QE II Hospital. Halifax NS.

Feb 24 2010.

436. Guest Speaker: 9th Annual Practicum on Neurology: Towards a New Treatment Era.

Stem Cells Transplant in MS. Montréal QC. Mar 27 2010.

437. Plenary Session: 9th Annual Practicum on Neurology: Towards a New Treatment Era.

Debate in MS and Hot Topics in MS. Montréal QC. Mar 27 2010.

438. Guest Speaker: MS Nurses National Consultation Meeting. Fingolimod in MS: Clinical

Trial Results. Montréal QC. Mar 27 2010.

439. Guest Speaker: Optimizing Treatment in MS. Moncton NB. Apr 1 2010.

440. Guest Speaker: Optimizing Treatment in MS. Fredericton NB. Apr 1 2010.

441. Medical Grand Rounds: Multiple Sclerosis: A treatable neurological condition.

Department of Medicine, U of Ottawa. Apr 7 2010.

442. Neuroscience Rounds: The cure lies in all of us. The Ottawa Hospital Civic Campus.

Apr 9 2010.


443. Guest Speaker: The use of BMT in MS: Patient selection and neurological outcomes.

EndMS Research and Training and Network. Montréal QC. Apr 30 2010.

444. Guest Speaker: Mesenchymal stem cell transplantation in MS (the CMSC Lecture).

BCTRIMS. Porto Alegre, Brazil. May 6 2010.

445. Guest Speaker: Bayer Symposium: Cognitive impairment in MS: Time is Brain.

BCTRIMS. Porto Alegre, Brazil. May 7 2010.

446. CME Event: Bayer: Diagnosis, treatment and followup: Update in Multiple Sclerosis.

Ottawa ON. May 11 2010.

447. Grand Rounds: Optimizing treatment for MS. Jewish General Hospital. Montréal QC.

May 18 2010.

448. Guest Speaker: New treatments for Multiple Sclerosis with bone marrow transplants and

Teriflunomide. 5th Annual Mini-Symposium on Multiple Sclerosis. Minneapolis MN.

May 20 2010.

449. Guest Speaker: New therapeutic algorithms. Top Seminars in Multiple Sclerosis.

Sorrento Italy. May 28 2010.

450. Meet the Expert: Teriflunomide. Top Seminars in Multiple Sclerosis. Sorrento Italy.

May 28 2010.

451. Guest Speaker: Cladribine Tablets – Data from the Pivotal CLARITY Trial. EMD

Serono MS Franchise Nurse Advisory Board. CMSC. San Antonio TX. June 2010.

452. Platform Presentation: Oral Teriflunomide added to interferon-beta in relapsing multiple

sclerosis patients: 1-year safety and efficacy results. ACTRIMS. San Antonio TX. June

2010.

453. Guest Speaker: Update on new therapeutics and clinical trials. CNSF. Québec QC .

June 2010.

454. Chair: MS Session. CNSF. Québec QC. June 2010.

455. Guest Speaker: Understanding disability in MS: Evolving measures in clinical practice.

Beckta Dining & Wine. Ottawa ON. Aug 10 2010.

456. Grand Rounds: Are bone marrow transplants the answer? St. Louis University. St.

Louis MI. Sept 24 2010.

457. Keynote Speaker: John L. Trotter Research Program. Are bone marrow transplants the

answer? NMSS. St. Louis MI. Sept 23 2010.


458. Grand Rounds: Are bone marrow transplants the answer? Washington University. St.

Louis MI. Sept 24 2010.

459. Guest Speaker: Satellite Symposium: Multiple Sclerosis and Movement Disorders:

How can we improve therapeutic approaches to meet patient needs? Multiple Sclerosis:

early treatment and maintenance to maximize long-term therapeutic benefit with disease-

modifying drugs. EFNS. Geneva. Sept 26 2010.

460. Guest Speaker: Optimizing treatment in MS. Bliss Fine Foods. Saskatoon SK. Sept 30

2010.

461. Neuroscience Grand Rounds Speaker: Treatment of multiple sclerosis: Past, present and

future. Saskatoon SK. Oct 1 2010.

462. Stanley F. Waterman Multiple Sclerosis Research Lecture Series: Stem cell based

therapies: The promise and challenges of treating MS. New England MS Society

Chapter of the NMSS. Marlborough MA. October 23 2010.

463. Guest Speaker: Should any treatment decisions be made based on MRI, such as change

from IFN to DMD, even if there is no clinical evidence of disease activity? 4th World

Congress on Controversies in Neurology (CONy). Barcelona Spain. Oct 30 2010.

464. Guest Speaker: How to treat a highly active RRMS patient after one disease modifying

drug (DMD) has failed. 4th World Congress on Controversies in Neurology (CONy).

Barcelona Spain. Oct 30 2010.

465. Guest Speaker: SSIF Conference on Multiple Sclerosis: Future treatments and goals.

New challenges in treatment: benefits and risk: The importance of patient monitoring

during new treatments. Vienna Austria. November 13 2010.

466. Guest Speaker: NOVARTIS MS/Parkinson’s: A Canadian Perspective. ECTRIMS

Update. Ottawa ON. Nov 16 2010.

467. Guest Speaker: Assessing and defining sub-optimal treatment responses in MS: A risk-

to-benefit discussion of therapies. Hamilton ON. Nov 25 2010.

468. Neurology Rounds: MS 2010: Year in Review – Key Developments in MS Care.

Trillium Health Centre. Mississauga ON. Nov 26 2010.

469. Presenter: Treatment of primary and secondary progressive MS. 2010 Meeting of the

European Charcot Foundation. Rome Italy. Dec 2 2010.

470. Presenter: Exploring the mode of action of cladribine. 2010 Meeting of the European

Charcot Foundation. Rome Italy. Dec 3 2010.


471. Keynote Speaker: endMS Conference. Stem Cells. Whistler BC. Dec 6-9 2010.

472. Guest Speaker: National Congress: Les Rencontres de Neurologies. Première ligne de

traitement et optimisation du bénéfice thérapeutique au long cours. Paris France. Dec 14

2010.

473. Guest Speaker: Bayer WebEx. MS 2011: A new perspective in treatment of MS.

Montréal QC. Jan 25 2011.

474. Faculty Speaker: QUINTILES CME Initiative: Clinical management of multiple

sclerosis: Optimizing function and improving quality of life in the post-treatment world.

The Palm Downtown. Los Angeles CA. Feb 1 2011.



Harris’. San Francisco CA. Feb 2 2011.



Donovan’s Steak House. Phoenix AZ. Feb 3 2011.

477. Guest Speaker: The potential use of haematopoietic stem cells for the treatment of MS.

University of Toronto Neuroinflammation Symposium. Toronto ON. Feb 4 2011.

478. Faculty Presenter: CME Multiple Sclerosis Virtual Grand Rounds. Selection of

treatment: Choosing treatment after a diagnosis of relapsing MS. Cleveland Clinic.

March 2011-March 2012.

479. Guest Speaker: New emerging treatments in MS. ISNI 2011. Annual Israel Society of

Neuroimmunology Conference. April 29 2011.

480. Guest Speaker: Managing the daily symptoms of MS. Bayer GP CME Event. Mamma

Teresa’s Restaurant. Ottawa ON. May 2 2011.

481. Guest Speaker: Treatment individualization: Different patients, different needs.

OPTIMIST Meeting. St. Petersburg Russia. May 2011.

482. Guest Speaker: Pain and multiple sclerosis. MS Society of Canada Ottawa Chapter.

Ottawa ON. May 10 2011.

483. Keynote Lecturer: MS treatment: Updates-Early intervention and refractory cases

management. Hong Kong. May 14 2011.

484. Keynote Lecturer: MS treatment updates – Future outlooks. Hong Kong. May 14 2011.


485. Guest Speaker: No disease activity: Where and how has this been used? What can

constitute no activity? How to weight different domains of activity. International

Advisory Committee on Clinical Trials in MS. Washington DC. May 19 2011.

Lecturer: Long term impact of current therapies for MS. CMSC Annual Meeting.

Montréal QC. June 1 2011.

486. Lecturer: Making an accurate diagnosis in multiple sclerosis: The utility of CSF in

diagnosing MS. CMSC Annual Meeting. Montréal QC. June 1 2011.

487. Guest Speaker: The potential use of bone marrow-derived stem cells as a treatment for

MS. UK MS Society. London UK. June 23 2011.

488. Commentator: Debate: Should MS be treated by escalation or induction therapy? Part

of MS Session: Therapies of Multiple Sclerosis. 5th World Congress on Controversies in

Neurology. Beijing China. Oct 14 2011.

489. Presenter: Debate: Biomarkers can be useful for diagnosis and prognosis in MS. Part of

MS Session: Therapies of Multiple Sclerosis. 5th World Congress on Controversies in

Neurology. Beijing China Oct 14 2011.

490. Lecturer: Neurology Grand Rounds: Bone marrow transplantation in multiple sclerosis.

UMDNJ, New Brunswick NJ. Nov 2 2011.

491. Guest Speaker: Managing the new and emerging therapies for multiple sclerosis. MS

Care. Boston MA. Nov 10 2011.

Guest Speaker: Seizing the window of opportunity: Treating early for long term safety

and efficacy. MS Symposium Egyptian MS Society. Cairo Egypt. Nov 24 2011.

492. Lecturer: Individualized treatment from the first demyelinating event. European Charcot

Foundation Symposium. Dec 2011.

493. Guest Speaker: Review of DMS’s and their role in treating CIS. Regional MEA CIS

Advisory Board Meeting on New insights in diagnosis and management. Raffles Hotel.

Dubai UAE. March 2012.

494. Guest Speaker: Impact of adherence on outcomes in MS: Data and Ideas. Regional

MEA CIS Advisory Board Meeting on New insights in diagnosis and management.

Raffles Hotel. Dubai UAE. March 2012.

495. Guest Speaker: Case studies in the treatment of CIS. Regional MEA CIS Advisory

Board Meeting on New insights in diagnosis and management. Raffles Hotel Dubai UAE.

March 2012.


496. Guest Speaker: Interferon-beta: An effective early treatment with long-term benefits.

Grand Hyatt Hotel. Dubai UAE. March 2012.


Radisson Blu Diplomat Hotel. Bahrain. March 2012.


Jordan Sheraton Amman. Amman Jordan. March 2012.

499. Lecturer: Teriflunomide. CONy MS Scientific Program. Vienna Austria. March 9

2012.

500. Guest Speaker: Theoretical considerations for future treatments. CMSC: Evolving

concepts in the management on multiple sclerosis. Coral Gables FL. March 24 2012.

501. Guest Speaker: Treatment optimization in MS: Dawn of a new era. Hot Topics in

Neurology. Toronto ON. April 14 2012.

502. Guest Speaker: From early first line treatment to long-term outcomes: Emerging data

from BENEFIT 5 and BENEFIT 8. Betaferon Council Meeting. Warsaw Poland. May 5

2012.

503. Facilitator: Workshop: Communication of early and sustained stabilization of MS and

prolonged life expectancy with Betaferon. Warsaw Poland. May 5 2012.

504. Guest Speaker: Personalized therapy: What findings may guide treatment decisions?

Warsaw Poland. May 5 2012.

505. Guest Speaker: Novel therapies in multiple sclerosis: A critical analysis. What’s new in

multiple sclerosis? Autoimmunity 2012 Congress. Granada Spain. May 10 2012.

506. Case Study Presenter: Treatment failure due to lack of adherence. SSIF CME Annual

Meeting in Multiple Sclerosis. Valencia Spain. May 18 2012.

507. Lecturer: Assessment of treatment response. SSIF CME Annual Meeting in Multiple

Sclerosis. Valencia Spain. May 19 2012.

508. Guest Speaker: Progressive MS: Innovative Therapies: Oral therapies. Top Seminars in

Multiple Sclerosis. Baveno Italy. May 25 2012.

509. Meet the Expert: Progressive MS: Innovative Therapies: Teriflunomide. Top Seminars

in Multiple Sclerosis. Baveno Italy. May 25 2012.

510. Lecturer: Knowledge in bloom: The past, present and future of MS care. Canadian

Association of Neuroscience Nurses. Ottawa ON. June 7 2012.


511. Guest Speaker: MS Society: Multiple Sclerosis Update 2012. Thunder Bay ON. June

20 2012.

512. Guest Speaker: Stem Cells Discussion. Sydney Australia. Aug 16 2012.

513. Guest Speaker: Clinical experience in MS. Melbourne Australia. Aug 16 2012.

514. Guest Speaker: What to expect with teriflunomide, side effects and how to manage.

Nurse Advisory Board Meeting. Melbourne Australia. Aug 17 2012.

515. Guest Speaker: Clinical experience in MS. Sydney Australia. Aug 17 2012.

516. Guest Speaker: Emerging therapies in MS. Sydney Australia. Aug 18 2012.

517. Panel Member: CCSVI can cure MS. Ask the Experts Panel. Sydney Australia. Aug 18

2012.

518. Guest Speaker: Emerging therapies in multiple sclerosis. GENZYME Neurology

Clinical Weekend 2012. Darling Harbour Sydney Australia. Aug 18 2012.

519. Guest Speaker: Stem cell transplantation in MS. GENZYME Neurology Clinical

Weekend 2012. Darling Harbour Sydney Australia. Aug 19 2012.

520. Guest Speaker: Treatment optimization in MS. GENZYME Neurology Clinical

Weekend 2012. Darling Harbour Sydney Australia. Aug 19 2012.

521. Guest Speaker: Mesenchymal stem cells in the treatment of MS. Quebec City QC. Sept

7 2012.

522. Guest Speaker: Regimen of fingolimod treatment. Mitsubishi Round Table Discussion.

Oct 11 2012.

523. Guest Speaker: Optimization of MS treatment outcomes. Merck Serono MS

Symposium. Cairo Egypt. Oct 18 2012.

524. Guest Speaker: MS treatment: The new oral alternative. Mexican Academy of

Neurology. Cancun Mexico. Nov 2012.

525. Discussion Panel Member: Early treatment vs late treatment of MS. MS Update

Program: The Latest in Research & Treatment in Multiple Sclerosis. MNI. Montréal

QC. Nov 16 2012.

526. Guest Speaker: Clinical considerations in the use of fingolimod: First dose, monitoring

and treatment optimization. NOVARTIS MS Nurses National Advisory Board Meeting.

Toronto ON. Dec 8 2012.


527. Guest Speaker: Managing aggressive MS. TEVA Practicum in Neurology 2013.

Chicago IL. Feb 21 2013.

528. Guest Speaker: 2013 Annual Meeting of Multiple Sclerosis: Oral immunomodulator in

multiple sclerosis: From innovative science to clinical practice. Bangkok Thailand. Mar

6 2013.

529. Grand Rounds Speaker: The changing landscape for treatment of RRMS. Grand

Rounds. UMass. Boston MA. Mar 12 2013.

530. Grand Rounds Speaker: Treatment optimization in RRMS. Grand Rounds. Lahey

Clinic. Burlington MA. Mar 14 2013.

531. Guest Speaker: Clinical management of MS: Are we getting confused with treatment

alternatives available today? Merck Serono Continuous Health Education Program.

April 11 2013.

532. Debate Host: Does interferon therapy delay or prevent the development secondary

progressive disease? CONy. Istanbul Turkey. Apr 12 2013.

533. Evolving MS treatment options: Quo Vadis? Meet the Experts Session. CONy. Istanbul

Turkey. Apr 13 2013.

534. Chair: Meet the experts: Outcome measures in multiple sclerosis clinical studies; origin

of MS: inflammatory or degenerative? Genetic or environmental? CONy. Istanbul

Turkey. Apr 13 2013.

535. Section Head: Debate: New players in MS: Teriflunomide. CONy. Istanbul Turkey.

Apr 13 2013.

536. Guest Speaker: Multiple Sclerosis. Internal Medicine Academic Half Day Ottawa

Hospital Civic Campus. Wed Apr 17 2013.

537. Guest Speaker: Clinical applications of cellular therapy. Workshop on Transplant and

Cellular Therapy for Autoimmune Diseasts. Froedtert & Medical college of Wisconsin

Clinical Cancer Center. Milwaukee WI. Apr 20 2013.

538. Guest Speaker: Case studies in treating MS. STEP Symposium. Budapest Hungary.

Apr 27 2013.

539. Guest Speaker: Special Issues in Women: Multiple sclerosis in pregnancy. 1st Kuwait

North-American Neurology Conference. Kuwait. Apr 28 2013.

540. Guest Speaker: Multiple Sclerosis & Neuro-Ophthalmology: Practical approach to MS

mimickers. 1st Kuwait North-American Neurology Conference. Kuwait. Apr 28 2013.


541. Guest Speaker: Multiple Sclerosis & Neuro-Ophthalmology: Diagnosis of MS –

Changes in criteria. 1st Kuwait North-American Neurology Conference. Kuwait. Apr 28

2013.

542. Guest Speaker: Multiple Sclerosis & Neuro-Ophthalmology: Emerging oral therapies in

MS. 1st Kuwait North-American Neurology Conference. Kuwait. Apr 28 2013.

543. Speaker: Symposia: Stem Cell Therapy for Multiple Sclerosis. Mesenchymal stem cells

as treatment for MS. CMSC. May 30 2013. Orlando FL.

544. Chair: ACTRIMS Program: Safety of new MS therapies. June 1 2013. Orlando FL.

545. Grand Rounds Speaker: Myelo-ablation and ASCT as a treatment for highly aggressive

MS. UCSF. June 7 2013.

546. Grand Rounds. The role of Teriflunomide therapy for relapsing forms of MS. U Cal San

Francisco. June 7 2013.

547. Speaker: Symposia: Defining goals at the start of treatment. ENS. Barcelona Spain.

June 9 2013.

548. Guest Speaker: Canadian treatment optimization recommendations in MS. Interactive

base-cased program. Ottawa ON. June 11 2013.

549. Changes in the multiple sclerosis landscape. Wayne State University. Detroit MI. June

18 2013.

550. Grand Rounds: Teriflunomide, a once-daily oral therapy for relapsing forms of MS.

Riverhills Neurology. Cincinnati OH. Aug 16 2013.

551. Current and future treatments in MS. MS in Focus Conference. Toronto ON. Oct 24

2013.

552. Benefits of early MS treatment. Canadian MR Imaging in MS Learning Program.

Ottawa ON. Oct 28 2013.

553. Chronic Disase Cluster: Multiple Sclerosis. Group for Research in Inflammation and

Pathogenesis (GRIP). Ottawa ON. Nov 1 2013.

554. Grand Rounds Speaker: Myeloablation & ASCT: A treatment for aggressive multiple

sclerosis. Tisch Multiple Sclerosis Research Center of New York. New York NY. Nov

7 2013.

555. Forensic analysis of the new orals for RRMS. Restaurant le Montego. Quebec City QC.

Nov 13 2013.


556. Induction vs escalation of treatment. MS Exchange. Montréal QC. Nov 15 2013.

557. Guest Speaker: Overall efficacy: Clinical benefit and Gilenya’s influence on disease

progression (relapses, MRI, disability progression and brain atrophy). Spanish Society of

Neurology National Congress. Barcelona Spain. Nov 20 2013.

558. When to start, when to shift, when to stop. European Charcot Foundation. Nov 29 2013.

Baveno Italy.

559. MS Pathophysiology. Residents’ ½ day. The Ottawa Hospital. December 3 2013.

560. Role for immunoablation and AHSCT in MS. endMS Conference. St Sauveur QC. Dec

13 2013.

561. Invited Lecturer: New oral treatments for MS. ISNI 2013. Mitzpe Ramon Israel. Dec

19 2013.

562. Moderator: New oral treatments for MS. ISNI 2013. Mitzpe Ramon Israel. Dec 20

2013.

563. Disease-modifying treatments in multiple sclerosis. Residents ½ day. The Ottawa

Hospital Civic Campus. Jan 14 2014.

564. Neuroscience Rounds: An oral debate on treating MS. The Ottawa Hospital Civic

Campus. Jan 17 2014.

565. Invited Speaker: Current disease modifying drugs: Evaluating the evidence. Central

Canada MS Nurse Consultancy Meeting. Ottawa ON. Jan 31 2014.

566. Invited Speaker: Where clinical trial and clinical practice meet: The changing landscape

in the treatment of multiple sclerosis. Ottawa ON. Feb 5 2014.

567. Invited Speaker: Treatment of MS: Starting and staying on the right track. Neurology

Update Mumbai 2014. Mumbai India. Feb 22 2014.

568. Invited Speaker: Multiple sclerosis: The road ahead. Neurology Update Mumbai 2014.

Mumbai India. Feb 22 2014.

569. Invited Speaker: Patient & Caregivers Session: MS. Multiple sclerosis: The road ahead.

Neurology Update Mumbai 2014. Mumbai India. Feb 22 2014.

570. Guest Speaker: Disease modifying medications for multiple sclerosis: Do the benefits

outweigh the risks? Health Canada, Marketed Health Products Directorate. Ottawa ON.

Mar 5 2014.


571. Guest Speaker: Evolving management of MS with oral therapies: New insights and new

directions. 19th Taiwan Neurological Society Congress. Taipei Taiwan. Apr 12 2014.

572. Debate Host: MS/Dementia/Movement Disorders, Cell based therapies hold particular

promise for treating MS. CONy. Berlin Germany. May 8 2014.

573. Guest Speaker: MS. Session on Ocrelizumab. CONy. Berlin Germany. May 8 2014.

574. Debate Coordinator: Can we aim for a disease-free status with contemporary MS

therapies. CONy. Berlin Germany. May 10 2014.

575. Guest Speaker: Where clinical trial and clinical practice meet: The changing landscape

in the treatment of MS. Montréal QC. May 13 2014.

576. Guest Speaker: Importance of early treatment in MS. Merck Serono Symposia:

Optimizarea Management – Ului Terapeutic in Scleroza Multipla. Bucharest Romania.

May 16 2014.

577. Guest Speaker: Clinical MS Management Aspects: Defining the goals of MS therapies:

The Canadian approach. ISS Bayer Symposium. Munich Germany. May 24 2014.

578. Guest Speaker: Novel endpoints and assessments. Connecting with MS patients:

Engagement through innovation: A Merck Serono Satellite Symposium. Istanbul Turkey.

June 2 2014.

579. Guest Speaker: Living with MS. Hilton St. Louis Frontenac. St. Louis MO. June 25

2014.

580. Grand Rounds "Update on new therapies for RRMS: Focus on Teriflunomide". Jewish

General Hospital, Montreal QC. Sept 23 2014.

581. Guest Speaker: The TEMSO Study. University of North Carolina. Chapel Hill, NC.

Oct 8 2014.

582. Neurosicence Grand Rounds: “Aggressive Disease Warrants Aggressive Treatment:

Immunoablation and Autologous Haematopoietic Stem Cell Treatment for MS”.

University of Vermont. Burlington, VT. Oct 17 2014.

583. Guest Speaker: “The Evolving MS Treatment goal: No Evidence of Disease Activity

(NEDA)”. Marriott Hotel. Montreal, QC. Oct 18 2014.

584. Guest Plenary Speaker: MS Treatment Sequencing. Ontario Neuro Summit. Toronto,

ON. Oct 25 2014.

585. Guest Plenary Speaker: Secondary progressive MS: What have we learned where should

we go? MS Xchange Conference. Montreal QC. November 7 2014.


586. Guest Speaker/Patient Program: “Living with MS-An informative event for people living

With MS and their care partners”. Antonella Ristorante. Santa Ana, CA. Nov 11 2014.

587. Guest Speaker: “Betaseron to Stem Cells”. MS Cure Fund Fall Health Fair. Boston, MA

Nov 22 2014.

588. Guest Speaker: Patient Education Program. “Living with MS- An informative event for

people living with MS and their care partners. Boston, MA. Nov 23 2014.

589. Guest Speaker: “Choosing Among a Growing Array of Treatment for Relapsing MS".

On behalf of EMD Seronon. Cambridge, ON Nov 24 2014.

590. Keynote Speaker: On behalf of the MS Society of Canada: an in person and online

interactive meeting about Relapsing Remitting MS. Ottawa, ON. Dec 1 2014.

591. Invited Speaker: “Aggressive Treatment for Multiple Sclerosis Rationale and Approach”.

Wayne State University 10th Annual MS Symposium. Birmingham, MI. Dec 6 2014.

592. Guest Speaker: “Choosing among a growing array of MS treatments for RRMS”.

Toronto, ON. Dec 13 2014.

593. Guest Speaker: CME titled “ECTRIMS/ACTRIMS 2014 New Research and Updates in

Multiple Sclerosis Presented in Boston, MA on Sept 10-13, 2014”. Bekta Dining and

Wine, Ottawa ON. January 26, 2015.

594. Guest Speaker: “MS Duels” Orals vs Injectables in MS; is this the start of new platform

therapies or just a novelty? Montreal, QC. February 5, 2015.

595. Organizer and Speaker: CME titled “MS for the general Practitioner-what you should

know”. Ottawa Conference and Event Center. Ottawa, ON. February 27, 2015.

596. Debate Host: “Is the measurement of brain atrophy the most suitale surrogate marker of

MS progression”? CONy. Budapest, Hungary. March 27 2015.

597. Debate Host: “Discontinuation of disease-modifying therapies in patients with long-term

stable disease is safe and appropriate”. CONy. Budapest, Hungary. March 27 2015.

598. Neuroscience Grand Rounds: Disease activity free, No evidence of disease activity-

NEDA and RIO scores in MS. Hôpital Régional De Saint-Jérôme, Saint-Jérôme, QC.

May 6 2015.

599. Plenary Speaker: “Treatment Sequencing in MS”. Practicum in Neurology 2015,

Montreal, QC. May 23 2015.


600. Keynote Speaker: On behalf of the MS Society of Canada. MS Research Town Hall

This by-phone and live-streamed audio event featured prominent MS researchers,

including Dr. Mark Freedman, Dr. Helen Genova and Dr. Ruth Ann Marrie, in

conversation with the CBC Radio’s Bob McDonald (Quirks and Quarks). May 27, 2015.

https://soundcloud.com/ms-society-canada/the-2015-ms-research-town-hall

601. Dalhousie University Neuroscience Rounds: "Stem Cell Therapy in MS". Halifax, NS.

June 17, 2015.

602. Neuroscience Grand Rounds Speaker: “Choosing Among a Growing Array of

Treatments for Relapsing MS”. Royal University Hospital and University of

Saskatchewan. Saskatoon, SK. June 19 2015.

603. “Faces of MS’’. Webinar presented to BC & Alberta’s MS nurses on behalf of TEVA

Canada. June 26, 2015.

604. Teaching Symposium: “Stem cells and MS”. Excemed Preceptorship on advances in

Multiple Sclerosis and Neuro-Myelits Optica. Vancouver, BC. July 6, 2015.

605. PeerVoice: An online venue designed to fill the unmet needs of the medical community

by reporting information pertaining to clinically relevant advances and developments in

the science and practice of medicine. “Progressive Multiple Sclerosis: Is there Light at

the End of the Tunnel”? This activity is supported by educational funding from Biogen

International GmbH

http://www.peervoice.com/progressive-multiple-sclerosis-there-light-end-

tunnel?pres=1&person_id=104041409&specialty=94&ProfID=12#featured-

presentations

605. Invited Speaker: “Treatment Strategies in Clinical Practice; When and How Should MS

Treatment be Switched or Escalated; Clinical Experience Sharing”. New Frontiers in MS

on behalf of Merck Istanbul, Turkey. September 4-5, 2015.

606. New directions of MS therapy: Assessing treatment response for the purposes of

optimizing management of relapsing MS.

RUCTRIMS. Yaroslavl, Russia. September 9-13, 2015.

607. Invited Guest Speaker: Online virtual CME Summit entitled “GLOBAL

PERSPECTIVES IN MULTIPLE SCLEROSIS MANAGEMENT FROM

ECTRIMS 2015” which was provided by the Albert Einstein College of Medicine of

Yeshiva University and Montefiore Medical Center, Center for Continuing Medical

Education and PlatformQ Health Education. Contributing talk was titled “Updates in MS

Management: Clinical Impact of Data from ECTRIMS 2015”. October 16, 2015.

608. Upstate Medical University Medical Grand Rounds, Syracuse, NY. “Identifying and

Treating Aggressive MS”. October 28, 2015.

https://soundcloud.com/ms-society-canada/the-2015-ms-research-town-hall

http://www.peervoice.com/progressive-multiple-sclerosis-there-light-end-tunnel?pres=1&person_id=104041409&specialty=94&ProfID=12#featured-presentations




609. Keynote Speaker: MS Connect ’15 on behalf of the MS Society of Canada. “Stem Cells

as a Potential for Multiple Sclerosis”. Edmonton, Alberta. October 30, 2015.

610. Guest Speaker: Patient Education Program on behalf of Genzyme. “Listen, Learn, Live

life with MS”. Montgomery Inn, Cincinnati, OH. November 3, 2015.

611. Panel Discussion: MS Xchange. “Panel discussion: New issues in MS”. Montreal

Neurological Institue and Hospital, Montreal, QC. November 6, 2015.

612. Invited Speaker: 4th Hong Kong Neurological Congress cum 28th Annual Scientific

Meeting of the Hong Kong Neurological Society. "Emerging insights in MS : Re-

evaluation of treatment algorithm” . Honk Kong, China. November 14, 2015.

613. Invited Speaker: CME: "Emerging insights in MS : Re-evaluation of treatment

algorithm". Kuala Lumpur Hospital, Malaysia. November 16, 2015.

614. Invited Speaker: National University Hospital, Neurology Department CME:

"Changing Treatment Paradigm: Rise of Oral Therapeutics in MS". Singapore, Asia.

November 17, 2015.

615. Neuroscience Academic Half Day: “Novel MS medications and their application for MS patients”. Ottawa, ON. January 19, 2016.

616. Neuroscience Grand Rounds Speaker: “Factors influencing long-term outcomes in

relapsing–remitting MS: PRISMS-15”. Hôpital Régional De Saint-Jérôme, Saint-Jérôme,

QC. February 12, 2016.

617. Debate Host: Anti B cell or non specific anti B+T therapy. CONy. Lisbon, Portugal.

March 18, 2016.

618. Invited Speaker: Advances in MS Management. Bayer Vision Academny Annual

Meeting. Barcelona, Spain. March 12, 2016.

619. Debate Speaker: My MRI worsened but I didn’t. Should I change my disease-modifying

treatment? Yes. CONy. Lisbon, Portugal. March 18, 2016.

620. Invited Speaker: Optimal Treatment Approach in MS & Teriflunomide. Seoul, Korea.

April 6, 2016.

621. Invited Speaker: “Changing Treatment Paradigm: Rise of Oral Therapeutics in MS”.

Taipei, Taiwan. April 7, 2016.

622. Invited Speaker: Lunch Symposium: “Emerging Insights in MS: Re-evaluation of

treatment algorithm”. Taiwan Neurology Society Annual Meeting. Taipei, Taiwan.

April 10, 2016.


623. Invited Speaker: "Defining the goals of MS therapy: Choosing the right medicine for the

right patient". Turkey. May 3-5, 2016.

624. Guest Speaker: What to do when nothing seems to work: Managing aggressive MS.

CNSF. Québec QC . June 23 2016

625. Internal Medicine Grand Rounds Guest Speaker: “Identifying and Treating Aggressive

MS”. University of Manitoba. Winnipeg, Manitoba. September 20, 2016

626. Neuroscience Rounds: The emerging landscape for the treatment of MS: Increasingly

complex. Ottawa General Hospital. Ottawa, ON. September 23, 2016

627. Invited Speaker: “Measuring Brain Atrophy as a Surrogate Marker for MS Progression

and the Efficacy of Treatments”. On behalf of Novartis Pharm. 13th International

Congress of Neuroimmunology. Jerusalem. September 28, 2016.

628. Invited Speaker: “Aggressive Immunotherapy with Autologous Hematopoietic Stem Cell

Transplantation in MS”. 13th International Congress of Neuroimmunology. Jerusalem.

September 27, 2016.

629. Invited Speaker: “B Cells in Clinical Practice: Treatment Trials in MS”. On behalf of

Roche Pharmaceuticals. 13th International Congress of Neuroimmunology. Jerusalem.

September 27, 2016.

630. Invited Speaker: “Managing MS Disease Activity in Pregnancy, Pre- and Post”. On

behalf of Sanofi Genzyme Pharm. 13th International Congress of Neuroimmunology.

Jerusalem. September 28, 2016.

631. Invited Speaker: “Immunoablation and autologous haemopoietic stem-cell

transplantation for highly active multiple sclerosis - proposal for a new treatment

algorithm”. 3rd International Symposium on Multiple Sclerosis and Myelin

Disorders. Berlin, Germany. October 8, 2016.

632. Invited Expert: “Train the Trainer”. Full day training session focused on multiple

sclerosis and used to introduce the subject material to a small group of opinion leaders.

These Neurologists will then be asked to lecture to other physicians, increasing

awareness of the benefits of the subject material and initiate discussion on the best use of

these programs in their region. Dubai. UAE. October 15, 2016

633. Invited Speaker: “Ask the Neurologist”. An education forum for patients presented by

the MS Society of Canada. Ottawa, ON November 13, 2016.

634. Invited Speaker: “Are Injectable therapies gone the way of the dodo? ". Jewish

General Hospital, Montreal, QC. Dec 13, 2016


635. Invited Speaker: “The Evolving Landscape in the Treatment of MS: Is there still a role

for injectable therapies?”. On behalf of Merck Belgium. Brussels, Belgium. Dec 20,

2016

636. Invited Speaker: “MS treatment intesnidfication-when and how to treat?” On behalf of

Bayer. Inselspital University of Neurology. DuBern, Switzerland. January 12, 2017

637. Invited Speaker: “Themes on MS: 3 Parallel workshops”. On behalf of Bayer. Dubai,

UAE. January 21, 2017

638. Invited Speaker: “Defining the goals ofMS therapies-The Cnaadaian approach”. On

behalf of Bayer. Dubai, UAE. January 21, 2017

639. Invited Speaker: “Responders vs non-responders”. On behalf of Bayer. Dubai, UAE.

January 21, 2017

638. Teaching Symposium: EXCEMED 19th MS Nurse International Workshop:

Immunosuprssion and PIRT: efficacy, risks and everyday management?

Paris, France. October 24, 2017

639. Teaching Symposium: EXCEMED 'MS Academia & MS Nurse’: “Efficacy and safety

of treatments with pleiotropic and antiproliferative MoA. Paris, France. October 24 2017

640. Teaching Session: EXCEMED “MS management: the value of experience: “Treatmnet

Goals and unmet needs in MS today”. Menactrims. Dubai, UAE. November 23, 2017

641. Invited Speaker: “Stem Cell Transplantation in MS: Where do we stand?” Menactrims 2017. Dubai, UAE. November 25 2017 642. EXCEMED Teaching session IV “How to measure treatment response”. 1st interactive Practice course in MS advanced management. Toronto, Canada. December 7, 2017

Other Activities: Ad Hoc Reviewer: Neurology Experimental and Molecular Pathology Clinical and Investigative Medicine Journal of Neuroimmunology Experimental Cell Research Journal of Neurology Annals of Neurology Canadian Journal of Neurological Sciences Journal of Neurological Sciences Clinical Chemistry UK MS Trust PLOS ONE


Editorial Board: Journal of Neurological Sciences Multiple Sclerosis International Journal of MS Care Multiple Sclerosis International Clinical Investigation Multiple Sclerosis and Demyelinating Disorders Grant Reviewer: Medical Research Council of Canada Multiple Sclerosis Society of Canada Physicians Services Incorporated of Ontario Fonds de la Recherche en Santé du Québec Canadian Institutes of Health Research National Institutes of Health ARSEP (France) Israel Science Foundation Physician Examiner: Medical Council of Canada (1994-1999) GRADUATE STUDENT SUPERVISION: Career Number: 22* Completed: MSc 3 Post-Doctoral Fellows 3 PhD 3 Clinical Research Fellow 13

1. Arianna Sartori – (an elective in Multiple Sclerosis –Sept 1- Dec 31, 2013

2. Reza Vosoughi

3. Hind Alnajashi

4. Fozia Alshamrani

5. Monica Badve

6. Carolina Rush

7. Heather MacLean

8. Francois Emond

9. Mohsen Khoshnam

10. Mohammad Abdoli

11. Roxanna Cruce

12. Maeed Alkathiri

13. Azzeza Aldwaihi Lab fellow 2 1. Darius Matusevicius 2. Petr Murzenok Resident 1 In Progress: MSc 0 PhD 0


Clinical Research Fellow 1 (Maeed Alkathiri) *Partial supervisor for Sameer D’Souza in 1993. TEACHING: McGill University Undergraduate: 1. Microbiology and Immunology 528-466B; "Virology & Immunology of Multiple

Sclerosis"; 1 lecture, February, 1992. (class of 50 students; 2 exam questions, essay type plus marking: total of 6 hours)

2. Microbiology and Immunology 528-466B; “Virology & Immunology of Demyelinating

Diseases”, 2 lectures, February, 1993. (Class size of 50 students; 2 exam questions, essay type each for term and final exam, plus marking: a total of 12 hours)

3. Medical School year III "Link Program" (1987-93). This intensive program involved

teaching groups of students for a block of four weeks, twice per year. During this time, set goals were required to be met. It involved teaching of basic neuroanatomy, physiology and pathology as it pertained to clinical disease as well as the basic and applied clinical skills. In groups of 2, students were evaluated on their basic skills of history and physical examination and at least 2 full case summaries were handed in for marking. Students were also guided into presenting seminars to each other covering specific topics. Two of these were also formally written and marked. The teaching was extensive and involved a minimum of 4-6 hours daily.

Post-Graduate: 1. Family Practice and Medical Residents, Queen Elizabeth Hospital (1990-93). (This

involved variable numbers usually in excess of 25 per year, on a 1:1 basis while I performed in-patient consultations. Total time teaching 3 hours per week)

2. Neurology Resident and Medical Resident clinical teaching (ward service) (1990-93).

(One full month per calendar year. Teaching rounds would usually take up most mornings, with formal seminars twice per week. Total time spent teaching varied from 15-20 hours/week)

University of Ottawa

Undergraduate

1. Neuro Systems Course: 1993-98. (A 1.5 hr lecture covering various neuroimmunological

topics was given to the full medical school class, and notes were prepared covering this

material; this required a total of 6 hours)

2. Neuro Block, Physicians Skill Development: 1993-96. (Two 3 hour sessions with a group of

6 medical students)


3. Immunology Block, Mini-elective program: 1993-94. (Two sessions, each 3-5 hours in a

wet lab, performing clinically relevant neuroimmunological assays)

4. Immunology Block Mini-elective program: 1996-97. (Multiple sessions, each 3-5 hours in a

neuroimmunology diagnostics laboratory)

5. Co-chair, first year medicine Immunology Block. 1997-99 (2 hr lecture plus 40-50 hours of

meetings, planning sessions and preparation, exam writing and marking and review of

comments, criticisms and block chair meetings). Post-Graduate 1. Neurology Resident and Medical Resident clinical teaching (ward service and out-

patient) (1993-). (For two months a year on the ward and one month on the consult service, a variable number of residents, medical students and interns are taught as a group (ward) or 1:1 (consult service) the basics of clinical neurology. Expertise in the area of multiple sclerosis is passed on through 5 hours weekly of out-patient work on a 1:1 basis, usually involving 1 or 2 individuals per clinic. (Two new patients to the clinic are booked weekly specifically for this purpose.) A minimum of 5-7 hours per week are spent teaching when not “on service” and this number increases to 20 hours when “on service”.

2. Neurology Resident Seminars. At least twice per year we are requested to participate in

neurology resident teaching sessions which combine a formal resident review of a topic with our own expertise. (Each session is 3 hours)

3. Ottawa General Hospital, Emergency Medicine Core Curriculum Seminars (1996).

Discussion on management of Stroke in the emergency room. (1 hour) 4. Neurology Resident Journal Club. (1-2 hours) 5. Microbiology & Immunology Journal Club. Every Tuesday morning (except holidays)

for 1 hour. At least 2-3 times per year presentation is required. 6. Immunology Journal Club. Meets every three out of four Tuesdays a month for 1 hour.

Presentation frequency usually once every two months. 7. Guest Lecturer: Recent Advances in Clinical Immunology Graduate Course at University

of Toronto. (1996) Lecture and review of 2-3 selected recent publications. Submission of another paper for discussion on final exam and marking of student exams covering this paper. (Session lasted 3 hours plus required preparation and travel time (12 hours) plus time taken to mark final exams).

8. Advanced Topics in Immunology (MIC 8122) 1999: Lecture on

Tolerance/Autoimmunity (3 hours) 9. Education Rounds: As myelin unravels, so does the mystery: Current views on the

pathogenesis of multiple Sclerosis. CHEO Genetics. Ottawa ON. October 7, 2008. 10. Multiple Sclerosis Journal Club. Meets monthly for 1 hour. 2007-present.


DIRECTED STUDIES: Undergraduate 1990: Lionel CHOW; honours immunology student research project. (Total supervision

time: 12 hours) 1991: Natalie BUU; honours immunology student research project. (Total supervision

time 30 hours) 1991: Steven ZIELINSKY; medical student summer and winter research project. (Total

supervision time 40 hours) 1991: Amin KANANI; medical student winter research project, McGill winter bursary

program. (Total supervision time 12 hours) 1991: Elizabeth KURIEN, medical student summer research project, McGill summer

bursary program. (Total supervision time 12 hours) 1992: Sameer D'SOUZA; Interdepartmental honours immunology research project and

partial supervisor for MSc degree. (Total supervision time 60 hours over 3 years)

1992: Isabelle FORTIN, McGill international summer bursary program. (Total supervision time 12 hours)

1994: Josh Abiscott, University of Ottawa, Faculty of Medicine, MRC summer research student. (Total supervision time 12 hours)

1995: Cindy Freeman, University of Glasgow, Faculty of Medicine, Summer research student. (Total supervision time 12 hours)

2004: Jessica Laks, University of Waterloo, Summer research student. (Total supervision time 12 hours)

2006: Jessica Laks, University of Waterloo, Summer research student. (Total supervision time 12 hours)

Graduate 1992-93: Richard BITAR, McGill graduate school, MSc (received April 1995). (Total

supervision time 60 hours over 1.5 years) 1993-95: Julie STONE, University of Ottawa, School of Graduate Studies, MSc (received

Aug. 1996.) (Total supervision time 60 hours per year) 1995-: Robert PON, University of Ottawa, Department of Microbiology & Immunology,

Ph.D. Program. (Degree received 2000). (Total supervision time 90 hours per year).

1999-2005: Melanie GREEN, University of Ottawa, Department of Microbiology, Immunology and Biochemistry, PhD Program (Degree received 2005). (Total supervision time 90 hours per year).

2003-: Zhihong CHEN, University of Ottawa, Department of Microbiology, Immunology and Biochemistry, PhD Program (Degree received 2009). (Total supervision time 90 hours per year).

2005-: Jennifer BEVERIDGE, University of Ottawa, Department of Microbiology; Immunology and Biochemistry, PhD Program (Degree expected 2012). Total supervision time 90 hours per year).

Postgraduate 1995-98: Rana ZEINE, MD, PhD, University of Ottawa, Departments of Medicine and

Microbiology & Immunology; Research Fellow 1998-01: Darius MATUSEVICIUS, MD, PhD, University of Ottawa, Departments of

Medicine, and Microbiology, Immunology and Biochemistry; Research Fellow


1999-: Piotr MURZENOK, PhD, Ottawa Hospital Research Institute, Research Fellow 2000-01: Heather MacLEAN, University of Ottawa, Department of Medicine, Division of

Neurology, Multiple Sclerosis Clinical Research Fellow 2002-03: Francois EMOND, University of Ottawa, Department of Medicine, Division of

Neurology, Multiple Sclerosis Clinical Research Fellow 2006-07 Monica BADVE, University of Ottawa, Department of Medicine, Division of

Neurology, Multiple Sclerosis Clinic Research Fellow – 6 months 2007-08: Carolina RUSH, University of Ottawa, Department of Medicine, Division of

Neurology, Multiple Sclerosis Clinic Research Fellow 2007-08: Sasithorn SIRITHO, University of Ottawa, Department of Medicine, Division of

Neurology, Multiple Sclerosis Clinic Research Fellow 2009-12: Roxanna CRUCE, University of Ottawa, Department of Medicine, Division of

Neurology, Multiple Sclerosis Clinic Research Fellow 2009-10: Reza VOUSOUGHI, University of Ottawa, Department of Medicine, Division of

Neurology, Multiple Sclerosis Clinic Research Fellow 2009: Vahid SHAYGANNEJAD, Observer in MS Research Clinic, The Ottawa

Hospital General Campus 2011-12: Mohsen KHOSHNAM, University of Ottawa, Department of Medicine, Division

of Neurology, Multiple Sclerosis Clinic Research Fellow 2011: Stephan SCHMIDT, Observer in MS Research Clinic, The Ottawa Hospital

General Campus BASIC RESEARCH FUNDING: 1990-92: Cellular basis of immune regulation in multiple sclerosis, Multiple Sclerosis

Society of Canada. $123,000 Sole P.I. 1991-92: Regulatory effects of Betaseron Interferon- (IFN-) on the growth and activity

of human T cells, Berlex Laboratories. $63,488 Sole P.I. 1993-: Canadian Collaborative Genetics Project in MS, Co-Investigator, Multiple

Sclerosis Society of Canada. Estimated budget $5,000,000. Co-investigator 1993-95: The mechanism of T-cell induced brain injury: relevance to MS, Multiple

Sclerosis Society of Canada. $125,000. Sole P.I. 1993-94: The potential regulatory role of Betaseron Interferon- (IFN-) in T cell

interactions, Berlex Biotechnology Laboratories. $72,000. Sole P.I. 1994-96: The role of Rebif in controlling suppressor cell function and inducing

lymphocytic apoptosis in multiple sclerosis, Ares-Serono, Switzerland. $33,500. Sole P.I.

1995-97: T cell heat shock protein Interactions in multiple sclerosis”, Multiple Sclerosis

Society of Canada. $128,000. Sole P.I. 1997-99: The generation, immortalization and characterization of MS T cells, Multiple

Sclerosis Society of Canada. $120,000. Sole P.I. 1997-99: Establishing and understanding CD28/B7 interactions in MS disease, Multiple

Sclerosis Society of Canada. $160,000. Co-P.I. 1999-02: Role of T cells in multiple sclerosis immunopathogenesis: Investigation of

regulatory properties, Multiple Sclerosis Society of Canada. $291,789. Sole P.I.


1999-00: T cells in MS: Correlation of cytokine profiles and perforin molecules with

disease activity and modulation by Interferon-1a (AVONEX™) therapy, Biogen Canada. $125,625. Sole P.I.

2001-03: Immunological determinants of disease progression in response to therapy,

Multiple Sclerosis Society of Canada. $137,594. Co-P.I. 2002-04: The role of T cells in MS: Friends or foes, Multiple Sclerosis Society of

Canada. $165,000. Sole P.I. 2002-03: A novel in vitro model of immune-induced demyelination, Multiple Sclerosis

Society of Canada. $34,917. Co-P.I. 2003: Virological and immunological studies in pediatric multiple sclerosis. Wadsworth

Foundation Grant. Co-investigator 2008-11 The role of T cell-mediated ADCC in alemtuzumab induced destruction of

CD52+ cells in MS. Genzyme Inc. $142,000. Sole P.I. CLINICAL RESEARCH FUNDING: 1994-96: A multi-centre, randomized double-blind, placebo controlled, Phase III study of

subcutaneous Rebif (recombinant-human interferon-beta) in the treatment of secondary-progressive multiple sclerosis", Ares-Serono. (SPECTRIMS study). $505,500. Co-investigator

1994-96: A double blind placebo controlled multi-centre study of oral myelin in the

treatment of early relapsing-remitting multiple sclerosis, AutoImmune Inc., USA. (MYLORAL study). $450,000. Co-investigator

1994-01: A multi-centre, randomized double-blind, placebo controlled, phase III study of

subcutaneous Rebif (recombinant-human interferon-beta) in the treatment of relapsing-remitting multiple sclerosis, ARES-SERONO, Switzerland. (PRISMS study) $219, 900. Co-investigator

1995-2000: A multi-centre, randomised, double-blind, placebo-controlled study of Rebif

(recombinant-human interferon-beta) in patients with relapsing multiple sclerosis, Ares-Serono, Switzerland. (OWIMS study). $253,800. Co-investigator

1995-96: Multiple sclerosis burden of illness study in Canada, Berlex Canada Inc.

$105,000.00. Co-investigator 1996-98: Double-blind, randomized, placebo-controlled, parallel group study of safety and

efficacy of Ro 45-2081 in patients with relapsing-remitting multiple sclerosis, Hoffman-La Roche Limited, Switzerland (Lenercept study). $314,300. Co-investigator

1996-01: A randomised, double-blind, placebo-controlled study of Avonex™ (Interferon-

1a) in the treatment of subjects as high risk for development of multiple sclerosis following the first onset of an isolated demyelinating event, Biogen Medical Research Department, USA. (CHAMPS study). $720,000. Co-investigator


1996-98: A randomized, third-party blinded, placebo-controlled, rising single-dose study of

subcutaneous rhuIL-10 (SCH 52000) in patients with relapsing-remitting multiple sclerosis with Gd-enhanced MRI evidence of disease activity, Schering-Plough Research Institute, USA. $726,000. Co-investigator

1998-99: A randomized, double-blinded, placebo-controlled, rising multiple-dose phase 1b

study of subcutaneous rhuIL-10 (SCH 52000) in patients with multiple sclerosis, Schering-Plough Research Institute, USA. $134,925. Co-investigator

1997-98: Phase II Study of Hu23F2G in acute exacerbations of multiple sclerosis, ICOS

Corporation, USA. $118,250. Co-investigator 1998-02: A randomized double-blind, placebo-controlled study to evaluate the efficacy of

AVONEX in the treatment of secondary progressive multiple sclerosis, Biogen Medical Research Department, USA. (IMPACT study.) $231,000. Co-investigator

1998-02: Multicentre randomized placebo-controlled double blind study to evaluate the

efficacy and safety of intravenous immune globulin (IVIg) in patients with secondary progressive multiple sclerosis, Bayer, Germany. (ESIMS study.) $764,340. Co-investigator

1999-01: Pilot MRI study of PEG-Intron (SCH 54031) in ambulatory subjects with

relapsing multiple sclerosis, Schering Canada, Inc. $384,744. Co-investigator 1999-00: A randomized, multicentre, double-blind, placebo-controlled safety, tolerability

and dose evaluation study of intravenous Antegren (Natalazumab) at three dose levels using magnetic resonance imaging in subjects with multiple sclerosis, Elan Pharmaceuticals, Inc. $90,492. Co-investigator

1999-02: Micellar Paclitaxel for the treatment of secondary progressive multiple sclerosis:

A phase 2 study, Angiotech Pharmaceuticals, Inc. $155,050. Co-investigator 1999-03: A multinational, multicentre, double-blind, placebo controlled study to evaluate

the efficacy, tolerability and safety of glatiramer acetate for injection in primary progressive multiple sclerosis, Teva Marion Partners, Inc. (PROMISE study). $538,750. Co-investigator

2000-02: A multinational, multicentre, randomized, double-blind, placebo-controlled study

to evaluate the efficacy, tolerability and safety of 2 Doses (5mg and 50mg) of glatiramer acetate orally administered in relapsing remitting multiple sclerosis patients. Teva Marion Partners, Inc, (CORAL study.) $145,392. Co-investigator

2000-01: Double-blind, randomized, placebo-controlled study to evaluate the safety and

tolerability of Mesopram in patients with multiple sclerosis, Berlex Canada. $370,680. Co-investigator

2000-01: Systematic reviews of the efficacy and safety of four medical uses of marijuana,

Medical Research Council of Canada. $202,698. Co-P.I. 2000-02: A multi-centre, open-label antigenicity and safety study of a human serum-free

pre-formulated solution of Avonex® (Interferon beta-1a) administered


intramuscularly to patients with relapsing multiple sclerosis. Biogen Inc. $212,500. Co-investigator

2000-03: A phase II study of the safety and efficacy of Teriflunomide (HR1726) in multiple

sclerosis with relapses, Aventis Pharma, France. $1,034,670. Co-investigator 2000-05: Multiple sclerosis as an autoimmune disease. Treatment of poor prognosis

patients with multiple sclerosis using intensive immunoablative therapy followed by immune cell depleted autologous stem cell transplantation (ASCT), Multiple Sclerosis Society of Canada. $4,500,000. Co-P.I.

2002-04: A phase II, randomized, double-blind, placebo controlled study to evaluate the

preliminary efficacy, pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis, Bristol-Myers Squibb. $92,500. Co-investigator

2002-05: A randomized, double-blind placebo-controlled, study to compare the effects of

different dose regimens of IGIV-Chromatography (IGIV-C), 10% treatment on relapse rates in patients with multiple sclerosis, Bayer, Germany. $169,645. Co-investigator

2002-03: Double-blind, randomized, multicentre, placebo-controlled, parallel-group phase

IIa study to evaluate the safety and tolerability of oral Mesopram (ZK 117137) up to 1.0 mg/d for up to 14 weeks in an intraindividual dose-escalation regimen in patients with clinically definite relapsing-remitting or secondary progressive multiple sclerosis, Schering AG. $126,963. Co-investigator

2002-04: Long-term efficacy and safety phase IV follow-up of the PRISMS cohort.

(Formerly known as: A multicentre, randomized, double-blind, placebo controlled, phase III study of subcutaneous Rebif in the treatment of relapsing-remitting multiple sclerosis). Aeros-Serono, Geneva. $264,856. Co-investigator

2002-05: Double-blind, placebo controlled, randomized, parallel group, multicenter, phase

III study in patients with a first clinical demyelinaing event suggestive of multiple sclerosis to evaluate the safety, tolerability, and efficacy of 8 MIU (250 mcg) interferon beta-1b (Betaseron) given subcutaneously every other day over a period of up to 24 months. (BENEFIT Study).Bayer Healthcare Pharmaceuticals. $157,193.75. Co-investigator

2003: Description and course of cognitive dysfunction in patients with multiple sclerosis

who lack neurological disability. A pilot study on neuropsychological evaluation

and MRI abnormalities. Cognitive (Caims): Serono Canada Inc. Co-P.I. 2003-05: A double-blind, randomized, placebo-controlled, parallel group, safety study of

Natalizumab in combination with glatiramer acetate (GA) in subjects with relapsing-remitting multiple sclerosis (MS), Biogen, Cambridge, MA. $173,265.95. Co-investigator

2003-: Extension of Protocol HMR 1726D/2001, A phase II study of the safety and

efficacy of Teriflunomide (HR1726) in multiple sclerosis with relapses, Aventis Pharma. $1,034,670. Co-investigator


2003-04: Double-blind, randomized, placebo-controlled, parallel-group, multicenter study evaluating safety, tolerability and effect on MRI lesion parameters of FTY720 vs placebo in patients with relapsing Multiple Sclerosis, Novartis Pharma, Switzerland. $313,725. Co-investigator

2003-04: A randomized, double-blind, placebo-controlled study to evaluate the safety,

tolerability and efficacy of NBI-5788 in patients with relapsing Multiple Sclerosis, Neurocrine BioSciences. $52,072. Co-investigator

2003-04: A randomized, rater-blinded, multicenter, parallel-group study comparing the

efficacy and safety of Betaseron 250g subcutaneously every other day with Avonex 30g intramuscularly once per week in relapsing remitting multiple sclerosis patients previously treated with Avonex, Berlex Laboratories, USA: (ABOVE Study). $12,943.75. Co-investigator

2004-08: Open label, multicentre, phase III extension of the double-blind, placebo

controlled BENEFIT study (no. 304747) to obtain long-term follow-up data of patients with clinically definite MS and patients with a first demyelinating event suggestive of MS treated with 8 MIU (250µg) interferon beta-1b (Betaseron) given sc every other day. Bayer Healthcare Pharmaceuticals. $157,193.75. Co-investigator

2004-05: A multi-center, randomized, single-blind, parallel group study to compare the

efficacy, tolerability and safety, of Copaxone to that of high dose interferon (Betaseron or Rebif) in the treatment of relapsing multiple sclerosis, TEVA (ACHIEVE study). $22,000. Co-investigator

2004-06: An open-label, baseline-to-treatment crossover clinical trial to evaluate the safety,

tolerability, pharmacokinetics and effects of vitamin B12 when used in combination with Interferon treatment in patients with relapsing remitting multiple sclerosis with MRI activity. Vitamin B12 Transition Therapeutics, Toronto, Canada. $53,040. P.I.

2004-: A randomized, multinational, double-blinded, placebo-controlled, parallel group

design pilot study to extimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of Teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis, Sanofi-Aventis (PDY 6046). $83,526. Global P.I.

2004-: A randomized, double-blind, placebo-controlled, parallel group design study to

evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses, Aventis Phase III. Protocol #: HMR1726D/3001. $590,499. Co-investigator

2004-06: A 24-week, randomized, double-blind, parallel group, placebo-controlled, dose

finding, safety, tolerability and efficacy study of the human anti-IL-12 antibody ABT 874 in subjects with multiple sclerosis with a 24-week double-blind, active extension phase, Abbott Laboratories, USA. $60,840. Co-investigator

2004-07: Retrospective, exploratory, blinded study to evaluate serum levels of antiglycans

antibodies in MS patients. Glycominds Ltd. Sole P.I.


2004-08: A phase II/III. randomized, double blind, parallel-group, placebo-controlled, multicenter study to evaluate the safety and efficacy of Rituximab (MabThera/Rituxin) in adults with primary progressive MS, Genentech, USA. (OLYMPUS study). $904,800. Co-investigator

2004-: A double-blind, placebo controlled multicenter study to evaluate the efficacy and

safety of MBP8298 in subjects with secondary progressive multiple sclerosis,

BioMS (Eli-Lilly), Canada. (MAESTRO #1). $601,088.80. Global P.I.

2004-05: Implementation study of treatment optimization recommendations comparing

subjects continuing treatment with INF-B-1a 30mcg qw IM (Avonex) or

glatiramer acetate 20mg qd SC (Copaxone) to those randomized to IFN-B-1a

44mcg tiw SC (Rebif), in a multicenter study of subjects with RRMS currently on

disease-modifying therapy. (IMPLEMENT study): Serono USA. $24,263.

Global P.I.

2004: An extension to the double-blind, randomized, placebo-controlled, parallel-group,

multicentre study evaluating safety, tolerability and effect on MRI lesion

parameters of FTY720 vs. placebo in patients with relapsing Multiple Sclerosis.

Novartis Extension, Novartis Pharmaceuticals Canada Inc. $569,907. Co-

investigator

2004-07: International, randomized, multicentre, phase IIIb study in patients with relapsing-

remitting Multiple Sclerosis comparing over a treatment period of 104 weeks: double-blinded safety, tolerability, and efficacy of Betaseron/Betaferon 250µg (8MIU) and Betaseron/Betaferon 500µg (16 MIU), both given subcutaneously every other day, and rater-blinded safety, tolerability, and efficacy of Betaseron/Betaferon s/c every other day with Copaxone 20mg s/c once daily, Bayer Schering Pharma AG, Germany. (BEYOND Study). $266,857.50. Co-investigator

2004-07: Serono Pfizer phase IV, multicentre, open label, randomized study of Rebif® 44

mcg administered three times per week by subcutaneous injection compared with Copaxone® 20mg administered daily by subcutaneous injection in the treatment of relapsing remitting multiple sclerosis, Merck Serono (REGARD study). $54,591. Co-investigator

2004-06: Open-label of AVP-923 (Destromethorphan/Quinidine) in patients with

pseudobulbar affect, INC Research. $26,632.25. Co-investigator 2004-06: Mitoxantrone (Novantrone) preceding treatment with glatiramer aetate

(copaxone) VS chronic treatment with glatiramer acetate alone in relapsing forms of MS, TEVA Neuroscience. (NC-100 study). $46,220. Co-investigator

2005: Detecting cognitive impairments using the computerized test of information

processing (CTIP), Multiple Sclerosis Society of Canada. $13,600. Co-P.I.

2005-07: Double-blind, placebo-controlled, 21-week, parallel group study to evaluate

safety and efficacy of oral fampridine-SR (10 mg bid) in subjects with multiple


sclerosis. Fampridine-SR (4AP): Accorda Therapeutics. $17,222. Co-

investigator

2005-06: Burden of pain in multiple sclerosis patients: A Canadian Burden of Illness Study,

Bayer/Pharmideas. $4,488.50. Co-investigator

2005-06: A Phase 1, open-label, multicentre study to evaluate the safety and activity of

Rituximab (MabThera/Rituxan) in adults with relapsing remitting multiple

sclerosis, Genentech, USA. $26,250.80. Co-investigator

2005-06: A phase 2a magnetic resonance imaging study of the safety and efficacy of

MLN1202 in patient with multiple sclerosis, Millennium, USA. $17,000. Co-investigator

2005-06 : Multicenter, single arm, open-label, phase IIIb study to evaluate the safety and

antigenicity of Rebif (IFNß-1a) RNF, in subjects with relapsing forms of multiple sclerosis, EMD Serono. $22,000. Co-investigator

2005-06: A randomized, double-blind, placebo-controlled, parallel groups study to assess

the effects of L-000124467 on disease activity in patients with relapsing remitting multiple sclerosis as measured by MRI, Merck Frosst Canada. $10,152.95. Co-investigator

2005- : A multi-center, double-blind, randomized study comparing the combined use of

Interferon Beta-1a and glatiramer acetate to either agent alone in patients with relapsing remitting multiple sclerosis (CombiRx-Phase III), NIH, USA. $79,710. Co-investigator

2005- : HMR1726D/ 2003 Randomized, multinational, double-blinded, placebo-

controlled, pilot study to extimate the tolerability, safety, pharmacokinetics, and

pharmacodynamic effects of Teriflunomide for 24 weeks when added to treatment

with Interferon-ß in subjects with multiple sclerosis, Sanofi-Aventis (PDY 6045).

$238,264. Global P.I.

2005- : Serono 25643 is a phase III, randomized, double-blind, three-arm, placebo-

controlled, multicentre study to evaluate the safety and efficacy of oral cladribine in subjects with relapsing remitting multiple sclerosis (RRMS). Merck Serono, Switzerland. $64,260. Co-investigator

2006-07: A double blind, randomised, placebo controlled, parallel group study of Sativex®

when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis, GW Pharmaceuticals, UK. $15,209.39. Co-investigator

2006: A phase IV, observational, open label, multicentre comparison study of newly

developed and validated MusiQoL (Multiple Sclerosis International Quality of Life questionnaire) instrument with health-related QoL (MSQOL-54) questionnaire in subjects with relapsing forms of multiple sclerosis on Rebif® therapy. (COMPARE study). $62,335. Co-investigator


2006- : A 12 month double-blind randomized multi-center active controlled parallel group study comparing the efficacy and safety of 0.5mg and 1.25mg fingolimod (FTY720) administered orally once daily VS interferon 1a (Avonex) administered IM once weekly in patients with relapsing remitting multiple sclerosis with optional extension, Novartis, Switzerland. $154,546.70. Co-investigator

2006-08: Comparison of structural biomarkers of axonal integrity in optic neuritis:

correlating VEP, MRI and optical coherence tomography measurements, Multiple Sclerosis Society of Canada. $180,536. Co-P.I.

2006-12: Long term outcomes following immunoablative therapy and autologous stem cell

transplant for poor prognosis multiple sclerosis, Multiple Sclerosis Society of Canada. $2,419,701. Co-P.I.

2007- : A phase III, randomized, double-blind, placebo-controlled, multicentre clinical

trial of Rebif new formulation (44mcg tiw and 44mcg ow) in subjects at high risk of converting to multiple sclerosis, Merck Serono, Switzerland (REFLEX study). $106,736. Co-investigator

2007: Randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study

to investigate the MRI efficacy and the safety of six months' administration of Firategrast (150 – 1200mg twice daily) in subjects with relapsing-remitting multiple sclerosis. $76,299.60. Co-investigator

2007- : An open-label follow-on study to assess the ongoing safety of MBP8298 in

subjects with secondary progressive multiple sclerosis, BioMS (Eli Lilly) (MAESTRO #2). $256,392.50. Global P.I.

2007- : International, multicentre, phase IIIb study of subcutaneous every-other-day

treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250µg or 500µg or open-label Betaseron/Betaferon 250µg and (Phase B) open-label Betaseron/Betaferon 500µg. (BEYOND Follow-up). $108,368. Co-investigator

2007-08: A two-arm, randomised, double-blind, control group-compared, multicenter,

phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® new formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosi, EMD Serono (IMPROVE Study). $9,650. Co-investigator

2007-11: The safety of two doses of teriflunomide (7 and 14mg) in patient with multiple

sclerosis with relapses, Sanofi-Aventis Canada Inc. Short title: LTS 6050. $217,098.70. Co-investigator

2008-09: Long-term extension of PDY 6045 and PDY 6046 of Teriflunomide when added

with interferon or glatiramer acetate in MS, Sanofi-Aventis Inc. $119,252. Global P.I.

2008: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study

comparing the efficacy and safety of 1.25mg FTY 720 administered orally once daily VS placebo in patients with primary progressive multiple sclerosis, Novartis Pharmaceuticals, Switzerland. $1,145,419.60. Co-investigator


2008: A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg and 1.25mg fingolimod (FTY 720) administered orally once daily VS placebo in relapsing-remitting multiple sclerosis. Novartis Pharmaceuticals, Switzerland. $190,092.50. Co-investigator

2008: A four-arm, randomized, double-blind, placebo-controlled, multicenter Phase II

study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of Atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 week treatment course. (Atacicept in RMS). Merck Serono Inc., Germany. $304,785. Co-investigator

2008: A two-arm, randomized, double-blind, placebo-controlled, multicenter Phase II

study to evaluate safety and tolerability and to explore the neuroprotective effect of Atacicept as assessed by optical coherence tomography (OCT) in subjects with optic neuritis (ON) as clinically isolated syndrome (CIS) over a 36 week treatment course (Protocol 28156 Atacicept in optic neuritis, Phase II), Merck Serono Inc., Germany. $97,110. Co-investigator

2008: A phase IIIb, double-blind, placebo-controlled, muticenter, parallel group,

extension trial to evaluate the safety and tolerability of oral cladribine in subjects with relapsing remitting multiple sclerosis who have completed Trial 25643 (Clarity), Merck Serono Inc. $128,631.15. Co-investigator

2008: A phase III, randomized, rater-blinded study comparing two annual cycles of

intravenous low- and high-dose alemtuzumab to tiw subcutaneous interferon beta-1a (Rebif) in patients with relapsing remitting multiple sclerosis who have relapsed on therapy (CAMMS 324), Genzyme Corporation, USA. $136,824. Co-investigator.

2008-11: Two year treatment with teriflunomide 7mg od and 14mg od VS placebo in

patients with a first clinical episode suggestive of MS, Sanofi-Aventis, France. $129,744. Co-investigator

2008-11 A new clinical test for measuring information processing in MS patients: The

Computerized Tests of Information Processing (CTIP) – Longitudinal follow-up (ISPMS 2). Multiple Sclerosis Society of Canada. $69,289 Co-P.I.

2008-13: A phase 3 randomized, rater-blinded study comparing two annual cycles of

intravenous alemtuzumab to 3-times weekly subcutaneous interferon beta-1a (Rebif) in treatment-naïve patients with relapsing-remitting multiple sclerosis, Genzyme Corporation, USA (CAMMS323). $102,596. Co-investigator

2008: Extension study of the BENEFIT (304747) and BENEFIT Follow-up (305207)

Studies to Further Evaluate the Progress of Patients With First Demyelinating

Event Suggestive of Multiple Sclerosis. $49,237.50. Co-investigator

2009: A phase II, double-blind, randomized,multi-center, adaptivedose-ranging,

placebo-controlled, parallel-group study evaluating safety, tolerability and

efficacy on MRI lesion parameters and determining the dose response curve of

BAF312 given orally once daily in patients with relapsingremitting multiple

sclerosis (CBAF312A2201). Novartis. $17, 3647.5. Co-investigator


2009: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in

subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety,

tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind

MRI follow-up over 12 weeks.(UCB C32322). Co-investigator

2009: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-

up data in patients with clinically definite MS and patients with a first

demyelinating event at high risk of converting to MS, treated with Rebif New

Formulation (REFLEXION). Merck Serono International. $125, 288. Co-

investigator

2009: A Phase III, randomized, double-blind, placebo-controlled, multi-center clinical

trial of oral cladribine in subjects with a first clinical event at high risk of

converting to MS (ORACLE MS). Merck Serono International. $32,424.6. Co-

investigator

2009: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-

finding study to evaluate the efficacy, safety, and tolerability of three doses of

ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks

in patients with relapsing-remitting multiple sclerosis (Actelion). Actelion

Pharmaceutical Canada Inc. $323,232.91. Co-investigator

2009: A phase IIIb, double-blind, placebo-controlled multicenter, parallel group,

extension trial to evaluate the safety and tolerability of oral cladribine in subjects

with relapsing-remitting multiple sclerosis who have completed Trial 25643

(CLARITY). Co-investigator

2009: A 14 week, randomized, double blind, placebo-controlled, parallel group study to

evaluate the efficacy, safety and tolerability of nerispirdine 50mg, 100mg and

200mg in patient with multiple sclerosis (DRI110566 Fatigue). Co-investigator

2009: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study

to evaluate the efficacy and safety of PEGylated Interferon Beta-1a (BIIB017) in

subjects with relapsing multiple sclerosis (Biogen 105MS301). Co-investigator

2009: A phase III double-blind, randomized, placebo-controlled trial of Minocycline in

clinically isolated syndromes (CIS) (Minocycline in CIS) $10,000.00 per patient.

Co-investigator

2009: “CONCEIVE” (COgnition and Neuroimaging in CIS: Effects of Interferon in

Very Early MS) – an investigator-driven clinical protocol to study cognitive change with fMRI and to evaluate the effect of early drug therapy. Bayer Healthcare. $329,838. P.I.

2009: The cognitive impact of anticholinergic drugs (ACD) used for urinary dysfunction

in multiple sclerosis (MS). TOHAMO Innovation Funds. P.I.


2010: Chronic Cerebrospinal Venous Insufficiency in relation to multiple sclerosis.

Torres C, Chakraborty S, Hogan MJ, Freedman MS, Lum C, Bussiere M,

Cameron I, Schweitzer M. MS Society of Canada. $140,166.00. Co-Investigator

2010: Epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients:

JEMS.Biogen Canada. $174, 932.00. P.I

2010: Multicenter, double-blind, randomized, parallel-group, monotherapy, active-

control study to determine the efficacy and safety of daclizumab high yield Process

(DAC HYP) versus AVONEX (Interferon B-1a) in patients with relapsing-

remitting multiple sclerosis.Biogen Canada. $88,924.00. P.I.

2010: A single arm, open-label, multicenter study evaluating the long-term safety and

tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in

patients with relapsing forms of multiple sclerosis. Protocol No. CFTY720D2399.

Novartis Pharmaceuticals Canada. $237,068.00. P.I

2010: Open-label extension study of oral fampridine-SR in MS. Biogen Canada Inc.

$10,696.00. P.I

2010: Dose blind extension study to the CBAF312A2201 study to evaluate long-term

safety, tolerability and efficacy of BAF312 given orally in patients with relapsing

multiple sclerosis. Novartis Parmaceuticals Canada. $89,434.00. P.I

2010: CAMMS03409 - An extension protocol for multiple sclerosis patients who

participated in Genzyme-sponsored studies of Alemtuzumab. Genzyme

Corporation. $320,201.00. P.I

2010: AC-058B202: Multicentre, randomized, double-blind, parallel-group extension to

study AC-058B201. Actelion Pharmaceutical Canada Inc. $175,988.40. P.I

2010: Controlled high risk AVONEX multiple sclerosis prevention study in ongoing

neurological surveillance (Champions Continuation Study). Biogen Canada Inc.

$32,194.50. P.I

2010: Prospective observational long-term safety registry of MS patients who have

participated in cladribine clinical trials. Merck Serono International S.A.

$31,200.00. P.I

2010: A multinational, multicenter, single visit, exploratory pharmacogenetic trial and

long-term follow-up of the PRISMS (prevention of relapses and disability by

Interferon Beta-1a subcutaneously in multiple sclerosis) Trial. Merck Serono

International S.A. $32,760.00. P.I

2011: Molecular determinants of brain plasticity and human application. CFI New

Initiatives Fund (NIF). uOBMRI-oriented application. Submitted September


2011.

2011- Autologous mesenchymal stem cell transplantation: A potential cell-based

treatment for inflammatory forms of multiple sclerosis. Applied to Multiple Sclerosis Society of Canada. Jan 2011. (LOI under review)

2011: A 6-month, randomized, active comparator, open-label, multi-center study to

evaluate patient outcomes, safety and tolerability of Fingolimod 0.5 mg/day in

patients with relapsing forms of multiple sclerosis who are candidates for MS

therapy change from previous disease modifying therapy (EPOC). Novartis

Pharmaceuticals Canada Inc. $53,910.00. P.I

2011: Multi-center, two-arm, non-comparative, observational, 96-week Phase IV study

to evaluate treatment adherence when using RebiSmart for self-injection of Rebif

in multi-dose cartridges in subjects with relapsing multiple sclerosis (RMS). EMD

Serono Canada Inc. $19,353.90. P.I

2011: TERIVA - Immune response to influenza vaccine in patients with MS on

Teriflunomide Treatment. Sanofi-Aventis Canada Inc. $53,089.13. P.I

2011: Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis

who are treated with Interferon-Beta. Sanofi-Aventis Canada Inc. $109,496.40. P.I

2011: Ocrelizumab in adults with primary progressive multiple sclerosis. Hoffmann-La

Roche Limited. $114,847.20. P.I

2011: Phase 1B, randomized, placebo-controlled dose study of IV infusion of human

placenta-derived cells (PDA001). Celgene Corporation. $18,925.40. P.I

2011: Long term outcomes of patients that received stem cell transplant for MS -

clinical, radiological, neuropsychological and health utility evaluations.

Submitted to MS Society of Canada Oct. 2011.

2011: Financial barriers to implementation of immune ablation and hematopoietic stem

cell transplantation (IA/HSCT) for multiple sclerosis (MS). AHSC AFP

Innovation Fund, TOHAMO. Submitted November 2011.

2012: Autologous mesenchymal stem cell transplantation: Exploring the potential for

this cell-based treatment for inflammation and repair in multiple sclerosis.

Multiple Sclerosis Society of Canada. Applied September 2012. $4,412,841/47.

2012: Regulatory role of innate immune cells in pro-inflammatory autoimmune T cell

responses. CIHR. Applied September 2012. $525,134.72

2012: Brief international cognitive assessment for multiple sclerosis (BICAMS):

Canadian contribution to the international validation project. Walker, L, Rees L,

Cousineau D, MacLean H, Taylor-Sussex R, Berard J, Freedman MS.


University of Ottawa Brain and Mind Research Institute. Applied Sept 20 2012.

$40,000.00

2013-14: Lung volume recruitment for lung function and cough impairment in multiple

sclerosis. McKim D, Srour N, Freedman MS. The Lung Association. Accepted.

Dec 2012. Department of Medicine Research Priority Award. $39,433.00. Co-

PI.

2013 Brief international cognitive assessment for multiple sclerosis (BICAMS):

Canadian contribution to the international validation project. Walker L ,Rees L,

Freedman MS, Cousineau D, MacLean H, Taylor-Sussex R, Berard J. uOBMRI.

$40,000.00

2013-14: Circulating glycerophospholipidome as a cerebral white matter disease. Hogan

MJ, Bennett S, Freedman MS, Dowlatshahi D, Glikstein R. Co-Investigator.

DoM Developmental Research Awards Program. 2013. $41,169.00

PUBLICATIONS:

a) Books authored: 2

b) Books edited: 2

c) Chapters in books: 13

d) Papers in refereed journals: 301

e) Papers in refereed conference proceedings: 6

f) Papers in non-refereed journals: 8

g) Abstracts: 427

h) Technical reports and other publications: 1 PUBLICATIONS:

Books

1. Freedman MS. Editor, Special Issue. Clinical Trends in Neurology. 2005.

2. Freedman MS (editor). Advances in Neurology. Multiple Sclerosis and Demyelinating

Diseases. Published by Lippincott Williams & Wilkins. Volume 98. 2006.

Book Chapters

1. Freedman MS, Antel JP, Richman D. Johnston MV, MacDonald R, Young AB (eds.),

Principles of Drug Therapy in Neurology. : Immune-mediated disorders. FA Davis Company: Philadelphia, 1992, pp 178-205.


2. Antel JP, Freedman MS: In: Herndon RM (ed), Multiple Sclerosis: Current Status of Research and Treatment, The immunologic basis for immunosuppressive and immunoregulatory therapy in MS. Demos Pub: New York, 1994, pp. 157-174.

3. Antel JP, Freedman MS, Pioro E, Preul M, Arnold DL. C. Clifford Rose (ed.),

Proceedings Forbes H. Norris Memorial Volume, ALS from Charcot to the present and into the future, Clinical-laboratory correlations in motor neuron disease: Assessment of upper motor neuron dysfunction. Smith-Gordon: London, 1994, pp. 35-42.

4. Freedman MS. Multiple Sklerose. Kausalorienterte, symptomatische und rehabilitative therapie. PRISMS-Studie – Ergebnisse der 4-Jahres-Auswertung: Klinische Dosis-Wirkungs-Beziehung der Interferon-beta-1a-Therapie bei MS. Springer, 2001, 105-108

5. Freedman MS, Matusevicius D. Encyclopedia of Immunology. Immune System, Overview. April 2003.

6. Atkins HL, Freedman MS. Neurologic Clinics. Immunoablative therapy as a treatment

for aggressive multiple sclerosis. February 2005. 23:1. pp. 273-300. 7. Atkins H, Freedman MS. Cook S (ed), Handbook of Multiple Sclerosis, Chapter 19

Immunosuppression. Taylor & Francis, New York, pages 423-441, 2006. 8. Freedman MS. Editor, Special Issue. Clinical Trends in Neurology. June 2005. 9. Thompson EJ, Freedman MS. Adv. Neurol. Cerebrospinal fluid analysis in the

diagnosis of multiple sclerosis. 98:147-60, 2006. 10. Freedman MS. Neuroimmunology in Clinical Practice. Cerebrospinal Fluid. Blackwell

Publishing. 2008:Ch 3.6; 54-56. 11. Badve MS, Freedman MS. Diseases and Disorders. Multiple Sclerosis. Ed. Wendy

Horobin, Marshall Cavendish Corporation, New York. 2008:589-592.

12. Freedman MS, Abdoli M. Oxford University Press. Cerebrospinal Fluid Profile Supporting a Clinical Definite Multiple Sclerosis Diagnosis.. Chapter 8:Primer on Multiple Sclerosis, Second Edition, Edited by Barbara S. Giesser. December 2015.

13. Freedman MS. Translational Neuroimmunology in Multiple Sclerosis. Emerging New Therapies on the Horizon. Chapter 21 Emerging Therapies for Multiple Sclerosis. Ed. Ruth Arnon, Ariel Miller. Academic Press 2016: 285-303. Highly commended by BMA Medical Book Awards 2017

Invited Book Reviews 1. Freedman MS. “Multiple Sclerosis Immunology, Pathology, and Pathophysiology.”

Edited by Herndon RM. 239 pp, ill, New York, Demos Medical Publishing. Neurology. 2003;61:1633.


2. Freedman MS. “Human Embryonic Stem Cells”. Edited by S. Sullivan, CA. Cowan and K. Eggan. Wiley. Canadian Journal of Neurological Sciences. 2007.

Editorials

1. Freedman MS, Atkins HL. Suppressing immunity in advancing MS: Too much too late,

or too late for much? Neurology 2004;62:168-9. Co-primary author 2. Freedman MS and Pachner AR. Neutralizing antibodies to biological therapies: A

“touch of gray” vs a “black and white” story. Neurology 2007;69:1386-87. Co-author

3. Freedman MS. Time is brain also in multiple sclerosis. Mult Scler 2009;15:1133–1134. 4. Freedman MS, Cohen JA. Meta-analysis of bone marrow transplantation treatment

studies: mixing ‘apples and oranges’. Mult Scler. 2011;17(2):131-2. Primary author.

5. Freedman MS, Ucelli A.. Neurorepair with mesenchymal stem cells: Hope or hype? Lancet Neurol. 2012:2(11):123-125.

6. Freedman MS. The use of natalizumab for treatment of MS: Do the risk still outweigh the gains? Can J Neurol Sci. 2012:39:559-560.

7. Freedman MS. Are we in need of NEDA? Mult Scler. 2016. Jan;22(1):5-6 Journals, Articles and Reviews Papers in Refereed Journals: 1. Freedman M, Clark BD, Cruz TF, Gurd J, Brown IR: Selective effects of LSD and

hyperthermia on the synthesis of synaptic proteins. Brain Research 1981;207:129-145.

Primary researcher

2. Koven IH, Freedman M, Miller D, Reece S, Maitland A, Sigurdson E, Blackstein ME:

Macro-creatine kinase 2: A possible marker of gastro intestinal cancer? Surgery

1983;94:631-634. Primary researcher (all the experiments and paper writing).

3. Freedman MS and MacDonald RD: Herpes zoster ophthalmicus with delayed cerebral

infarction and meningoencephalitis. Can J Neurol Sci 1987; 14:312-314. Primary

researcher

4. Freedman MS, Schneiderman JH, Turley J, DePetrillo AD: Neurological complications

following intra-arterial CIS-platinum chemotherapy. Can J Neurol Sci 1987;14:325.

Primary researcher.

5. Freedman MS: The current status of multiple sclerosis. Modern Medicine of Canada

1987;42:GP21-29.

6. Freedman MS and Gray TA: Vascular headache: A presenting symptom of multiple

sclerosis. Can J Neurol Sci 1989;16:63-66. Primary researcher


7. Freedman M and Antel JP: Immunoregulatory circuits in multiple sclerosis: Is there a

short? (Editorial) Ann Neurol 1988;24:183-84. Primary writer

8. Antel JP, Freedman M, Brodovsky S, Francis GS, Duquette P: Activated suppressor

cell function in severely disabled multiple sclerosis patients. Ann Neurol 1989;25:204-

07. Primary researcher

9. Farmer JP, Antel JP, Freedman M, Cashman NR, Villemure JG: Characterization of

lymphoid cells isolated from human gliomas. J Neurosurgery 1989;71:528-533. Co-

primary researcher (performed up to 50% of experiments and assisted with the writing of

the manuscript.)

10. Ruijs TCG, Freedman MS, Grenier Y, Olivier A, Antel JP: Human oligodendrocytes

are susceptible to cytolysis by major histocompatibility complex class I-restricted

lymphocytes. J Neuroimmunol 1990;27:89-97. Co-primary researcher (performed up to

50% of experiments and assisted with the writing of the manuscript.)

11. Freedman MS, Loertscher R, Cashman NR, Duquette P, Blain M, Antel JP:

Immunoregulatory properties of T-cell lines derived from the systemic and intrathecal

compartments: A phenotypic and functional study. Ann Neurol 1990;27:258-265.

Primary researcher

12. Yong VW, Yong FP, Moumdjian R, Ruijs TCG, Freedman MS, Cashman N, Antel JP:

-interferon from CD8 or CD4 lymphocytes is a mitogen for human adult astrocytes.

PNAS 1991;88:7016-7020. Co-researcher (performed some of the experiments and

assisted in the preparation of the manuscript.)

13. Freedman MS, Blain M, Antel JP: Differential responses of CD4+CD45RA+ and

CD4+CD29+ subsets to activated CD8+ cells: Enhanced stimulation of the

CD4+CD45RA+ subset by cells from patients with multiple sclerosis. Cell Immunol

1991;133:306-316. Primary researcher

14. Freedman MS, Ruijs TCG, Blain M, Antel JP: Phenotypic and functional characteristics

of activated CD8+ cells: A CD11b-CD28- subset mediates non-cytolytic functional

suppression. Clin Immunol Immunopathol 1991;60:254-267. Primary researcher

15. Freedman MS, Ruijs TCG, Selin LK, Antel JP: Peripheral blood T cells lyse fresh

human brain-derived oligodendrocytes. Ann Neurol 1991;30:794-800. Primary

researcher

16. Freedman MS, Muth KL, Trotter JL, Yoshizawa CN, Antel JP: Prospective serial

analysis of interleukin-2 and soluble interleukin-2 receptor in patients with relapsing-

remitting multiple sclerosis. Neurology 1992;42:1596-1601. Primary researcher


17. Johns LD, Babcock G, Green D, Freedman M, Sriram S, Ransohoff RM: Transforming

growth factor-1 differentially regulates proliferation and MHC class II antigen

expression in forebrain and brainstem astrocyte primary cultures. Brain Research

1992;585:229-236. Co-researcher (performed some of the experiments and assisted in

the preparation of the manuscript.)

18. Couldwell WT, Yong VW, Dore-Duffy P, Freedman MS, Antel JP: Production of

soluble autocrine inhibitory factors by human glioma cell lines. J Neurol Sci

1992;110:178-185. Co-researcher (performed some of the experiments and assisted in

the preparation of the manuscript.)

19. Freedman MS, Buu NN, Kanani A, Ruijs TCG, Williams K, Antel JP: Differential

expression of heat shock proteins by human glial cells. J Neuroimmunol 1992;41:231-

238. Primary researcher

20. The IFNb Multiple Sclerosis Study Group*: Interferon- 1B is effective in relapsing-

remitting multiple sclerosis: Clinical results of a multicentre, randomized, double blind,

placebo-controlled trial. Neurology 1993;43:655-661. Co-investigator

21. Paty DW, Li DKB, The MS/MRI Study Group*, is effective in relapsing-remitting

multiple sclerosis: II - MRI analysis results of a multicentre randomized, double-blind

placebo control trial. Neurology 1993;43:662-667. Co-investigator

22. D'Souza SD, Antel JP, Freedman MS: Cytokine induction of heat shock protein

expression in human oligodendrocytes: an IL-1 mediated mechanism. J Neuroimmunol

1994;50:17-24. Primary supervisor

23. Prabhakar S, Kurien E, Gupta RS, Zielinski S, Freedman MS: Heat shock protein

immunoreactivity in CSF: Correlation with oligoclonal banding and demyelinating

disease. Neurology 1994;44:1644-48. Primary supervisor

24. The IFN Multiple Sclerosis Study Group* and the University of British Columbia

MS/MRI Analysis Group: Interferon- 1b in the treatment of MS: Final outcome of the

randomized controlled trial. Neurology 1995;45:1277-1285. Co-investigator

25. Ebers GC, Sadovnick AD, Risch NJ and the Canadian Collaborative Study Group*: A

genetic basis for familial aggregation in multiple sclerosis. Nature 1995;377:150-151.

Co-investigator

26. Sadovnick AD and the Canadian Collaborative Study Group*: Evidence for genetic

basis of multiple sclerosis. Lancet 1996;347:1728-1730. Co-investigator

27. Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Anderson C, Armstrong H,

Cousin K, Bell RB, Hader W, Paty DW, Hashimoto S, Oger J, Duquette P, Warren S,

Gray T, O’Connor P, Nath A, Auty A, Metz L, Francis G, Paulseth JE, Murray TJ, Pryse-


Phillips W, Nelson R, Freedman M, Brunet D, Bouchard J-P, Hinds D, Risch N: A full

genome search in multiple sclerosis. Nature Genetics 1996;13:472-476. Co-investigator

28. The IFN Multiple Sclerosis Study Group* and the University of British Columbia

MS/MRI Analysis Group: Neutralizing antibodies during treatment of multiple sclerosis

with interferon beta-1b: Experience during the first three years. Neurology 1996;47:889-

894. Co-investigator

29. Freedman MS, D’Souza S, Antel J. T cell-human glial cell interactions: 1) In vitro

induction of T cell expansion by human glial cells. J. Neuroimmunol 1997;74:135-

142. Primary Researcher

30. Freedman MS, Bitar R, Antel J. T cell-human glial Cell interactions: 2) Relationship

between heat shock protein expression and susceptibility to cytolysis. J. Neuroimmunol

1997;74:143-148. Primary researcher

31. Melegos DN, Freedman MS, Diamandis EP. Prostaglandin D synthase concentration in

cerebrospinal fluid and serum of patients with neurological disorders. Prostaglandins

1997;54:463-474. Co-primary researcher (performed up to 50% of experiments and

assisted with the writing of the manuscript.)

32. The Canadian Burden of Illness Study Group*. Burden of illness of multiple

sclerosis: Part I: Cost of Illness. Can J Neurol Sci 1998;25:23-30. Co-investigator

33. The Canadian Burden of Illness Study Group*. Burden of illness of multiple

sclerosis: Part II: Quality of life in multiple sclerosis. Can J Neurol Sci 1998; 25:31-38.

Co-investigator

34. Sadovnick AD, Risch NJ, Ebers GC and the Canadian Collaborative Study Group*.

Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and

method. Can J Neurol Sci 1998;25:216-21. Co-investigator

35. Francis GS, Freedman MS, Antel JP. Failure of intravenous immunoglobulin to arrest

progression of multiple sclerosis: A clinical and MRI based study. Mult Scler

1998;3:370-376. Co-primary researcher (assisted with up to 50% of the research and

writing of the manuscript.)

36. Zeine R, Pon R, Ladiwala U, Antel JP, Filion LG, Freedman MS. Mechanism of T

cell-induced human oligodendrocyte cytotoxicity: Relevance to multiple sclerosis. J.

Neuroimmunol 1998;87:49-61. Primary supervisor

37. The PRISMS Study Group*. Randomised, double-blind, placebo-controlled study of

interferon -1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-1504.


38. Freedman MS, Ransohoff R, Talbot PJ and Zamvil S. Highlights from the fifth

international congress of the international society of neuroimmunology. J Neuroimmunol

1999;97:4-8.

39. The Lenercept multiple sclerosis Study Group* and The University of British

Columbia MS/MRI Analysis Group. TNF Neutralization in Multiple Sclerosis: Results

of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-465.

Co-investigator

40. Li DKB, Paty DW, the UBC MS/MRI Analysis Research Group and the PRISMS Study

Group*. Magnetic resonance imaging results of the PRISMS trial: A randomized,

double blind, placebo-controlled study of interferon--1a in relapsing-remitting multiple

sclerosis. Ann Neurol 1999;46:197-206. Co-investigator

41. Freedman MS and the OWIMS Study Group. Evidence of interferon -1a dose

response in relapsing-remitting MS: The OWIMS Study. Neurology 1999;53:679-686.

Primary author and co-investigator

42. Oger J and MS Freedman. Consensus statement of the Canadian MS Clinics Network

on: the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci

1999;26:274-275. Co-author

43. Smith-Walker L, Della Malva L, Freedman M, Tellier A and B Collins. Stability of

performance on measures of subcortical functioning in the early phase of relapsing-

remitting multiple sclerosis. J Int Neuropsych Soc 1999;5:96. Co-investigator

44. Freedman MS. Clinical Applications of BMT aim to stop autoimmune disease in its

tracks. Advances in Immunotherapy 2000;7(1):13-17.

45. Ebers GC, Yee IM, Sadovnick AD, Duquette P and the Canadian Collaborative Study

Group*. Conjugal multiple sclerosis: population-based prevalence and recurrence risks

in offspring. Ann Neurol 2000;48:927-31. Co-investigator

46. Steckley JL, Dyment DA, Sadovnick AD, Risch N, Hayes C, Ebers GC and the

Canadian Collaborative Study Group*. Genetic analysis of vitamin D related genes in

Canadian multiple sclerosis patients. Neurology 2000;54(3):729-32. Co-investigator

47. Sadovnick AD, Yee IM, Ebers GC and the Canadian Collaborative Study Group*.

Factors influencing sib risks for multiple sclerosis. Clin Genet 2000;58(6):431-5. Co-

investigator

48. Jacobs LS, Beck RW, Simon JH, et al, and the CHAMPS Study Group*. Intramuscular

interferon beta-1a therapy initiated during a first demyelinating even in multiple sclerosis.

N Engl J Med 2000;343:898-904. Co-investigator


49. Blumhardt LD, Chofflon M, Comi G, Freedman MS, Hartung H-P, Khan O, Lisak R,

Paty DW and Rivera V. Multiple Sclerosis: an overview of the clinical data related to

key issues raised by interferon beta therapy. J Drug Assessment 2001;4:1-7. Co-writer

50. The PRISMS* (Prevention of Relapses and Disability by Interferon--1a

Subcutaneously in Multiple Sclerosis) Study Group* and the University of British

Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon--1a in

relapsing MS. Neurology 2001;56:1628-1636.

51. SPECTRIMS Study Group*. Hughes RAC et al. Randomized controlled trial of

interferon-beta-1a in secondary progressive multiple sclerosis: Clinical Results.

Neurology 2001;56:1496-1504. Co-investigator

52. SPECTRIMS Study Group*. Li DKB et al. Randomized controlled trial of interferon-

beta-1a in secondary progressive multiple sclerosis: MRI Results. Neurology 2001;56:

1505-1513. Co-investigator

53. Maclean HJ and MS Freedman. Immunologic therapy for relapsing-remitting multiple

sclerosis. Current Neurology and Neuroscience Reports 2001;1:277-285. Supervisor and

co-writer

54. Dyment DA, Willer CJ, Scott B, Armstrong H, Ligers A, Hillert J, Paty DW, Hashimoto

S, Devonshire V, Hooge J, Kastrukoff L, Oger J, Metz L, Warren S, Hader W, Power C,

Auty A, Nath A, Nelson R, Freedman M, Brunet D, Paulseth JE, Rice G, O'Connor P,

Duquette P, Lapierre Y, Francis G, Bouchard JP, Murray TJ, Bhan V, Maxner C, Pryse-

Phillips W, Stefanelli M, Sadovnick AD, Risch N, Ebers GC. Genetic susceptibility to

MS: a second stage analysis in Canadian MS families Neurogenetics 2001;3:145-151.

Co-investigator

55. Ligers A, Dyment DA, Willer CJ, Scott B, Armstrong H, Cousin K, Rice G, Bell RB,

Hader W, Paty DW, Hashimoto S, Oger J, Duquette P, Warren S, Gray T, O'Connor P,

Nath A, Auty A, Metz L, Francis G, Paulseth JE, Pryse-Phillips W, Nelson R, Freedman

MS, Brunet D, Bouchard JP, Hillert J, Sadovnick, Risch N and G Ebers. The genetic

contribution of the HLA-DR in DRB1 locus to MS susceptibility. Am J Hum Genet

2001;69:900-903. Co-investigator

56. CHAMPS Study Group*. Interferon -1a for optic neuritis patients at high risk for

multiple sclerosis. Am J Ophthalmol 2001;132:463-71. Co-investigator

57. Sadovnik AD, Ebers GC, Yee IML and the Canadian Collaborative Research Group*.

Familial risks for MS in offspring of consanguineous matings. Neurology 2001;56:784-

785. Co-investigator


58. Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sanberg-Wollheim

M, Soelberg Sorensen P. International consensus statement on the use of disease-

modifying agents in multiple sclerosis. Mult Scler 2002; 8:19-23. Primary author.

59. Dyment DA, Steckley JL, Willer C, Sadovnik AD, Risch N, Ebers GC and the Canadian

Collaborative Research Group*. No evidence to support CTLA-4 as a susceptibility

gene in Canadian families. J Neuroimmunol 2002;123:193-8. Co-investigator.

60. Beck RW, Chandler DL, Cole SR, et al for the CHAMPS study group*. Inteferon b-1a

for early Multiple Sclerosis: CHAMPS trial subgroup analyses. Ann Neurol


61. Murzenok P, Matusevicius D, Freedman MS. T cells in multiple sclerosis:

Chemokine and chemokine receptor expression. Clinical Immunol 2002;103:309-16.

Supervisor

62. Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman MS, Markowitz C, Rammohan K,

Reder T, Sharief M, Wolinaky J. Optimizing immunomodulatory therapy for MS

patients. Int J MS Care. 2002;201:89-90. Primary author.

63. CHAMPS study group*. Baseline MRI characteristics of patients at high risk for

multiple sclerosis: results from the CHAMPS trial. Controlled High-Risk Subjects

Avonex Multiple Sclerosis Prevention Study. Mult Scler 2002;8:330-8. Co-investigator

64. CHAMPS study group*. MRI predictors of early conversion to clinically definite MS

in the CHAMPS placebo group. Neurology 2002; 59:998-1005. Co-investigator

65. CHAMPS study group*. Predictors of short-term disease activity following a first

clinical demyelinating event analysis of the CHAMPS placebo group. Mult Scler


66. Patten SB, Metz LM and the SPECTRIMS Study Group*. Interferon 1a and

depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology


67. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF,

Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; the

IMPACT Investigators*. Benefit of interferon beta-1a on MSFC progression in

secondary progressive MS. Neurology 2002;59:679-87. Co-investigator

68. Freedman MS, Jeffery DR, Wolinsky JS. MS patient management: Optimizing the

benefits of immunomodulatory therapy. Int J MS Care 2002 Suppl:3-7.

69. Filion LG, Graziani-Bowering G, Matusevicius D, Freedman MS. Monocyte-derived

cytokines in multiple sclerosis. Clin Exp Immunol 2003;131:324-34. Co-primary


researcher (performed up to 50% of experiments and assisted with the writing of the

manuscript.)

70. Proulx NL, Freedman MS, Chan JW, Toye B, Code CC. Acute disseminated

encephalomyelitis associated with pasteurella multocida meningitis. Can J Neurol Sci

2003;30:155-158. Supervisor

71. Pon RA, Freedman MS. Study of Herpesvirus saimiri immortalization of T cells

derived from peripheral blood and CSF of multiple sclerosis patients. J Neuroimmunol

2003;139:119-132. Supervisor

72. Filion LG, Matusevicius D, Graziani-Bowering GM, Kumar A, Freedman MS.

Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and

progressive multiple sclerosis. Clin Immunol 2003;106:127-138. Co-primary researcher

(performed up to 50% of experiments and assisted with the writing of the manuscript.)

73. Filion LG, Graziani-Bowering G, Marusevicius D, Freedman MS. Monocyte-derived

cytokines in multiple sclerosis. Clin Exp Immunol 2003;131:324-34. Co-primary

researcher (performed up to 50% of experiments and assisted with the writing of the

manuscript.)

74. Willer CJ, Dyment A, Risch NJ, Sadovnick AD, Ebers GC and the Canadian

Collaborative Study Group*. Twin concordance and sibling recurrence rates in

multiple sclerosis. PNAS 2003;100:12877-72. Co-investigator

75. The diagnosis of primary progressive multiple sclerosis. J Neurol Sciences 2006;145-

152. Freedman MS Member of PROMISE Study Group. Co-investigator

76. Freedman MS, Patry DG, Grand’Maison F, Myles ML, Paty DW, Selchen DH, on

behalf of the Canadian MS Working Group. Treatment optimization in multiple

sclerosis. Can J Neurol Sci 2004;31:157-168. Primary author.

77. Freedman MS. Primary progressive multiple sclerosis: Cerebrospinal fluid

considerations. Mult Scler 2004;10:S31-S35.

78. Phillips JE, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J, Eggenberger E,

Freedman MS, Stuart W, Cunha L et al. A multicenter, open-label, phase II study of the

immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in

patients with multiple sclerosis. Clin Ther 2004;26:511-521. Co-investigator

79. Freedman MS, Thompson EJ, Reiber H, Sindic C, Grimsley G, Tourtellotte W, Racke

M, Giovannoni G, Sharief M, Deisenhammer F, Keir G, Sellebjerg S. Recommended

standard of cerebrospinal analysis in the diagnosis of multiple sclerosis: report of the

Consortium of MS Clinics CSF Task Force. Arch Neurol 2005;62:865-70. Primary

author


80. Dyment DA, Steckley JL, Morrison K, Willer CJ, Cader MZ, DeLuca GC, Sadovnick

AD, Risch N, Ebers GC, for the Canadian Collaborative Study Group*. TCR

polymorphisms and multiple sclerosis. Genes Immun 2004;5:337-342. Co-investigator

81. Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O,

Pozzilli C, O'Connor P, Freedman MS (Member, Study Group). Intravenous

immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-

controlled trial. Lancet 2004;25:364:1149-56. Co-investigator.

82. Petkau AJ, White RA, Ebers GC, Reeder AT, Sibley WA, Lublin FD, Paty DW and the

IFNB Multiple Sclerosis Study Group*. Longitudinal analyses of the effects of

neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.

Mult Scler 2004;10:126-138. (MS Freedman is a co-investigator and member of the

Study Group).

83. Wolinsky JS and the PROMISE Study Group*. The PROMISE Trial: Baseline data

review and progress report. Mult Scler 2004;10:S65-S72. (MS Freedman is a co-

investigator and member of the Study Group.)

84. Freedman MS, Francis GS, Sanders EA, Rice GP, O’Connor P, Comi G, Duquette P,

Metz L, Murrary TJ, Bouchard JP, Abramsky O, Pelletier J, O’Brien F. Once weekly

interferon beta-1alpha for Multiple Sclerosis Study Group*. Randomized study of one-

weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the

OWIMS Study. Mult Scler 2005;41-5. Primary author

85. Chen JT, Collins DL, Freedman, MS, Atkins HL,and Arnold DL, the Canadian

MS/BMT Study Group*, Arnold DL. Local magnetization transfer ratio signal in

homogeneity is related to subsequent change in MTR in lesions and normal-appearing

white-matter of multiple sclerosis patients. NeuroImage 2005; 25:1272-1278. Co-

primary researcher (contributed up to 50% with the analysis and writing of the

manuscript.)

86. McFarland H, Barkhof F, Calabresi P, Clanet M, Cohen J, Cutter G, Freedman MS,

Lublin F, Metz L, Miller A, Montalban X, Noseworthy J, O’Connor P, Panitch H, Petkau

J, Polman C, Reingold S, Schwid S, Thompson A, Wolinsky J. On behalf of the National

MS Society Advisory Committee on Clinical Trials of New Agents in MS. The future of

MS therapies: redesigning MS clinical trials in a new therapeutic era. Mult Scler

2005;11:669-676. Co-panel member (assisting with the writing and review of this

manuscript)

87. Uitdehaag BM, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R, Polman CH.

Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of

multiple sclerosis. A proposal for standardization. Mult Scler 2005;11:227-31. Co-

writer and investigator (assisting with up to 50% of the analysis and writing of this

manuscript)


88. Chen JT, Collins DL, Freedman MS, Atkins HL, Arnold DL, The Canadian MS/BMT

Study Group. Local magnetization transfer ratio signal in homogeneity is related to

subsequent change in MTR in lesions and normal-appearing white-matter of multiple

sclerosis patients. Neuroimage 2005;25:1272-8. Co-primary researcher (assisted with up

to 50% of the analysis and the writing of the manuscript.)

89. Freedman MS. Defining the standards of multiple sclerosis research. Clinical Trends in

Neurology 2005;1:20-24.

90. Francis GS, Rice GP, Alsop JC; PRISMS Study Group*. Interferon beta-1a in MS:

results following development of neutralizing antibodies in PRISMS. Neurology

2005;65:48-55. (MS Freedman is a co-investigator and member of the Study Group.)

91. Gold R, Rieckmann P, Chang P, Abdalla J; PRISMS Study Group*. The long-term

safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple

sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005;12:649-56. (MS

Freedman is a co-investigator and member of the Study Group.)

92. Oger J, Francis G, Chang P; on behalf of the PRISMS Study Group*. Prospective

assessment of changing from placebo to IFN beta-1a in relapsing MS: The PRISMS

study. J Neurol Sci 2005;237:45-52. (MS Freedman is a co-investigator and member of

the Study Group.)

93. Karussis D, Biermann LD, Bohlega S, Boiko A, Choffon M, Fezekas F, Freedman MS,

Gebeily S, Gouider R, Havrodova E, Jakab G, Karabudak R, Miller A, the International

Working Group for Treatment Optimization in MS. A recommended treatment algorithm

in relapsing multiple sclerosis: report of an international consensus meeting. Eur J

Neurology 2006;13:61-71. Co-writer (responsible for up to 50% of the manuscript)

94. Banwell BL, Reder AT, Krupp LB, Tenembaum S, Eraksoy M, Boiko A, Pohl D,

Freedman MS, Schelensky L and Antonijevic I. A multicenter review of the safety and

tolerability of interferon beta-1b in pediatric multiple sclerosis, based on the data

collected and discussed in the expert group. Neurology 2006;66:472-6. Co-investigator

and author (assisting with up to 50% of the analysis and the writing of the manuscript).

95. Kinkel RP. IM interferon -1a delays definite multiple sclerosis 5 years after a first

demyelinating event. The CHAMPIONS Investigators Group*. Neurology

2006;66:678-84. (MS Freedman is a co-investigator and member of the Study Group.)

96. O’Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C, Paty DW,

Stewart JA, Scheyer R. On behalf of the Teriflunomide Multiple Sclerosis Trial Group

and the University of British Columbia MS/MRI Research Group. A phase II study of

the safety and efficacy of Teriflunomide in multiple sclerosis with relapses. Neurology

2006;66:894-900. Co-author (assisting with up to 50% of the analysis and writing of the

paper)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Rice+GP%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Alsop+JC%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22PRISMS+Study+Group%22%5BCorporate+Author%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Gold+R%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Rieckmann+P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Chang+P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Abdalla+J%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22PRISMS+Study+Group%22%5BCorporate+Author%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Oger+J%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Francis+G%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Chang+P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22On+behalf+of+the+PRISMS+Study+Group%22%5BCorporate+Author%5D


97. Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, Freedman MS,

Zackon DH, Kardon RH. Quantifying axonal loss after optic neuritis with optical

coherence tomography. Ann Neurol 2006;59:963-9. Co-researcher (assisting with up to

50% of the analysis and writing of the manuscript)

98. Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnolg DL, Canadian MS

BMT Study Group. Brain atrophy after immunoablation and stem cell transplantation in

multiple sclerosis. Neurology 2006;66:1935-7. Co-primary researcher (assisted with up

to 50% of the analysis and the writing of the manuscript.)

99. Thompson EJ, Freedman MS. Cerebrospinal fluid analysis in the diagnosis of multiple

sclerosis. Adv Neurol 2006;98:147-60. Co-author

100. Kappos L, Traboulsee A, Constantinescu C, Erälinna J-P, Forrestal F, Jongen P, Pollard

J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D. PRISMS Study

Group*. Neurology 2006;67:930-1. Co-investigator

101. Freedman MS. Disease-modifying drugs for multiple sclerosis: current and future

aspects. Expert Opinion on Pharmacotherapy 2006;(Suppl. 1) S1-10.

102. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X,

Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R. Treatment with interferon beta-1b

delays conversion to clinically definite and McDonald MS in patients with clinically

isolated syndromes. Neurology 2006;67:1242-9. Co-researcher (assisting with up to

50% of the analysis and writing of the manuscript)

103. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung H-P, Polman CH, Miller

DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L and Sandbrink

R. Lack of association between antimyelin antibodies and progression to multiple

sclerosis. New England Journal of Medicine 2007;356:371-8. Co-researcher (assisting

with up to 50% of the analysis and writing of the manuscript)

104. Saikali P, Antel Jp, Newcombe J, Chen Z, Freedman MS, Blain M, Cayrol R, Prat A,

Hall JA, Arbour N. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a

mechanism for tissue injury in multiple sclerosis. J Neuroscience 2007;27:1220-1228.

Co-researcher and supervisor

105. O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, Robinson WH,

Cherry SV, Bar-Or A, Banwell B, Fakaura H, Fukazawa T, Tenembaum S, Wong SJ,

Tavakoli NP, Idrissova Z, Viglietta V, Rostasy K, Pohl D, Dale RC, Freedman MS,

Steinman L, Buckle GJ, Kuchroo VK, Hafler DA, Wucherpfennig KW. Self-antigen

tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat

Med 2007;211-217. Co-researcher (assisting with up to 50% of the analysis of

experiments and writing of the manuscript)


106. Feasby T, Banwell B, Benstead T, Bril V, Brouwers M, Freedman MS, Hahn A, Hume

H, Freedman J, Pi D, Wadsworth L. Guildeines on the use of intravenous immune

globulin for neurologic conditions. Transfus Med Rev 2007;21:S57-107. Co-author

(responsible for the entire section on Multiple Sclerosis)

107. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS,

Azzarelli B, Kolar OJ, Atkins HL, Brück W. Autologous hematopoietic stem cell

transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis.

Brain 2007;130:1254-62. Co-researcher (assisting with up to 50% of the analysis and

writing of the manuscript)

108. Duddy M, Niino M, Adatia F, Hebert S, Freedman MS, Atkins HL, Kim HJ, and Bar-Or

A. Distinct effector cytokine profiles of memory and naive human B cell subsets and

implication in multiple sclerosis. J Immunol 2007;178:10. Co-primary researcher

(assisted with up to 50% of the analysis and the writing of the manuscript.)

109. Reicker LI, Tombaugh TN, Walker L, Freedman MS. Reaction time: An alternative

method for assessing the effects of multiple sclerosis on information processing speed.

Arch Clin Neuropsychol 2007;22:655-664. Co-primary researcher (assisted with up to

50% of the analysis and the writing of the manuscript.)

110. Chen JT, Kuhlmann T, Jansen GH, Collins DL, Atkins HL, Freedman MS, O’Connor

PW, Arnold DL; Canadian MS/BMT Study Group. Voxel-based analysis of the

evolution of magnetization transfer ratio to quantify remyelination and demyelination

with histopathological validation in a multiple sclerosis lesion. Neuroimage

2007;36:1152-8. Co-primary researcher (assisted with up to 50% of the analysis and the

writing of the manuscript.)

111. Nielsen JM, Moraal B, Polman CH, Poppe P, de Vos M, Freedman MS, Kappos L,

Barkhof F, Bauer L, Pohl C, Sandbrink R, Hartung H-P, Uitdehaag BMJ. Classification

of patients with a clinically isolated syndrome on signs and symptoms is supported by

magnetic resonance imaging results. Mult Scler 2007;13:717-721. Co-researcher

(assisting with up to 50% of the analysis and writing of the manuscript)

112. Kappos L, Freedman MS, Polman CH, Edan G, Hartung H-P, Miller DH, Montalbán X,

Barkhof F, Radü E-W, Bauer L, Dahms S, Lanius V, Christoph P and Sandbrink R, for

the BENEFIT Study Group. Early versus delayed interferon beta-1b treatment after a

first clinical event suggestive of multiple sclerosis: Impact on disability. Lancet

2007;370:389-97. Co-researcher (assisting with up to 50% of the analysis and writing of

the manuscript)

113. Freedman MS. Bone marrow transplantation: Does it stop MS progression. J Neurol

Sci 2007;259:85-89. Main writer of this review.

114. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, Belman A, Boiko A,

Bykova O, Waubant E, Mah J, Stoian C, Kremenchutzky M, Bardini MR, Ruggieri M,


Rensel M, Hahn J, Weinstock-Guttman B, Yeh A, Farrell K, Freedman MS, Iivanainen

M, Sevon M, Bhan V, Dilenge M-E, Stephens D, and Bar-Or A. Clinical features and

viral serologies in pediatric multiple sclerosis: results of a multinational study. Lancet

Neurol 2007;6:773-81. Co-researcher (assisting with up to 50% of the analysis and


115. Dahms S, Edan G, Freedman MS, Hartung H-P, Kappos L, Atihlasri F, Miller D,

Montalban X, Polman CH, Poppe PA, Radue EW, Devos ML, Wagner K. MRI effects of

interferon-beta1b in the BENEFIT Study: Integrated 2-year results. Arch Neurol

2007;64:1292-1298. Co-researcher (assisting with up to 50% of the analysis and writing

of the manuscript)

116. Piwko C, Desjardins OB, Bereza BG, Machado M, Jaszewski B, Freedman MS,

Einarson TR, Iskedjian M. . Pain due to multiple sclerosis: Analysis of the prevalence

and economic burden in Canada. Pain Res Manag 2007;12(4):259-65. Co-researcher


117. Chen Z, Freedman MS. Correlation of specialized CD16+ γδ cells with disease course

and severity in multiple sclerosis. Journal of Neuroimmology 2008;194:147-152.

Supervisor

118. Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL, for the Canadian MS/BMT

Study Group. Magnetization transfer ratio evolution with demyelination and

remyelination in multiple sclerosis lesions. Ann Neurol 2008;63:254-262. Co-primary

researcher (assisted with up to 50% of the analysis and the writing of the manuscript.)

119. Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen A, Cutter GR,

Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban

X, O’Connor PW, Panitch H, Richart JR, Petkau J, Schwid SR, Sormani MP, Thompson

AJ, Weinshenker BG, Wolinsky JS. Ethics of placebo-controlled clinical trials in

multiple sclerosis: A reassessment. Neurology 2008;70:1134-1140. Co-author (assisting

with up to 50% of the writing of the manuscript)

120. Darlington PJ, Podjaski C, Horn KE, Costantino S, Blain M, Saikali P, Chen Z, Baker

KA, Newcombe J, Freedman MS, Wiseman PW, Bar-Or A, Kennedy TE, Antel JP.

Innate immune-mediated neuronal injury consequent to loss of astocytes. J Neuropathol

Exp Neurol 2008;67:590-599. Co-researcher (assisting with up to 50% of the analysis

and writing of the manuscript)

121. Fazekas F, Lublin FD, Li D, Freedman MS, Hartung H-P, Rieckmann P, Sorenson P,

Maas-Enriquez M, Sommerauer B, Hanna K. Intravenous immunoglobulin in relapsing-

remitting multiple sclerosis: a dose-finding trial. Neurology 2008;71:265-71. Co-

researcher (assisting with up to 50% of the analysis and writing of the manuscript)

122. Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X,

Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R,

BENEFIT Investigators. Subgroups of the BENEFIT Study: Risk of developing MS and


treatment effect of interferon beta-1b. J Neurol 2008;255:470-487. Co-researcher


123. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D,

Deutsch F, Arnold DL. Glatiramer acetate after induction therapy with mitoxantrone in

relapsing multiple sclerosis. Mult Scler 2008;14;663-670. Co-researcher (assisting with

up to 50% of the analysis and writing of the manuscript)

124. Freedman MS, Hughes B, Micol DD, Bennett R, Cuffel B, Divan V, LaVallee N, Al-

Sabbagh A. Efficacy of disease modifying therapies in relapsing remitting multiple

sclerosis: A systematic comparison. European Neurology 2008;60:1-11. Primary author

125. Chen Z, Freedman MS. CD16(+) gammadelta T cells mediate antibody dependent

cellular cytoxicity: Potential mechanism in the pathogenesis of multiple sclerosis. Clin

Immunol 2008;128:219-227. Supervisor

126. Freedman MS. Induction vs. escalation of therapy for relapsing multiple sclerosis: The

evidence. Neurol Sci 2008;29;S47-S51. Main writer of this review.

127. Ramagopalan SV, Valdar W, Dyment DA, DeLuca GC, Orton S-M, Yee IM, Criscuoli

M, Ebers GC, Sadovnick, for the Canadian Collaborative Study Group*. No effect of

preterm birth on the risk of multiple sclerosis: A population based study. BMC

Neurology 2008;31:181-4. (MS Freedman is a member of the Study Group.)

128. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta

SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban

X, Panitch H, Richert J, Reingold SC, Polman CH. Differential diagnosis of suspected

multiple sclerosis: A consensus approach. Mult Scler 2008;14:1157-1174. Co-author

(responsible for the entire section on spinal cord presentation)

129. Freedman MS, Forrestal F. Canadian Treatment Optimization Recommendations (TOR)

as a predictor of disease breakthrough in patients with multiple sclerosis treated with

interferon beta-1a: analysis of the PRISMS study. Mult Scler 2008;14(9):1234-41.

Primary researcher

130. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B,

Uitdehaag BMJ on behalf of the REGARD study group*. Comparison of subcutaneous

interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the

REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study; a multicentre,

randomized, parallel, open-label trial. Lancet Neurol 2008;7:903-914. (MS Freedman is

a co-investigator and member of the Study Group.)

131. Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK,

Vollmer T. Glatiramer acetate after mitoxantrone induction improves MRI markers of

lesion volume and permanent tissue injury in MS. J Neurol 2008;255:1473-1478. Co-

investigator.


132. MacLean HJ, Freedman MS. Multiple Sclerosis: following clues from cause to cure.

Lancet Neurol 2009;8:6-8. Co-writer of this review.

133. Ramagopalan SV, Valdar W, Criscuoli M, DeLuca GC, Dyment DA, Orton SM, Yee IM,

Ebers GC, Sadovnick AD; Canadian Collaborative Study Group*. Age of puberty and

the risk of multiple sclerosis: a population based study. Eur J Neurol. 2009;16:342-7.

(MS Freedman is a member of the CCSG.)

134. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN,

Blight AR; Fampridine MS-F203 Investigators*. Sustained-release oral fampridine in

multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;

373(9665):732-8. (MS Freedman is a co-investigator and member of the Study Group.)

135. Ramagopalan SV, Valdar W, Dyment DA, DeLuca GC, Yee IM, Giovannoni G, Ebers

GC, Sadovnick AD; Canadian Collaborative Study Group*. Association of infectious

mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology.

2009;32(4):257-62. (MS Freedman is a co-investigator and member of the Study Group.)

136. Freedman MS, Laks J, Dotan N, Altstock RT, Dukler A, Sindic CJM. Anti--glucose

based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first

neurological event. Mult Scler. 2009;15(4):422-430. Primary researcher

137. Moraal B, Pohl C, Uitdehaag BMJ, Polman CH, Edan G, Freedman MS, Hartung H-P,

Kappos L, Miller DH, Montalbán X, Lanius V, Sandbrink R, Barkhof F. MRI predictors

for conversion to multiple sclerosis in the BENEFIT Study. Arch Neurol. 2009;66:1345-

1352. Co-researcher (assisting with up to 50% of the analysis and writing of the

manuscript)

138. Siritho S, Freedman MS. The prognostic significance of cerebrospinal fluid in multiple

sclerosis. J Neurol Sci. 2009:279:21-5. Supervisor

139. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H,

Kappos L; FTY720 D2201 Study Group*. Oral fingolimod (FTY720) in multiple

sclerosis: two-year results of a phase II extension study. Neurology. 2009;72:73-9. (MS

Freedman is a co-investigator and member of the Study Group.)

140. Reingold SC, Steiner JP, Polman CH, Cohen JA, Freedman MS, Kappos L, Thompson

AJ, Wolinsky JS. The challenge of follow-on biologists for treatment of multiple

sclerosis. Neurology. 2009;73:552-559. Co-author (assisting with up to 50% of the


141. Smith AM, Walker LA, Freedman MS, Demeulemeester C, Hogan MJ, Cameron I.

fMRI investigation of disinhibition in cognitively impaired patients with multiple

sclerosis. J Neurol Sci. 2009;28:58-63. Co-researcher (assisting with up to 50% of the

analysis and writing of the manuscript)

http://www.ncbi.nlm.nih.gov/pubmed/19122034?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=20

http://www.ncbi.nlm.nih.gov/pubmed/19122034?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=20


142. Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer

L, Sandbrink R, Kappos L, Uitdehaag BMJ. MRI characteristics are predictive for

CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.

BMC Neurology. 2009;9:19. Co-researcher (assisting with up to 50% of the analysis and


143. Freedman MS, Cohen B, Dhib-Jalbut S, Jeffery D, Reder AT, Sandberg-Wollhaim M,

Weinstock-Guttman B. Recognizing and treating suboptimally controlled multiple

sclerosis: Steps toward regaining command. Curr Med Res Opin. 2009;25:2549-2470.

Primary author (main person responsible for the organization, writing and editing of the

manuscript).

144. Bar-Or A, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, Shi FD, Campagnolo

D, Jalili F, Rhodes S, Yamashita , Fan B, Freedman MS, Panitch H, Arnold DL,

Vollmer T. Serial combination therapy: Is immune modulation in multiple sclerosis

enhanced by initial immune suppression? Mult Scler. 2009;15:959-964. Co-researcher


145. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X,

Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C. Long-term

effect of early treatment with interferon beta-1b after a first clinical event suggestive of

multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Lancet Neurol. 2009;8:987-97. Co-researcher (assisting with up to 50% of the analysis

and writing of the manuscript)

146. Hawker K, O’Connor P, Freedman MS. Calabresi PA, Antel J, Simon J, Hauser S,

Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS Trial Group.

Rituximab in patients with primary progressive multiple sclerosis: Results of a

randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460-

71. Co-researcher (assisting with up to 50% of the analysis and writing of the

manuscript)

147. Costello F, Hodge W, Pan YI, Freedman M, DeMeulemeester C. Differences in retinal

nerve fiber layer atrophy between multiple sclerosis subtypes. J Neurol Sci.

2009;281:74-9. Co-researcher (assisting with up to 50% of the analysis and writing of

the manuscript).

148. De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D,

Heubach JF, Sandbrink R, Tyblova M, Lelkova P; Steering committee of the BENEFIT

study*; Steering committee of the BEYOND study; Steering committee of the LTF

study; Steering committee of the CCR1 study, Integration of genetic risk factors into a

clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score.

Lancet Neurol. 2009;8:1111-9. (MS Freedman is a co-investigator and member of the

Study Group.)


149. Atkins H, Freedman MS. Immune ablation followed by autologous hematopoietic stem

cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods of

Molecular Biology. 2009;549:231-46. (Co-writer of this review)

150. Freedman MS, Uccelli A, Bar-Or A, Atkins H, Karussis D, Frassoni F, Lazarus H,

Scolding N, Slavin S, Le Blanc K. The Therapeutic Potential of Mesenchymal Stem Cell

Transplantation as a Treatment for Multiple Sclerosis: Consensus report of the

International MSCT Study Group. Mult Scler. 2010;16:503-510. (Leader of the

consensus group.)

151. Pasquini MC, Griffith LM, MD, Arnold DL, MD, Atkins HL, Bowen JD, Chen JT,

Freedman MS, Kraft GH, Mancardi GL, Muraro PA, Nash RA, Racke MK, Storek J,

Saccardi R. Workshop Summary, Hematopoietic Stem Cell Transplantation for Multiple

Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical

Studies. Accepted for publication. Biol Blood and Marrow Transplant.

2010;16(8):1076-1083. Co-author (main author responsible for the Multiple Sclerosis

section).

152. Freedman, M., Amato MP, Atkins HL, Athanassios F, Griffith LM, Kerr D, Martin R,

Massacesi L, Muraro P, Nash R, Pasquini M, Saccardi R, Sormani MP, Mancardi G.

(Consensus on the concept of a prospective trial with HSCT in MS. Haematopoietic Stem

Cell Transplantation for Severe Autoimmune Diseases. Florence, Italy, Bone Marrow

Transplantation. 2010. 45: S8-S10. Key writer of this review.

153. Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L,

Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G,

Espino M, Fainardi E, Franciotta D, Freedman MS, Giedraitis V, Gilhus NE,

Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R,

Ingelsson M, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier

BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive PH, Lannfelt L,

Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N,

Papuc E, Paraskevas GP, Pirttila T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L,

Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular

B, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vécsei L, Van Pesch V,

Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang

C, Yao K, Teunissen CE. Neurofilament ELISA validation. J Immunol Methods.

2010;352(1-2):23-31. Co-researcher (helped to design protocol, analyze some of the data

and assist with analysis and writing of the manuscript).

154. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch

P, Chang P, Hamlett A, Musch B, Greenberg J for the CLARITY Study Group*. A

placebo-controlled trial or oral cladribine for relapsing multiple sclerosis. N Engl J Med.

2010;362:416-426. (MS Freedman is a member of the CLARITY Study Group.)

155. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra

R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S,


Kappos L, for the TRANSFORMS Study Group*. Oral fingolimod or intramuscular

interferon for relapsing multiple sclerosis. N Eng J Med. 2010;1-14. (MS Freedman is a

member of the TRANSFORMS Study Group.)

156. Kahn O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassman H, Trapp B, Bar-

Or A, Zak I, Siegel MJ, Lisak R. Chronic cerebrospinal venous insufficiency and

multiple sclerosis. Ann Neurol. 2010;67:286-290. Co-writer of this opinion paper.

157. Walker LAS, Mendella PD, Stewart AF, Freedman MS, Smith AM. Meaningful change

in cognition in multiple sclerosis: Method matters. Can J Neurol Sci. 2011;38(2):282-8.

Co-researcher (helped to design protocol, analyze some of the data and assist with

analysis and writing of the manuscript).

158. Martino G, Franklin RJM, Baron Van Evercooren A, Kerr DA, and the Stem Cells in

Multiple Sclerosis (STEMS) Consensus Group*. Stem cell transplantation in multiple

sclerosis: Current status and future prospects. Nat Rev Neurol. May 2010;6:247-255.

Co-writer of this review with the consensus group.

159. Vosoughi R, Freedman MS. Therapy of MS. Clinical Neurology and Neurosurgery.

Clin Neurol Neurosurg. 2010;112:365-385. Supervisor

160. Newell MK, Tobin RP, Cabrera JH, Sorensen M, Huckstep A, Villalobos-Menuey EM,

Harvey CP, Burnett M, Buddiga A, McCrea E, Bar-Or A, Freedman MS, Nalbantoglu J,

Arbour N, Zamvil S, Antel J. TLR-Mediated B Cell Activation Results in Ectopic CLIP

Expression that Promotes B Cell-Dependent Inflammation. J Leuko Biol. 2010;88;4:779-

89. Co-researcher (helped to design protocol, analyze some of the data and assist with

analysis and writing of the manuscript).

161. Vosoughi R, Freedman MS. MS & ALS: A case report. Int J MS Care. 2010;12:142-

145. Supervisor

162. O'Connor KC, Lopez-Amaya C, Gagne D, Lovato L, Moore-Odom NH, Kennedy J,

Krupp L, Tenembaum S, Ness J, Belman A, Boyko A, Bykova O, Mah JK, Stoian CA,

Waubant E, Kremenchutzky M, Ruggieri M, Bardini MR, Rensel M, Hahn J, Weinstock-

Guttman B, Yeh EA, Farrell K, Freedman MS, Iivanainen M, Bhan V, Dilenge M,

Hancock MA, Gano D, Fattahie R, Kopel L, Fournier AE, Moscarello M, Banwell B,

Bar-Or A. Anti-myelin antibodies modulate clinical expression of childhood multiple

sclerosis. J Neuroimmunol. 2010;223(1-2):92-9. Co-researcher (helped to design

protocol, analyze some of the data and assist with analysis and writing of the manuscript).

163. Darlington PJ, Boivin M-N, Renoux C, Frencois M, Galipeau J, Cohen JA, Freedman

MS, Atkins HL, Solchaga L, Bar-Or A. Reciprocal Rh1 and Th17 regulation by

mesenchymal stem cells: Implication for MS. Ann Neurol. 2010;68:540-5. Co-

researcher (helped to design protocol, analyze some of the data and assist with analysis

and writing of the manuscript).

http://www.ncbi.nlm.nih.gov/pubmed/20381173



164. Tombaugh TN, Berrigan LI, Walker L, & Freedman MS. The Computerized Test of

Information Processing (CTIP) offers an alternative to the PASAT for assessing cognitive

processing speed in individuals with multiple sclerosis. Cog Behav Neurol.

2010;23:3192-198. Co-researcher (helped to design protocol, analyze some of the data

and assist with analysis and writing of the manuscript).

165. Costello F, Hodge W, Pan YI, Eggenberger E, Freedman MS. Using retinal architecture

to help characterize multiple sclerosis patients. Can J Ophthalmol. 2010;45:620-6. Co-

researcher (helped in protocol design, data analysis and writing of manuscript).

166. Chen Z, Freedman MS. T cells and multiple sclerosis: Friends, foes, or both?

Autoimmunity Reviews. 2011. 364-367. Supervisor

167. Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer

L. Sandbrink R, Kappos L, Uitdehaag BM. Correction: Prognostic implications of a

carefully performed neurological assessment in patients with a first event suggestive of

multiple sclerosis. BMC Neuro. 2011. Feb 4:11:19. Co-researcher (helped in protocol

design, data analysis and writing of manuscript).

168. Vosoughi R, Freedman MS. Managing relapsing-remitting multiple sclerosis following

first drug failure. Future Medicine. 2011. 1(2):115-126. Supervisor

169. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of

multiple sclerosis and other neurological diseases. Lancet Neurol. 2011. 10:649-656.

Co-writer of this review.

170. Freedman MS, Metzig C, Kappos L, Polman CH, Edan G, Hartung H-P, Miller DH,

Montalban X, Yarden J, Spector L, Fire E, Dotan N, Schwenke S, Lanius V, Sandbrink

R, Pohl C. Predictive nature of IgM anti-a-glucose serum biomarker for relapse activity

and EDSS progression in CIS patients: A BENEFIT study analysis. Mult Scler. Epub

ahead of print. 2011. Co-researcher (helped in protocol design, data analysis and writing

of manuscript).

171. Hartung H-P, Freedman MS, Polman C, Edan G, Kappos L, Miller D, Montalban X,

Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V,

Sandbrink R, and Christoph Pohl C for the BENEFIT Study Group. Interferon & [beta]-

1b neutralizing antibodies 5 years after clinically isolated syndrome. Neurol. 2011.

77(9):835-843. Co-researcher (helped in protocol design, data analysis and writing of

manuscript).

172. Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D,

Hartung H-P, Krantz M, Ferenczi L, Verco T. A phase III study evaluating the efficacy

and safety of MBP8298 in secondary progressive MS. Neurol. 2011. 18:77(16):1551-

1560. Global principal investigator and lead of manuscript committee. (Designed

protocol as head of steering committee, analyzed the data and was main writer of the


manuscript.)

173. Patsopoulos NK, Esposito F, Reischi J, Lehr S, Bauer D, Heubach J. Sandbrink R, Pohl

C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung H-P,

Amason BGW, Comi G, Cook S, Filippi M, Goodin DS, Jeffrey D, O’Connor P, Ebers

GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk J, Hiller J, Behlo M, Booth

DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM,

chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott

M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott

RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J,

Matthews P, Filippo MB, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A,

Oskenberg JR, Pericak-Vance M, Sawcer, SJ, De Jager PL, Hafler DA, de Bakker PIW,

the BSP MS Genetics Working Group and the Steering Committee of Studies evaluating

IFNb-1b and a CCR1-antagonist, ANZgene Consortium, GeneMSA, International

Multiple Sclerosis Genetics Consortium. Genomewide meta-analysis identifies novel

multiple sclerosis susceptibility. Ann Neurol. 2011. 70(6):897-912. Co-researcher

(helped in protocol design, data analysis and writing of manuscript).

174. Freedman MS. Improving long-term follow-up studies of immunomodulatory therapies.

Neurol. 2011:76(Suppl 1):S35-S38.

175. Freedman MS. Long-term follow-up of clinical trials of MS therapies. Neurol. 2011.

76(Suppl1):S26-34.

176. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H,

Truffinet P, Miller A, Freedman MS for the TEMSO Trial Group. Randomized trial of

oral teriflunomide for relapsing multiple sclerosis. NEJM. 2011. 365:14:1993-1303.

177. Freedman MS. Introduction to research in MS. MS in Focus. 2011. Issue 17.

178. Freedman MS. Multiple sclerosis therapeutic strategies. Neurol: Clinical Practice. Dec

2011. p.66-68.

179. Saccardi R, Freedman MS, Sormani MP, Atkins HL, Farge D, Griffith LM, Kraft G,

Mancardi GL, Nash R, Pasquini M, Martin R, Muraro P on behalf of the European Blood

and Marrow Transplantation Group (EBMT), the Center for International Blood and

Marrow Research (CIBMTR) and the aHSCT in MS International Study Group. A

prospective, randomized, controlled trial of autologous haematopoietic stem cell

transplantation for aggressive multiple sclerosis: A position paper. Mult Scler J. 2012.

18(6):825-834.

180. Walker LAS, Cheng A, Berard J, Berrigan LI, Rees LM, Freedman MS. Tests of

information processing speed: What do people with multiple sclerosis think about them?

Int J MS Care. 2012. 14:92-99 Co-researcher (helped in protocol design, data analysis

and writing of manuscript).


181. Smith AM, Walker LAS, Freedman MS, Berrigan LI, St. Pierre J, Hogan MJ, Cameron

I. Activation patterns in multiple sclerosis on the Computerized Tests of Information

Processing. J Neurol Sci. 2012. 312(1-2)131-137.

182. Comi G, De Stefano N, Freedman MS, Barkhof F, Polman H, Uitdehaag BMJ, Casset-

Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. Comparison of

two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical

demyelinating event suggest of multiple sclerosis (REFLEX): A phase 3 randomised

controlled trial. Lancet Neurol. 2012. 11(1):33-41.

183. Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A,

Traboulsee AL, Reimen LE, O’Connor PW for the Teriflunomide Multiple Sclerosis

Trial Group. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing

multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler J. 2012.

18(9):1278-89.

184. Freedman MS, Ucelli A. Neurorepair with mesenchymal stem cells: Hope or hype?

Lancet Neurol. 2012. 11(2):123-125.

185. Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, Olsson T,

Miller AE, Benzerdjeb H, Li H, Simonson C, O'Connor P. Teriflunomide added to

interferon- in relapsing multiple sclerosis: A randomized phase II trial. Neurol. 2012.

78:1877-1885.

186. Freedman MS. Do not treat from CIS onset: Evaluate disease course and prognosis first

– No (treat). Mult Scler J. 2012. 18:4:394-5.

187. Polman CH, Balcer LJ, Banwell B, Barkhof F, Calabresi P, Clanet M, Cohen JA, Comi

G, Cutter GR, Freedman MS, Goodman AD, Kappos L, Kieseier BC, Lubetzki C,

Lublin FD, Miller A, Montalban X, O’Connor P, Petkau J, Pozzilli C. Disability

outcomes in multiple sclerosis trials: Current status and future prospects. Lancet Neurol.

2012. 11:467-476. (Member of the International Advisory Committee on Clinical Trials

in Multiple Sclerosis).

188. Walker LAS, Berard JA, Berrigan LI, Rees LM, Freedman MS. Detecting cognitive

fatigue in multiple sclerosis: Method matters. J Neurol Sci. 2012. 316:86-92.

189. Greene DN, Schmidt RL, Wilson AR, Freedman MS, Grenache DG. Cerebrospinal

fluid myelin basic protein is frequently ordered but has little value: a test utilization

study. Am J Clin Pathol. 2012. 138(2). 262-72.

190. Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP,

Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink

R. Effects of interferon beta-1b on cognitive performance in patients with a first event

suggestive of multiple sclerosis. Mult Scler. 2012. 18(10):1466-71.









191. Cruce R, Vosoughi R, Freedman MS. Cognitive impact of anticholinergid medication

in MS: Adding insult to injury? Multiple Sclerosis and Related Disorders. 2012.

1(4):156-161.

192. Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P,

Wang L, D'Castro L, Comi G, Freedman MS. for the Teriflunomide Multiple Sclerosis

Trial Group. Pre-specified subgroup analyses of a placebo-controlled phase III trial

(TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler. 2012.

18(11). 1625-1632.

193. Costello F, Hodge W, Pan YI, Burton JM, Freedman MS, Stys PK, Trufyn J, Kardon R.

Sex-specific differences in retinal nerve fiber layer thinning after acute optic neuritis.

Neurol. 2012. 30:79(18). 1866-72.

194. Khoshnam M, Freedman MS. Disease-specific therapy of idiopathic inflammatory

demyelinating disorders. Expert Rev Neurother. 2012. 12(9). 1113-24.

195. Ucelli A, Laroni A, Freedman MS. Mesenchymal stem cells as treatment for MS –

progress to date. Mult Scler. 2012. 18(9):1278-89.

196. Selchen D, Bhan V, Blevins G, Devonshire V, Duquette P, Grand’Maison F,

Kremenchutzky M, Lapierre Y, Li D, von Riedemann SJ, Freedman MS. MS, MRI and

the 2010 McDonald criteria: A Canadian expert commentary. Neurol. 2012. 79:23. S2.

197. Cruce R, Freedman MS. Timely therapeutic interventions and long-term therapeutic

benefits in multiple sclerosis. Hot Topics in Neurology & Phychiatry. 2012. 5:137-17.

198. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP,

Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL,

Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II Investigators.

Alemtuzemab for patients with relapsing remitting multiple sclerosis after disease-

modifying therapy: A randomised controlled phase 3 trial. Lancet. 2012.

380(9856):1829-39.

199. Wolinsky JS, Narayana PA, Nelson F, Datta Sushmita, O’Connor P, Confavreux C, Comi

G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS for the

Teriflonomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance

imaging outcomes from a phase III trial of teriflunomide. Mult Scler J.

2013:19(10):1310-9.

200. Darlington PJ, Touil T, Doucet JS, Gaucher D. Zeidan J, Gauchat D, Corsini R, Kim HJ,

Duddy M, Jalili F, Arbour N, Kebir H, Chen J, Arnold DL, Bowman M, Antel J, Prat A,

Freedman MS, Atkins H, Sekaly R, Chenier R, Bar-Or A; Canadian MS/BMT Study

Group. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease

abrogation after hametopoietic stem cell transplantation. Ann Neurol. 2013.







Mar:73(3):341-54.

201. Atkins HL, Freedman MS. Hematopoietic stem cell therapy for multiple sclerosis: Top

10 lessons learned. Neurotherapeutics. 2013. 10:68-76.

202. Kremenchutzky M, Yeung M, Vorobeychik G, Grand’Maison F, Duquette P, Antel J, Lee

L, Ma C, Yong VW, Hill M, Marriott J, Topor T, Freedman MS, Bhan V, Riddehough

A, Lee A, Lam K, Thibault M, Blevins G, Cerchiaro G, Metz L, Eliasziw M, Traboulsee

T, Kang H, Cheng Y, Zhao G. Application and a proposed modification of the 2010

McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients

with clinically isolated syndromes. Mult Scler J. 2013;20(4):458-63.

203. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, Morgenthau D,

Lapierre Y, on behalf of the Canadian Multiple Sclerosis Working Group. Treatment

optimization in MS: Canadian MS Working Group updated recommendations. Can J

Neurol Sci. 2013. 40:307-323.

204. Selmaj K, Li DK, Hartung H-P, MD; Hemmer B, Kappos L, Freedman MS, Stüve O,

Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke

F, Wallström E. Siponimod for patients with relapsing-remitting multiple sclerosis

(BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013.

12(8)756-67.

205. Freedman MS. Fingolimod versus intramuscular interferon for patients with multiple

sclerosis who have a suboptimal response to interferon-therapy. J Neurol. 2013; 260

POSTER(8):2023-32.

206. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells as treatment for MS –

progress to date. Mult Scler. 2013. 19(5):515-9.

207. Menon S, Shirani A, ZhaoY, Oger J, Traboulsee A, Freedman MS, Tremlett H.

Characterizing aggressive multiple sclerosis. J Neurol, Neurosurg and Psychiatry. 2013

Nov;84(11):1192-8..

208. Grand’maison F, Bhan V, Freedman MS, Myles ML, Patry DG, Selchen DG, Moriarty

P, Traboulsee A. Utility of the Canadian Treatment Optimization Recommendations

(TOR) in MS care. Can J Neurol Sci. 2013. 40(4):527-35.

209. Freedman MS. Present and emerging therapies for multiple sclerosis. Continuum.

2013. 19:968-91. Aug 2013.

210. Berrigan LI, Lefevre JA, Rees LM, Berard J, Freedman MS. Walker LA. Cognition in

early relapsing-remitting multiple sclerosis: Consequences may be relative ito working

memory. J Int Neuropsychol Soc. 2013. 18:1-12.

Commente d [MSF1]: Should this be there?


211. O’Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson

TP, Miller AE, Dive-Pouletty C, Bégo-Le-Babousse G, Kappos L. Teriflunomide

reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol.

2013:260(10):2472-80.

212. Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodi S,

Truffinet P, Benamor M, Chambers S, O’Connor PW. Teriflunomide effect on immune

response to influenza vaccine in patients with multiple sclerosis. Neurol. 2013.

81(6):552-8.

213. Walker LAS, Berard JA, Atkins HL, Bowman M, Lee H, Freedman MS. Cognitive

change and neuroimaging following immunoablative therapy and hematopoietic stem cell

transplantation in multiple sclerosis: A pilot study. Mult Scler Relat Disord. 2014

Jan;3(1):129-35

214. Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the

therapeutic efficacy of alemtuzumab in multiple sclerosis. Clinical & Cellular

Immunology. 2013:4:4.

215. Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, Tremlett H.

Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psych.

2013:8;84(11):1192-8.

216. Freedman MS. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther

Adv Chronic Dis. 2013:4(5):192-205.

217. De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM,

Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, Jack DL, Barkhof F. Efficacy of

subcutaneous interferon -1a on MRI outcomes in a randomised controlled trial of

patients with clinical isolated syndromes. J Neurol Neurosurg Psychiatry. 2014

Jun;85(6):647-53.

218. AlTahan AM, Alsharoqi I, Bohlega SA, Dahdaleh M, Daif Abdulkader, Deleu D, Esmat

K, Giampaolo D, Freedman MS, Gwilt M, Hosny H, Inshasi JI, Aljimuah M, Khalifa A,

Pakdaman H. Szolics M, Yamout BI, Sahraian MA, Zakaria MF. Characteristics of

multiple sclerosis in the Middle East with special reference to the applicability of

international guidelines to the region. Int J Neurosci. 2014 Sep;124(9):635-41.

219. Edan G, Kappos L, Montalban X, Polman C, Freedman MS, Hartung H-P, Miller D,

Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D. Long-

term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J

Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9

220. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P,

Casset-Semanaz F, Scaramozza M: oral cladribine for early MS (ORACLE MS) Study

Group. Effect of oral cladribine on time to conversion to clinically definite multiple


sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3

randomised trial. Lancet Neurol. 2014 Mar;13(3):257-67

221. Clanet MC, Wolinsky JS, Ashton RJ, Hartung H-P, Reingold SC. Risk evaluation and

monitoring in multiple sclerosis therapeutics. Workshop attendee. 2013. Epub ahead of

print.

222. Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D,

Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH,

Sandbrink R, Barkhof F. Interferon beta-1b reduces black holes in a randomised trial of

clinical isolated syndrome. Mult Scler. 2014;20(2):234-42.

223. Berard JA, Bowman M, Atkins HL, Freedman MS, Walker LAS. Cognitive fatigue in

individuals with multiple sclerosis undergoing immunoablative therapy and

hematopoietic stem cell transplantation. J Neurol Sci. 2014 Jan 15;336(1-2):132-137.

224. Freedman MS. Treatment options for patients with multiple sclerosis who have a

suboptimal response to interferon-b therapy. European J Neurol.. 2014 Mar;21(3):377-

387.

225. Pohl C, Polman CH, Miller D, Barkhof F, Edan G, Hartung HP, Kappos L, Freedman

MS, Montalban X, Radue EW, Köchert K, Munger K. White R, Simon KC, Pleimes D,

Sandbrink R. Vitamin D as an early predictor of multiple sclerosis activity and

progression. JAMA. 2014;71(3):306-14.

226. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky

JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial GroOral

teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised,

double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar;13(3):247-56

227. Berrigan L, Fisk J, Walker L, Wojtowicz M, Rees L, Freedman MS, Marrie RA.

Reliability of regression-based normative data for the oral symbol digit modalities test:

An evaluation of demographic influences, construct validity and impairment

classification rates in multiple sclerosis samples. Clin Neuropsychol. 2014;28(2):281-

99.

228. Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BMJ, Casset-

Semanaz F, Hennessy B, Lehr L, Stubinski B, Jack DL, Kappos L. Patient subgroup

analyses of the treatment effect of subcutaneous interferon b-1a on development of

multiple sclerosis in the randomized controlled REFLEX Study. J Neurol. 2014

Mar;261:3(2014):490-99.

229. Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky

JS, Bagulho T, Delhay J-L, Dukovic D, Truffinet P, Kappos L, for the TOWER Trial

Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a

randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014





Mar;13(3):247-56.

230. Ascherio A, Munger K, White R, Köchert K, Simon KC, Polman CH, Freedman MS,

Hartung H-P, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü E-W,

Sandbrink R, Kappos L, Pohl C. Vitamin D as an early predictor of multiple sclerosis

activity and progression. JAMA Neurol. 2014 Mar;71(3):306-14.

231. Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BMJ, Lehr L,

Stubinski B. Kappos L. Moving toward earlier treatment of multiple sclerosis: Findings

from a decade of clinical trials and implications for clinical practice. MSARD.

2014;3:147-155.

232. Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, Berkani O,

Mueller MS, Sidorenko TV, Radue EW. Oral ponesimod in relapsing-remitting multiple

sclerosis: A randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014

Nov;85(11):1198-208

233. Correale J, Abad P, Alvarenga R, Alves-Leon S, Arms E, Barahona J, Buzo R, Corono T,

Cristiano E, Gracia F, Bonitto JG, Macias MA, Soto A, Vizcarra D, Freedman MS.

Management of relapsing-remitting multiple sclerosis in Latin-America: Practical

recommendations for treatment optimization. J Neurol Sci. 2014 Apr 15;339(1-2):196-

206

234. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson

TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman

MS, O’Connor P; TENERE Trial Group. Mult Scler. 2014:20(6):705-16.

235. Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M,

Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group. Atacicept in

multiple sclerosis (ATAMS): a randomized, placebo-controlled, double-blind, phase 2

trial. Lancet Neurol. 2014;13(4):353-63.

236. Sartori A, Carle D, Freedman MS, Teriflunomide: A novel oral treatment for relapsing

multiple sclerosis. Expert Opin Pharmacother. 2014;15(7):1019-27.

237. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson

TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman

MS, O'Connor P; TENERE Trial Group. Teriflunomide versus subcutaneous interferon-

beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3

trial. Mult Scler. 2014 May;20(6):705-16

238. Miller A, MacDonell R, Comi G, Freedman MS, Kappos L, Maeurer M, Olsson T,

Wolinsky J, Bozzi S, Dive-Pouletty C, O’Connor P. Teriflunomide reduces relapses with

sequelae and relapses leading to hospitalizations: Results from the TOWER Study. J

Neurol. 2014 Sep;261(9):1781-8


239. Freedman MS. Efficacy and safety of subcutaneous interferon--1a in patients with a

first demyelinating event and early multiple sclerosis. Expert Opin Biol Ther. 2014

Aug;14(8):1207-14

240. Freedman MS. Multiple sclerosis: Does aggressive MS warrant aggressive treatment?

Nat Rev Neurol. 2014 Jul;10(7):368-70

241. Sartori A, Carle D, Freedman MS. Teriflunomide: A novel oral treatment for relapsing

multiple sclerosis. Expert Opin Pharmacother. 2014 May;15(7):1019-27

242. Reingold JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell

BL, Barkhof F, Bebo B, Calabresi PA. Clanet GM, Comi G, Fox RJ, Freedman MS,

Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln J, Lubetzki C, Miller AE,

Montalban X, O’Connor P, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stuve O,

Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: The 2013

revisions. Neurology. 2014 Jul 15;83(3):278-86

243. Lublin F, Bowen J, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy J,

Freedman MS, Krupp L, Paulo C, Hariri R, Fischkoff S. Human Placenta-Derived Cells

(PDA-001) for the Treatment of Adults With Multiple Sclerosis: A Randomized,

Placebo-Controlled, Multiple-Dose Study. Mult Scler Relat Disord. 2014 Nov;3(6):696-

704

244. Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP,

Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl

C. Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Ann Clin Transl Neurol. 2014 Aug;1(8):605-17

245. Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick

LP, Agashivala N, Schofield L, McCague K, Hashmonay R, Barbato L; EPOC study

investigators. First-dose effects of fingolimod after switching from injectable therapies in

the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in

relapsing multiple sclerosis. Mult Scler Relat Disord. 2014 Sep;3(5):620-8

246. Freedman MS Evidence for the efficacy of interferon beta-1b in delaying the onset of

clinically definite multiple sclerosis in individuals with clinically isolated syndrome.

Therapeutic Advances in Neurological Disorders. Nov 2014 7: 279-88

247. Wolinsky J, Kappos L, Giancarlo C, Freedman MS, Olsson T, Oral teriflunomide for

patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a

randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014

Oct;13(10):977-86

248. Miller A, Wolinsky J, Kappos L, Comi G, Freedman MS, Olsson T, Bauer D, Benamor

M, Truffinet P, O’Connor P, Oral teriflunomide for patients with a first clinical episode

suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-






controlled, phase 3 trial. Lancet Neurol. 2014 Oct;13(10):977-86

249. V Bhan, Lapierre Y, Freedman MS, Duquette P, Selchen D, Migounov V, Walt L,

Zhang A. Anti-JC Virus Antibody Prevalence in Canadian MS Patients. Can J Neurol

Sci. 2014 Nov 4:1-5

250. Goodman AD1, Bethoux F2, Brown TR3, Schapiro RT4, Cohen R5, Marinucci LN5,

Henney HR 3rd5, Blight AR6; on behalf of the MS-F203, MS-F204, and Extension Study

Investigators; on behalf of the MS-F203 MS-F204 and Extension Study Investigators.

Freedman MS (collaborator). Long-term safety and efficacy of dalfampridine for

walking impairment in patients with multiple sclerosis: Results of open-label extensions

of two Phase 3 clinical trials. Mult Scler. 2015 Jan 12. pii: 1352458514563591.

251. Gibbs E, Karim ME, Oger J; Steering Committee of the BENEFIT study. Antibody

dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of

interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus

sustained NAbs. Clin Immunol. 2015 Mar;157(1):91-101

252. Freedman MS, Abdoli M. Evaluating response to disease-modifying therapy in

relapsing multiple sclerosis. Expert Rev Neurother. 2015 Apr;15(4):407-23.

253. Traboulsee A, Létourneau-Guillon L, Freedman MS, O'Connor PW, Bharatha A,

Chakraborty S, Girard JM, Giuliani F, Lysack JT, Marriott JJ, Metz LM, Morrow SA, Oh

J, Sharma M, Vandorpe RA, Vertinsky TA, Wadhwa VS, von Riedemann S, Li DK.

Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.

Can J Neurol Sci. 2015 May;42(3):159-67.

254. MacMillan EL, R Tam, Y Zhao, IM Vavasour, DKB Li, J Oger, MS Freedman,

SH Kolind and AL Traboulsee. Progressive multiple sclerosis exhibits

decreasing glutamate and glutamine over two years. Mult Sclerosis Journal. 2015 May

26. pii: 1352458515586086.

255. Mahzari M, Arnaout A, Freedman MS. Alemtuzumab Induced Thyroid Disease in

Multiple Sclerosis: A Review and Approach to Management. Can J Neurol Sci. 2015

May 20:1-8.

256. Rush CA , MacLean HJ , Freedman MS. Aggressive multiple sclerosis: proposed

definition and treatment algorithm. Nat Rev Neurol. 2015 Jul;11(7):379-89

257. Abdoli M, Freedman MS. Neuro-oncology dilemma: Tumour or tumefactive

demyelinating lesion.Mult Scler Relat Disord. 2015 Nov;4(6):555-66

258. Kassandra L. Munger, Kathryn C. Fitzgerald, Mark S. Freedman, Hans-Peter Hartung,

David H. Miller, Xavier Montalbán, Gilles Edan, Frederik Barkhof, Gustavo Suarez,

Ernst-Wilhelm Radue, Rupert Sandbrink, Ludwig Kappos, Christoph Pohl, and Alberto

Ascherio. No association of multiple sclerosis activity and progression with EBV or

http://www.ncbi.nlm.nih.gov/pubmed/?term=Goodman%20AD%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Bethoux%20F%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Brown%20TR%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Schapiro%20RT%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Cohen%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Marinucci%20LN%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Henney%20HR%203rd%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=Blight%20AR%5BAuthor%5D&cauthor=true&cauthor_uid=25583832

http://www.ncbi.nlm.nih.gov/pubmed/?term=on%20behalf%20of%20the%20MS-F203%2C%20MS-F204%2C%20and%20Extension%20Study%20Investigators%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed/?term=on%20behalf%20of%20the%20MS-F203%2C%20MS-F204%2C%20and%20Extension%20Study%20Investigators%5BCorporate%20Author%5D

http://www.ncbi.nlm.nih.gov/pubmed/?term=on%20behalf%20of%20the%20MS-F203%20MS-F204%20and%20Extension%20Study%20Investigators%5BCorporate%20Author%5D










http://www.ncbi.nlm.nih.gov/pubmed/?term=Mahzari%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25990097

http://www.ncbi.nlm.nih.gov/pubmed/?term=Arnaout%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25990097

http://www.ncbi.nlm.nih.gov/pubmed/?term=Freedman%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=25990097



http://www.ncbi.nlm.nih.gov/pubmed/?term=Rush%20CA%5BAuthor%5D&cauthor=true&cauthor_uid=26032396

http://www.ncbi.nlm.nih.gov/pubmed/?term=MacLean%20HJ%5BAuthor%5D&cauthor=true&cauthor_uid=26032396

http://www.ncbi.nlm.nih.gov/pubmed/?term=Freedman%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=26032396





tobacco use in BENEFIT. Neurology November 10, 2015 85:1694-1701

259. Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, Sormani

MP, Smith T, Häring DA, Piani Meier D, Tomic D. Inclusion of brain volume loss in a

revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting

multiple sclerosis. Mult Scler. 2015 Nov

260. Govindarajan, K.A., Datta, S., Hasan, K.M., Choi, S., Rahbar, M.H., Cofield, S.S.,

Cutter, G.R., Lublin, F.D., Wolinsky, J.S., Narayana, P.A., Nelson, F., Vainrub, I., He,

R., Gates, B., Ton, K., Agius, M., Bashir, K., Baumhefner, R., Birnbaum, G., Blevins, G.,

Bomprezzi, R., Boster, A., Brown, T., Burkholder, J., Camac, A., Campagnolo, D.,

Carter, J., Cohen, B., Cooper, J., Corboy, J., Cross, A., Dewitt, L., Dunn, J., Edwards, K.,

Eggenberger, E., English, J., Felton, W., Fodor, P., Ford, C., Freedman, M., Galetta, S.,

Garmany, G., Goodman, A., Gottesman, M., Gottschalk, C., Gruental, M., Gudesblatt,

M., Hamill, R., Herbert, J., Holub, R., Honeycutt, W., Hughes, B., Hutton, G., Jacobs, D.,

Johnson, K., Kasper, L., Kattah, J., Kaufman, M., Keegan, M., Khan, O., Khatri, B., Kita,

M., Koffman, B., Lallana, E., Lava, N., Lindsey, J., Loge, P., Lynch, S., McGee, F.,

Mejico, L., Metz, L., O'Connor, P., Pandey, K., Panitch, H., Preiningerova, J.,

Rammohan, K., Riley, C., Riskind, P., Rolak, L., Royal, W., Scarberry, S., Schulman, A.,

Scott, T., Sheppard, C., Sheremata, W., Stone, L., Stuart, W., Subramaniam, S., Thadani,

V., Thomas, F., Thrower, B., Tullman, M., Turel, A., Vollmer, T., Waldman, S.,

Weinstock-Guttman, B., Wendt, J., Williams, R., Wynn, D., Yeung, M. Effect of in-

painting on cortical thickness measurements in multiple sclerosis: A large cohort study.

Human Brain Mapping volume 36, issue 10, year 2015, pp. 3749 - 3760

261. MS Freedman, JS Wolinsky, P Truffinet, G Comi, L Kappos, AE Miller, TP Olsson,

M Benamor, S Chambers and PW O’Connor. A randomized trial of teriflunomide added

to glatiramer acetate in relapsing multiple sclerosis. Multiple Sclerosis Journal -

Experimental, Translational and Clinical 2016, 1: 1-10

261. Daniele D’Ambrosio, MS Freedman and Joerg Prinz. Ponesimod, a selective S1P1

receptor modulator: a potential treatment for multiple sclerosis and other immune-

mediated diseases. Ther Adv Chronic Dis. 2016, Vol 7(1) 18-33

262. Yves Lapierre, Paul O’Connor, Virginia Devonshire, Mark S Freedman, Marcelo

Kremenchutzky, Michael Yeung, Robyn Schecter. Canadian Experience with

Fingolimod: Adherence to Treatment and Monitoring. Can J Neurol Sci. 2016; 00: 1-6

263. MacMillan EL, Tam R, Zhao Y, Vavasour IM, Li D, Oger J, Freedman MS, Kolind SH,

Traboulsee AL. Progressive multiple sclerosis exhibits decreasing glutamate and

glutamine over two years. Mult Scler. 2016;22(1):112-6.

264. Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW,

Benamor M, Dukovic D, Truffinet P, Leist TP. Pooled safety and tolerability data from

four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord.

2016 Jan;5:97-104









265. O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-

Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ,

Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-

AC in Houston, Texas; Teriflunomide Multiple Sclerosis Oral TEMSO Trial Group and

the MRI-AC in Houston Texas. Long-term safety and efficacy of teriflunomide: Nine-

year follow-up of the randomized TEMSO study. Neurology. 2016 Feb. pii: 10.1212

266. Walker LA, Osman L, Berard JA, Rees LM, Freedman MS, MacLean H, Cousineau

D.Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Canadian

contribution to the international validation project. J Neurol Sci. 2016 Mar;362:147-52.

267. Fred Lublin, David H Miller, MS Freedman, Bruce A C Cree, Jerry Wolinsky, Howard

Weiner, Catherine Lubetzki, Hans-Peter Hartung, Xavier Montalban, Bernard M J

Uitdehaag, Martin Merschhemke, Binging Li, Norman Putzki, Fonda Liu, Dieter Haring,

Ludwig Kappos. Oral fingolimod in primary progressive multiple sclerosis (INFORMS):

a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. Volume 387, No.

10023, p1075–1084, March 2016

268. Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery

D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-

Plus, an improved endpoint for disability progression in secondary progressive multiple

sclerosis. Mult Scler. 2016 Mar

269. Torres C, Lum C, Chakraborty S, Hogan MJ, Nguyen T, Bussiere M, Freedman MS.

Extracranial venous abnormalities: A pathological finding in multiple sclerosis or a

normal anatomical variant? Eur Radiol. 2017 Jan;27(1):239-246.

270. Atkins H, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I,

Birch P, Bredeson C, Chen J, Fergusson D, Halpenny H, Hamelin L, Huebsch L, Hutton

B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O’Connor P, Ramsay T,

Sabloff M, Walker L, and MS Freedman. Immunoablation and autologous haemopoietic

stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group

phase 2 trial. The Lancet. 2016 Aug 6;388(10044):576-85.

271. Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. Lee

H, Narayanan S, Brown RA, Chen JT, Atkins HL, Freedman MS, Arnold DL.Mult

Scler. 2017 Mar; 23(3):420-431

272. Multiple sclerosis relapses are associated with increased fatigue and reduced health-

related quality of life - A post hoc analysis of the TEMSO and TOWER studies. Mäurer

M, Comi G, Freedman MS, Kappos L, Olsson TP, Wolinsky JS, Miller AE, Dive-

Pouletty C, Bozzi S, O'Connor PW. Mult Scler Relat Disord. 2016 May;7:33-40

273. Freedman MS, Rush CA. Severe, Highly Active, or Aggressive Multiple

Sclerosis.Continuum (2016 Jun;22(3, Multiple Sclerosis and Other Demyelinating

Diseases):761-784.





http://www.thelancet.com/journals/lancet/issue/vol387no10023/PIIS0140-6736(16)X0012-8

http://www.thelancet.com/journals/lancet/issue/vol387no10023/PIIS0140-6736(16)X0012-8




http://www.ncbi.nlm.nih.gov/pubmed/?term=300.+Torres+C%2C+Lum+C%2C+Chakraborty+S%2C+Hogan+MJ%2C+Nguyen+T%2C+Bussiere+M%2C+Freedman+MS.+Extracranial+venous+abnormalities%3A+A+pathological+finding+in+multiple+sclerosis







274. Disability progression in aggressive multiple sclerosis. Menon S, Zhu F, Shirani A, Oger

J, Freedman MS, Tremlett H. Mult Scler. 2017 Mar;23(3):456-463

275. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting

Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.

Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P,

Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K. JAMA Neurol.

2016 Sep 1;73(9):1089-98

276. ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple

sclerosis. Khoury SJ, Rochon J, Ding L, Byron M, Ryker K, Tosta P, Gao W, Freedman

MS, Arnold DL, Sayre PH, Smilek DE; ACCLAIM Study Group. Mult Scler. 2017

Apr;23(5):686-695

277. The EDSS-Plus, an improved endpoint for disability progression in secondary

progressive multiple sclerosis. Cadavid D, Cohen JA, Freedman MS, Goldman MD,

Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S,

Shang S, Mikol D. Mult Scler. 2016 Mar 22

278. Haematopoietic stem cell transplants should be a second-line therapy for highly active

MS – YES. Mark Freedman and Harold L Atkins. Mult Scler. 2016 Sep;22(10):1258-9

279. Severe, Highly Active, or Aggressive Multiple Sclerosis.. Freedman MS, Rush CA.

Continuum (Minneap Minn). 2016 Aug;22(3):761-84

280. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ,

Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G,

Wicklein EM; BENEFIT Study Group. Neurology. 2016 Sep 6;87(10):978-87

281. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a

in MS. Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung

HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH,

Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators.

Neurology. 2016 Oct 4;87(14):1464-1472

282. Is there a safe time to discontinue therapy in MS? Freedman MS. Nat Reviews

Neurology. 2016 Dec 28;13(1):10-11

283. Foziah Alshamrani, Hind Alnajashi , MS Freedman (2016): brain isolated syndrome:

watchful waiting vs. active treatment, Expert Review of Neurotherapeutics. 2017

May;17(5):441-447

284. Mohammad Abdoli, Santanu Chakraborty, MS Freedman, Heather J MacLean.

The evaluation of MRI diffusion values of active demyelinating lesions in multiple sclerosis.

Multiple Sclerosis and Related Disorders: November 2016 (Volume 10) pp 97-102.








https://www.ncbi.nlm.nih.gov/pubmed/27261681





285. Mark S. Freedman, Xavier Montalban, Aaron E. Miller, Catherine Dive-Pouletty,

Steven Hass, Karthinathan Thangavelu, Thomas P. Leist. Comparing outcomes from

clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and

teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to

treat analysis. Multiple Sclerosis and Related Disorders 10 (2016) 204–212

286. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW,

Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II

Investigators. Alemtuzumab improves preexisting disability in active relapsing-

remitting MS patients. Neurology. 2016 Nov 8; 87(19):1985-1992

287. Long-term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for

Multiple Sclerosis. Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas

A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis

VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J,

Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP,

Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation

(MS-AHSCT) Long-term Outcomes Study Group. JAMA Neurol. 2017 Apr 1;74(4):459-

469

288. Mohammad Abdoli, Santanu Chakraborty, Heather J. MacLean, Mark S. Freedman.

The evaluation of MRI diffusion values of active demyelinating lesions in

multiple sclerosis. Multiple Sclerosis and Related Disorders 10 (2016) 97–102

289. Mark S Freedman, Corey C. Ford, Series Editor. What can Cerebral Spinal Fluid tell us

about MS? CSF Biomarkers of MS Progression Overcoming Barriers to Lumbar

Puncture. The Science of MS Management. Fall 2016 Vol 6 Number 2.

290. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. Montalban X,

Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung

HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A,

Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS;

ORATORIO Clinical Investigators. N Engl J Med. 2017 Jan 19; 376(3):209-220

291. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Hauser SL, Bar-

Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X,

Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G,

Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA

I and OPERA II Clinical Investigators. N Engl J Med. 2017 Jan 19; 376(3):221-234

292. The efficacy of teriflunomide in patients who received prior disease-modifying

treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER study.

Mark S Freedman, Jerry S Wolinsky, Giancarlo Comi, Ludwig Kappos, Tomas P


Olsson, Aaron E Miller, Karthinathan Thangavelu, Myriam Benamor,Philippe Truffinet

and Paul W O’Connor; for the TEMSO and TOWER Study Groups. Multiple Sclerosis

Journal. 2018 Apr; 24(4)535-539

293. Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up

study. Sartori A, Abdoli M, Freedman MS. J Neurol. 2017 Jun; 264(6):1068-1075,

Volume

294. Immunoablation and aHSCT for aggressive multiple sclerosis - Authors' reply. Atkins H,

Freedman MS. Lan cet. 2017 Mar 4; 389(10072):908

295. Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year

and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION

study. Comi G, De Stefano N, Freedman MS, Barkhof F, Uitdehaag BM, de Vos M,

Marhardt K, Chen L, Issard D, Kappos L. J Neurol Neurosurg Psychiatry. 2017

Apr;88(4):285-294.

296. Increased sodium intake is not associated with multiple sclerosis activity or

progression in BENEFIT. Kathryn C Fitzgerald,, Kassandra L Munger ,Hans P Hartung ,

MS Freedman, Xavier Montalbán , Gilles Edan , Eva-Maria Wicklein , Ernst-Wilhelm

Radue , Ludwig Kappos , Christoph Pohl , Alberto Ascherio . Annals of Neurology.

2017 July; 82(1):20-29

297. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. Luanne M.

Metz, David K.B. Li, Anthony L. Traboulsee, Pierre Duquette, Misha Eliasziw, Graziela

Cerchiaro, Jamie Greenfield, Andrew Riddehough, Michael Yeung, Marcelo

Kremenchutzky, Galina Vorobeychik, Mark S. Freedman, Virender Bhan, Gregg

Blevins, James J. Marriott, Francois Grand’Maison, Liesly Lee, Manon Thibault,

Michael D. Hill, and V. Wee Yong, for the Minocycline in MS Study Team* N Engl J

Med 2017; 376:2122-2133 June 1, 2017

298. Early MRI results and odds of attaining ‘no evidence of disease activity’ status in MS

patients treated with interferon β-1a in the EVIDENCE study. Patricia K. Coyle,

Anthony T. Reder, Mark S. Freedman, Juanzhi Fang, Fernando Dangond. Journal of

the Neurological Sciences. 2017 Aug 15; 379:151-156

299. Impact of immunoablation and autologous hematopoietic stem cell transplantation on

gray and white matter atrophy in multiple sclerosis. Lee H, Nakamura K, Narayanan

S, Brown R, Chen J, Atkins HL, Freedman MS, Arnold DL. Mult Scler. 2017 Jun 1

(EPub ahead of print)

300. Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell

Transplantation for the Treatment of Multiple Sclerosis. Harold L. Atkins, Mark S.

Freedman. Neurotherapeutics. 2017 Oct; 14(4):888-893

http://www.nejm.org/doi/full/10.1056/NEJMoa1608889?query=featured_home&#footNotesItemFN1

http://www.nejm.org/toc/nejm/376/22/

http://www.sciencedirect.com/science/article/pii/S0022510X17303568





http://www.sciencedirect.com/science/journal/0022510X

http://www.sciencedirect.com/science/journal/0022510X

https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20H%5BAuthor%5D&cauthor=true&cauthor_uid=28617152

https://www.ncbi.nlm.nih.gov/pubmed/?term=Nakamura%20K%5BAuthor%5D&cauthor=true&cauthor_uid=28617152

https://www.ncbi.nlm.nih.gov/pubmed/?term=Narayanan%20S%5BAuthor%5D&cauthor=true&cauthor_uid=28617152

https://www.ncbi.nlm.nih.gov/pubmed/?term=Narayanan%20S%5BAuthor%5D&cauthor=true&cauthor_uid=28617152

https://www.ncbi.nlm.nih.gov/pubmed/?term=Brown%20R%5BAuthor%5D&cauthor=true&cauthor_uid=28617152

https://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=28617152

https://www.ncbi.nlm.nih.gov/pubmed/?term=Atkins%20HL%5BAuthor%5D&cauthor=true&cauthor_uid=28617152

https://www.ncbi.nlm.nih.gov/pubmed/?term=Freedman%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=28617152

https://www.ncbi.nlm.nih.gov/pubmed/?term=Arnold%20DL%5BAuthor%5D&cauthor=true&cauthor_uid=28617152



301. Brain atrophy and disability worsening in PPMS: insights from the INFORMS study.

David Miller, Fred Lublin, Maria Pia Sormani, Ludwig Kappos, Özgür Yaldizli, Mark

Freedman, Bruce Cree, Howard Weiner, Catherine Lubetzki, Hans Peter Hartung,

Xavier Montalban, Bernand Uitdehaag, David MacManus, Tarek Yousry, Claudia

Wheeler-Kingshott, Bingbing Li, Norman Putzki, Martin Merschhemke Dieter Haering,

Jerry Wolinsky. Annals of Clinical and Translational Neurology. 2018 Mar; 5(3): 346–

356.

302. A comparison of multiple sclerosis disease activity after discontinuation of fingolimod

and placebo. Patrick Vermersch, Ernst-Wilhelm Radue, Norman Putzki, Shannon Ritter,

Martin Merschhemke and Mark S Freedman. Mult Scler J Exp Transl Clin. 2017 Jul-

Sep; 3(3): 2055217317730096.

303. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of

MS using modern criteria; Results from the ORACLE-MS study. Mark S Freedman,

Thomas P Leist, Giancarlo Comi, Bruce AC Cree, Patricia K Coyle, Hans-Peter Hartung,

Patrick Vermersch, Doris Damian and Fernando Dangond. Mult Scler J Exp Transl Clin

2017 Oct 9; 3(4):2055217317732802

304. Effect of HLA-DRB1 alleles and genetic variants on the dvelopments of neutralizing

Antibodies to interferon beta in the BEYOND and BENEFIT trails. D. Buck, T.F.M.

Andlauer, W. Igl, E.M Wickleib, M. Muhlau, F. Weber, K. Kochert, C. Pohl, B. Arnason,

G. Comi, S. Cook, M. Flilippi, H-P. Hartung, D. Jeffery, L. Kappos, F. Barkhof, G. Edan,

M.S. Freedman, X. Montalban , B. Muller-Myhsok, B. Hemmer and The BEYOND and

BENEFIT Study Groups. Multiple Sclerosis Journal. Mar 1 2018 (epub ahead of print)

305. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis

(ASCEND), a phase 3, randomized, double-bind, placebo-controlled trial with an open-

label extension. Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin,

Fioba Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman, Myla D

Goldman, Han-Peter Hartung, Eva Kubala Havdova, Douglas Jeffery, Aaron Miller, Finn

Sellebjerg, Diego Cadavid, Dan Mikol, Deborah Steiner. Lancet Neurology. 2018 May; 17

(5) :405-415.

Papers in refereed conference proceedings

1. Freedman MS, Kappos L, Polman C, Hartung H-P, Edan G, Miller D, Montalban X,

Bauer L, Dahms S, Pohl C and Sandbrink R. Analysis of neutralizing antibodies in the

Betaferon® in newly emerging multiple sclerosis for initial treatment (BENEFIT) Study.

Free paper. International proceedings. 8th International Congress of Neuroimmology.

Nagoya (Japan). 2006.

Papers in non-refereed Journals:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624444/


1. Freedman MS: The current status of multiple sclerosis. Modern Medicine of Canada

1987;42(10):GP21-29.

2. Freedman MS. The immunology of MS lesion generation. The Chronicle of Neurology

& Psychiatry 1998;3(7):17-18.

3. Freedman M. Clinical applications of BMT aim to stop autoimmune disease in its

tracks. Advances in Immunotherapy 2000;7(1):13-17.

4. Maclean HJ and MS Freedman. Immunologic therapy for relapsing-remitting multiple

sclerosis. Current Neurology and Neuroscience reports 1:277-285, 2001.

5. Freedman MS. Defining the standards of multiple sclerosis research. Clinical Trends in

Neurology 2005;1:20-24.

6. Freedman MS. Patient management in Multiple Sclerosis: A Canadian expert

viewpoint. Part of Medscape® Conference Coverage. American Academy of Neurology

(AAN). 2005. Miami Beach, Florida.

7. Freedman MS. New perspectives in multiple sclerosis: An expert interview with Mark

S. Freedman, HBSc, MSc, MD. Medscape Neurology & Neurosurgery. 2006;8(2).

8. Freedman MS. Introduction to research in MS. MS in Focus. 2011. Issue 17.

Letters to the Editor:

1. Freedman MS, Ruijs TCG, Selin LK, Antel JPA: Heat shock proteins as targets for T

cells in multiple sclerosis-reply. Ann Neurol 1992;32:410-411.

2. Freedman MS, Muth KL, Trotter JL, Yoshizawa CN, Antel JP: Analysis of interleukin-2

in multiple sclerosis-reply. Neurology 1993;43:1449-1450.

3. Melegos DN, Freedman MS, Diamandis EP. Prostate-specific antigen in cerebrospinal

fluid. Clinical Chemistry 1997;43:855.

4. Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman MS, Markowitz C, Rammohan K,

Reder T, Sharief M, Wolinsky J. Optimizing immunomodulatory therapy for MS

patients: An integrated management model. J Neurol Sci 2002;201:89-90.

5. Freedman MS, King J, Oger J, Sharief M, Hartung HP, PRISMS Study Investigators.

Interferons in relapsing remitting multiple sclerosis. Lancet 2003;361:1822-3; author

reply 1823-4.


6. Freedman MS. Comments on the report of the EFNS task force on IFN-beta antibodies

in multiple sclerosis. Eur J Neurol 2007;14(6).

7. Metz I, Lucchinetti CF, Openhshaw H, Garcia-Merino A, Lassmann H, Freedman MS,

Azzarelli B, Kolar OJ, Atkins HL, Brück W. Autologous hematopoietic stem cell

transplantation: The glass seems to be half full for aggressive, early forms of MS and half

empty for advanced MS. The Author Published by Oxford University Press on behalf of

the Guarantors of Brain. 2007.

8. Galea I, Freedman MS, Thompson EJ. CSF analysis in the 2010 revised McDonald’s

MS diagnostic criteria. Ann Neurol 2011 July;70(1):183.

Invited Presentations:

1. Freedman MS. The Immunology of MS Lesion Generation. The Chronicle of

Neurology & Psychiatry. 2000.

Abstracts:

1. Freedman M, Cruz T, Gurd J, Brown I: Selective effects of LSD on the synthesis of

synaptic proteins and glycoproteins. Abstract and talk at the Clinical Research Society

Meeting in Toronto, 1979.

2. Freedman M, Cruz T, Gurd J, Brown I: Selective effects of LSD on the synthesis of

synaptic proteins and glycoproteins. Abstract and poster session at the XIst International

Congress of Biochemistry, (Toronto, July 1979).

3. Freedman M, Cruz T, Gurd J, Brown I: Effect of LSD on molecular events at the

synapse. Abstract and poster session at the International Society of Neurochemistry

meetings. (Israel, Sept, 1979).

4. Heikkila J, Freedman M, Brown IR: Sensitivity of brain protein synthesis to

hyperthermia induced by various treatments. Abstract and poster session at the

International Society of Neurochemistry meetings, (Israel, Sept, 1979).

5. Freedman M, Koven IH, Gordon A, Blackstein MB, Miller B: Macro CK: A New

Marker for Colorectal Cancer? The Annals RCPSC 15(4):325, 1982.

6. Levitan M, Bruni J, Freedman M: Repetitive Pseudoseizures incorrectly managed as

status epilepticus. Can J Neurol Sci 12(2): 192, 1985.

7. Freedman MS and Gray TA: Vascular headache: A presenting symptom of multiple

sclerosis. Can J Neurol Sci 14(2):242-243, 1987.

8. Ruijs TCG, Olivier A, Freedman MS, Antel JP: Generation of cytotoxic lymphocytes

for human glial cells in culture. Soc Neurosci Abs, p. 788, 1988.


9. Freedman MS, Loertscher R, Cashman NR, Antel JP: Differential growth of

immunoregulatory T-cell subsets. 7th International Congress of Immunology, p. 609

(Abs92-20), 1989.

10. Ruijs TCG, Olivier A, Freedman MS, Antel JP: Cultured human oligodendrocytes are

susceptible to lysis by MHC class I-directed cytotoxic lymphocytes. Soc Neurosci Abs

15:13, 1989.

11. Freedman MS, Blain M, Antel JP: Comparison of systemic intrathecal

immunoregulatory mechanisms. Neurology 39:417, 1989.

12. Freedman MS, Blain M, Antel JP: Reduced numbers of phenotypic and functional

suppressor T cells in cerebrospinal fluid (CSF). Neurology 40(Suppl 1):392, 1990.

13. Yong VW, Yong FP, Freedman M, Antel JP: Cytokines and proliferation of human

adult astrocytes. Neurology 40(Suppl 1):208, 1990.

14. Freedman MS, Blain M, Antel JP: Differential responses of CD4+CD45RA+ and

CD4+CD29+ subsets to activated CD8+ cells. FASEB J 4(7):A2256, 1990.

15. Freedman MS, Blain M, Antel JP: Enhanced stimulation of virgin T cells

(CD4+CD45RA+) by activated CD8+ cells in multiple sclerosis. Ann Neurol, 28:244,

1990.

16. Freedman MS, Muth KL, Trotter JS, Yoshizawa CN, Larocca AT, Francis G, Duquette

P, Antel JP: Prospective serial analysis of soluble interleukin-2 receptor (sIL-2R) in

relapsing-remitting MS. Neurology 41(Suppl 1):219, 1991.

17. Freedman MS, Buu N, Ruijs TCG, Antel JP: The expression of heat-shock protein (hsp

72) in cultured human brain cells. Can J Neurol Sci 18:236, 1991.

18. Freedman MS, Ruijs TCG, Antel JP: Human oligodendrocytes are killed by peripheral

blood T cells. Ann Neurol 30:303, 1991.

19. Freedman MS, Ruijs TCG, Antel JP: The role of heat shock proteins in oligodendrocyte

T cell interaction. J Neuroimmunol (Suppl. 1):112, 1991.

20. Freedman MS, Ruijs TCG, Yong VW, Antel JP: T cell induced lysis of human

CNS-derived cells does not correlate with expression of hsp. Neurology 42 (Suppl

3):247, 1992.

21. Freedman MS, Antel JP, De Guzman T, Minuk J: Measurement of IgM antibodies to

Gm1 gangliosides in the evaluation of motor neuronopathies. Can J Neurol Sci 19:281,

1992.


22. Freedman MS, Prabhakar S, Gupta RS, Kurien E, Antel JP: CSF immunoreactivity to

heat shock protein (hsp60) is elevated in Multiple Sclerosis (MS). Ann Neurol 32:110,

1992.

23. Freedman MS, Zielinski S, Grant I, Antel JP: Correlation of anti-Gm1 ganglioside

antibody reactivity with peripheral nerve and clinical phenotype. Neurology 43 (suppl

2):A343, 1993.

24. Freedman MS, Antel JP, D'Souza SD: Cytokine induced heat shock expression in

human oligodendrocytes. Ann Neurol. 34 (2):310, 1993.

25. Freedman MS, Bitar R. T cell-induced lysis of human oligodendrocytes: A heat

shock protein mediated mechanism. J Neuroimmunol. 54:159 (w05.0709), 1994.

26. Stone JE, Freedman MS. Differential effects of recombinant human interferon beta-1b

(IFN -1b) on and T cells. J Neuroimmunol. 54:199 (p12.09), 1994.

27. Freedman MS, J. Abiscott, Goldstein R. HSP70 gene polymorphism correlates with

cellular reactivity to HSP in Multiple Sclerosis. Neurology. 45 (suppl 4):A467, 1995.

28. Freedman MS, Nelson RF, Rabinovitch H, Christie S, Denis L, Corman C, Benavente

M., Intensive immunosuppressive therapy for progressive multiple sclerosis (MS):

Experience using a booster regimen of cyclophosphamide and methylprednisolone. Can J

Neurol Sci 23 (Suppl 1):S46, 1996.

29. Zeine R, Pon R, Nguyen V, Freedman MS. Mechanism of T cell cytotoxicity in

multiple sclerosis. Ann Neurol. 40:555, 1996. ACTRIMS meeting, Miami, October,

1996.

30. Grenier J-F and the Canadian Burden of Illness Study Group*. Multiple Sclerosis:

Evaluation of the burden of illness in Canada. AAN meeting, Boston, April, 1997.

31. Zeine R and Freedman MS. Mechanism of T cell-induced human oligodendrocyte

cytotoxicity: Relevance to multiple sclerosis. ACTRIMS meeting, San Diego, CA,

October, 1997. (Mult Scler. 3:405, 1998).

32. Filion LG, Chabot J, Freedman M, Kumar A. Modulation of adhesion molecules with

interferon- in multiple sclerosis patients. ISAC XIX International Congress, Colorado

Springs, CO. USA, March, 1998.

33. Christen U, Thuerkauf R, Lesslauer W and the Lenercept Rheumatoid Arthritis and

Multiple Sclerosis Study Groups. Immunogenicity of a human TNFR55-IgG1 fusion

protein (Lenercept) in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients. 7th

International TNF Congress, Hyannis, MA, May, 1998.


34. The Lenercept multiple sclerosis Study Group* and The University of British

Columbia MS/MRI Analysis Group. TNF neutralization induces an increase in relapses

in patients with multiple sclerosis. Canadian Congress of Neurological Sciences,

Montréal, Canada, June, 1998. (Can J Neurol Sci. 25:(Suppl 2) S31).

35. Filion LG, Chabot J, Kumar A and M Freedman. Cytokine alteration of co-stimulatory

molecules in MS. Fifth International Congress of the International Society for

Neuroimmunology, Montréal, Canada, August, 1998. (J Neuroimmunol )

36. Pon R and M Freedman. Phenotypic and functional properties of transformed T

cell lines and clones from MS CSF and blood. Fifth International Congress of the

International Society for Neuroimmunology, Montréal, Canada, August, 1998.

37. Zeine R, Freedman M and F Mandy. Role of NK receptors in T cell cytotoxicity in

multiple sclerosis. Fifth International Congress of the International Society for

Neuroimmunology, Montréal, Canada, August, 1998.

38. Freedman MS and the OWIMS Study Group. Dose dependent clinical and MRI

efficacy of interferon 1a (Rebif) in multiple sclerosis. American Neurological

Association Meeting. Montréal, QC, October, 1998.

39. Freedman MS. Clinical and MRI Efficacy of interferon -1a (Rebif®) in Relapsing

Remitting Multiple Sclerosis: Special Benefits of High Doses for Patients with Greater

Disability. Joint Meeting of the International Cytokine Society and the International

Society for Interferon and Cytokine Research, Jerusalem, Israel. October, 1998. Eur

Cytokine Network 9:336 (A566).

40. Smith-Walker L, Della-Malva L, Freedman M, Tellier A, Collins B. Stability of

performance on measures of subcortical functioning in early phase relapsing-remitting

multiple sclerosis. International Neuropsychological Society Meeting. Boston MA,

USA. February, 1999.

41. Matusevicius D and Freedman MS. IFN- in vitro induces TNF- and IFN-

secretion by T cells from multiple sclerosis patients. Presented at the joint

ACTRIMS/ECTRIMS meeting. September, 1999. Basel, Switzerland.

42. Matusevicius D and Freedman MS. Elevated production of TNF- by / T cell lines

generated from CSF of MS patients. Presented at the American Neurological Association

meeting. October, 1999. Seattle, Washington. (Ann Neurol. 46:470 Abstract 96).

43. Atkins HL, Freedman MS, Antel J, Arnold D, Bence-Bruckler I, Bredeson C, Duquette

P, Huebsch L, Launeville P, Messner H, Sekaly R and P O’Connor. Targeting multiple

sclerosis as an autoimmune disease with intensive immunoablative therapy and

immunological reconstitution. Canadian Bone Marrow Transplant Meeting.


44. Freedman MS. On behalf of the PRISMS study group. Long-term efficacy of

interferon-beta 1a (Rebif™) in relapsing-remitting MS: 4-year results of the PRISMS

Study. American Academy of Neurology Late Breaking News Session. San Diego, CA,

May, 2000. (Neurology. 54:2351, #3, 2000).

45. Freedman MS, The immunological rationale for bone marrow transplant, ACTRIMS

Meeting, Boston, MA. October, 2000.

46. Rice G and the PRISMS study group*. Interferon-neutralizing antibodies reduce

clinical and magnetic resonance imaging efficacy in multiple sclerosis patients treated

with Interferon -1a (Rebif): Observations from the PRISMS 4-year extension study.

American Neurological Association Meeting, Boston, MA. October, 2000. (Ann Neurol.

48:477 Abstract 232, 2000.)

47. Zhao GJ, So G, Li DKB, Riddenhough A, Jones C, Paty DW, the PRISMS study

group* and the UBC MS/MRI research group. Changes of the third ventricular width in

multiple sclerosis over 2 years. American Neurological Association Meeting, Boston,

MA. October, 2000. (Ann Neurol 48:481 Abstract 246, 2000.)

48. Murzenok P, Matusevicius D, and Freedman MS. Chemokine and chemokine receptor

expression in T cells generated from peripheral blood and cerebrospinal fluid of MS

patients. American Neurological Association Meeting, Boston, MA. October, 2000.

(Ann Neurol. 48:476 Abstract 227, 2000.)

49. Freedman MS, on behalf of the PRISMS study group. Low rate of progression to EDSS

6 in patients with relapsingremitting multiple sclerosis (RRMS) treated with interferon

beta-1a: 4-year data from the PRISMS study. First LACTRIMS meeting, Buenos Aires,

Argentina. November, 2000.

50. Freedman MS, on behalf of the PRISMS study group. Endpoints to assess progression

of disability in long-term clinical trials in relapsingremitting multiple sclerosis (RRMS).

First LACTRIMS meeting, Buenos Aires, Argentina. November, 2000.

51. Freedman MS, on behalf of the PRISMS study group. Long term safety and tolerability

of interferon beta-1a in relapsingremitting multiple sclerosis (RRMS). First

LACTRIMS meeting, Buenos Aires, Argentina. November, 2000.

52. Freedman MS, Matusevicius D, Kumar A and Filion LG. Immunological correlates of

disease progression: The role of monocyte IL-12 secretion and co-stimulatory molecule

expression. Neurology 56 Supp 3:A295 (Abstract P04.136).

53. Freedman MS on behalf of the PRISMS study group. Disability progression in RRMS:

treatment effect and functional system determinants of change in PRISMS-4. Neurology.

56 Supp 3:A360 (Abstract P05.119).


54. Pon RA and Freedman MS. Probing the biological role of CNS and blood derived

T cells in MS pathogenesis: Application of a T cell immortalisation technique using

Herpesvirus saimiri. International Society for Neuroimmunology Meeting, Edinburgh,

Scotland, September 2001. J Neuroimmunol. 118:Abstract #249, p.86, 2001.

55. Murzenok PP and Freedman MS. CCR5 expression and Herpes virus Saimiri

Transformation of T cells in Multiple Sclerosis patients. International Society for

Neuroimmunology Meeting, Edinburgh, Scotland, September 2001. J Neuroimmunol.

118:Abstract # 33, p.18, 2001.

56. Matusevicius D, Murzenok P and Freedman MS. Chemokine production and

chemokine receptor expression by and T cell lines generated from blood and

CSF of Multiple Sclerosis patients. International Society for Neuroimmunology Meeting,

Edinburgh, Scotland, September 2001. J Neuroimmunol. 118:Abstract # 34, p.18, 2001.

57. Green M and Freedman MS. T cell-mediated cytotoxicity in multiple sclerosis

(MS): Comparison of cytotoxic mechanisms between peripheral blood and cerebrospinal

fluid derived cells. Platform presentation at the International Society for

Neuroimmunology Meeting, Edinburgh, Scotland, September 2001. J Neuroimmunol

118:Abstract #252, p.86, 2001.

58. Filion GL, Matusevicius D and Freedman MS. Monocyte-derived cytokines:

Correlation with disease stage and response to treatment with interferon- . International

Society for Neuroimmunology Meeting, Edinburgh, Scotland, September 2001. J

Neuroimmunol. 118:Abstract #286, p.97, 2001.

59. Freedman MS on behalf of the OWIMS study group. Three-year results of weekly

interferon in RRMS. ECTRIMS meeting, Dublin, Ireland, September, 2001. Mult Scler.

(Suppl 1.)

60. Freedman MS. Bone marrow transplantation in MS: the rationale for the Canadian

study. ECTRIMS meeting, Dublin, Ireland, September, 2001. Mult Scler. (Suppl 1.)

61. Green MLD, Matusevicius D and Freedman MS. IFN- (Avonex) treatment alters the

expression of killer inhibitory receptors (KIR) on MS T cells. ECTRIMS meeting,

Dublin, Ireland, September, 2001. Mult Scler. 7 (Supplement 1): S99 [Abstract P327],

2001.

62. Matusevicius D, Green MLD and Freedman MS. IFN- (Avonex) treatment modulates

cytokine profile produced by T cells. ECTRIMS meeting, Dublin, Ireland,

September, 2001. Mult Scler 7 (Supplement 1): S99 [Abstract P326], 2001.

63. Li D, O'Connor P, Freedman MS, Bar-Or A, Rice G, Confavreux C, Paty D, Stewart J,

Fourre J, Saoud J, Styren S, Scheyer R. Oral teriflunomide is safe and effective in

multiple sclerosis with relapses: results of a randomized, placebo controlled phase II


study. Teriflunomide Multiple Sclerosis Trial Group. ECTRIMS meeting, Dublin,

Ireland, September, 2001.

64. Atkins H, Freedman MS, Bowman MJ, Antel J, Arnold D, Bar-Or A, Bence-Bruckler I,

Cheynier R, Duquette P, Huebsch L, Laneuville P, Lapierre Y, Messner H, O’Connor P,

and RP Sekaly. Targeting multiple sclerosis with intensive immunoablative therapy and

immunological reconstitution. Hematopoietic stem cell therapy in autoimmune diseases,

City of Hope National Medial Center, Duarte CA, October, 2001.

65. Freedman MS and the PRISMS study group. Evidence of an early dose effect of

interferon- 1a on relapse-free outcomes. American Academy of Neurology, Denver,

CO, April, 2002. Neurology. 58(Suppl 3):A456, P06.076, 2002.

66. Freedman MS, Atkins HL, Arnold D, Bowman MJ, and the Canadian MS BMT study

group. Reduction in gadolinium enhancing lesions and clinical stability in Multiple

Sclerosis patients receiving a combination of cyclophosphamide and filgrastim (G-CSF)

in preparation for stem cell mobilization. Presented at the American Academy of

Neurology, Denver, CO, April, 2002. Neurology. 58(Suppl 3):A457, P06.077, 2002.

67. Freedman MS, Atkins HL, Bowman MJ and the Canadian MS BMT Study Group. High

intensity immunosuppression with autologous stem cell transplantation: a treatment for

aggressive Multiple Sclerosis. Presented at the Canadian Congress of Neurological

Sciences, Vancouver, June 2002. Can J Neurol Sci.

68. Freedman MS, Edan G, Hartung H-P, Kappos L, Miller D, Montalban X, Polman C,

Barkhof F, Bauer L, Ghazi M, Sandbrink R. Betaferon®/Betaseron® (interferon beta-1b)

in early treatment of multiple sclerosis: the BENEFIT study. Presented at the

ACTRIMS/ECTRIMS Meeting, Baltimore MD, Sept. 2002.

69. Freedman MS, Atkins HL, Bowman MJ and the Canadian MS BMT Study Group. High

intensity immunosuppression with autologous stem cell transplantation: a treatment for

aggressive Multiple Sclerosis. Presented at the 55th Annual Meeting of the American

Academy of Neurology, Honolulu, Hawaii. Neurology 60:5(Suppl 1):A85, 2003.

(S11.006).

70. Freedman MS, Edan G, Hartung H-P, Kappos L, Miller D, Montalban X, Polman C,

Barkhof F, Bauer L, Ghazi M, Sandbrink R. Betaferon®/Betaseron® (interferon beta-1b)

in early treatment of multiple sclerosis: the BENEFIT study. Presented at the 55th Annual

Meeting of the American Academy of Neurology, Honolulu, Hawaii. March, 2003.

Neurology. 60:5(Suppl 1):A483. March 11, 2003. (P06.114).

71. Freedman MS, Abdalla J, Forrestal F, for the SPECTRIMS Investigators. A

multicentre, randomised, double-blind, placebo-controlled, phase III study of

subcutaneous Rebif in the treatment of secondary progressive multiple sclerosis – 6-year

results. European Neurological Society, Istanbul, Turkey. J Neurol. 250 (Suppl 2):142.

May, 2003. (P537).


72. Greenway DC, Cheung P, Freedman MS. Oligoclonal bands determination in CSF by

isoelectric focusing using a commercial kit method (HELENA IgG-IEF). Canadian

Society for Clinical Chemistry. 2003.

73. Atkins H, Freedman MS, Bar-Or A, Farzaneh J, Ho Jo K, Chen J, Sekaly, Cheynier R,

Jalili F, Chen J, Corsini and the Canadian MS/BMT Study Group. Immune events

following immunoablative therapy for the treatment of Multiple Sclerosis (MS). Poster

presentation. International Bone Marrow Transplant Registry Meeting. February 2004.

74. Kuhlmann T, Metz I, Brück W, Jansen G, Freedman MS, Atkins HL. A case report:

Histopathology of MS lesions after high-dose chemotherapy and haematopoietic stem

cell rescue. Poster presentation. American Academy of Neurology 56th Annual Meeting.

April 27, 2004.

75. Chen JT, Arnold DL, Freedman MS, Atkins HL. The Canadian MS BMT Study Group.

The impact of immunoablation with autologous stem cell transplant on lesion

remyelination and demyelination in aggressive multiple sclerosis. Poster presentation.

American Academy of Neurology 56th Annual Meeting. April 28, 2004.

76. Freedman MS, Atkins HL, Bowman MJ, Bar-Or A, Arnold DL. The Canadian MS

BMT Study Group. Immune system regeneration following immunoablative therapy and

autologous stem cell transplantation for multiple sclerosis. Poster presentation.

American Academy of Neurology 56th Annual Meeting. April 29, 2004.

77. Bar-Or A, Kim HJ, Corsini R, Gauchat D, Cheynier R, Rafick P Sekaly, Atkins HL,

Freedman MS, Jalili F, Bowman M, Théorêt G and the Canadian MS/BMT Study

Group. Immune reconstitution in patients with aggressive multiple sclerosis (MS) treated

with immune ablation and autologous hemapoeitic stem cell transplant (HSCT).

European Neurological Society (ENS) meeting, Barcelona, Spain, June 2004.

78. Goodman A, Bar-Or A, Miller D, Panzara M, Rossman H, Schmierer M, GLANCE

Investigators*. A double-blind, randomized, placebo-controlled, parallel-group safety

study of natalizumab (Antegren) in combination with glatiramer acetate (Copaxone) in

subjects with relapsing-remitting multiple sclerosis. European Neurological Society

(ENS) meeting, Barcelona, Spain, June 2004.

79. Kappos L, Radue EW, Antel J, Comi G, Montalban X, O’Connor P, Bettoni-Ristic O,

Korn A, Hiestand P, Foster CA, FTY720D2201 Study Group*. FTY720: A novel

immunomodulator under clinical investigation in multiple sclerosis. European

Neurological Society (ENS) meeting, Barcelona, Spain, June 2004.

80. Kappos L, Sandberg-Wolheim M, Uitdehaag B, Erälinna, Traboulsee A, Li D, Forrestal

F, Abdalla J., The PRISMS Study Investigators*. Long-term outcomes of patients

treated with IFN beta-1a compare favourably to natural history: 8-year follow-up of the


PRISMS cohort. European Neurological Society (ENS) meeting, Barcelona, Spain, June

2004.

81. Li D, O'Connor P, Freedman MS, Bar-Or A, Rice G, Confavreux C, Paty D, Stewart J,

Fourre J, Saoud J, Styren S, Scheyer R on behalf of the Teriflunomide Multiple Sclerosis

Trial Group. Oral teriflunomide is safe and effective in multiple sclerosis with relapses:

results of a randomised, placebo-controlled phase II study. Poster Presentation 20th

Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

9th Annual Meeting of Rehabilitation in MS. Vienna, October 6-9, 2004.

82. Chen J, Narayanan S, Arnold D, Freedman MS, Atkins H and the Canadian MS BMT

Study Group. The effect of immunoablation with autologous stem cell transplantation

therapy on dynamic changes of magnetisation transfer ratio in multiple sclerosis patients.

Poster Presentation 20th Congress of the European Committee for Treatment and

Research in Multiple Sclerosis. 9th Annual Meeting of Rehabilitation in MS. Vienna,

October 6-9, 2004.

83. Krupp L, Banwell B, Boiko A, Eraksoy M, Freedman MS, Pohl D, Reder A,

Tenembaum S. Treatment of childhood and adolescent MS with interferon-beta-1b.

ECTRIMS. Vienna, October 2004.

84. Banwell B, Tellier R, Krupp L, Bar-Or A, Kennedy J, Tenembaum S, Belman A, Ness J,

Hahn J, Waubant E, Mah J, Stoian C, Rensel M, Farrell K, Freedman MS, Bhan V,

Dilenge M, Ruggieri M, Iivanainen M, Weinstock-Guttman B, Boiko A. Viral exposures

in pediatric multiple sclerosis: Preliminary data from a multinational collaborative study.

Poster presentation at the 20th Congress of the European Committee for Treatment and

Research in Multiple Sclerosis ECTRIMS. October 2004.

85. Uitdehaag, BMJ, Kappos L, Bauer L. Freedman MS, Miller D, Sandbrink R, Polan CH.

Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of MS.

Poster presentation at the 20th Congress of the European Committee for Treatment and

Research in Multiple Sclerosis ECTRIMS. October 2004.

86. Costello F, Coupland S, Zackon D, Lorello G, Koroluk J, Freedman MS. Measurement

of axon loss in optic neuritis with optical coherence tomography. Poster presentation at

the 20th Congress of the European Committee for Treatment and Research in Multiple

Sclerosis ECTRIMS. October 2004.

87. Karussis D, Freedman MS, Fazekas F. On behalf of the International Working Group

for Treatment Optimization in MS. A recommended treatment algorithm in relapsing

multiple sclerosis. Poster presentation at the 20th Congress of the European Committee

for Treatment and Research in Multiple Sclerosis ECTRIMS. October 2004.

88. Freedman MS. On behalf of the PRISMS Study Group. Utility of treatment

optimization recommendations applied to clinical trial data: Results from the PRISMS


Study. Poster presentation at the 20th Congress of the European Committee for

Treatment and Research in Multiple Sclerosis ECTRIMS. October 2004.

89. Uitdehaag B, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R, Polman C. A

standardized approach to assess the contribution of clinical findings to the diagnostic

criterion of dissemination in space in first clinical events suggestive for MS. American

Academy of Neurology Annual Meeting. April 2005.

90. Banwell B, Tellier R, Krupp L, Bar-Or A, Kennedy J, Tenembaum S, Boiko A, Bykova

O, Belman A, Mah J, Stoian C, Ness J, Rensel M, Hahn J, Weinstock-Guttman B, Yeh A,

Waubant E, Farrell K, Freedman MS, Bhan V, Dilenge M, Iivanainen M,

Kremenchutzky M, Ruggieri M. Viral exposures in pediatric multiple sclerosis:

Preliminary data from a multinational collaborative study. Poster presentation at the

American Academy of Neurology Annual Meeting. April 2005.

91. Chen, JT, Collins DL, Arnold D, Freedman MS, Atkins HL. Evidence for acute brain

pseudo-atrophy after treating MS with immunoablation followed by autologous stem cell

transplantation. American Academy of Neurology Annual Meeting. April 2005.

92. Tenembaum S, Banwell B, Boiko A, Eraksoy M, Freedman MS, Krupp L, Pohl D,

Reder A, Schelensky L, Antonijevic I. Treatment of Childhood and Adolescent Multiple

Sclerosis with Interferon Beta-1b. Poster Presentation at the American Academy of

Neurology Annual Meeting. April 2005.

93. Freedman MS, Forrestal FG, on behalf of the PRISMS Study Group, Geneva,

Switzerland. Treatment optimization recommendations (TOR) can predict relapse rates

in patients with MS: Analysis of the PRISMS study data. American Academy of

Neurology Annual Meeting. April 2005.

94. Freedman MS, Atkins HL, Théorêt G & the Canadian MS BMT Study Group.

Immunoablation followed by autologous stem cell transplantation as a treatment for

aggressive multiple sclerosis: 3 year follow-up of the first 6 patients. American

Academy of Neurology Annual Meeting. April 2005.

95. Lopez-Amaya C, O’Connor K, Kopel L, Fattahie R, Moore N, Gano D, Fournier A,

Moscarello M, Banwell B, Kennedy J, Krupp L, Tenembaum S, Boiko A, Bykova O,

Belman A, Mah J, Stoian C, Ness J, Rensel M, Hahn J, Weinstock-Guttman B, Yeh A,

Waubant E, Farrell K, Freedman MS, Bhan V, Dilenge M, Iivanainen M,

Kremenchutzky M, Ruggieri M, Bar-Or A. Anti-myelin antibodies in pediatric MS.

Poster presentation at the American Academy of Neurology Annual Meeting. April

2005.

96. Chen JT, Narayanan S, Collins DL, Freedman MS, Atkins HL, the Canadian MS BMT

Study Group, Arnold DL. All enhancing voxels are not equal: quantifying destruction

and repair within gadolinium-enhancing lesions in multiple sclerosis. International

Society for Magnetic Resonance in Medicine.


97. Uitdehaag B, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R, Polman C. A

standardized approach to assess the contribution of clinical findings to the diagnostic

criterion of dissemination in space in first clinical events suggestive for MS. Poster

Presentation at the American Academy of Neurology Annual Meeting. April 2005.

98. Freedman MS, Polman C, Kappos L, Edan G, Hartung H-P, Miller D, Montalban X,

Uitdehaag B, Barkhof F, Bauer L, Sandbrink R. The BENEFIT Study: Betaseron in

newly emerging MS for initial treatment. Poster Presentation. Consortium for Multiple

Sclerosis Centers. Orlando, Florida. June 2005.

99. Desjardins O, Piwko C, Bereza B, Gordon A, Devonshire V, Freedman MS, Ursell M,

Vicente C, Iskedjian M, Jaszewski B, Einarson TV, Gagni A. Development and pre-

testing of a willingness-to-pay instrument for a treatment for pain in Multiple Sclerosis.

Poster Presentation. CAHSPR Conference. Montréal, Québec. September 2005.

100. Kappos L, Polman C, Freedman MS, Edan G, Hartung H-P, Miller D, Montalban X,

Barkhof F, Bauer L, Jakobs P, Sandbrink R for the BENEFIT Study Group. Betaferon

in newly emerging multiple sclerosis for initial treatment (BENEFIT): Clinical Results.

Poster Presentation. ECTRIMS. Thessaloniki, Greece. September 2005.

101. Nielsen J, Korteweg T, Uitdehaag B, Barkhof F, Edan G, Freedman MS, Hartung H-P,

Kappos L, Miller D, Montalban X, Polman C, Bauer L, Pohl C, Wagner K, Sandbrink R.

Validation of the clinical classification scheme using MRI in the BENEFIT Study. Poster

Presentation. ECTRIMS. Thessaloniki, Greece. September 2005.

102. Théorêt G, Bowman M, Freedman MS, Atkins HL. Quality of Life in MS patients

receiving high intensity immunoablation followed by autologous stem cell rescue in MS:

Effect on quality of life. Poster #367. ECTRIMS. Thessaloniki, Greece. September

2005.

103. Chen JT, Kuhlmann T, Jansen GH, Collins DL, Freedman MS, Atkins HL, Bar-Or A,

Arnold DL and the Canadian MS/BMT Study Group. Histopathological confirmation of

voxel-based analysis of in vivo magnetization transfer ratio images to assess

remyelination and demyelination following acute focal demyelination in multiple

sclerosis. Poster Presentation. Poster #536. ECTRIMS. Thessaloniki, Greece.

September 2005.

104. Freedman MS. Combinations of treatments. Platform Presentation. ECTRIMS.

Thessaloniki, Greece. September 2005.

105. Freedman MS. Algorithm: Evidence-based medicine and therapy selection to MS.

Platform Presentation. ECTRIMS. Thessaloniki, Greece. September 2005.

106. Freedman MS. BENEFIT: Implications for patient welfare. Platform Presentation.

ECTRIMS. Thessaloniki, Greece. September 2005.


107. Freedman MS, Laks J, Dotan N, Schwarz M, Weishaus O, Dukler A, Miller A, Sindic

C. Anti-Glc(alpha 1,4)Glc(alpha)IgM antibodies for predicting the development of

relapsing-remitting multiple sclerosis after the first neurological event. Poster #678.

ECTRIMS. Thessaloniki, Greece. September 2005.

108. Vollmer T, Panitch H, Dunn S, Lublin FD, O’Connor PW, Bar-Or A, Freedman MS,

Hendin B, Gazda S, Campagnolo D, Shi F. Induction treatment with Mitoxantrone

(Novantrone) preceding treatment with glatiramer acetate (Copaxone) a multi-centre,

randomized, two-arm, open-label study in RRMS patients. Poster #342. ECTRIMS.


109. Barkhof F, Polman C, Radü E-W, Kappos L, Freedman MS, Edan G, Hartung H-P,

Miller DH, Montalban X, Bauer L, Dahms S, Sandbrink R. On behalf of the BENEFIT

Study Group. Betaferon in newly emerging multiple sclerosis for initial treatment

(BENEFIT): Magnetic resonance imaging outcomes. Poster #583. ECTRIMS.


110. Freedman MS, Forrestal FG. On behalf of the PRISMS Study Group. Treatment

optimization recommendations can predict disease breakthrough in patients with MS on

disease modifying drugs: Analysis of the PRISMS Study Data. Poster #585. ECTRIMS.


111. MacLean H, Freedman MS, Atkins HL, Costello F, Demeulemeester C, Rabinovitch H,

Denis L, Gagnon N. Mitoxantrone in severe relapsing MS: A phase IV experience in 81

patients attests to its safety and efficacy. Poster #646. ECTRIMS. Thessaloniki, Greece.

September 2005.

112. Freedman MS, Forrestal FG, on behalf of the PRISMS Study Group. Recommendations

for treatment optimization (TOR) can predict disease breakthrough in patients with MS

on treatment: Analysis using the PRISMS Study data. XVIIIth World Congress of

Neurology. Sydney, Australia. November 2005.

113. Kappos L, Freedman MS, Edan G, Hartung HP, Miller D, Montalban X, Barkhof F,

Bauer L, Jakobs P, Pohl C, Sandbrink R for the BENEFIT Study Group. Betaseron in

newly emerging multiple sclerosis for initial treatment (BENEFIT): Subgroup Anaylses.

S02.002. AAN 58th Annual Meeting. San Diego, USA. April 4, 2006.

114. Chen JT, Freedman MS, Atkins HL, Narayanan S, Arnold D. Immunoablation and

autologous hematopoietic stem cell transplantation may enhance remyelination in acute

multiple sclerosis lesions. Platform Presentation. AAN 58th Annual Meeting. San

Diego, USA. P02.098. April 7, 2006.

115. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X,

Bauer L, Pohl C, Sandbrink R for the BENEFIT Study Group. Betaseron® in newly

emerging multiple sclerosis for initial treatment (BENEFIT): Safety, tolerability and


adherence outcome. P01.073. AAN 58th Annual Meeting. San Diego, USA. April 7,

2006.

116. Freedman MS, Kappos L, Polman CH, Edan G, Hartung H-P, Miller D, Montalban X,

Bauer L, Pohl C, Sandbrink R for the BENEFIT Study. Safety, tolerability and

adherence to treatment in the BENEFIT Trial. Platform Presentation. CMSC.

Scottsdale, AZ. June 2006.

117. Fazekas F, Freedman MS, Hartung H-P, Li D, Lublin F, Rickmann P, Soelberg-

Sørensen P, Maas-Enriquez M, Sommerauer B, Anderesi M. Prevention of relapse with

intravenous immunoglobulin study: Initial results of a dose-finding trial in relapsing-

remitting multiple sclerosis. Platform Presentation. CMSC. Scottsdale, AZ. June 2006.

118. Freedman MS. Efficacy of up to 8 years of subcutaneous interferon bera-1a treatment in

multiple sclerosis. Poster Presentation. CMSC. Scottsdale, AZ. June 2006.

119. Freedman MS, Kappos L, Polman C, Edan G, Hartung H-P, Miller D, Montalban X,

Bauer L, Polh C, Sandbrink R, the BENEFIT Study Group. Safety, tolerability and

adherence to treatment in BENEFIT Trial. Poster Presentation. CMSC. Scottsdale, AZ.

June 2006.

120. Freedman MS. Early and long-term data: Implications for patient welfare. Poster

Presentation. LACTRIMS. Margarita Island, Venezuela. June 29, 2006.

121. Kappos L, Polman CH, Freedman MS, Edan G, Hartung H-P, Miller D, Montalban X,

Barkhof F, Bauer L, Dahms S, Pohl C, Sandbrink R for the BENEFIT Study Group.

Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT):

Clinical outcomes. ENS. Lausanne. September 2006.



Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT):

Subgroup analyses. ENS. Lausanne. September 2006.

123. Fazekas F, Freedman MS, Hartung, Li D, Lublin F, Rieckmann P, Soelberg-Sørensen P,

Maas-Enriquez M, Sommerauer B, Anderesi M. Prevention of Relapse With Intravenous

Immunoglobulin Study: Initial Results of a Dose-Finding Trial in Relapsing-Remitting

Multiple Sclerosis. ENS. Lausanne. September 2006.



Betaferon in newly emerging multiple sclerosis for initial treatment (BENEFIT): Clinical

outcomes. European Federation of Nurological Sciences. Glasgow. September 4, 2006.


125. Freedman MS. Maximising the benefits of MS treatment: Early intervention with high-

efficacy IFH beta therapy. SCHERING Satellite Symposium. ECTRIMS 2006. Madrid.

September 2006.

126. Walker L, Smith A, Freedman MS, DeMeulemeester C. Differential fMRI activation

paterns on the computerised tests of information processing (CTIP) in patients with

multiple sclerosis with low expanded disability status scale scores. Poster Presentation.

ECTRIMS 2006. Madrid. September 28, 2006.

127. Smith A, Walker L, Freedman MS, DeMeulemeester C. Differential fMRI activation

patterns on a response inhibition task in patients with multiple sclerosis with low

expanded disability status scale scores. Poster Presentation. ECTRIMS 2006. Madrid.

September 29, 2006.

128. Chen JT, Collins DL, Freedman MS, Atkins HL, Arnold DL. Detection of subpial

demyelination in vivo: Methodology and evaluation in normal subjects and patients with

multiple sclerosis. Poster Presentation. ECTRIMS 2006. Madrid. September 29, 2006.

129. Metz L, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS,

Azzarelli B, Kolar OJ, Atkins HL, Brück W. Multiple sclerosis pathology after

autologous stem cell transplantation: ongoing demyelination and neurodegeneration

despite suppressed inflammation. ECTRIMS 2006. Madrid. September 2006.

130. Vollmer T, Panitch H, Freedman MS, Gasda SK. Bar-Or A, Arnold DL. Short term

induction with mitoxantrone preceding treatment with glatiramer acetate offers early and

pronounced effects on MRI-disease activity in patients with relapsing forms of multiple

sclerosis. ECTRIMS 2006. Madrid. September 2006.

131. Kuhle J, Kappos L, Pohl C, Mehling M, Edan G, Freedman MS, Hartung H-P, Miller

DH, Montalbán X, Polman C, Barkhof F, Bauer L, Dahms S, Lindberg RLP, Sandbrink

R. Prognostic relevance of antimyelin antibodies for progression to multiple sclerosis

after a first demyelinating event: Results from the BENEFIT Study. ECTRIMS 2006.

Madrid. September 2006.

132. Costello F, Eggenberger E, Demeulemeester C, Coupland S, MacLean H, Rabinovitch H,

Freedman MS, Pan I, Hodge W. Comparison of retinal nerve fibre layer measurements

and visual function among patients with multiple sclerosis. ECTRIMS 2006. Madrid.

September 2006.

133. Freedman MS. Treat early, treat right: Optimising MS therapy. ECTRIMS 2006.


134. O’Connor P, Li D, Freedman MS, Bar-Or A, Rice G, Confavreux C on behalf of the

Teriflunomide Multiple Sclerosis Trial Group. Oral teriflunomide is effective and well

tolerated in multiple sclerosis with relapses: results of an open-label 144-week extension

study. ECTRIMS 2006. Madrid. September 2006.


135. Tombaugh TN, Reicker LI, Walker L, Freedman MS. Alternatives to the PASAT for

measuring speed of information processing in multiple sclerosis patients: the Adjusting-

PASAT and the computerised tests of information processing. ECTRIMS 2006. Madrid.

September 2006.

136. Reicker LI, Tombaugh TN, Freedman MS, Walker L. Reaction time: A viable

alternative for assessing processing speed in multiple sclerosis. ECTRIMS 2006.


137. Freedman MS, Miller A, Schwarz M, Weisshaus O, Altstock RT, Dukler A, Dotan N,

Sindic C. A panel of anti-blycan IgM antibodies for predicting the development of

relapsing-remitting multiple sclerosis after the first neurological event. ECTRIMS 2006.


138. Soucy N, Cardinal K, Theoret G, MacLean H, Freedman MS. Double dose interferon-

beta-1b (500mcg) re-establishes efficacy and lowers neutralising antibodies in patients

with breakthrough of multiple sclerosis disease on standard high-dose interferon-beta

therapy. ECTRIMS 2006. Madrid. September 2006.

139. Polman C, Kappos L, Freedman MS, Edan G, Hartung H-P, Miller DH, Montalbán X,

Barkhof F, Bauer L, Dahms S, Pohl R, Sandbrink R for the BENEFIT Study. Difference

in natural history and treament effect of interferon-beta-1b in CIS patients with mono- vs.

multifocal presentations: subgroup analysis of the BENEFIT Study. ECTRIMS 2006.


140. BENEFIT study group*. Betaseron in newly emerging multiple sclerosis for initial

treatment (BENEFIT): Disability outcomes. Poster Presentation. Poster #M-10. ANA

131st Annual Meeting. Chicago, IL. October 2006.

141. O’Connor PW, Li D, Freedman MS, Rice GP, Confavreux C, Teriflunomide Multiple

Sclerosis Trial Group. Oral teriflunomide is effect and well tolerated in multiple sclerosis

with relapses: Results of an open-label 144-week extension study. ANA 131st Annual

Meeting. Chicago, IL. October 2006.

142. O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bar-Or A, Banwell B, Fukaura

H, Tenembaum S, Wong SL, Tavakoli NP, Rosatasy K. Dale RC, Freedman MS,

Rwucherpgennig KW, Hafler DA. Autoantibodies recognizing myelin oligodendrocyte

glycoprotein are rarely present in the serum of CSF of patients with multiple sclerosis.

ANA 131st Annual Meeting. Chicago, IL. October 2006.

143. Arnold DL, Bar-Or A, Freedman MS, Gazda S, Panitch H, Vollmer T. Reductions in

Gd enhancing lesions observed with glatiramer acetate following a brief and low dose

course of mitoxantrone in patients with relapsing remitting multiple sclerosis (RRMS) are

paralleled by favorable effects on MRI markers of disease burden and black hole

evolution. Poster Presentation. P06-104. 59th AAN. Boston, MA. April 2007.


144. Bar-Or A, Gibbs E, Masaaki N, Aziz T, Alatab S, Dong Shi F, Campagnolo D, Jalili F,

Freedman MS, Panitch H, Arnold D, Arnold D, Vollmer T, Oger J. Tracking in vivo

immune modulation in MS patients treated with glatiramer acetate (GA) alone, or with

GA preceded by mitoxantrone, provides novel insights into the mode of action of

therapeutic strategies that combine immune suppression and immune deviation. Poster

presentation. P01-046. 59th AAN. Boston, MA. April 2007.

145. Freedman MS, Polman C, Kappos L, Edan G, Hartung H-P, Miller D, Montalban X,

Barkhof F, Bauer L, Dahms S, Pohl C, Sandbrink R. Betaseron® in newly emerging

multiple sclerosis for initial treatment (BENEFIT): Effects of immediate vs early onset

of interferon beta-1b treatment. Scientific Platform. S02-004. 59th AAN. Boston, MA.

April 2007.

146. Edan G, Barkhof F, Freedman MS, Hartung H-P, Kappos L, Miller D, Montalban X,

Polman C, Bauer L, Pohl C, Sandbrink R. The BENEFIT Study: Characteristics of

placebo-treated patients with a clinically isolated syndrome who do not show any further

disease activity over 2 years. Scientific Platform. S22-006. 59th AAN. Boston, MA.

April 2007.

147. McLaughlin KA, O’Connor KC, DeJager P, Chitnis T, Bettelli E, Xu C, Robinson W,

Cherry SV, Bar-Or A, Banwell B, Fukaura H, Tenembaum S, Wong S, Tavakoli NP,

Idrissova Z, Viglietta V, Rostasy K, Pohl D, Dale RC, Freedman MS, Steinman L,

Khoury S, Weiner H, Kuchroo VK, Wucherpfennig DH. Autoantibodies to myelin

oldigodendrocyte glycoprotein in human demyelinating diseases. Scientific Platform.

S26-003. 59th AAN. Boston, MA. April 2007.

148. Chen JT, Freedman MS, Atkins HL, Arnold D. A controlled study of the acute effect of

immunoablation and autologous hematopoietic stem cell transplantation on changes in

brain volume, axonal integrity, myelin and parenchymal water in multiple sclerosis.

Scientific Platform. S42-008. 59th AAN. Boston, MA. April 2007.

149. Stewart A, Walker L, Freedman MS, DeMeulemeester, Smith A. A prospective

investigation of cognitive deficits in patients with multiple sclerosis: A pilot study.

Poster presented at the annual meeting of the Canadian Psychological Association,

Ottawa, ON. June 2007.

149.150. Kappos L, Freedman MS, De Stefano N, Labauge P, Comi G, Strubinski B on

behalf of the REFLEX Study Group. REFLEX: A phase III trial to assess the effect of

dosing frequency of interferon beta-1a (Rebif®) in delaying conversion of patients with a

clinically isolated syndrome to clinically definite multiple sclerosis. Poster Presentation.

17th Meeting of the European Neurological Society. Rhodes, Greece. June 2007.

150.151. Kappos L, Edan G, Freedman MS, Hartung H-P, Miller D, Montalban X,

Polman C, Barkhof F, Bauer L, Lanius V, Pohl C, Sandbrink R. The BENEFIT Study:


Characteristics of patients with potentially benign multiple sclerosis. Poster Presentation.

17th Meeting of the European Neurological Society. Rhodes, Greece. June 2007.

151.152. Freedman MS. Use of DMD’s in clinical practice. MS Preceptorship: Updating

knowledge on multiple sclerosis. Barcelona, Spain. June 2007.

152.153. Freedman MS, Atkins HL, Arnold D, Bar-Or A and the Canadian BMT Study

Group. Immune ablation and autologous stem cell transplantation for aggressive multiple

sclerosis: Interim 5-year report. Prague. ECTRIMS 2007. Poster Presentation. Poster

No. 452. October 11-14, 2007.

153.154. Edan G, Freedman MS, Hartung H-P, Kappos L, Miller DH, Montalbán X,

Polman CH, Bauer L, Lanius V, Pohl C, Sandbrink R for the BENEFIT Study Group.

Adherence, tolerability and quality of life: interferon beta-1b therapy over 3 years in

patients with a first event suggestive of multiple sclerosis. Prague. ECTRIMS 2007.

Poster Presentation. October 11-14, 2007.

154.155. Kappos L, Freedman MS, Polman CH, Edan G, Hartung H-P, Miller D,

Montalbán X, Barkhof F, Radü E-W, Bauer L, Lanius V, Dahms S, Pohl C, Sandbrink R

for the BENEFIT Study Group. Early versus delayed interferon beta-1b treatment in

patients with a first event suggestive of MS: the impact on progression of disability.

Prague. ECTRIMS 2007. Poster Presentation. October 11-14, 2007.

155.156. Freedman MS, Edan G, Hartung H-P, Kappos L, Miller DH, Montalbán X,

Polman CH, Bauer L, Lanius V, Pohl C, Sandbrink R for the BENEFIT Study Group.

The Betaferon® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT)

studies: neutralising antibodies did not affect clinical outcomes after 3 years. Prague.

ECTRIMS 2007. Poster Presentation. October 12, 2007.

156.157. Freedman MS, Atkins HL, Arnold D, Bar-Or A on behalf of the Canadian BMT

Study Group. Immune ablation and autlogous stem cell transplantation for aggressive

multiple sclerosis: Interim 5-year report. Prague. ECTRIMS 2007. 124th Annual

Meeting of Rehbilitation in MS. Oral Presentation. October 11-14, 2007.

157.158. Kappos L, Comi G, De Stefano N, Freedman MS. Rebif new formulation in

patients at risk of converting to multiple sclerosis: A phase III, double blind, placebo-

controlled, multicentre trial. Prague. ECTRIMS 2007. Poster Presentation. October 11-

14, 2007.

158.159. Hawker K, Freedman MS, O’Connor P, Calabresi P, Antel J-P, Panitch H,

Simon J, Hauser S, Sarkar N. Agarwal S, Langer-Gould A, Smith C. Rituximab in

patients with primary progressive multiple sclerosis: Demographics in a Phase II/III

randomised, double-blind, placebo-controlled multicentre trial. Prague. ECTRIMS

2007. Poster Presentation. October 11-14, 2007.


159.160. Costello F, Hodge W, Pan I, Coupland S, Demeulemeester C, MacLean H,

Rabinovitch H, Freedman MS. Retinal nerve fibre layer loss after optic neuritis: A

prospective study with optical coherence tomography. Prague. ECTRIMS 2007. Poster

Presentation. October 11-14, 2007.

160.161. Atkins HL, Freedman MS, Hilliker C, McDiarmid S for the Canadian MSBMT

Group. Busulphan dose, regimen-related toxicity and outcome of patients treated with

immune ablation and stem cell transplantation. Prague. ECTRIMS 2007. Poster

Presentation. October 11-14, 2007.

161.162. Reicker LI, Tombaugh TN, Walker L, Freedman MS. A comparison of methods

for improving the detection of slowed processing speed in multiple sclerosis. 36th Annual

Meeting International Neuropsychological Society. Waikoloa, Hawaii USA. February

2008.

162.163. McFarland H, Lisak R, Panitch H, Rudick MD, Johnson K, Freedman MS,

Noseworthy J, Conwit R, Narayana PA, Utz U, Reingold S, Scott T. Diagnosis criteria

and MRI at baseline in Combi-Rx – A preliminary analysis. 60th AAN. Poster

Presentation. April 15, 2008.


Noseworthy J, Conwit R, Narayana PA, Utz U, Reingold S, Scott T. Variability in the

EDSS: What does it mean for progression? 60th AAN. Poster Presentation. April 16,

2008.


Noseworthy J, Conwit R, Narayana PA, Utz U, Reingold S, Scott T. The modified

Rankin score compared to EDSS and MRI measures using CombiRx baseline

assessments. 60th AAN. Poster Presentation. April 16, 2008.

165.166. Freedman MS, Edan G, Hartung H-P, Kappos L, Miller DH, Montalbán X,

Polman CH, Bauer L, Lanius V, Pohl C, Sandbrink R, for the BENEFIT Study Group.

Betaseron® treatment after a first event: adherence, tolerability and quality of life.

CMSC. Poster Presentation. Denver CO. May 2008.

166.167. Nielsen J, Polman CH, Barkhof F, Freedman MS, Edan G, Kappos L, Miller DH,

Bauer L, Pohl C, Sandbrink R, for the BENEFIT Study Group, Uitdehaag BMJ. The

importance of clinically-defined spatial dissemination for prediction of MS risk. CMSC.

Platform Presentation. Denver CO. May 2008.

167.168. Siritho S, Freedman MS. What is the natural history of oligoclonal band

negative multiple sclerosis patients? CMSC. Poster Presentation. Poster # S74. Denver

CO. May 2008.

168.169. Hartung H-P, Edan G, Freedman MS, Kappos L, Miller DH, Montálban X,

Polman CH, Bauer L, Lanius V, Pohl C, Sandbrink R, for the BENEFIT Study Group.


The BENEFIT Studies: Adherence, tolerability and quality of life with Betaferon®

treatment after a first event suggestive of multiple sclerosis. Poster Presentation. ENS

Congress. Nice France. June 2008.

169.170. Hartung H-P, Edan G, Freedman MS, Kappos L, Miller DH, Montálban X,

Polman CH, Bauer L, Lanius V, Pohl CH, Sandbrink R, for the BENEFIT Study Group.

Neutralising antibodies do not affect efficacy of Interferon Bera-1b: Further analysis of

the Betaferon® in newly emerging multiple sclerosis for initial treatment study

(BENEFIT). Poster Presentation. ENS Congress. Nice France. June 2008.

170.171. O’Connor PW, Contavreux C, Comi G, Kappos L, Wollinsky JS, Olsson TP,

Miller A, Freedman MS for the Teriflunomide Multiple Sclerosis Trial Group. Oral

teriflunomide in patients with relapsing multiple sclerosis: Baseline clinical features of

patients in the TEMSO Phase III trial. Poster Presentation. Poster # P193. WCTRIMS.

Montréal, QC. September 2008.

171.172. Bastiaan M, Pohl C, Uitdehaag B, Polman C, Edan G, Freedman MS, Hartung

H-P, Kappos L, Miller D, Espejo C, Bauer L, Sandbrink R, Barkhof F. Baseline

magnetic resonance imaging predictors for conversion to clinically definite multiple

sclerosis and McDonald multiple sclerosis, based on integrated 3-year data from the

BENEFIT Study. Parallel Session. WCTRIMS. Montréal QC. September 2008.

172.173. Freedman MS, Atkins HL, Bowman M, for Canadian MS Bone Marrow

Transplant Group. High intensity immunoablation and autologous stem cell treatment for

aggressive multiple sclerosis can improve quality of life and fatigue. Poster Presentation.

Poster # P46. WCTRIMS. Montréal QC. September 2008.

173.174. Grand’Maison F, Freedman MS, Traboulsee A, Bhan V, Myles M, Patry DG,

Selchen D for the CanTOR investigators. Assessment of the utility of the Canadian

Treatment Optimization Recommendations (CanTOR) in the routine care of multiple

sclerosis. Poster Presentation. Poster # P54. WCTRIMS. Montréal QC. September

2008.

174.175. Hemmer B, Edan G, Freedman MS, Hartung H-P, Kappos L, Miller D,

Montalban X, Polman CH, Kuhle J, Nessler S, Zhou D, Bauer L, Lanius V, Metzig C,

Pohl C, Sandbrink R. Antibodies to native myelin oligodendrocyte glycoprotein do not

predict progression from clinically isolated syndrome to multiple sclerosis: Complete

analysis of the BEtaferons® in Newly Emerging Multiple Sclerosis For Initial Treatment

(BENEFIT) Study. Poster Presentation. Poster # P66. WCTRIMS. Montréal QC.

September 2008.

175.176. Horga A, Hemmer B, Edan G, Freedman MS, Hartung H-P, Kappos L, Miller D,

Montalban X, Polman CH, Nessler S, Bauer L, Lanius V, Metzig C, Pohl C, Sandbrink

R. Antibodies to aquaporin-4 in patients with a clinically isolated syndrome: Analyses

from the BENEFIT Study (BEtaferons® in Newly Emerging Multiple Sclerosis For Initial


Treatment). Poster Presentation. Poster # P67. WCTRIMS. Montréal QC. September

2008.

176.177. Plitz T, Freedman MS, Hartung H-P, Boiko AN, Dahlke F, Kappos L for the

ATAMS Study Group. Design of a four-arm, randomized, placebo,-controlled phase II

study of 36 weeks of atacicept monotherapy in relapsing multiple sclerosis. Poster

Presentation. Poster # P493. WCTRIMS. Montréal QC. September 2008.

177.178. Scherling CS, Smith A, Walker L, Hogan M, Freedman MS. Multiple sclerosis

patients reveal neural compensation during information processing with no additional

performance decline: A longitudinal functional magnetic resonance imaging study.

Poster Presentation. Poster # P645. WCTRIMS. Montréal QC. September 2008.

178.179. Scherling CS, Smith A, Walker L, Hogan M, Freedman MS. Neural

compensation in cognitively impaired patients with multiple sclerosis during a response

inhibition task. Poster Presentation. Poster # P645. WCTRIMS. Montréal QC.

September 2008.

179.180. Siritho S, Freedman MS. A comparison of multiple sclerosis patients who have

negative cerebrospinal fluid oligoclonal bands to those with positive testing: Baseline

characteristics and prognosis. Poster Presentation. Poster # P881. WCTRIMS.

Montréal QC. September 2008.

180.181. Freedman MS, Kappos L, Polman CH, Edan G, Hartung H-P, Miller D,

Montalban X, Barkhof F, Bauer L, Lanius V, Metzig C, Pohl C, Sandbrink R for the

BENEFIT Study Group. Impact of early interferon beta-1b treatment on disease

evolution over five years in patients with a first event suggestive of multiple sclerosis.

Poster Presentation. Poster # P901. WCTRIMS. Montréal QC. September 2008.

181.182. Hawker K, O'Connor P, Freedman MS, Calabresi P, Antel J, Simon J, Hauser S,

Waubant E, Vollmer T, Panitch H, Zhang J, Smith C, Chin P, for the OLYMPUS trial

group. Safety and Efficacy of rituximab in Patients with Primary Progressive Multiple

Sclerosis: Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial.

Poster Presentation. WCTRIMS. Montréal QC. September 2008.

182.183. Chen Z, Freedman M.S. Gamma delta T cells derived from multiple sclerosis

patients mediate antibody dependent cell cytoxicity and potentially regulate humoral

immunity. Poster Presentation. International Congress of Neuroimmunology. Fort

Worth, Texas. October 26-30, 2008.

183.184. Darlington PJ, Doucet JS, Touil T, Kevir H. Gaucher D, Fawaz L, Zeidan J, Chen

J, Jalili F, Gauchat D, Bowman M, Antel J, Arnold D, Freedman MS, Atkins HL, Sekaly

R, Cheynier R, Prat A, Bar-Or A, for the Canadian BMT Study Group. Regulatory NK

cells mediate the decreased Th17 responses associated with abrogated new disease

activity in MS patients treated with bone marrow transplantation. 61st AAN Meeting.

Seattle WA Poster Presentation. April 2009.


184.185. Freedman MS, Atkins HL, Bowman M, Canadian BMT Study Group.

Neurological recovery following treatment of aggressive MS with immunoablation and

autologous stem cell transplantation. 61st AAN Meeting. Seattle WA Poster

Presentation. April 2009.

185.186. Freedman MS, Polman C, Edan G, Hartung H-P, Kappos L, Miller DH,

Montalban X, Metzig C, Lanius V, Pohl C, Sandbrink R. The impact of neutralizing

antibodies within 5 years of treatment with interferon beta-1b initiated at the first event

suggestive of multiple sclerosis. 61st AAN Meeting. Seattle WA Poster Presentation.

April 2009.

186.187. Hawker K, O’Connor P, Freedman MS, Calabresi P, Antel J, Simon J, Hauser S,

Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH. Efficacy and safety of

Rituximab in patients with primary progressive multiple sclerosis (PPMS): Results of a

randomized double-blind placebo-controlled multicenter trial. 61st AAN Meeting.

Scientific Session. Seattle WA April 2009.

187.188. Bowman M, Freedman MS, Atkins HL and the Canadian MS/BMT Study

Group. Treatment of aggressive MS with high intensity immunoablation and autlogous

stem cell transplant can stabilize or improve disease outcomes without compromising on

patient related outcomes. CMSC. Atlanta GA. Poster Presentation. May 2009.

188.189. Chen JT, Atkins HL, Freedman MS, Arnold DL. Pre-treatment predictors of

brain volume changes following immunoablation and haematopoietic stem cell

transplantation for treatment of multiple sclerosis. ECTRIMS. Poster Presentation.

Dusseldorf, Germany. September 2009.

189.190. Freedman MS, Uccelli A on behalf of the International MSCT Study Group.

Exploring the potential of autologous mesenchymal stem cell transplantation as a

treatment for inflammatory forms of multiple sclerosis. ECTRIMS. Oral presentation.

September 2009.

190.191. Chen JT, Atkins HL, Freedman MS, Arnold DL. Pre-treatment predictors of

brain volume changes following immunoablation and haematopoietic stem cell

transplantation for treatment of multiple sclerosis. ECTRIMS. Poster Presentation.


191.192. Freedman MS,A on behalf of the International MSCT Study Group. Exploring

the potential of autologous mesenchymal stem cell transplantation as a treatment for

inflammatory forms of multiple sclerosis. ECTRIMS. Dusseldorf, Germany. September

2009.

192.193. Freedman MS, Edan G, Hartung HP, Kappos L, Miller D, Montalban X, Polman

CH, Dotan N, Lanius V, Metzig C, Schwenke S, Pohl C, Sandbrink R for the BENEFIT

Study Group. Anti-alpha-glucose-based glycan IgM antibodies in patients with a


clinically isolated syndrome: analyses from the BEtaferon® in newly emerging multiple

sclerosis for initial treatment (BENEFIT) study. ECTRIMS. Poster Presentation.


193.194. Black J, Freedman MS. Neurofascin immunoreactivity in multiple sclerosis.

ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

194.195. Wallström E, Selmaj K. Kappos L, Freedman MS, Goodin D, Hartung HP,

Montalban X, Hemmer B, Rieckmann P, StüveO, Rochotte E, Grünbauer H, Pohlmann

H. Mercier F, Pinheiro J, Leppert D. Reduction of placebo exposure and improved does-

finding by an adaptive design and modelling methods, the BAF312 phase II trial for

relapsing-remitting multiple sclerosis. ECTRIMS. Poster Presentation. Dusseldorf,

Germany. September 2009.

195.196. Grand’Maison F, Bhan V, Freedman MS, Myles JL, Patry D, Selchen D,

Traboulsee A. Assessment of the utility of the Canadian Treatment Optimization

Recommendations (CanTOR) in the routine care of multiple sclerosis – final results.

ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

196.197. Freedman MS, Verco T, Ossanna M, Nilsson M, Ferenczi L, Chappell A, Lin D,

Arfors L, Krantz M. A double-blind, placebo-controlled, multi-centre study to evaluate

the efficacy and safety of dirucotide in patients with secondary progressive multiple

sclerosis. ECTRIMS. Poster Presentation. Dusseldorf, Germany. September 2009.

197.198. Freedman MS, Wolinsky J, Byrnes WJ, Confavreux C, Comi G, Frangin G,

Kappos L, Olsson T, Miller A, O’Connor PW for the Teriflunomide Multiple Sclerosis

Trial Group. Oral teriflunomide or placebo added to interferon beta for 6 months in

patients with relapsing multiple sclerosis: safety and efficacy results. ECTRIMS. Poster

Presentation. Dusseldorf, Germany. September 2009.

198.199. Calabrese P, Penner IK, Freedman MS, Polman C, Edan G, Hartung H-P, Miller

D, Montalban X, Barkhof F, Lanius V, Sandbrink R, Pohl C, Stemper B, Kappos L.

Relationship between cognitive performance and neurological disability in early MS.

AAN. Poster Presentation. Toronto ON. April 2010.

199.200. Freedman MS, Wolinsky JS, Frangin GA,Confavreux C, Comi G, Byrnes WJ,

Kappos L, Olsson T, Miller A, O’Connor P. Oral Teriflunomide or placebo added to

glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: Safety and

efficacy results. AAN. Scientific Session. Toronto ON. April 2010.

200.201. Penner IK, Calabrese P, Freedman MS, Polman C, Edan G, Hartung H, Miller D,

Montalban X, Barkhof F, Lanius V, Sandbrink R, Pohl C, Stemper B, Kappos L.

Treatment effects of IFNB-1b on cognitive performance in patients with a first event

suggestive of MS. AAN. Poster Presentation. Toronto ON. April 2010.


201.202. Cheng A, Walker L, Berrigan L, Smith A, Freedman MS. Longitudinal

evaluation of information processing speed for persons with multiple sclerosis.

International Neuropsychological Society Meeting. Poster Presentation. Acapulco,

Mexico. April 2010.

202.203. Atkins H, Chen J, Bowman M, Arnold D, Freedman MS and the MS-BMT

Study Group. Balancing toxicity and effectiveness: The impact of dose on the central

nervous system (CNS) following autologous stem cell transplantation (ASCT) for

multiple sclerosis (MS). Poster Presentation. Canadian Blood & Marrow Transplant

Group 2010 Biennial Conference. Vancouver BC. April 2010.

203.204. Freedman MS, Atkins HL, Bowman MJ for the Canadian MS/BMT Study

Group. Outcome measurement in patients with aggressive Multiple Sclerosis treated with

high intensity immunoablation and autologous stem cell transplantation: Correlation of

objective and subjective measures. ACTRIMS 15th Annual Meeting. San Antonio TX.

June 2010.

204.205. Freedman MS, Atkins HL, Bowman MJ for the Canadian MS/BMT Study

Group. Treatment of aggressive MS with high intensity immunoablation and autologous

stem cell transplant (IA/ASCT) can stabilize or improve disease outcomes without

compromising on patient related outcomes. CNSF. Québec City QC. June 2010.

205.206. Walker LAS, Berrigan L, Rees L, Cheng A, Freedman MS. Self and informant

ratings of cognition in MS and healthy controls: Relationship to objective measures.

Poster Presentation. Annual Meeting of the National Academy of Neuropsychology.

Vancouver BC. October 2010.

206.207. Cognitive change following bone marrow transplant for multiple sclerosis.

Bharadia V, Walker LAS, Freedman MS & Atkins HL. Poster presentation. Annual

Meeting of the National Academy of Neuropsychology Conference. Vancouver BC.

October 2010.

207.208. Confavreux C, O’Connor PW, Freedman MS, Benzerdjeb Wang HS, Bar-Or A

for the Teriflunomide Multiple Sclerosis Trial Group. Safety of teriflunomide in the

treatment of relapsing multiple sclerosis: Results over an 8-year extension. Poster

Presentation. ECTRIMS. Gothenburg Sweden. October 2010.

208.209. Berard J, Walker LAS, Berrigan LI, Cheng A, Rees LM, Freedman MS. Impact

of PASAT scoring method when measuring cognitive fatigue in multiple sclerosis.

Poster presentation. Annual Meeting of the International Neuropsychological Society.

Boston, MA. February 2011.

209.210. Berrigan L, Walker LAS, Rees LM, Cheng A, Freedman MS. Cognitive

processing speed is linked to vocational status in individuals with relapsing-remitting

multiple sclerosis. Poster presentation. Annual Meeting of the International

Neuropsychological Society. Boston, MA. February 2011.


210.211. Rees LM, Walker LAS, Berrigan L, Cheng A, Freedman MS. Learning and

memory in MS: Are difficulties due to acquisition or retrieval of information? Poster

presentation. Annual Meeting of the International Neuropsychological Society. Boston,

MA. February 2011.

211.212. Cheng A, Walker LAS, Berrigan LI, Rees LM, Freedman MS. Subjective

ratings of MS subjects and healthy controls on tests of information processing speed.

Poster presentation. Annual Meeting of the International Neuropsychological Society.

Boston, MA. February 2011.

212.213. Comi G, De Stefano N, Freedman MS, Kappos L, Hennessy B, Rocak S,

Stubinski B. Efficacy of two dosing frequencies of subcutaneous interferon beta 1-a on

risk of conversion to multiple sclerosis in patients with clinically isolated syndrome:

Results of a Phase III, randomized, double-blind placebo-controlled, multicenter trial

(REFLEX). AAN. Honolulu HI. April 2011.

213.214. De Stefano N, Comi G, Freedman MS, Kappos L, Hennessy B, Lehr L,

Stubinski B. Magnetic resonance imaging results from a Phase III, randomized, double-

blind, placebo-controlled, multicenter trial of two dosing frequencies of subcutaneous

interferon beta-1a in patients with clinically isolated syndrome at high risk of multiple

sclerosis (REFLEX). AAN. Honolulu HI. April 2011.

214.215. Foley F, Benedict R, Penner I-K, Kappos L, Edan G, Calabrese P, Freedman

MS, Hartung H-P, Miller D, Montalban X, Polman CH, Barkhof F, Lanius V, Beckmann

K, Stemper B, Pohl C, Sandbrink R, Pleimes D. Treatment effects of IFNB-1b on paced

auditory serial addition test performance in patients with clinically isolated syndrome

(CIS). AAN. Honolulu HI. April 2011.

215.216. Kappos L, Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH,

Uitdehaag BMJ, Casset-Semanaz F, Hennessy B, Rocak S, Stubinski B. Efficacy of two

dosing frequencies of subcutaneous interferon -1a on risk of conversion from a first

demyelinating event to multiple sclerosis: Results of a Phase III, randomized, double-

blind, placebo-controlled, multicentre trial (REFLEX). 21st Meeting of the European

Neurological Society (ENS). Lisbon Portugal. May 2011.

216.217. Comi G, Kappos L, De Stefano N, Freedman MS, Casset-Semanaz F, Hennessy

B, Rocak S, Lehr L, Stam Moraga M. Safety of two dosing frequencies of subcutaneous

interferon -1a in patients at high risk of conversion to multiple sclerosis: Results of the

Phase III, randomized, double-blind, placebo-controlled REFLEX trial. 21st Meeting of

the European Neurological Society (ENS). Lisbon Portugal. May 2011

217.218. De Stefano N, Comi G, Freedman MS, Kappos L, Polman C, Uitdehaag B,

Casset-Semanaz F, Hennessy B, Rocak S, Stubinski B, Barkhof F. MRI results from a

phase III, randomized, double-blind, placebo-controlled, multi-centre trial (REFLEX) of

two dosing frequencies of subcutaneous interferon -1a in patients with a first


demylinating event suggestive of multiple sclerosis. 21st Meeting of the European

Neurological Society (ENS). Lisbon Portugal. May 2011.

218.219. Nelson F, Miller A, O’Connor P, Confavreux C, Comi G, Kappos L, Olsson T,

Freedman MS, Benzerdjeb H, Truffinet P, Wang L, Wolinsky J for the Teriflunomide

Multiple Sclerosis Trial Group and the MRI Analysis Center in Houston, US. 21st

Meeting of the European Neurological Society (ENS). Lisbon Portugal. May 2011.

219.220. Comi G, Kappos L, De Stefano N, Freedman MS, Casset-Semanaz F, Hennessy

B, Rocak S, Lehr L, Stam Moraga M. Safety of subcutaneous IFN beta-1a in patients

with CIS: The REFLEX Study. 25th Annual Meeting Consortium of Multiple Sclerosis

Centers (CMSC). Montréal QC. June 1-4 2011.

220.221. Freedman MS, Comi G, De Stefano N, Kappos L, Barkhof F, Polman CH,

Uitdehaag BMJ, Casset-Semanaz F, Hennessy B, Rocak S, Stubinski B. Efficacy of sc

IFN beta-1a weekly or three times weekly in patients with CIS. 46th Annual Congress of

the Canadian Neurological Sciences Federation (CNSF). Vancouver BC. June 15-17

2011.

221.222. Darlington PJ, Touil T, Doucet J-S, Boivin M-N, Fawaz L, Roberts M, Freedman

MS, Atkins HL, Bar-Or A, on behalf of the Canadian MS/BMT Study Group.

Modulation of human Th17 cell responses by natural killer cells: Implication for

autologous hematopoietic stem cell transplantation in multiple sclerosis. Federation of

Clinical Immunological Studies. Washington DC. June 23-26 2011.

222.223. Stubinski B, Kappos L, Freedman MS, Comi G, De Stefano N, Barkhof F,

Polman CH, Uitdehaag BMJ,Casset-Semanaz F, Hennessy B, Stam Moraga M, Rocak S.

Efficacy and safety of two dosing frequencies of subcutaneous interferon beta-1a in

patients with a first clinical demyelinating event suggestive of multiple sclerosis: results

of the Phase III, randomized, double-blind, placebo-controlled REFLEX trial.

PACTRIMS. Singapore. Aug 28-30 2011.

223.224. Kappos L, Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH,

Uitdehaag BMJ, Casset-Semanaz F, Hennessy B, Rocak S, Stubinski B. Clinical and

radiological efficacy of two dosing frequencies of subcutaneous interferon beta-1a in

patients with a first demyelinating event: results of a Phase III, randomized, double-blind,

placebo-controlled, multicentre trial (REFLEX). Amsterdam. ECTRIMS. October

2011.

224.225. Freedman MS, Comi G, Kappos L, De Stefano N, Hennessy B, Haller S, Stam

Moraga M, Lehr L, Stubinski B. Safety and immunogenicity of two dosing frequencies

of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event

suggestive of multiple sclerosis: results of the Phase III, randomized, double-blind,

placebo-controlled, REFLEX Trial. Amsterdam. ECTRIMS. October 2011.


225.226. Polman CH, De Stefano N, Kappos L, Freedman MS, Barkhof F, Uitdehaag B,

Hennessy B, Casset-Semanaz F, Rocak S, Stubinski B, Comi G. Efficacy of two dosing

frequencies of subcutaneous interferon beta-1a in patients with a first clinical

demyelinating event: Subgroups of the Phase III, randomized, double-blind, placebo-

controlled, multicentre REFLEX Trial. Amsterdam. ECTRIMS. October 2011.


Uitdehaag BMJ, Hennessy B, Rocak S, Stubinski B. Efficacy of subcutaneous interferon

beta-1a in patients with a first clinical demyelinating event: the Rebif FLEXible dosing in

early multiple sclerosis (REFLEX) Study – outcomes in patients stratified by the 2010

MacDonald Criteria. Amsterdam. ECTRIMS. October 2011.

227.228. Comi G, De Stefano N, Kappos L, Freedman MS, Barkhof F, Polman CH,

Uitdehaag BMJ, Lehr L, Rocak S, Stubinski B. Treatment of patients with a first clinical

demyelinating event: what have we learnt from trials of interferon and glatiramer

acetate? Amsterdam. ECTRIMS. October 2011.

228.229. O’Connor P, Lublin F, Wolinsky J, Comi G, Kappos L, Freedman MS, Olsson T,

Miller A, Burrell A, Dive-Pouletty A, Grand A, Confavreux C. Effect of teriflunomide

on relapses leading to healthcare resource use: Results from the TEMSO Study.

Amsterdam. ECTRIMS. October 2011.

229.230. Cruce R, Vosoughi R, Freedman MS. Anticholinergic medication for bladder

dysfunction in multiple sclerosis can adversely affect cognitive functioning. Amsterdam.

ECTRIMS. October 2011.

230.231. Miller A, O’Connor P, Wolinsky J, Confavreux C, Comi G, Kappos L, Olsson T,

Truffinet P, Wang L, Freedman MS on behalf of the Teriflunomide Multiple Sclerosis

Trial Group. Efficacy of oral teriflunomide in multiple sclerosis with relapses: Cognitive

outcomes from a Phase III trial (TEMSO). Amsterdam. ECTRIMS. October 2011.

231.232. Comi G, O’Connor P, Wolinksy J, Confavreux C, Kappos L, Olsson T,

Benzerdjeb J, Benamor M, Truffinet P, Wang D, Miller A, Freedman MS on behalf of

the Teriflunomide Multiple Sclerosis Trial Group. Extension of a Phase III trial

(TEMSO) of oral teriflunomide in multiple sclerosis with relapses: Safety outcomes with

up to four years of follow-up. Amsterdam. ECTRIMS. October 2011.

232.233. Montalbán X, Hartung H-P, Edan G, Kappos L, Polman C, Freedman MS, Miller

D, Barkhof F, Lanius V, Stolz C, Stemper B, Sandbrink R, Pohl C, Pleimes D. The use

of disease-modifying therapy in the BENEFIT extension study. Amsterdam. ECTRIMS.

October 2011.

233.234. Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, Tremlett H.

Characteristics of aggressive multiple sclerosis: Findings from British Columbia, Canada.



234.235. Freedman MS, Atkins HL, Bowman MJ, on behalf of the Canadian MS/BMT

Study Group. Neurological recovery following treatment of aggressive multiple sclerosis

with immunoablation and autologous stem cell transplantation. Amsterdam. ECTRIMS.

October 2011.

235.236. Confavreux C, O’Connor P, Freedman MS, Benzerdjeb H, Wang D, Bar-Or A,

for the Teriflunomide Multiple Sclerosis Trial Group. Long-term safety and tolerability

of teriflunomide in multiple sclerosis: 9-year follow-up of a Phase II study. Amsterdam.


236.237. Edan G, Kappos L, Montalbán X, Polman C, Freedman MS, Hartung H-P, Miller

D, Barkhof F, Lanius V, Stolz C, Stemper B, Pohl C, Sandbrink R, Pleimes D. Long-

term effect of early treatment with interferon-beta-1b after a first clinical even suggestive

of multiple sclerosis: 8-year observational extension of the Phase 3 BENEFIT Trial.


237.238. Barkhof F, Nagtegaal G, Polman C, Freedman MS, Hartung H-P, Miller D,

Montalbán X, Kappos L, Edan G, Pleimes D, Beckmann K, Pohl C, Stemper B,

Sandbrink R. IFNB-1b therapy started at CIS reduces the evolution of persistent T1

hypointensities on brain MRI. Amsterdam. ECTRIMS. October 2011.

238.239. Costello F, Hodge W, Pan I, Burton J, Freedman MS, Stys P, Trufyn J, Kardon R

for CORE: The Calgary Optic Neuritis Research Group. The impact of gender on retinal

nerve fibre layer integrity after acute optic neuritis. Amsterdam. ECTRIMS. October

2011.

239.240. Freedman MS, Hartung H-P, Miller D, Montalbán X, Kappos L, Polman C, Edan

G, Barkhof F, Petkau J, Beckmann K, Stemper B, Pohl C, Sandbrink R. Predictors of

disease activity in CIS patients treated with IFNB-1b in the BENEFIT Study.


240.241. Kappos L, Hartung H-P, Freedman MS, Boyko A, Mikol D, Freudensprung U,

Plitz T, for the ATAMS Study Group. ATAMS: A randomized trial of the B-cell-

targeting agent atacicept in patients with relapsing multiple sclerosis. Amsterdam.


241.242. Freedman MS, Polman CH, De Stefano N, Kappos L, Barkhof F, Uitdehaag

BMJ, Hennessy B, Casset-Semanaz F, Rocak S, Stubinski B, Comi G. Efficacy of

subcutaneous interferon -1a in patients with a first demyelinating event: Subgroups of

the REFLEX Trial. World Congress in Neurology. Marrakesh Morocco. November

2011.


Uitdehaag BMJ, Hennessy B, Lehr L, Stubinski B. Treatment of patients with a first

clinical demyelinating event: Lessons from trials of interferon b and glatiramer acetate.


World Congress in Neurology. Marrakesh Morocco. November 2011.

243.244. Walker LAS, Berard J, Bowman M, Atkins HL, Freedman MS. PASAT

performance before and after immunoablative therapy and bone marrow transplant in

individuals in MS. 40th Meeting International Neuropsychological Society. Montréal

QC. Feb 2012.

244.245. Berard J, Walker LAS, Bowman M, Atkins HL, Freedman MS. Cognitive

fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and

bone marrow transplant. 40th Meeting International Neuropsychological Society.

Montréal QC. Feb 2012.

245.246. Berard J, Walker LAS, Bharadia V, Bowman M, Lee H, Atkins HL, Freedman

MS. Neuroimaging correlates of cognitive change following immunoablative therapy

and bone marrow transplant in MS: A pilot study. 40th Meeting International

Neuropsychological Society. Montréal QC. Feb 2012.

246.247. Atkins H, Bowman M, Allan D, Bence-Bruckler I, Bredeson C, Faught C,

Freedman MS, Halpenny M, Hamelin L, Lucas K, Martin L, McDiarmid S, Sabloff M,

Tay J, Huebsch L, Canadian Blood Services (Ottawa, CA). Fifteen years of stem cell

transplantation for autoimmune diseases at The Ottawa Hospital. 36th Annual Meeting of

the European Group for Blood and Marrow Transplantation. Geneva Switzerland. April

2012.

247.248. Atkins H, Bowman M, Allan D, Anstee G, Bence-Bruckler I, Bredeson C, Faught

C, Freedman MS, Halpenny M, Hamelin L, Hodgins M, Lucas K, Martin L, McDiarmid

S, Mitchell Sabloff, Tay J(1), Huebsch L. Fifteen years of stem cell transplantation for

autoimmune diseases at The Ottawa Hospital. Canadian Blood and Marrow Transplant

Group Conference. Toronto ON. April 2012.

248.249. Darlington P, Ouamara N, Stonebridge I, Rozenberg A, Freedman MS, Antel J,

Bar-Or A. Fingolimod treatment in multiple sclerosis increases the ability of circulating

γδ T cells to regulate pro-inflammatory Th1 and Th17 T cell responses. AAN. Apr 25

2012.

249.250. Miller A, Lublin F, O'Connor P, Wolinsky J, Comi G, Kappos L, Freedman MS,

Olsson T, Dive-Pouletty C, Bego-Le-Bagousse G, Confavreux C. AAN. Apr 25 2012.

S30: Multiple Sclerosis: Clinical Interventions and Clinical Trials.

250.251. Freedman MS, O'Connor P, Wolinsky J, Confavreux C, Comi G, Kappos L,

Olsson T, Truffinet P, Dukovic D, Miller A. Teriflunomide increases the proportion of

patients free from disease activity in the TEMSO Phase III Study... AAN. Apr 25 2012.

Poster Discussion: Multiple Sclerosis: Clinical Trial Disease Activity Freedom.

251.252. Stuve O, Selmaj K, Lodz K, Li D, Hartung H-P, Hemmer B, Kappos L,

Freedman MS, Rieckmann P, Montalban X, Auberson LZ, Pohlmann H, Mercier F,


Dahlke F, Wallstrom E. BAF312, a selective sphingosine-1-phosphate receptor

modulator improves MRI and clinical outcomes in relapsing-remitting multiple sclerosis

(RRMS). AAN. Apr 25 2012. Session S30: Multiple Sclerosis: Clinical Interventions

and Clinical Trials.

252.253. Edan G, Kappos L, Montalban X, Polman C, Freedman MS, Hartung H, Miller

D, Barkhof F, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D. Early initiation of

interferon beta-1b after a first clinical event suggestive of multiple sclerosis: Clinical

outcomes and use of disease-modifying therapy from the BENEFIT Extension Study.

AAN. Apr 25 2012. Poster Discussion Session: Multiple Sclerosis: Clinical Trial

Disease Activity Freedom.

253.254. Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BMJ,

Verdun di Cantogno E, Lehr L, Issard D, Haller S, Hennessy B, Kappos L. Efficacy of

two dosing frequencies of subcutaneous interferon beta-1a on the risk of conversion from

a first demyelinating event to multiple sclerosis: 3-year results of a phase III, double-

blind multicentre trial (REFLEXION). ENS 22nd Annual Meeting. Prague, Czech

Republic. June 2012.

254.255. Vermersch P, Czlonkowska A, Grimaldi L. Confavreux C, Comi G, Kappos L,

Olsson T, Jodl S, Bauer D, Truffinet P, Miller A, Wolinsky J, Freedman MS, O’Connor

P, for the TENERE Trial Group. Evaluation of patient satisfaction from the TENERE

study: A comparison of teriflunomide and subcutaneous interferon beta-1a in patients

with relapsing multiple sclerosis. ENS 22nd Annual Meeting. Prague, Czech Republic.

June 2012.

255.256. De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BMJ,

Verdun di Cantogno E, Lehr L, Issard D, Hennessy B, Barkhof F. Effect of two dosing

frequencies of subcutaneous interferon beta 1-a on lesion volumes in patients with a first

clinical demyelinating event suggestive of multiple sclerosis: Results of the phase III

REFLEX study extension (REFLEXION). ENS 22nd Annual Meeting. Prague, Czech

Republic. June 2012.

256.257. Lublin F, Bowen J, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy J,

Freedman MS, Krupp L, Paulo C, Hariri R, Fischkoff. A phase 1b, randomised,

placebo-controlled, multiple-dose study of human placenta-derived cells (PDA-001) for

the treatment of adults with multiple sclerosis. ECTRIMS. Lyon France. Oct 11 2012

257.258. Li DKB, Hemmer B, Stuve O, Hartung H-P, Freedman MS, Rieckmann P,

Montalban X, Zhang-Auberson L, Pohlmann H, Wallstrom E, Selmaj K, Kappos L.

Siponimod (BAF312) treatment leads to early MRI benefits in relapsing remitting

multiple sclerosis patients: Results from a phase 2 study. Poster presentation.

ECTRIMS. Lyon France. Oct 11 2012.

258.259. Freedman MS, Arnold DL, Cohen J, Confavreux C, Fox EJ, Hartung H-P,

Havrdova E, Selmaj K, Weiner H, Miller T, Twyman CL, Vallee M, Margolin DH,


Panzara M, Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients

who relapsed on prior therapy (CARE-MS-II): subgroup analyses by previous DMT use.


259.260. Barkhof G, Nagtegaal G, Wattjes MP, Polman CH, Hulst HE, Freedman MS,

Hartung H-P, Miller DH, Montalban X, Kappos L, Edan G, Pleimes D, Beckmann K,

Pohl C, Stemper B, Sandbrink R. Early therapy with IFNB-1b started at the first event

suggestive of MS reduces the evolution of persistent T1 hypointensities on brain MRI.


260.261. Polman CH, Cree B, Lubetzki C. Miller D, Lublin F, Weiner H, Hartung H-P,

Wolinsky JS, Kappos L, Freedman MS, Montalban X, Kornyeyeva E, Pirozzi C.

Holdbrook F. Trial design and baseline data of the INFORMS (fingolimod in patients

with primary progressive multiple sclerosis) study. Poster presentation. ECTRIMS.

Lyon France. Oct 12 2012.

261.262. Hartung H-P, Pigeolet E, Li D, Hemmer B, Kappos L, Freedman MS, Stüve O,

Rieckmann P, Montalban X, Ziemssen T, Zhang-Auberson L, Wallström E, Selmaj K.

The selective sphingosine 1-phosphate receptor modulator siponimod (BAF312):

magnetic resonance imaging lesion and lymphocyte relationship in a phase 2 study in

relapsing-remitting multiple sclerosis. Poster presentation. ECTRIMS. Lyon France.

Oct 12 2012.

262.263. Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, Berkani O,

Mueller M, Sidorenko T, Melanson M. Efficacy and safety of ponesimod, an oral,

selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-

remitting multiple sclerosis: results from a phase IIb, randomized, double-blind, placebo-

controlled trial. Poster presentation. ECTRIMS. Lyon France. Oct 12 2012.

263.264. Fernandez O, Pozzilli C, Freedman MS, Olsson T, Melanson M, Bach D,

Berkani O, Mueller M, Sidorenko T, Boster A. Pharmacodynamic effect, safety and

tolerability of ponesimod, a selective sphingosine 1-phosphate receptor-1 modulator, in

patients with relapsing-remitting multiple sclerosis. Poster presentation. ECTRIMS.


264.265. Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D,

Jodl S, Truffinet P, Benamor M, O’Connor P. Effect of teriflunomide on immune

responses to seasonal influenza vaccination in patients with relapsing multiple sclerosis:

results from the TERIVA Study. Poster presentation. ECTRIMS. Lyon France. Oct 12

2012.

265.266. Walker LAS, Berard J, Bowman M, Atkins HL, Lee H, Freedman MS.

Longitudinal change in PASAT performance following immunoablative therapy and

haematopoietic stem cell transplant in MS. Poster presentation. ECTRIMS. Lyon

France. Oct 12 2012.


266.267. Montalban X, Kappos L, Freedman MS, Hartung H-P, Edan G, Miller DH,

Polman CH, Barkhof F, Stemper B, Herrmann J, Stolz C, Sandbrink R, Pohl D, Pleimes

D. Application of the revised version of the 2010 McDonald diagnostic criteria:

retrospective comparison using the BENEFIT clinical study dataset. Poster presentation.


267.268. Ascherio A, Munger K, Simon C, Kappos L, Polman CH, Freedman MS,

Hartung H-P, Miller DH, Montalban X, Edan G, Barkhof F, White R, Sandbrink R, Pohl

C. Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts

conversion to multiple sclerosis, MRI lesions and brain volume loss. Poster presentation.


268.269. Barkhof F, Freedman MS, Comi G, Kappos L, Polman CH, Uitdehaag BMJ,

Lehr L, Issard D, Haller S, Hennessy B, De Stefano N. Effect of two dosing frequencies

of subcutaneous interferon-beta-1a on brain volume changes in patients with a first

clinical demyelinating event: 36-month results of a phase III, double-blind, multicentre

trial (REFLEX) and its extension (REFLEXION). Poster presentation. ECTRIMS.


269.270. Comi G, Freedman MS, De Stefano N, Barkhof F, Polman CH, Uitdehaag BMJ,

Lehr L, Issard D, Haller S, Bennessy B, Kappos L. Effect of two dosing frequencies of

subcutaneous interferon-beta-1a on conversion to MS and MRI measures of disease in

patients with a first clinical demyelinating event: 3-year results of phase III, double-blind,

multicentre trials (REFLEX/REFLEXION). Poster presentation. ECTRIMS. Lyon

France. Oct 12 2012.

270.271. Freedman MS, Olsson T, Melanson M, Fernandez O, Boster A, Bach D, Berkani

O, Mueller M, Sidorenko T, Pozzilli C. Dose-dependent effect of ponesimod, an oral,

selective sphingosine 1-phosphate receptor-1 modulator, on magnetic resonance imaging

outcomes in patients with relapsing-remitting multiple sclerosis. Poster presentation.


271.272. Long-term outcomes after autologous haematopoietic cell transplantation for

multiple sclerosis: a joint study from the Center for International Blood and Marrow

Research (CIBMTR) and the European Group for Blood and Marrow Transplantation

(EBMT). Muraro P, Pasquini M, Atkins H, Bowen J, Farge D, Fassas A, Freedman MS,

Georges G, Hamerschlak N, Havdrova E, Kozak T, Mancardi GL, Morais D, Nash R,

Pavletic S, Ouyang J, Saiz A, Badoglio M, Zhong X, Sormani MP, Saccardi R. Oral

presentation. EBMT 2013 (39th Annual Meeting of the European Group for Blood &

Marrow Transplantation). London UK. April 7 2013.

272.273. Long-term efficacy, safety and tolerability of ponesimod in patients with

relapsing–remitting multiple sclerosis. Freedman MS, Boster A, Fernandez O,

Melanson M, Pozzilli C, D'Ambrosio D, Sidorenko T, Olsson T. Poster presentation.

AAN. San Diego CA. Mar 18 2013.

http://www.abstracts2view.com/aan/view.php?nu=AAN13L_P01.156



273.274. Immune response to seasonal influenza vaccination in patients with relapsing

multiple sclerosis treated with teriflunomide: The TERIVA study. O'Connor P, Bar-Or

A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Truffinet P,

Benamor M. Poster presentation. AAN. San Diego CA. Mar 18 2013.

274.275. Frequency of infections during treatment with teriflunomide: Pooled data from

three placebo-controlled teriflunomide studies. Singer B, Comi G, Milan, Miller A,

Olsson T, Wolinsky J, Kappos L, Confavreux C, Freedman MS, Benzerdjeb H, Li H,

Philippe Truffinet P, O'Connor P. Poster presentation. AAN. San Diego CA. Mar 18

2013.

275.276. Phase 2 BOLD extension study safety results for siponimod (BAF312) in patients

with relapsing–remitting multiple sclerosis. Hartung H-P, Selmaj K, Li DKB, Hemmer

B, Freedman MS, Stuve O, Rieckmann P, Montalban X, Ziemssen T, Zhang-Auberson

L, Hunter B, Rochotte E, Wallstrom E, Kappos L, Basel. Poster presentation. AAN.

San Diego CA. Mar 18, 2013.

276.277. Oral cladribine safety profile in patients with a first demyelinating event: Top line

results from the Phase III ORACLE MS study. Leist T, Comi G, Cree B, Coyle P,

Freedman MS, Hartung H, Vermersch P, Orejudos A, Lachenal N, Scaramozza M.

Poster presentation. AAN. San Diego CA. Mar 18, 2013.

277.278. Contribution of CSF to the diagnosis of McDonald MS: Retrospective analysis in

the BENEFIT study. Montalban X, Kappos L, Freedman MS, Hartung H, Edan G,

Miller D, Polman C, Barkhof F, Stemper B, Herrmann J, Stolz C, Sandbrink R, Pohl C,

Pleimes D. Poster presentation. AAN. San Diego CA. Mar19 2013.

278.279. Teriflunomide reduces relapse-related sequelae, hospitalizations and

corticosteroid use: A post-hoc analysis of the phase 3 TOWER study. O'Connor P,

Lublin F, Wolinsky J, Comi G, Confavreux C, Lyon, Freedman MS, Miller A, Olsson T,

Dive-Pouletty C, Taniou C, Selzer M, Kappos L. Poster presentation. AAN. San Diego

CA. Mar 21 2013.

279.280. Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in

patients with relapsing–remitting multiple sclerosis. Stuve O, Hartung H-P, Freedman

MS, Li DKB, Hemmer B, Kappos L, Rieckmann P, Montalban X, Ziemssen T, Zhang-

Auberson L, Hunter B, Rochotte E, Wallstrom E, Selmaj K. Poster presentation. AAN.

San Diego CA. Mar 21, 2013.

280.281. Efficacy of alemtuzumab vs IFNB-1a in relapsing-remitting multiple sclerosis

patients who experienced disease activity while on prior therapy (CARE-MS II):

Subgroup analysis by previous disease modifying therapy (DMT) use. Freedman MS,

Arnold D, Cohen J, Coles A, Confavreux C, Fox E, Hartung H, Havrdova E, Selmaj K,

Weiner H, Miller T, Twyman C, Lake S, Margolin D, Panzara M, Compston A. Poster

presentation. AAN. San Diego CA. Mar 21, 2013.



















281.282. Oral cladribine delays time to conversion to clinically cefinite MS in patients with

a first demyelinating event: Top line results from the phase III ORACLE MS study. Leist

T, Comi G, Cree B, Coyle P, Freedman MS, Hartung H, Vermersch P, Orejudos A,

Lachenal N, Scaramozza M. Poster presentation. AAN. San Diego CA. Mar 21 2013.

282.283. Study design and baseline characteristics of the INFORMS Study: Fingolimod in

patients with primary progressive multiple sclerosis. Miller D, Cree B, Dalton C,

Freedman MS, Hartung H, Kappos L, Lubetzki C, Lublin F, MacManus D, Montalban

X, Weiner H, Wolinsky J, De Vera A, Kornyeyeva E, Li B, Pirozzi C, von Rosenstiel P,

Polman C. Poster presentation. AAN. San Diego CA. Mar 21 2013.

283.284. Long term impact of early initiation of Interferon beta-1b after a first clinical

event suggestive of multiple sclerosis: Additional relapse rate, EDSS, and MSSS analyses

after 8 years. Edan G, Kappos L, Montalban X, Polman C, Freedman MS, Hartung H,

Miller D, Barkhof F, Lanius V, Herrmann J, Stolz C, Stemper B, Pohl C, Sandbrink R,

Pleimes D. Poster presentation. AAN. San Diego CA. Mar 21 2013.

284.285. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis:

Results from TOWER, a second, pivotal, phase 3 placebo-controlled study. Miller A,

Kappos L, Comi G, Confavreux C, Freedman MS, Olsson T, Wolinsky J, Bagulho T,

Delhay J-L, Zheng Y, Truffinet P, O'Connor P. Poster presentation. AAN. San Diego

CA. Mar 19 2013.

285.286. Pre-defined subgroups analyses of TOWER, a placebo-controlled phase 3 trial of

teriflunomide in patients with relapsing multiple sclerosis. Moses H, Freedman MS,

Kappos L, Miller A, Olsson T, Wolinsky J, Confavreux C, Comi G, Bagulho T, Zheng Y,

Truffinet P, O'Connor P. Poster presentation. AAN. San Diego CA. Mar 21 2013.

286.287. Confavreux C, Olsson TP, Comi G, Freedman MS, Miller A, Wolinsky JS,

Kappos L, Delhay J-L, Li H, Truffinet P, O’Connor P. Teriflunomide hepatic safety

results: pooled data from three placebo-controlled studies. ENS. June 10 2013.

Barcelona Spain. Poster presentation.

287.288. Freedman MS, Confavreux C, Olsson T, Comi G, Miller A. Wolinsky J, Kappos

L, Benzerjeb H, Dukovic D, Truffinet P, O’Connor P. Teriflunomide efficacy and safety

analyses: Results from TEMSO and TOWER. Poster presentation. CMSC. May 2013.

Orlando FL.

288.289. Arnaout A, Mahzart M, Freedman MS. Conservative management of

hyperthyroidism arising from alemtuzumab treatment in MS. Poster presentation.

CMSC. May 2013. Orlando FL.

289.290. Ascherio, Munger K, Simon C, Kappos L, Polman CH, Freedman MS, Hartung

H-P, Miller D, Montalban X, Edan G, Barkhof F, Sandbrink R, Kochert K, Pohl C. 25-

hydroxyvitamin D and multiple sclerosis activity during therapy with interferon beta-1b.








http://www.abstracts2view.com/aan/view.php?nu=AAN13L_S01.004





Poster presentation. CMSC. May 2013. Orlando FL.

290.291. Freedman MS, Kappos L, Edan G, Montalban X, Polman CH, Hartung H-P,

Miller DH, Barkhof F, Lanius V, Hermann J, Stolz C, Stemper B, Pohl C, Sandbrink R,

Pleimes D. Predictors of disease activity in patients with clinically isolated syndrome

(CIS) treated with interferon beta 1b in the BENEFIT trial. ECTRIMS. Copenhagen

Denmark. October 3 2013. Poster presentation.

291.292. Freedman MS, Ben-Amor A-F, Issard D, Casset-Semanaz F. Assessing a tool to

predict disease activity in patients with multiple sclerosis: A post-hoc analysis of clinical

trial data on patients treated with subcutaneous interferon beta-1a. ECTRIMS.

Copenhagen Denmark. October 3 2013. Poster presentation.

292.293. Kappos L, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS,

Truffinet P, Cavalier S, Delhay JL, Dukovic D, O’Connor P. Pooled efficacy data from

two phase 3 placebo-controlled trials of oral, once-daily teriflunomide. ECTRIMS.


293.294. Vollmer T, Radue E, Vermersch P, Von Rosenstiel P, Putzki N, Meinel M, Sfikas

N, Merschhemke M, Freedman MS. Clinical and magnetic resonancy imaging (MRI)

disease activity after fingolimod discontinuation. ECTRIMS. Copenhagen Denmark.

October 3 2013. Poster presentation.|

294.295. Freedman MS, Atkins H, Bowman M on behalf of the Canadian MS/BMT Study

Group. Long-term outcome of the Canadian multiple sclerosis BMT Study: Efficacy and

safety of treating aggressive multiple sclerosis with immunoablation and autologous stem

cell transplantation. ECTRIMS. Copenhagen Denmark. October 3 2013. Poster

presentation.

295.296. Freedman MS, Wolinsky J, Comi G, Kappos L, Olsson T, Miller A, Benamor M,

Dukovic D, Liang J, Truffinet P, O’Connor P. Long-term safety and efficacy of

teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO

extension trial. ECTRIMS. Copenhagen Denmark. October 3 2013. Poster

presentation.

296.297. Leist T, Freedman MS, Kappos L, Olsson T, Miller A, Wolinsky J, O’Connor P,

Benamor M, Delhay J, Truffinet P, Dukovic D, Li J, Comi G. Pooled safety data from

three placebo-controlled teriflunomide studies. ECTRIMS. Copenhagen Denmark.

October 3 2013. Poster presentation.

297.298. Ascherio A, Munger K, White R, Kochert K, Simon C, Polman C, Freedman

MS, Hartung H-P, Miller DH, Montalban X, Edan G, Barkhof F, Pleimes D, Sandbrink

R, Kappos L, Pohl C. Vitamin D as a predictor of multiple sclerosis activity and

progression. ECTRIMS. Copenhagen Denmark. October 3 2013. Platform

presentation.


298.299. Miller A, wolinsky J, Kappos L, Comi G, Freedman MS, Olsson T, Rugina A,

Bauer D, Delhay J, Wamil B, Truffinet P, O’Connor P. TOPIC main outcomes: efficacy

and safety of once-daily oral teriflunomide in patients with clinically isolated syndrome.

ECTRIMS. Copenhagen Denmark. October 3 2013. Platform presentation.

299.300. Torres C, Lum C, Chakraborty S, Hogan MJ, Nguyen T, Bussiere M, Freedman

MS. Extracranial venous abnormalities: A pathological finding in multiple sclerosis or a

normal anatomical variant? ECTRIMS. Copenhagen Denmark. October 4 2013. Poster

presentation.

300.301. Mäurer M, Lublin F, Comi G, Freedman MS, Kappos L, Miller A, Olsson T,

Wolinsky J, Dive-Pouletty C, Bozzi S, O’Connor P. Impact of severe relapses on

disability, fatigue and health-related quality of life outcomes: a pooled dataset of the

phase 3 TEMSO and TOWER studies. ECTRIMS. Copenhagen Denmark. October 4

2013. Poster presentation.

301.302. Garg S, Tam R, Li D, Roy-Hewitson C, Zhao Y, Freedman MS, Traboulsee A.

Cortical atrophy in SPMS and its assosication with cognitive impairment and whole brain

over two years. ECTRIMS. Copenhagen Denmark. October 4 2013. Poster

presentation.

302.303. MacMillan EL, Tam R, Zhao Y, Vavasour IM, Li DKB, Oger J, Freedman MS,

Kolind SH, Traboulsee AL. Progressive MS shows significant decreases in brain

glutamate and glutamine over 2 years. ECTRIMS. Copenhagen Denmark. October 4,

2013. Poster presentation.

303.304. Pozzilli C, Fernández Ó, Olsson T, Freedman MS, Melanson M, Boster A,

Radue E-W, Hennessy B, Rames A, D’Ambrosio D. Maintenance of efficacy, safety and

tolerability of ponesimod in patients with relapsing remitting multiple sclerosis: phase II

extension study. ECTRIMS. Copenhagen Denmark. October 4 2013. Poster

presentation.

304.305. Munger KL, Kochert K, Simon C, Kappos L, Polman C, Freedman MS, Hartung

H-P, Miller DH, Montalban X, Edan G, Barkhof F, Sandbrink R, Ascherio A, Pohl C.

Molecular dissection of the role of vitamin D in determining multiple sclerosis activity.

ECTRIMS. Copenhagen Denmark. October 4 2013. Poster presentation.

305.306. Mikol D, Freedman MS, Goldman MD, Hartung H-P, Havrdova E, Jeffery D,

Kappor R, Miller A, Sellebjerg F, Lee S, Chen D, Cadavid D, Ticho B. ASCEND study

of natalizumab efficacy on reducing disability in patients with secondary progressive

multiple sclerosis: baseline demographics and disease characteristics. ECTRIMS.


306.307. Macdonell R, Lublin F, Comi G, Freedman MS, Kappos L, Mäurer M, Miller A,

Olsson TP, Wolinsky JS, Bozzi S, Dive-Pouletty C, O’Connor P. Teriflunomide reduces

relapse-related sequelae, severe relapses, hospitalisations and corticosteroid use: pooled


data from the phase 3 TEMSO and TOWER studies. ECTRIMS. Copenhagen Denmark.

October 4 2013. Poster presentation.

307.308. Kang H, Tam R, Traboulsee A, Zhao U, Riddehough A, Freedman MS. Corpus

callosum atrophy in a large SPMS cohort and its correlation with PASAT as a cognitive

marker. Parallel Session 13. ECTRIMS. Copenhagen Denmark. October 5 2013.

Platform presentation.

308.309. Freedman MS, Macdonell R, Maurer M, Dukovic D, Truffinet P, Bozzi S, Dive-

Pouletty C, Comi G. Teriflunomide demonstrates consistent clinical efficacy across two

phase 3 studies: Results from TEMSO and TOWER. European CHARCOT Foundation.

Nov 2013. Poster presentation.

309.310. Walker LAS, Berard JA, Bowman M, Freedman MS, Atkins HL. Cognitive

correlates of health-related quality of life in MS patients undergoing immunoablative

therapy and autologous hematopoietic stem cell transplantation (IA-HSCT). Annual

Meeting of the International Neuropsychological Society. Waikoloa HI. Feb 2014.

Poster presentation.

310.311. Atif S, Walker LAS, Berard JA, Rees LM, Freedman MS. Relationship between

MSNQ and objective cognition in early relapsing-remitting multiple sclerosis: Self and

informant ratings. Annual Meeting of the International Neuropsychological Society.

Waikoloa HI. Feb 2014. Poster presentation.

311.312. Osman L, Berard JA, Rees LM, Cousineau D, Freedman MS, MacLean H,

Walker LAS. Group differences and test-retest reliability of a working memory measure

in multiple sclerosis and controls: A preliminary analysis. Rotman Institute Conference.

Toronto ON. March 10-11 2014. Poster presentation.

312.313. Freedman MS. Application of immune tolerance approaches to the treatment of

MS. 9th International Congress on Autoimmunity. Nice, France. March 28, 2014.

313.314. Schippling S, Pleimes D, Gilles Edan G, Montalban X, Freedman MS, Hartung

H, Miller D, Barkhof F, Radu E-W, Hermann J, Pohl C, Sandbrink S, Martin R. MRI

phenotypes as predictors of clinical outcomes in patients with CIS in the BENEFIT

population. Poster Session I: MS and CNS inflammatory Disease: Clinically Isolated

Syndromes. AAN. Apr 28 2014.

314.315. Metz LM, Traboulsee A, Li D, Duquette P, Yeung M, Kremenchutzky M,

Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott J, Grand'Maison F, Lee L,

Thibault M, Eliasziw M, Wee Yong V, Cerchiaro G, Wiebe S, Cheng Y, Zhao G,

Greenfield J, Topor M, Riddehough A. Randomized trial of minocycline for clinically

isolated syndrome and early single relapse multiple sclerosis: Study design, participant

characteristics, and recruitment challenges. Poster Session I: MS and CNS inflammatory

Disease: Clinically Isolated Syndromes. AAN. Apr 28 2014.


315.316. Sormani MP, Barkhof F, Kappos L, Edan G, Freedman MS, Montalban X,

Hartung H,7 Miller D, Hermann J, Lanius V, Beckmann K, Sandbrink R, Pohl C, Pleimes

D. Predicting response to interferon beta-1b therapy in patients with clinically isolated

syndrome. Poster Session I: MS and CNS inflammatory Disease: Clinically Isolated

Syndromes. AAN. Apr 28 2014.

316.317. Singer B, Comi G, Miller A, Freedman MS, Benamor M, Truffinet P.

Teriflunomide treatment is not associated with increased risk of infections: Pooled data

from the Teriflunomide Development Program. Poster Session II: MS and CNS

Inflammatory Disease: Treatment Safety. AAN. Apr 29 2014.

317.318. Leist T, Freedman MS, Benamor M, Truffinet P, Dukovic D, Comi G. Pooled

safety data from four placebo-controlled teriflunomide studies. Poster Session II: MS

and CNS Inflammatory Disease: Treatment Safety. AAN. Apr 29 2014.

318.319. Freedman MS, Wolinsky J, Comi G, Kappos L, Olsson T, Miller A, Benamor M,

Dukovic D, Liang J, Truffinet P, O'Connor P. Safety and efficacy of teriflunomide for up

to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO Extension

Trial. Poster Session III: MS and CNS Inflammatory Disease: Clinical Trials Outcomes.

AAN. Apr 29 2014.

319.320. Kappos L, Stuve O, Hartung H, Freedman MS, Li D, Hemmer B, Rieckmann P,

Montalban X, Ziemssen T, Hunter B, Arnould S, Wallstrom E, Selmaj K. Safety and

efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis:

Results from dose-blinded extension phase of BOLD Study. Poster Session III: MS and

CNS Inflammatory Disease: Clinical Trials Outcomes. AAN. Apr 29 2014.

320.321. Olsson T, Comi G, Freedman MS, Miller A, Wolinsky J, Truffinet P, Cavalier S,

Dukovic D, O'Connor P, Kappos L. Patients free of clinical MS activity in TEMSO and

TOWER: pooled analyses of two phase 3 placebo-controlled trials. Poster Session III:

MS and CNS Inflammatory Disease: Clinical Trials Outcomes. AAN. Apr 29 2014.

321.322. Freedman MS, Ben-Amor A-F, Aycardi E, Issard D, Casset-Semanaz F.

Assessing a scoring system to predict disease activity in patients with multiple sclerosis:

Post hoc analyses of data from clinical trials of subcutaneous interferon Beta-1a. Poster

Session III: MS and CNS Inflammatory Disease: Clinical Trials Outcomes. AAN. Apr

29 2014.

322.323. Virender Bhan V, Lapierre Y, Freedman MS, Duquette P, Selchen D, Migounov

V, Walt L, Zhang A . Anti-JC virus antibody prevalence in canadian MS patients. Poster

Session IV: MS and CNS Inflammatory Disease: Biomarkers. AAN. Apr 30 2014.

323.324. Edan G, Kappos L, Montalban X, Freedman MS, Hartung H, Miller D, Barkhof

F, Hermann J, Lanius V, Pohl C, Sandbrink R, Pleimes D. Patient-reported quality of life

in the BENEFIT trial. Poster Session IV: MS and CNS Inflammatory Disease:


Biomarkers. AAN. Apr 30 2014.

324.325. Ascherio A, Munger K, White R, Kochert K, Claire Simon KC, Freedman MS,

Hartung H, Miller D, Montalban X, Edan, Barkhof F, Pleimes D, Sandbrink R, Kappos L,

Pohl C. Vitamin D as predictor of multiple sclerosis activity and progression in patients

with CIS treated early with interferon beta-1b. ePoster Session: MS and CNS

Inflammatory Disease II. AAN. Apr 30 2014.

325.326. Freedman MS, Wolinsky JS, Giancarlo C, Kappos L, Miller A, Olsson T, Liang

J, Dukovic D, Benamor M, Truffinet P, O’Connor P, for the TERACLES Study Group.

Safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis treated

with interferon-beta. CONy. Berlin Germany. May 2014.

326.327. Miller AE, Wolinsky JS, Freedman MS, Bauer D, Benamor M, Truffinet P,

O’Connor, for the TOPIC Study Group. TOPIC: Efficacy and safety of once-daily oral

teriflunomide in patietns with early stage MS. CONy. Berlin Germany. May 2014.

327.328. Chan A, Freedman MS, Truffinet P, Dukovic D, Kappos L. Patients with high

disease activity in TEMSO and TOWER: Pooled analyses of two phase 3 placebo-

controlled trials. CONy. Berlin Germany. May 2014.

328.329. Freedman MS, Dukovic D, Benamor M, Truffinet P, Kappos L. Consistent

treatment effect of teriflunomide in subgroups based on pre-trial therapy: Pooled analyses

of TEMSO and TOWER. Poster presentation. CMSC. May 30 2014.

329.330. Freedman MS, O’Connor P, Duquette P, Schecter R. High continuation rate,

good disease control after switching from natalizumab to fingolimod. Poster

presentation. CMSC. May 30 2014.

330.331. Ascherio A, Munger K, White RA, Kochert K, Simon KC, Polman CH,

Freedman MS, Hartung H-P, Miller DH, Montalban X, Edan G, Barkhof F, Pleimes D,

Radu EW, Sandbrink R, Kappos L, Pohl C. Vitamin D deficiency as an early predictor of

long-term disease activity in patients starting interferon beta-1b at clinically isolated

syndrome. Poster presentation. CMSC. May 30 2014.

331.332. Atkins HL, Bowman M, Allan D, Arnold D, Bar-Or A, Bence-Buckler I,

Bredeson C, Hamelin L, Huebsch L, McDiarmid S, Sabloff M, Sheppard D, Tay J,

Walker L, Freedman MS. Recovery of functional disabilities in multiple sclerosis

patients following hematopoietic stem cell transplant suggests regional difference in

repair capacity of the central nervous system. 12th Annual Meeting International Society

for Stem Cell Research. Vancouver BC. June 2014.

332.333. Freedman MS, Montalban X, Miller A, Dive-Pouletty, Leist P. Assessing the

comparative outcomes from teriflunomide and dimethyl fumarate studies in relapsing

MS: use of “number needed to treat” analysis. ISPOR Submitted June 2014


333.334. Freedman MS, Burton J, Schecter R. Real-life patient adherence and follow-up

monitoring with fingolimod. CNSF. June 5 2014. Banff AB.

334.335. Walker LAS, Osman L, Berard J, Rees L, Cousineau D, MacLean H, Freedman

MS. Brief International Cognitive Assessment for MS (BICAMS): Preliminary findings

from the Canadian validation study. A/ECTRIMS Sept 11 2014. Poster presentation.

Boston MA.

335.336. Walker LAS, Berard J, Berrigan L, Rees L, Freedman MS. CTIP performance in

early relapsing-remitting MS: Group differences and potential confounds. A/ECTRIMS

Sept 11 2014. Poster presentation. Boston MA.

336.337. Freedman MS. Assessing a predictive score for disease activity in secondary

progressive multiple sclerosis: post-hoc analysis of data from the SPECTRIMS study.

A/ECTRIMS Sept 12 2014. Poster presentation. Boston MA.

337.338. Freedman MS. Assessing a predictive score for long-term disability progression

in relapsing-remitting multiple sclerosis: 7/8-year follow-up in the PRISMS study.

A/ECTRIMS Sept 12 2014. Poster presentation. Boston MA.

338.339. Osman L, Berard J, Rees L, Cousineau D, Freedman MS, MacLean H, Walker

LAS. Subjective and objective measures of cognition in MS: A preliminary ahnalysis of

correlations and test-retest reliability. Poster presentation. A/ECTRIMS Sept 12 2014.

Boston MA.

339.340. Black J, Freedman MS. Inflammation and neurodegneration. Platform

presentation . A/ECTRIMS Sept 12 2014. Boston MA.

340.341. Berard J, Rees L, Freedman MS, Walker LAS. A longitudinal evaluation of

cognitive fatigue in MS using the PASAT. Poster presentation. A/ECTRIMS Sept 11

2014. Boston MA.

341.342. Sellebjerg FT, Miller A, Freedman MS, Kapoor R, Hartung H-P, Havrodova E,

Jeffrey D. Correlations between patient-reduced ambulatory function (MSWS-12) and

objective disability measurements in SPMS: Analysis of ASCEND baseline data. Poster

presentation. A/ECTRIMS Sept 12 2014.

342.343. Freedman MS, Dukovic D, Benamor M, Truffinet P, Kappos L. Evaluating the

effect of teriflunomide in subgroups defined by prior treatment: pooled analyses of phase

3 TEMSO and TOWER studies. Poster presentation. A/ECTRIMS Sept 2014.

343.344. Kappos L, Radue E-W, Freedman MS, Cree B, Sormani MP, Sfikas N, Francis

G, Tomic D, Piani Meier D, De Stefano N. Inclusion of brain volume loss in a revised

measure of multiple sclerosis disease-activity freedom: the effect of fingolimod. Poster

presentation. A/ECTRIMS Sept 2014. Boston MA


344.345. Putzki N, Clifford DB, Bischof D, Moore A, Weinshenker BG, Freedman MS.

Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from

natalizumab. Platform presentation. A/ECTRIMS Sept 2014. Boston MA

345.346. Kappos L, Edan G, Freedman MS, Montalban X, Miller DH, Hartung H-P,

Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrik R,

Suarez G, Wicklein E-M. Clinical outcomes in patients with CIS treated with interferon

beta-1b: 11-year follow-up of BENEFIT. Poster presentation. A/ECTRIMS Sept 2014.

Boston MA

346.347. Comi G, Freedman MS, Kappos L, Miller AE, Olsson TP, Wolinsky JS,

Benamor M, Dukovic D, Truffinet P, O’Connor PW. Effect of teriflunomide on

lymphocyte and neutrophil counts: pooled analyses from four placebo-controlled studies.

Poster presentation. A/ECTRIMS Sept 2014. Boston MA

347.348. Leist TP, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS,

O’Connor PW, Benamor M, Truffinet P, Dukovic D, Comi G. Pooled safety analyses

from the teriflunomide clinical development program. Poster presentation. A/ECTRIMS

Sept 2014. Boston MA

348.349. De Stefano N, Sprenger T, Freedman MS, Cree B, Sormani MP, Haring DA,

Francis G, Piani Meier D, Tomic D, Kappos L. Including threshold rates of brain volume

loss in the definition of disease-activity-free in multiple sclerosis using fingolimod phase

3 data. Poster presentation. A/ECTRIMS Sept 2014. Boston MA

349.350. Munger K, Kochert K, Fitzgerald K, Arnason B, Barkhof F, Comi G, Cook S,

Edan G,Filippi M, Freedman MS, Goodin D, Hartung H-P, Jeffery D, Kappos L, Miller

D, Montalban X, O’Connor P, Hemmer B, Mueller-Myhsok C, Muhlau M, Suarez G,

Sandbrink R, Ascherio A, Pohl C. Genetic modification of 25(OH)D levels in MS.

Poster presentation. A/ECTRIMS Sept 2014. Boston MA

350.351. Black JD, Freedman MS. Neuro-axonal damage in MS may be mediated by

interaction of innate immunity and anti-axonal antibodies. Platform presentation.

A/ECTRIMS Sept 2014. Boston MA

351.352. Freedman MS The new landscape of MS centres organization. 16th MS Nurse

international workshop Sept 9 2014 A/ECTRIMS Boston MA

352.353. Freedman MS MS Academia Multiple sclerosis advanced course: Current

disease modifying drugs: evaluating the evidence. Sept 9 2014. A/ECTRIMS Boston

MA

353.354. Vermersch P, Thangavelu K, Benamor M, Truffinet P, Freedman MS. Effect of

teriflunomide across patient subgroups based on prior treatment: pooled analyses of the

phase 3 Temson and Tower studies. CONy. Budapest, Hungary. March 27 2015.


354.355. Thomas P. Leist, Mark Freedman, Aaron E. Miller, Catherine Dive-Pouletty,

Xavier Montalban . Assessing Comparative Outcomes from Teriflunomide and Dimethyl

Fumarate Studies in Relapsing MS: Use of “Number Needed to Treat” Analysis. AAN.

Wahington, DC. April 21 2105.

355.356. Kathryn Fitzgerald, Kassandra Munger, Mark Freedman, Hans Hartung, David

Miller, Xavier Montalban, Gilles Edan, Frederik Barkhof, Rupert Sandbrink, Ludwig

Kappos, Gustavo Suarez, Christoph Pohl, Alberto Ascherio .Vitamin D as a Predictor of

Functional Deficits in Multiple Sclerosis. AAN. Wahington, DC. April 22 2015.

356.357. Juanzhi Fang, Patricia K. Coyle, Ali Hassan, Choon Cha, Fernando Dangond,

Anthony T. Reder, Mark S. Freedman. No Evidence of Disease Activity in Patients

with Relapsing MS Treated with Interferon Beta-1a SC tiw versus Interferon Beta-1a IM

qw: Subgroup Analyses of the EVIDENCE Study. AAN Washington, DC. April 23

2015.

357.358. Mark Freedman, Giancarlo Comi, Nicola De Stefano, Frederik Barkhof, Bernard

Uitdehaag, Ludwig Kappos, Tanya Fischer, Liang Chen . Effect of Two Dosing

Frequencies of Subcutaneous Interferon (scIFN) β-1a on Conversion to Multiple

Sclerosis (MS) in Patients with a First Clinical Demyelinating Event (FCDE): 5-year

Results of Phase III, Double-blind, Multicenter Trials (REFLEX/REFLEXION). AAN.


358.359. Mark Freedman, Giancarlo Comi, Nicola De Stefano, Frederik Barkhof,

Bernard Uitdehaag, Ludwig Kappos, Tanya Fischer, Liang Chen .Safety and

Immunogenicity of Two Dosing Frequencies of Subcutaneous Interferon (scIFN) β-1a in

Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III,

Double-blind, Multicenter Trials (REFLEX/REFLEXION) AAN. Wahington, DC. April

23 2015.

359.360. Richard Macdonell, Martin Stangel, Matthias Mäurer, Deborah Dukovic, Philippe

Truffinet, Sylvie Bozzi, Catherine Dive-Pouletty, Mark S. Freedman .Teriflunomide

Shows Consistent Clinical Efficacy on Severe Relapses across Two Phase 3 Trials in

Patients with Relapsing forms of Multiple Sclerosis, TEMSO and TOWER. AAN.


360.361. Gilles Edan, Mark Freedman, Xavier Montalban, David Miller, Hans Hartung,

Bernhard Hemmer, Edward Fox, Frederik Barkhof, Sven Schippling, Andrea Schulze,

Dirk Pleimes, Christoph Pohl, Rupert Sandbrink, Gustavo Suarez, Eva-Maria Wicklein,

Ludwig Kappos

Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical,

MRI, Employment, and Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of

BENEFIT (BENEFIT 11). AAN. Wahington, DC. April 23 2015.

361.362. Daniel Mikol, Jeff A. Cohen, Mark Freedman, Myla Goldman, Hans-Peter

Hartung, Eva Havrdova, Douglas Jeffery, Raj Kapoor, Aaron Miller, Finn Sellebjerg,


Deborah Kinch, Sophia Lee, Diego Cadavid . Rationale for EDSS-Plus, the Primary

Composite Endpoint of Disability Progression in the ASCEND Phase 3 Study of

Natalizumab for Secondary Progressive Multiple Sclerosis: A Post Hoc Analysis of

IMPACT Study Data. AAN. Wahington, DC. April 23 2015.

362.363. Marcelo Kremenchutzky, Mark S. Freedman, Amit Bar-Or, Deborah Dukovic,

Myriam Benamor, Philippe Truffinet, Paul W. O'Connor . 12-Year Clinical Efficacy and

Safety Data for Teriflunomide: Results from a Phase 2 Extension Study. AAN.


363.364. Frederik Barkhof, Giancarlo Comi, Mark S. Freedman, Bernard Uitdehaag,

Tanya Fischer, Liang Chen, Ludwig Kappos, Nicola De Stefano . Effect of Two Dosing

Frequencies of Subcutaneous Interferon (scIFN) β-1a on MRI Lesion and Brain Volume

Changes in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of

Phase III REFLEX Study Extension (REFLEXION). AAN. Wahington, DC. April 23

2015.

364.365. Anthony T. Reder, Mark S. Freedman, Juanzhi Fang, Ali Hassan, Choon Cha,

Fernando Dangond, Patricia K. Coyle .Early Effects of Interferon Beta-1a SC tiw Versus

Interferon Beta-1a IM qw on MRI Outcomes in Patients with Relapsing MS in the

EVIDENCE Study. AAN. Wahington, DC. April 23 2015.

365.366. Thomas P. Leist, Mark S. Freedman, Ludwig Kappos, Tomas P. Olsson, Aaron

E. Miller, Jerry S. Wolinsky, Paul W. O'Connor, Myriam Benamor, Philippe Truffinet,

Deborah Dukovic, Giancarlo Comi . Pooled Safety Analyses from Teriflunomide

Clinical Studies. AAN. Wahington, DC. April 23 2015.

366.367. Raj Kapoor, Douglas L. Arnold, Aaron Miller, Mark S. Freedman, Myla D.

Goldman, Hans-Peter Hartung, Eva Havrdova, Douglas Jeffery, Finn Sellebjerg, Carmen

Castrillo-Viguera, Yun Chen, Diego Cadavid, Daniel Mikol .Gray Matter Volume

Correlates with Information Processing as Measured by the Symbol Digit Modalities Test

(SDMT) but Not with Physical Disability as Measured by the Expanded Disability Status

Scale (EDSS) in Patients with Secondary Progressive Multiple Sclerosis (SPMS):

Analysis of Baseline Correlations from the ASCEND Natalizumab Study. AAN.


367.368. MS Freedman, Xavier Montalban, Aaron E Miller, Catherine Dive-Pouletty,

Thomas P Leist. Number Needed to Treat” Analysis to Assess the Comparative

Outcomes From Teriflunomide and Dimethyl Fumarate Studies in Relapsing Multiple

Sclerosis. ISPOR. Philadelphia, PA. May 20 2015.

368.369. Richard Macdonell, Martin Stangel, Matthias Mäurer, Deborah Dukovic, Philippe

Truffinet, Sylvie Bozzi, Catherine Dive-Pouletty, Mark S. Freedman .Teriflunomide

Shows Consistent Clinical Efficacy on Severe Relapses across Two Phase 3 Trials in

Patients with Relapsing forms of Multiple Sclerosis, TEMSO and TOWER: 2 phase 3


trials. ISPOR. Philadelphia, PA. May 20 2015.

369.370. L Kappos, EW Radue, T Sprnger, E Havrdova, MS Freedman, B.A.C. Cree, MP

Sormani, N Sfikas, N Bergvall, D Piani Meier, D Tomic, N de Stefano. Effect of

fingolimod on the revised, more comprehensive measure of no evidence of disease

activity and worsening (NEDA-4) at 12 and 24 months. EAN. Berlin, Germany. June

2015.

370.371. MS Freedman, Xavier Montalban, Aaron E Miller, Catherine Dive-Pouletty,

Thomas P Leist. Number Needed to Treat” Analysis to Assess the Comparative

Outcomes From Teriflunomide and Dimethyl Fumarate Studies in Relapsing Multiple

Sclerosis. EAN. Berlin, Germany. June 2015.

371.372. G Edan, MS Freedman, X Montalban, H-P Hartung, B Hemer, EJ Fox, F

Barkhof, S Schippling, IK Penner, FW Foley, A Schulze, D Pleimes, C Pohl, R

Sandbrink, G Suarez, EM Wickleink, L Kappos for the BENEFIT Study Group. Impact

of early treatment of MS with interferon beta-1b: Patient-reported outcomes at the 11-

year follow-up of BENEFIT (BENEFIT 11). EAN. Berlin, Germany. June 2015.

372.373. Martin Marziniak, MS Freedman, Myriam Benamor, Philippe Truffinet,

Karthinathan Thangavelu, Thomas P Leist. Teriflunomide: Pooled Hepatic Safety

Outcomes From Placebo-Controlled Studies and Long-term Extensions. EAN. Berlin,

Germany. June 2015.

373.374. Y. Lapierre, P. O’Connor, V. Devonshire, MS Freedman, M. Kremenchutzky, M.

Yeung, P. Haddad, R. Schecter. High persistence with fingolimod in Canadian routine

clinical practice. ECTRIMS. Barcelona, Spain. October 2015.

374.375. F. Barkhof, MP. Wattjes, G. Eden, MS Freedman, X. Mantalban, H-P. Hartung, B.

Hemmer, EJ Fox, F. Barkhof, S. Schippling, R. Koelbach, D. Pleimes, C. Pohl, R. Sandbrink,

G. Suarez, E-M Wicklein, L. Kappos. MRI results in patients with CIS treated with

interferon beta-1b: 11-year follow up in BENEFIT (BENEFIT 11). ECTRIMS. Barcelona,

Spain. October 2015.

375.376. S. Lukas, JVM Hanson, G. Edan, MS Freedman, X. Mantalban, H-P Hartung, B.

Hemmer, EJ Fox, F. Barkhof, R. Koelbach, D. Pleimes, S. Schippling. Optical coherence

tomography and ophthalmaological findings in patients with CIS treated with interferon beta-

1b: 11-year follow-up in BENEFIT (BENEFIT 11). ECTRIMS. Barcelona, Spain. October

2015.

376.377. F. Foley, I-K. Penner, G. Edan, MS Freedman, X. Mantalban, H-P. Hartung, B.

Hemmer, EJ Fox, F. Barkhof, S. Schippling, R. Koelbach, D. Pleimes, C. Pohl, R. Sandbrink,

G. Suarez, E-M Wicklein, L. Kappos. Impact of early treatment of MS with interferon beta-

1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11). ECTRIMS.

Barcelona, Spain. October 2015.


377.378. MS Freedman, L. Kappos, BAC. Cree, E-W. Radue, G. Giovannoni, S. Ritter, D.

Piani Meier, D. Tomic. Efficacy of fingolimod on NEDA-4 in pooled FREEDOMS and

FREEDOMS II studies by subgroups of baseline characteristics. ECTRIMS. Barcelona,

Spain. October 2015.

378.379. BAC.Cree, L. Kappos, MS Freedman, JA. Cohen, T. Sprenger, S. Ritter, D. Tomic,

D. Piani Meier. Long-term effects of fingolimod on NEDA by year of treamtnt. ECTRIMS.


379.380. A. Sartori, M. Abdoli, MS Freedman. Is it possible to predict behign multiple

sclerosis? ECTRIMS. Barcelona, Spain. October 2015.

380.381. KC. Fitzgerald, K. Munger, MS Freedman, H-P. Hartung, X. Mantalban, G. Edan,

F. Barkhof, R. Sandbrink, L. Kappos, G. Suarez, C. Pohl, A. Ascherio. Vitamin D and the

development and evolution of permanent black holes among patients with clinically isolated

syndrome. ECTRIMS. Barcelona, Spain. October 2015.

381.382. MS Freedman, P. Duquette, V. Bhan, . Lee, M. Pedros, E. Loefroth, J. Medin, R.

Schecter, P. Haddad. Clinical and economic outcomes in MS patients treated with DMTs

(SWITCH study): Canadian real-world experience. ECTRIMS. Barcelona, Spain. October

2015.

382.383. K. Bendfeldt, B. Taschler, L. Gaetano, P. Madoerin, P. Kuster, N. Mueller-Lenke, M.

Amann, H. Vrenken, F. Barkhof, S. Borgwardt, S. Klöppel, TE. Nichols, G. Suarez, L.

Kappos, G. Edan, MS Freedman, X. Montalban, H-P. Hartung, C. Pohl, R. Sandbrink, J.

Würfel, E-W. Radue, T. Sprenger. Predicting conversion to clinically definite multiple

sclerosis using machine learning on the basis of cerebral grey matter segmentations.


383.384. K. Edwards, MS Freedman. Safety and efficacy of transitioning to terflunomide in

patients switching from other disease-modifying therapies, including natalizumab.


384.385. JS. Wolinsky, MS Freedman, K. Thangavelu, P. Truffinet, P. Rufi, PW O’Connor,.

Efficacy of teriflunomide treatment in achieving no evidence of disease activity ini the

TEMSO long-term extension studay. ECTRIMS. Barcelona, Spain. October 2015.

385.386. A. Uccelli, L. Brundin, M. Clanet, O. Fernandez, A. Laroni, P. Muraro, R. Oliveri,

E-W. Radue, P. Soelberg Sorensen, MP Sormani, MS Freedman. MESEMS: a randomized,

double blind placebo-controlled cross-ver study to evaluate safety and efficacy of intravenous

administration of autologous mesenchymal stem cells in patients with multiple sclerosis.


386.387. L. Kappos, MS Freedman, G. Cormi, AE Miller, JS Wolinsky, K. Thangavelu, P.

Truffinet, P. Rufi, PW O’Connor. Teriflunomide efficacy on annualized relapse rate and

expanded disability status scale scores: 2.5-year follow-up in the TOWER extension study in

patients with relapsing MS. ECTRIMS. Barcelona, Spain. October 2015.


387.388. S. Krieger, MS Freedman, T. Moreau, E. Havrdova, KW Selmaj, DH Margolin, L.

Kasten. Durable efficacy of alemtuzumab in CARE-MS II patients with highly active

relapsing-remitting multiple sclerosis: 4-year outcomes. ECTRIMS. Barcelona, Spain.

October 2015.

388.389. PK. Coyle, MS Freedman, F. Dangond, J. Fang, AT Reder. Predictive value of

early MRI measures for long-term disease activity in patients with relapsing-remitting

multiple sclerosis receiving IFN ß-1a SC tiw or IFN ß-1a IM qw: post hoc analyses of the

EVIDENCE study. ECTRIMS. Barcelona, Spain. October 2015.

389.390. EA Ljungberg, SH. Kolind, R. Tam, MS Freedman, DK Li, AL Traboulsee.

Correcting cervical spinal cord area for cord length strengthens correlation between atrophy

and ambulation. ECTRIMS. Barcelona, Spain. October 2015.

390.391. MS Freedman, L. Kappos, G. Comi, AE Miller, JS Wolinsky, K. Thangavelu, P.

Truffinet, M. Benamor, P. Rufi, PW O’Connor. Long-term safety of teriflunomide: 2.5-year

follow-up in the TOWER extension study in patients with relapsing MS. ECTRIMS.


391.392. EL MacMillan, R Tam, Y Zhao, IM Vavasour, DKB Li, J Oger, MS Freedman,

SH Kolind, AL Traboulsee… Brain Glutamate and Glutamine Levels Decline Over Two

Years In Progressive Multiple Sclerosis. Tykeson Fellows Conference. Fort Worth,

Texas, Oct. 29, 2015.

392.393. JS. Wolinsky, MS Freedman, K. Thangavelu, P. Truffinet, P. Rufi, PW

O’Connor. Efficacy of teriflunomide treatment in achieving no evidence of disease

activity: post hoc analysis of the TEMSO long-term extension study. ECF. Baveno, Italy.

Nov 27, 2015.

393.394. MS Freedman. Clinical and MRI efficacy of IFN β-1a SC tiw in MS patients

with more advanced disease (EDSS 4.0–6.0). ACTRIMS. New Orleans, USA. February

19, 2016.

394.395. S Krieger, B Singer, MS Freedman, J Lycke, R Berkovich, D Margolin, K

Thangavelu, E Havrdova. Treatment-Naive Patients with Highly Active RRMS

Demonstrated Durable Efficacy with Alemtuzumab over 5 Years. AAN. Vancouver, BC.

April 2016.

395.396. K Fitzgerald, K Munder, MS Freedman, H Hartung, X Montalban, G Edan, F

Barkhof, EW Radue, L Kappos, G Suarez, A Ascherio. Increased Sodium Intake Is Not

Associated with MS Activity or Progression in BENEFIT. AAN. Vancouver, BC. April

2016.

396.397. J Wolinsky, D Haring, M Pia Somani, F Lublin, D Miller, MS Freedman, B Cree,

H Weiner, C Lubetzki, HP Hartung, X Montalban, B Uitdehaag, M Merschhemke, B Li, N

Putzki, L Kappos. Brain Volume as a Predictor of Disability in Primary Progressive

Multiple Sclerosis: Evidence from the INFORMS Trial. AAN. Vancouver, BC. April


2016.

397.398. MS Freedman, T Leist, G Comi, B Cree, P Coyle, HP Hartung, P Vermersch, D

Damian, F DangondEfficacy of cladribine tablets in patients with clinically isolated

syndrome (CIS) who retrospectively met 2010 McDonald multiple sclerosis (MS) criteria

at baseline. AAN. Vancouver, BC. April 2016.

398.399. F Lublin, MS Freedman, B Cree, J Wolinsky, H Weiner, C Lubetzki, HP Hartung,

X Montalban, B Uitdehaag, M Merschhemke, B Li, N Putzki, D Haering, L Kappos.

Lymphocyte Dynamics During and After Fingolimod Therapy: Long-Term Data from the

INFORMS Trial. AAN. Vancouver, BC. April 2016.

399.400. P Coyle, G Comi, MS Freedman, L Chen, K Marhardt, L Kappos. Effect of Early

Versus Delayed Subcutaneous Interferon (scIFN) β-1a to Achieve No Evidence of Disease

Activity (NEDA) in Patients with Clinically Isolated Syndrome (CIS): A Post-hoc Analysis

of REFLEXION. AAN. Vancouver, BC. April 2016.

400.401. M Kremenchutzky, MS Freedman, A Bar-Or, A Purvis, M Benamor, P Truffinet,

P O’Connor. Final Outcomes of the Teriflunomide Phase 2 Extension Study: 13 Years of

Efficacy and Safety Results. AAN. Vancouver, BC. April 2016.

401.402. MS Freedman, L Kappos, G Edan, X Montalban, H Hartung, B Hemmer, E Fox, F

Barkhof, S Schippling, R Koelbach, D Pleimes, G Suarez, EM Wicklein. Baseline

Predictors of Disease Activity in Patients with CIS Treated with Interferon beta-1b in the

BENEFIT 11 Trial. AAN. Vancouver, BC. April 2016.

402.403. MS Freedman, K Edwards, P Wang, X You, S FamAnalysis of Relapse Events

in the DECIDE Study Using a Novel Weighted Hurdle Model. AAN. Vancouver, BC.

April 2016.

403.404. AT Reder, MS Freedman, J Fang, F Dangond, PK Coyle. MRI frequency and no

evidence of disease activity status among patients with RRMS receiving IFN beta-1a SC

tiw or IFN beta-1a IM qw: post hoc analyses of EVIDENCE. AAN. Vancouver, BC.

April 2016.

404.405. PK Coyle, MS Freedman, F Dangond, J Fang, AT Reder. Predictive value of

early MRI measures for long-term disease activity in patients with RRMS receiving IFN

beta-1a SC tiw or IFN beta-1a IM qw: post hoc analyses of EVIDENCE. AAN.

Vancouver, BC. April 2016.

405.406. MS Freedman, T Leist, G Comi, B Cree, PK Coyle, H-P Hartung, P Vermersch,

D Damian, F Dangond. A Retrospective Analysis of Efficay in McDonald 2010 Multiple

Sclerosis (MS) Patients in the ORACLE-MS Study. EAN. Copenhagen, Denmark. May

2016.


406.407. MS Freedman, G Comi, AE Miller, J Wolinsky, J Oh, K Thankgavelu, P

Truffinet, L Kappos. Long-term Efficacy of Teriflunomide in Patients Recently

Diagnosed With Relapsing Forms of MS. Ean. Copenhagen, Denmark. May 2016.

407.408. MS Freedman, AE Miller, K Thangavelu, S Hass, TP Leist. Number Needed to

Treat Analysis Comparing Teriflunomide With Injectable and Oral Disease-Modifying

Therapies in Relapsing Multiple Sclerosis. EAN. Copenhagen, Denmark. May 2016.

408.409. L Kappos, MS Freedman, G Comi, AE Miller, K Thangavelu, P Truffinet, F

Lublin. Early Treatment With Teriflunomide Reduces the Risk of Advancing to EDSS≥6

and EDSS≥7 Over the Long-term. EAN. Copenhagen, Denmark. May 2016.

409.410. MS Freedman, L Kappos, G Comi, AE Miller, J Wolinsky, K THangavelu, P

Truffinet, M Benamor, P Rufi, P O’Connor. Final Outcomes from the Teriflunomide

TOWER Extension Study: Up to 6 Years of Follow-up (Core Plus Extension) in Patients

with Relapsing Forms of MS. CMSC. Maryland. June 2016.

410.411. M Abdoli, S Chakraborty, H MacLean, MS Freedman. The Evaluation of MRE

Diffusion Values of Active DemyuelinatingLesions in Multiple Sclerosis. CMSC.

National Harbor, Maryland, June 2016.

411.412. EJ Fox, G Edan, MS Freedman, X Monalban, H-P Hartung, B Hemmer, F

Barkhof, S Schippling, FW Foley, I-K Penner, R Koelbach, D Pleimes, G Suarez, E-M

Wicklein, L Kappos. Correlation of Clinical, MRI, and OCT Outcomes in the 11-Year

Follow-up from BENEFIT: BENEFIT 11. CMSC. National Harbor, Maryland. June

2016.

412.413. BA Singer, S Krieger, R Berkovich, MS Freedman, DH Margolin, K

Thangavelu, A Boster on behalf of the CARE-MS I and CARE-MS II Investigators.

Patients with Highly Active Relapsi g-Remitting Multiple Sclerosis Despite Prior

Therapy Show Durable Improvement with Alemtuzumag over 5 Years. CMSC. National

Harbor, Maryland. June 2016.

413.414. MS Freedman, G Comi, PK Coyle,, L Chen, K Marhardt, L Kappos. Effect of

early versus delayed scIFN β-1a on radiological or clinical activity-free status in patients

with CIS: a post-hoc analysis of REFLEXION. ECTRIMS. London, UK. September 14,

2016.

414.415. AE Miller, L Kappos, G Comi, MS Freedman, J Oh, J De Seze, P Truffinet, M

Benamor, A Purvis, JS Wolinsky. Outcomes of the TEMSO extension study of

teriflunomide: 10.5 years of clinical results. ECTRIMS. London, UK. September 14,

2016.

415.416. MS Freedman, T Sprender, EW Radue, J Weurfel, AE Miller, K Thangavelu,

MA Panzara, S Cavalier, L Kappos. Teriflunomide is effective in reducing brain volume

loss in previously treated patients: a subgroup analysis of TEMSO SIENA data.


ECTRIMS. London, UK. September 14, 2016.

416.417. MS Freedman, H Atkins, MJ Bowman H MacLean, C Rush. Immunoablation

and haematopoietic stem cell transplantation completely aborts inflammation in

aggressive relapsing forms of MS. ECTRIMS. London, UK. September 14, 2016.

417.418. K Thangavelu, J Morawski, MS Freedman. Effect of teriflunomide on relapse

and disability worsening an analysis of the TOWER study with 2 years of treatment.


418.419. AE Miller, L Kappos, G Comi, MS Freedman, J Oh, J DeSeze, P Truffinet, M

Benamor, A Purvis, JS Wolinsky. Outcomes of the TOPIC extension study of

Teriflunomide in patients with early multiple sclerosis: up to 7 years of clinical results.


419.420. F Lublin, MS Freedman, G Comi, AE Miller, K Thangavelu, P Truffinet, L

Kappos. Benefit of long-term treatment with teriflunomide on disability outcomes:

results from TEMSO and TOWER. ECTRIMS. London, UK. September 14, 2016.

420.421. F Alshamrani, MS Freedman, H Al Najashi. Cladribine safety and efficacy in

patients with rapidly evolving or early secondary progressive MS. ECTRIMS. London,

UK. September 14, 2016.

421.422. J Black, Douglas L Arnold, M Bowman, H Atkins, MS Freedman. aHSCT

Reduces Axonal Loss in MS as Evidenced by a Reduction in the Levels of CSF

Neurofilaments. 13th International Congress of Neuroimmunology. Jerusalem.

September 28, 2016.

422.423. Hans-Peter Hartung, Douglas L. Arnold, MS Freedman, Eva Havrdova, Douglas

Jefferrey, Raj Kapoor, Aaron Miller, Finn Sellebjerg, Haihang Li, Nisha Lucas, Diego

Cadavid, Nolan Campbell, Pei-Ran Ho, Deb Steiner. " Natalizumab may delay disability

progression in secondary progressive multiple sclerosis (SPMS): results from the

ASCEND phase 3 trial open-label extension study ". European Charcot Foundation. Nov

25, 2016. Baveno, Italy.

423.424. Giancarlo Comi, Thomas Leist, MS. Freedman, Bruce A. C. Cree, Patricia K.

Coyle,Hans-Peter Hartung, Patrick Vermersch, Doris Damian, Fernando Dangond.

“Cladribine tablets in the ORACLE-MS study open-label maintenance period: analysis of

efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS)”.

European Charcot Foundation. Nov 25, 2016. Baveno, Italy.

424.425. L. Kappos, G. Comi, MS Freedman, L. Chen, K. Marhardt, P. K. Coyle. “Effect

of early versus delayed subcutaneous interferon β-1a (scIFNβ-1a) to achieve no evidence

of disease activity (NEDA) in patients with clinically isolated syndrome (CIS): A post-

hoc analysis of REFLEXION. European Charcot Foundation. Nov 25, 2016. Baveno,


Italy.

425.426. Mark S. Freedman, Patrick Vermersch, Doris Damian, Fernando Dangond,

ORACLE-MS study group. Analyse rétrospective d’efficacité chez les patients atteints

de (SEP)

répondant aux critères de McDonald 2010 dans l’étude ORACLE-MS. Revue

neurologique 173S (2 0 1 7) S81–S132

426.427. Christine Lebrun-Frénay, Mark S. Freedman, Aaron E. Miller, Giancarlo Comi,

Ludwig

Kappos, Jerry S. Wolinski, pour le Groupe de l’étude TEMSO. Données d’extension de

l’étude TEMSO avec le tériflunomide : 10,5 ans de résultats cliniques. Revue

neurologique 173S (2 0 1 7) S81–S132

427.428. Wei-Qiao Liu, Luanne Metz, Dina Lavorato, Jamie Greenfield, Famaz

Amoozegar, B Anthony Traboulsee, Pierre Duquette, Michael Yeung, Marcelo

Kremenchutzsky, Galina Vorobeychik, Virender Ghan, MS Freedman, Gregg Blevins,

James Marriott, Francois Grand-Maison, Liesly Lee, Manon Thibault, Minocycline in

CIS Trial Investiagtors. Headache is a Common and Disabling Comorbidity in People

with Clnically Isolated Syndrome. AAN. Boston, USA. April 25, 2017

428.429. MS Freedman, Till Sprenger, Ernst-Wilhelm Radue, Jens Wuerfel, Aaron Miller,

Kathinathan Thangavelu, Steven Cavalier. Teriflunomide is Effective in Reducing Brain

Volume Loss in Previously Treated Patients: A Subgroup Analysis of TEMSO SIENA

Data. AAN. Boston, USA. April 28, 2017

429.430. Yves Lapierre, MS Freedman, Francois Grand-Maison, Liesly Lee, Katayoun

Alikhani, Lorne Kastrukoff, Gregg MacLean, Paola Haddad, Robyn Schecter.

Tolerability and Retention to Fingolimod in RRMS Patients who switched from other

Oral DMTs". AAN. Boston, USA. April 28, 2017

430.431. MS Freedman, Giancarolo Comi, Patricia Coyle, Liang Chen, Kurt Marhardt,

Ludwig Kappos. Effect of early versus delayed treatment (DT) with subcutaneous IFN ß-

1a (scIFNß-1a) on radiological activity free (RAF) or clinical activity free (CAF) status

in patients with clinically isolated syndrome (CIS): A post-hoc analysis of

REFLEXION. AAN. Boston, USA. April 28, 2017

431.432. Aaron Miller, MS Freedman, Jiwon Oh, Jerome De Seze, Philippe Truffinet,

Myriam Benamor, Annie Purvis, Giancarlo Comi. Outcomes of the TOPIC Extension

Study of Teriflunomide in Patients with Early Multiple Sclerosis: Up to 7 years of

Clinical Results. AAN. Boston, USA. April 24, 2017

432.433. Barry Singer, Heinz Wiendl, Simon Broadley, MS Freedman, Guillermo

Izquierdo, Jan Lycke, Carlo Pozzilli, Brian Steingo, David Margolin, Sourav Santra,

Karthinathan Thangavelu, Aaron Boster, On Behalf of the CAR Investigators. Durable

Efficacy of Alemtuzumab in CARE-MS II Patients with RRMS with Disease Activity


(Relapse) Between Courses 1 and 2. AAN. Boston, USA. April 27, 2017

433.434. Hans-Peter Hartung, Douglas Arnold, MS Freedman, Eva Havrdova, Douglas

Jeffery, Raju Kapoor, Aaron Miller, Finn Sellebjerg, Haihong Li, Nisha Lucas, Diego

Cadavid, Nolan Campbell, Pei-Ran Ho, Deborah Steiner. ASCEND Phase 3 Trial

Open-Label Extension Study Results: Natalizumab May Delay Disability Progression in

Secondary Progressive Multiple Sclerosis (SPMS). AAN. Boston, USA. April 27, 2017

434.435. Giancarlo Comi, Thomas Leist, MS Freedman, Bruce Cree, Patricia Coyle,

Hans-Peter Hartung, Patrick Vermersch, Doris Damian, Fernando Dangond. Cladribine

tablets in the ORACLE-MS study open-label maintenance period: analysis of efficacy in

patients after conversion to clinically definite multiple sclerosis (CDMS). AAN. Boston,

USA. April 28, 2017

435.436. Mathias Maurer, Aaron Miller, Giancarlo Comi, Ludwig Kappos, Jerry Wolinsky,

Martin Stangel, Richard Macdonell, Philippe Truffinet, Kathinathan Thangavelu, MS

Freedman. Impact of Long-term Terflunomide Treatment on Severe Relapses: Analysis

of TEMSO and TOWER Extensions. AAN. Boston, USA. April 28, 2017

436.437. Giancarlo Comi, Raed Alroughani, Regina Berkovich, Volker Limmroth, Richard

Macdonell, Thibault Moreau, Heinz Wiendl, Bart Van Wijmeersch, Maria Melanson,

Kathinathan Thangavelu, MS Freedman, Aaron Boster. Number Needed to Treat

Analyses to Assess Clinical Outcomes in Patients With Relapsing-Remitting Multiple

Sclerosis Treated With Alemtuzumab or Ocrelizumab. AAN. Boston, USA. April 28,

2017

438. Mark S Freedman, Aaron Miller, Giancarlo Comi, Ludwig Kappos, Christine

Lebrun-Frenay, Philippe Truffinet, Annie Purvis, Myriam Benamot, Jerry S Wolinsky.

Outcomes of the TEMSO Extension Study of Teriflunomide:10.5 years of Clinical

Results. Deutschen Gesellschaftfür für Neurologie. Leipzig, Germany. September 2017

439. Aaron E Miller, Mathias Maurer, Giancarlo Comi, Ludwig Kappos, Jerry S Wolinsky,

Martin Stangel, Richard Macdonell, Philippe Truffinet, Karthinathan Thangavelu, Mark

Freedman. Impact of Long-term Teriflunomide Treatment on Severe Relapses : Analysis

of TEMSO and Tower Extensions. Società Italiana di Neurologia (SIN). Naples, Italy.

October 2017

440. G. Comi, A.E Miller, M. Benamor, P. Truffinet, K. Thangavelu, M. Mandel, M.S.

Freedman. Effect of Teriflunomide on Lymphocyte Counts and Infections Over the

Long-term in the Pooled TEMSO and TOWER Extension Studies. ECTRIMS. Paris,

France. October 2017

441. M.P Sormani, M.S Freedman, J. Aldridge, K. Marhardt, N. De Stefano. Disease

Activity as Assessed by the MAGNIMS Score Predicts Long-Term Clinical Disease

Activity Free Status and Disability Proegression in Patients Tretaed with Subcutaneous

Inteferon Beta-1a. ECTRIMS. Paris, France. October 2017


442. M.S Freedman, G. Comi, P.K Coyle, J. Alridge, K. Marhardt, L. Kappos. Impact of the

Presence of Gadolinium-Enhancing Lesions at the Baseline on NO Evidence of Disease

Activity Status in Patients Treated with Subcutaneous Inteferon Beta-1a: A Post Hoc

Analysis of REFLEXION. ECTRIMS. Paris, France. October 2017

443. P. Vermersch, P. Truffinet, E.M Poole, M. Mandel, M.S Freedman. Baseline

Characteristics and Long-Term Disability Outcomes: Subgroup Analysis of the TEMSO

and Tower Core and Extension Studies. ECTRIMS. Paris, France. October 2017

444. M.S Freedman, A. Bar-Or, M. Benamor, P. Truffinet, E. Poole, M. Mandel,

M. Kremenchutzky. Long-Term Disability Outcomes in Patients Treated With

Teriflunomide for up to 14 years: Group and Patient Level Data from the Phase 2

Extension Study. ECTRIMS. Paris, France. October 2017.

445. H. Wiendl, S. Broadley, O. Fernandez, M.S Freedman, G. Izquiero, J. Lycke,

C. Pozzilli, B. Sharrack, B.V Singer, B. Steingo, P. Vermersch, S. Wray, B.

van Wijmeersch, T. Ziemssen, D.H Margolin, S. Santra, K. Thangavelu, A.

Boster.Long-term Improvement in Clinical Outcomes in Alemtuzumab-treated RRMS

Patients Who Relapsed Between Courses 1 and 2(CARE-MS I). ECTRIMS. Paris,

France. Oct 2017

446. Richard Macdonell, Mark S Freedman, Xianhao Xu, Steve Vucic, Philippe Truffinet,

Myriam Benamor, Karthinathan Thangavelu, Aaron E Miller. A Subgroup Analysis of

the Phase 3 Tower Study Assessing Efficacy and Safety of Teriflunomide in Asian

Patients With Relapsing Forms of MS. PACTRIMS. Ho Chi Minh, Vietnam. Nov 2017

447. Giancarlo Comi, Thomas Leist, MS Freedman, Bruce Cree, Patricia Coyle, Hans-Peter

Hartung, Patrick Vermersch, Doris Damian, Fernando Dangond. Cladribine tablets in the

ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after

conversion to clinically definite multiple sclerosis (CDMS). MENACTRIMS. Dubai,

UAE. Nov 24 2017.

448. Giancarlo Comi, Aaron Miller, Myriam Benamor, Philippe Truffinet, Karthinathan

Thangavelu, Matt Mandel, Mark S Freedman. Limited Impact of Long-term

Teriflunomide Treatment on Lymphocyte Counts and Infection Rates in the Pooled

TEMSO and Tower CORE and Extension Trials. P041. ACTRIMS. San Diego, USA.

February 2018.

449. Thiebault S, Tessier D, Stonebridge I, Tabard-Cossa V, Freedman MS. Neurofilament

Light Chains Levels Significantly Reduced After Bone Marrow Transplant in MS Patient

Serum and CSF. ACTRIMS. San Diego, USA. February 2018.

450. M.P. Sormani, M.S. Freedman, J. Aldridge, K. Marhardt, N. De Stefano. Disease

Activity Assed by the MAGNIMS Score Predicts Long-term Clinical Disease Activity-


free Status and Disability Progression in Patients Treated with Subcutaneous Interferon

beta-1a.P005. AAN. Los Angeles. April 24 2018

451. MS Freedman, G. Comi, P. Coyle, J. Aldridge, K. Marhardt, L. Kappos. Impact Impact

of the presence or absence of gadolinium-enhancing lesions at baseline on no evidence of

disease activity status in patients treated with subcutaneous interferon beta-1a: A post-

hoc analysis of REFLEXION. P6.387. AAN. Los Angeles. April 27 2018

452. MS Freedman, A. Bar-Or, E. Poole, M. Kremenchutzky, M. Mandel, M. Benamor, P.

Truffinet. Long-term Disability Outcomes in Patients Treated with Teriflunomide for up

to 14 Years: Group- and Patient-Level Data from the Phase 2 Extension Study. P6. 389.

AAN. Los Angeles. April 27 2018.

453. S. Khan, J. Schafhauser, L. Davila, F. Saleh, S. Hodgins, C. Hiliker, M.S Freedman and

D.W. Courtman. The Mesenchymal Stem Cell Therapy for Canadians with MS

(MESCAMS) clinical trial: Cell Manufacturing for Autologous Bone Marrow-derived

MSCs in Ottawa. ISCT. Montreal, Canada. May 1-2 2018

454. Giancarlo Comi, Richard Madonell, Myriam Benamor, Philippe Truffiney, Karthinathan

Thangavelu, Matt Mandel, Mark Freedman. Impact of long-term teriflunomide

treatment on lymphocyte countds and infections in pooled TEMSO and TOWER studies.

ANZAN. Darwin, Australia. May 28-June 1 2018

455. P. Darrlington, D. Stopnikci, T. Touil, JS Doucet, L. Fawaz, M. Roberts, M.N Boivin, N.

Arbour, MS Freedman, A Bar-Or. Natural Killer Cells regulate Th17 cells After

Autologous Hematopoietic Stem Cell Transplantation for RRMS. CSI. London, Ontario.

June 1-4 2018.

(*MS Freedman is a member of the indicated study group)

I confirm this is my up to date CV provided to Sponsor/CRO

Feb 5 2018

Mark S. Freedman BSc MSc MD CSPQ FRCP(C)

Professor of Medicine (Neurology)

Mark Steven FREEDMAN 2 - ECTRIMS

Documents

Transcript of Mark Steven FREEDMAN 2 - ECTRIMS